

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 September 2000 (14.09.2000)

PCT

(10) International Publication Number  
**WO 00/53776 A3**

(51) International Patent Classification<sup>7</sup>: C12N 15/57,  
9/64, 15/63, C07K 16/40, C12Q 1/68, G01N 33/53, A61K  
39/395, 48/00, 38/48, A01K 67/027

(74) Agents: VAN ZANT, Joan M., et al.; Swabey Ogilvy Re-  
nault, 77 Bloor Street West, Suite 1407, Toronto, Ontario  
M5S 1M2 (CA).

(21) International Application Number: PCT/CA00/00258

(22) International Filing Date: 9 March 2000 (09.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/124,260 11 March 1999 (11.03.1999) US  
60/127,386 1 April 1999 (01.04.1999) US  
60/144,919 21 July 1999 (21.07.1999) US

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,  
UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,  
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): MOUNT  
SINAI HOSPITAL [CA/CA]; Samuel Lunenfeld Re-  
search Institute, Office Of Technology Transfer &  
Industrial Liaison, 600 University Avenue, Toronto, On-  
tario M5G 1X5 (CA).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): YOUSEF, George,  
M. [EG/CA]; Suite 1701, 50 Stephanie St., Toronto,  
Ontario M5T 1B3 (CA). DIAMANDIS, Eleftherios, P.  
[CA/CA]; Suite 44, 1504 Gerrard St. W., Toronto, Ontario  
M5G 2X2 (CA).

**Published:**

- With international search report.
- Before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments.

(88) Date of publication of the international search report:  
14 December 2000

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: HUMAN KALLIKREIN-LIKE GENES

(57) Abstract: The invention relates to nucleic acid molecules, kallikrein-like proteins encoded by such nucleic acid molecules; and use of the proteins and nucleic acid molecules

**BEST AVAILABLE COPY**

WO 00/53776 A3

**TITLE: Novel Human Kallikrein-Like Genes****FIELD OF THE INVENTION**

5 The invention relates to nucleic acid molecules, proteins encoded by such nucleic acid molecules; and use of the proteins and nucleic acid molecules

**BACKGROUND OF THE INVENTION**

10 Kallikreins and kallikrein-like proteins are a subgroup of the serine protease enzyme family and exhibit a high degree of substrate specificity (1). The biological role of these kallikreins is the selective cleavage of specific polypeptide precursors (substrates) to release peptides with potent biological activity (2). In mouse and rat, kallikreins are encoded by large multigene families. In the mouse genome, at least 24 genes have been identified (3). Expression of 11 of these genes has been confirmed; the rest are presumed to be pseudogenes (4). A similar family of 15-20 kallikreins has been found in the rat genome (5) where at least 4 of these are known to be expressed (6).

15 Three human kallikrein genes have been described, i.e. prostatic specific antigen (PSA or KLK3) (7), human glandular kallikrein (KLK2) (8) and tissue (pancreatic-renal) kallikrein (KLK1) (9). The PSA gene spans 5.8 Kb of sequence which has been published (7); the KLK2 gene has a size of 5.2 Kb and its complete structure has also been elucidated (8). The KLK1 gene is approximately 4.5 Kb long and the exon sequences and the exon/intron junctions of this gene have been determined (9).

20 The mouse kallikrein genes are clustered in groups of up to 11 genes on chromosome 7 and the distance between the genes in the various clusters can be as small as 3-7 Kb (3). All three human kallikrein genes have been assigned to chromosome 19q13.2 – 19q13.4 and the distance between PSA and KLK2 has been estimated to be 12 Kb (9).

25 A major difference between mouse and human kallikreins is that two of the human kallikreins (KLK2 and KLK3) are expressed almost exclusively in the prostate while in animals none of the kallikreins is localized in this organ. Other candidate new members of the human kallikrein gene family include protease M (10) (also named Zyme (11) or neurosin (12) and the normal epithelial cell-specific gene-1 (NES1) (13). Both genes have been assigned to chromosome 19q13.3 (10,14) and show structural homology with other serine proteases and the kallikrein gene family (10-14).

**SUMMARY OF THE INVENTION**

30 In efforts to precisely define the relative genomic location of PSA, KLK2, Zyme and NES1 genes, an area spanning approximately 300 Kb of contiguous sequence on human chromosome 19 (19q13.3 –q13.4) was examined. The present inventors were able to identify the relative location of the known kallikrein genes and, in addition, they identified other kallikrein-like genes which exhibit both location proximity and structural similarity with the known members of the human kallikrein family. The novel genes exhibit homology with the currently known members of the kallikrein family and they are co-localized in the same genomic region. These new genes, like the already known kallikreins have utility in various cancers including those of the breast, testicular, and prostate.

The kallikrein-like proteins described herein are individually referred to as "KLK-L1, KLK-L2,

KLK-L3, KLK-L4, KLK-L5, or KLK-L6", and collectively as "kallikrein-like proteins" or "KLK-L Proteins". The genes encoding the proteins are referred to as "*klk-11, klk-12, klk-13, klk-14, klk-15, or klk-16*", and collectively as "kallikrein-like genes" or "*klk-l* genes".

Broadly stated the present invention relates to an isolated nucleic acid molecule which comprises:

- 5 (i) a nucleic acid sequence encoding a protein having substantial sequence identity with an amino acid sequence of KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6 as shown in SEQ.ID.NO. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67, respectively;
- (ii) a nucleic acid sequence encoding a protein comprising an amino acid sequence of KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6 as shown in SEQ.ID.NO. 2, 3,  
10 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67, respectively;
- (iii) nucleic acid sequences complementary to (i);
- (iv) a degenerate form of a nucleic acid sequence of (i);
- (v) a nucleic acid sequence capable of hybridizing under stringent conditions to a nucleic acid sequence in (i), (ii) or (iii);
- 15 (vi) a nucleic acid sequence encoding a truncation, an analog, an allelic or species variation of a protein comprising an amino acid sequence of KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6 as shown in SEQ.ID.NO. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67, respectively; or
- (vii) a fragment, or allelic or species variation of (i), (ii) or (iii).

20 Preferably, a purified and isolated nucleic acid molecule of the invention comprises:

- (i) a nucleic acid sequence comprising the sequence of SEQ.ID.NO. 1, 13, 21, 43, 56, or 65 wherein T can also be U;
- (ii) nucleic acid sequences complementary to (i), preferably complementary to the full nucleic acid sequence of SEQ.ID.NO. 1, 13, 21, 43, 56, or 65;
- 25 (iii) a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid of (i) or (ii) and preferably having at least 18 nucleotides; or
- (iv) a nucleic acid molecule differing from any of the nucleic acids of (i) to (iii) in codon sequences due to the degeneracy of the genetic code.

The invention also contemplates a nucleic acid molecule comprising a sequence encoding a  
30 truncation of a KLK-L protein, an analog, or a homolog of a KLK-L Protein or a truncation thereof. (KLK-L Proteins and truncations, analogs and homologs of KLK-L Proteins are also collectively referred to herein as "KLK-L Related Proteins").

The nucleic acid molecules of the invention may be inserted into an appropriate expression vector, i.e. a vector that contains the necessary elements for the transcription and translation of the inserted coding  
35 sequence. Accordingly, recombinant expression vectors adapted for transformation of a host cell may be constructed which comprise a nucleic acid molecule of the invention and one or more transcription and translation elements linked to the nucleic acid molecule.

The recombinant expression vector can be used to prepare transformed host cells expressing KLK-

L Related Proteins. Therefore, the invention further provides host cells containing a recombinant molecule of the invention. The invention also contemplates transgenic non-human mammals whose germ cells and somatic cells contain a recombinant molecule comprising a nucleic acid molecule of the invention, in particular one which encodes an analog of a KLK-L Protein, or a truncation of a KLK-L Protein.

5       The invention further provides a method for preparing KLK-L Related Proteins utilizing the purified and isolated nucleic acid molecules of the invention. In an embodiment a method for preparing a KLK-L Related Protein is provided comprising (a) transferring a recombinant expression vector of the invention into a host cell; (b) selecting transformed host cells from untransformed host cells; (c) culturing a selected transformed host cell under conditions which allow expression of the KLK-L Related Protein; and (d) isolating the KLK-L Related Protein.

10       The invention further broadly contemplates an isolated KLK-L Protein comprising an amino acid sequence as shown in SEQ.ID.NO. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67.

      The KLK-L Related Proteins of the invention may be conjugated with other molecules, such as proteins, to prepare fusion proteins. This may be accomplished, for example, by the synthesis of N-terminal or C-terminal fusion proteins.

15       The invention further contemplates antibodies having specificity against an epitope of a KLK-L Related Protein of the invention. Antibodies may be labeled with a detectable substance and used to detect proteins of the invention in tissues and cells.

      The invention also permits the construction of nucleotide probes which are unique to the nucleic acid molecules of the invention and/or to proteins of the invention. Therefore, the invention also relates to a probe comprising a nucleic acid sequence of the invention, or a nucleic acid sequence encoding a protein of the invention, or a part thereof. The probe may be labeled, for example, with a detectable substance and it may be used to select from a mixture of nucleotide sequences a nucleic acid molecule of the invention including nucleic acid molecules coding for a protein which displays one or more of the properties of a protein of the invention.

20       The invention still further provides a method for identifying a substance which binds to a protein of the invention comprising reacting the protein with at least one substance which potentially can bind with the protein, under conditions which permit the formation of complexes between the substance and protein and detecting binding. Binding may be detected by assaying for complexes, for free substance, or for non-complexed protein. The invention also contemplates methods for identifying substances that bind to other intracellular proteins that interact with a KLK-L Related Protein. Methods can also be utilized which identify compounds which bind to KLK-L gene regulatory sequences (e.g. promoter sequences).

25       Still further the invention provides a method for evaluating a compound for its ability to modulate the biological activity of a KLK-L Related Protein of the invention. For example a substance which inhibits or enhances the interaction of the protein and a substance which binds to the protein may be evaluated. In an embodiment, the method comprises providing a known concentration of a KLK-L Related Protein, with a substance which binds to the protein and a test compound under conditions which permit the formation of complexes between the substance and protein, and removing and/or detecting complexes.



Compounds which modulate the biological activity of a protein of the invention may also be identified using the methods of the invention by comparing the pattern and level of expression of the protein of the invention in tissues and cells, in the presence, and in the absence of the compounds.

The proteins of the invention and substances and compounds identified using the methods of the invention, and peptides of the invention may be used to modulate the biological activity of a KLK-L Related Protein of the invention, and they may be used in the treatment of conditions such as cancer (e.g. breast, testicular, and prostate cancer). Accordingly, the substances and compounds may be formulated into compositions for administration to individuals suffering from cancer.

Therefore, the present invention also relates to a composition comprising one or more of a protein of the invention, a peptide of the invention, or a substance or compound identified using the methods of the invention, and a pharmaceutically acceptable carrier, excipient or diluent. A method for treating or preventing cancer is also provided comprising administering to a patient in need thereof, a KLK-L Related Protein of the invention, or a composition of the invention.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

The invention will now be described in relation to the drawings in which:

Figure 1 shows an approximate 300 Kb of contiguous genomic sequence around chromosome 19q13.3 - q13.4 represented by 8 contigs, each one shown with its length in Kb. The contig numbers refer to those reported in the Lawrence Livermore National Laboratory website. Note the localization of the seven known genes (PSA, KLK2, Zyme, NES1, HSCCE, neuropsin and TLSP) (see abbreviations for full names of these genes). All genes are represented with arrows denoting the direction of transcription. The gene with no homology to human kallikreins is termed UG (unknown gene). The five new kallikrein-like genes (KLK-L1 to KLK-L5) were numbered from the most centromeric to the most telomeric. Numbers just below or just above the arrows indicate appropriate Kb lengths in each contig. Gene lengths and distances between genes are rounded to the nearest 6.5 kb. The site of the gap is marked with an asterisk.

Figure 2 shows a contiguous genomic sequence around chromosome 19q13.3- q13.4. Genes are represented by horizontal arrows denoting the direction of the coding sequence. Distances between genes are in base pairs.

Figure 3 shows tissue expression of the prostate/KLK-L1 gene as determined by RT-PCR. Actin and PSA are control genes. Interpretations are presented in Table 9.

Figure 4 shows the sequence of PCR product obtained with cDNA from female breast tissue using prostate/KLK-L1 primers. Primer sequences are underlined. The sequence is identical to the sequence obtained from prostatic tissue.

Figure 5 is a blot showing the results of experiments for hormonal regulation of the prostate/KLK-

L1 gene in the BT-474 breast carcinoma cell lines. DHT = dihydrotestosterone. Steroids were added at  $10^{-8}$  M final concentrations. Actin (not regulated by steroid hormones), pS2 (up-regulated by estrogens) and PSA (up-regulated by androgens and progestins), are control genes. Prostase/KLK-L1 is up-regulated by androgens and progestins.

5 Figure 6 is a schematic diagram showing comparison of the genomic structure of PSA, KLK1, KLK2, zyme, neuropsin and prostase/KLK-L1 genes. Exons are shown by open boxes and introns by the connecting lines. Arrow head shows the start codons and the vertical arrow represents stop codons. Letters above boxes indicate relative positions of the catalytic triad; H denotes histidine, D aspartic acid and S serine. Roman numbers indicate intron phases. The intron phase refers to the location of the intron within  
10 the codon; I denotes that the intron occurs after the first nucleotide of the codon, II the intron occurs after the second nucleotide, 0 the intron occurs between codons. Numbers inside boxes indicate exon lengths in base pairs.

Figure 7 shows the genomic organization and partial genomic sequence of the KLK-L2 gene. Intronic sequences are not shown except for the splice junctions. Introns are shown with lower case letters  
15 and exons with capital letters. The start and stop codons are encircled and the exon-intron junctions are boxed. The translated amino acids of the coding region are shown underneath by a single letter abbreviation. The catalytic residues are inside triangles. Putative polyadenylation signal is underlined.

Figure 8 shows an approximate 300 Kb region of almost contiguous genomic sequence around chromosome 19q13.3- q13.4. Genes are represented by horizontal arrows denoting the direction of the coding sequence. Distances between genes are mentioned in base pairs .  
20

Figure 9 shows the alignment of the deduced amino acid sequence of KLK-L2 with members of the kallikrein multi-gene family. Genes are (from top to bottom) : Prostase/KLK-L1, enamel matrix serine proteinase 1 (EMSP1) (GenBank accession # NP\_004908), KLK-L2, zyme (GenBank accession # Q92876), neuropsin (GenBank accession # BAA28673), trypsin-like serine protease (TLSP) (GenBank  
25 accession # BAA33404), PSA (GenBank accession # P07288), KLK2 (GenBank accession # P20151), KLK1 (GenBank accession # NP\_002248), and trypsinogen ( GenBank accession # P07477). (See SEQ.ID. NOs. 68-77) Dashes represent gaps to bring the sequences to better alignment. The residues of the catalytic triad are represented by (✚) and the 29 invariant serine protease residues by (I or ✚). Conserved areas around the catalytic triad are boxed. The predicted cleavage sites are indicated by (♣). The dotted area  
30 represents the kallikrein loop sequence. The trypsin like cleavage pattern is indicated by (⊕).

Figure 10(A) shows a dendrogram of the predicted phylogenetic tree for some kallikrein genes. Neighbor-joining/UPGMA method was used to align KLK-L2 with other members of the kallikrein gene family. Gene names and accession numbers are listed in Figure 9. The tree grouped the classical kallikreins (KLK1, KLK2, and PSA) together and aligned the KLK-L2 gene in one group with EMSP, prostase, and  
35 TLSP. (B) Plot of hydrophobicity and hydrophilicity of KLK-L2.

Figure 11 is a blot showing tissue expression of KLK-L2 gene as determined by RT-PCR. Actin and PSA are control genes. Interpretations are presented in Table 12.

Figure 12 is a blot showing hormonal regulation of the KLK-L2 gene in BT-474 breast carcinoma

cell lines. DHT = dihydrotestosterone. Steroids were at  $10^{-8}$  M final concentrations. Actin (not regulated by steroid hormones), pS2 (up-regulated by estrogens) and PSA (upregulated by androgens and progestins), are control genes. KLK-L2 is upregulated by estrogens and progestins.

Figure 13 are blots of EtBr-stained agarose gels. Total RNA was extracted from normal, benign,  
5 and cancer tissues and used to generate cDNA. PCR was performed on cDNA

Figure 14 shows an approximate 300 Kb region of almost contiguous genomic sequence around chromosome 19q13.3- q13.4. Genes are represented by horizontal arrows denoting the direction of the coding sequence. Gene lengths and distances between genes are rounded to the nearest 0.5 kb. The site of the gap is marked with an asterisk. Telomeric to TLSP there are likely another three kallikrein-like genes.

10 Figure 15 shows the genomic organization and partial genomic sequence of the KLK-L3 gene. Intronic sequences are not shown except for the splice junctions. Introns are shown with lower case letters and exons with capital letters. For the full sequence, see SEQ.ID. NO. 21. The start and stop codons are encircled and the exon-intron junctions are boxed. The translated amino acids of the coding region are shown underneath by a single letter abbreviation. The catalytic residues are inside triangles. Putative  
15 polyadenylation signal is underlined.

Figure 16 is a plot of hydrophobicity and hydrophilicity, comparing the pattern of the KLK-L3 with that of the zyme gene. Note the hydrophobic region around the first twenty amino acids, likely representing the signal peptide.

Figure 17 is an alignment of the deduced amino acid sequence of KLK-L3 with members of the  
20 kallikrein multi-gene family. Genes are (from top to bottom and in brackets is the GenBank accession #): PSA (P07288), KLK2 (P20151), KLK1 (NP002248), trypsinogen (P07477), KLK-L3 (AF135026), trypsin-like serine protease (TLSP) (BAA33404), neuropsin (BAA28673), zyme (Q92876), human stratum corneum chymotryptic enzyme (HSCCE) (AAD49718), and/prostase/KLK-L1 (AAD21581). (See SEQ.ID. NOs. 78 to 84). Dashes represent gaps to bring the sequences to better alignment. The residues of the  
25 catalytic triad are bold and in italics, and the 29 invariant serine protease residues are denoted by (♦). Cysteine residues are marked by (•). Conserved areas around the catalytic triad are highlighted in black. The arrow heads (▲) represent the potential cleavage sites. The dotted area represents the kallikrein loop sequence.

Figure 18 is a dendrogram of the predicted phylogenetic tree for some serine proteases and  
30 kallikrein genes. Neighbor-joining/UPGMA method was used to align KLK-L3 with other members of the kallikrein gene family. Gene names and accession numbers are listed in Figure 17. The tree grouped the classical kallikreins (KLK1, KLK2, and PSA) together and aligned the KLK-L3 gene in one group with TLSP, neuropsin, and NES 1 genes. KLK-L4 (SEQ.ID.NO. 43) lies further telomeric to TLSP (21).

Figure 19 is a blot showing tissue expression of the KLK-L3 gene as determined by RT-PCR.  
35 Actin and PSA are control genes.

Figure 20 shows hormonal regulation of the KLK-L3 gene in the BT-474 breast carcinoma cell line. DHT = dihydrotestosterone. Steroids were at  $10^{-8}$  M final concentrations. Actin (not regulated by steroid hormones), pS2 (up-regulated by estrogens) and PSA (upregulated by androgens and progestins),

are control genes. KLK-L3 is upregulated by progestins, estrogens and androgens, in that order.

Figure 21 is a schematic diagram showing the comparison of the genomic structure of PSA, KLK2, neuropsin, NES1, and KLK-L3 genes. Exons are shown by black boxes and introns by the connecting lines. Arrowheads show the start codon, and arrows show the stop codon. Letters above boxes indicate relative positions of the catalytic triad; H denotes histidine, D aspartic acid and S serine. Roman numbers indicate intron phases. The intron phase refers to the location of the intron within the codon; I denotes that the intron occurs after the first nucleotide of the codon, II the intron occurs after the second nucleotide, 0 the intron occurs between codons. Numbers inside boxes indicate exon lengths in base pairs.

Figure 22 shows a comparative genomic structure of the ESTs (Table 16), the clone from The German Genome Project, and the long form of KLK-L4. Exons are represented by solid bars and introns by the connecting lines. Exon numbers on top of solid bars refer to GenBank submission #AF135024. The EST IDs represent GenBank accession numbers. Asterisks represent the positions of stop codons. Horizontal arrows indicate the direction of the PCR primers (described in Table 15) and arrowheads their position along the exons. Vertical dotted lines show alignment of identical fragments.

Figure 23 shows tissue expression of the KLK-L4 gene as determined by RT-PCR. Actin and PSA are control genes. KLK-L4 is highly expressed in breast, prostate, salivary gland and testis.

Figure 24 in the Upper Panel is a Diagram showing the comparative genomic structure of the long KLK-L4 form and the short KLK-L4 variant. Exons are represented by boxes and introns by the connecting lines. Exon numbers refer to SEQ. ID. NO. 43 and GenBank Accession No. AF135024. The black region indicates the extra fragment (214 bp) that is found in the long, but not in the short form of the gene. The positions of the stop codons of the two forms are marked with asterisks. Frame shifting occurs as a result of utilization of an alternative splice site, and a stop codon is generated at the beginning of exon 4 in the short form. The Lower Panel shows PCR products of the amplification of the KLK-L4 gene using L4-R1 and L4-X1 primers (Figure 22 and Table 15). Note the predominant long form and a minor band representing the short form of KLK-L4 mRNA. (M); Markers with sizes in bp shown on the left. Tissues used: (1), salivary gland; (2), mammary gland; (3), prostate; (4), testis; (5), uterus; (6), breast cancer tissue; (7), negative control.

Figure 25 shows the genomic organization and partial genomic sequence of the KLK-L4 gene. Intronic sequences are not shown except for the splice junction areas. Introns are shown with lower case letters and exons with capital letters. For full sequence, see SEQ. ID. NO.43 or GenBank Accession #AF135024. The start and stop codons are encircled and the exon-intron junctions are underlined. The translated amino acids of the coding region are shown underneath by a single letter abbreviation. The catalytic residues are boxed. The putative polyadenylation signal is underlined.

Figure 26 is a plot of hydrophobicity and hydrophilicity of the KLK-L4 protein, as compared with the glandular kallikrein gene 2 (KLK2). Note the hydrophobic region at the amino terminus, suggesting presence of a signal peptide.

Figure 27 shows an alignment of the deduced amino acid sequence of KLK-L4 with members of the kallikrein multi-gene family. Genes are (from top to bottom, and in brackets are the GenBank accession

#: KLK-L1/prostase (AAD21581), enamel matrix serine proteinase 1 (EMSP) (NP\_004908), KLK-L2 (AF135028), PSA (P07288), KLK2 (P20151), KLK1 (NP\_002248), trypsinogen (P07477), zyme (Q92876), KLK-L4 (AF135024), trypsin-like serine protease (TLSP) (BAA33404), KLK-L3 (AF135026), neuropsin (BAA28673), and the normal epithelial cell-specific 1 gene (NES1) (O43240). (See SEQ.ID. NOs. 78-88). Dashes represent gaps to bring the sequences to better alignment. The residues of the catalytic triad are typed in bold, and conserved motifs around them are highlighted in grey. The 29 invariant serine protease residues are denoted by (●), and the cysteine residues by (◆). The predicted cleavage sites are indicated by (▲). The dotted area represents the kallikrein loop sequence. The trypsin-like cleavage pattern of KLK-L4 with the D residue, is indicated by (⊙).

Figure 28 shows an approximate 300 Kb region of almost contiguous genomic sequence around chromosome 19q13.3- q13.4. Genes are represented by horizontal arrows denoting the direction of the coding sequence. Their lengths are shown on top of each arrow. Distances between genes are mentioned in base pairs below the arrows. The distance between KLK1 and PSA is not accurately known. For gene names, see under abbreviations.

Figure 29 shows is a dendrogram of the predicted phylogenetic tree for some kallikrein and serine protease genes. The neighbor-joining/UPGMA method was used to align KLK-L4 with other serine proteases and members of the kallikrein gene family. The tree grouped the classical kallikreins (KLK1, KLK2, and PSA) together and aligned the KLK-L4 gene in one group with zyme, NES1, neuropsin, KLK-L3, and TLSP. Other serine proteases were aligned in different groups, as shown.

Figure 30 is a blot showing the hormonal regulation of the KLK-L4 gene in the BT-474 breast carcinoma cell line. DHT = dihydrotestosterone. Steroids were added at  $10^{-8}$  M final concentrations. Actin (not regulated by steroid hormones), pS2 (up-regulated by estrogens) and PSA (upregulated by androgens and progestins) are control genes. KLK-L4 is up-regulated by androgens and progestins and to a lesser extent by estrogens. H<sub>2</sub>O was used to check for PCR specificity in all PCR reactions. For more details, see text.

Figure 31 is a schematic diagram showing the comparison of the genomic structure of PSA, KLK2, neuropsin, NES1, and KLK-L4 genes. Exons are shown by black boxes and introns by the connecting lines. The arrowhead shows the start codons and the arrow the stop codons. Letters above boxes indicate the relative positions of the amino acids of the catalytic triad; H denotes histidine, D aspartic acid and S serine. Roman numbers indicate intron phases. The intron phase refers to the location of the intron within the codon; I, the intron occurs after the first nucleotide of the codon, II the intron occurs after the second nucleotide, 0 the intron occurs between codons. Numbers inside boxes indicate exon lengths in base pairs. The question mark indicates the possibility of more untranslated bases.

Figure 32 is a diagram showing the comparative genomic structure of the three splice forms of KLK-L5; the classical kallikrein form, related protein-1, and related protein-2. Exons are represented by solid bars and introns by the connecting lines. Exon numbers refer to SEQ.ID. NO.56 and GenBank Accession #AF135025. Start codons are represented by the inverted arrowhead (▼) and stop codons are represented by asterisks (\*). Primer locations are represented by vertical arrowheads (▲) and their

directions by horizontal arrows. For primer sequences and codes see Table 17 and SEQ.ID. NOs. 61-64, and 9-12.

Figure 33 shows the genomic organization and partial genomic sequence of the KLK-L5 gene. Intronic sequences are not shown except for short sequences around the splice junctions. Introns are shown with lower case letters and exons with capital letters. For full sequence, see SEQ.ID.NO. 56. The start and stop codons are encircled and the exon-intron junctions are underlined. The translated amino acids of the coding region are shown underneath by a single letter abbreviation. The catalytic residues are boxed. Putative polyadenylation signal is underlined. The extra intron of the related protein-1 form is represented by non-bold capital letters between brackets. When this intron is spliced, the frame continues with codon AAC (asparagine, N, instead of lysine, K) until it encounters the stop codon TAA (encircled).

Figure 34 is a schematic diagram showing the comparison of the genomic structure of PSA, KLK2, neuropsin, NES1, KLK-L4 and KLK-L5 genes. Exons are shown by solid bars and introns by the connecting lines. Arrowhead marks the site of the start codon, and the arrow represents the stop codon. Letters above boxes indicate relative positions of the catalytic triad; H denotes histidine, D aspartic acid and S serine. Roman numbers indicate intron phases. The intron phase refers to the location of the intron within the codon; I denotes that the intron occurs after the first nucleotide of the codon, II the intron occurs after the second nucleotide, 0 the intron occurs between codons. Numbers inside boxes indicate exon lengths in base pairs. Question marks indicate that exact length is not accurately known.

Figure 35 is a plot of hydrophobicity and hydrophilicity of KLK-L5 protein compared to prostate specific antigen (PSA). The hydrophobic N-terminus may harbor a signal and activation peptide.

Figure 36 shows an alignment of the deduced amino acid sequence of KLK-L5 with members of the kallikrein multigene family. (See SEQ.ID. NOs. 78-81, 83, 84). Dashes represent gaps to bring the sequences to better alignment. The residues of the catalytic triad are represented by bold letters, and the 29 invariant serine protease residues are marked with (•). The cysteine residues are marked by (♦). Conserved areas are highlighted in grey. The predicted cleavage sites in signal peptide are indicated by (♣). The dotted area represents the kallikrein loop sequence. A vertical arrow marks the trypsin like cleavage site.

Figure 37 is a dendrogram of the predicted phylogenetic tree for some serine proteases and other kallikrein proteins. Neighbor-joining/UPGMA method was used to align KLK-L5 with other serine proteases and members of the kallikrein gene family. The tree grouped the classical kallikreins (hK1, hK2, and PSA) together and aligned the KLK-L5 protein in one group with NES1 and neuropsin. Other serine proteases were aligned in different groups.

Figure 38 shows tissue expression of the KLK-L5 gene as determined by RT-PCR. The upper band (905 base pairs, bp) is the classical form (see Figure 32, the middle (776 bp) the related protein-1, and the lower band (644 bp) the related protein-2. For splice variant discussion see text. The primers used were L5-F2 and L5-R2, as shown in Table 17.

Figure 39 shows hormonal regulation of the KLK-L5 gene in the LnCaP prostatic carcinoma cell line, BT-474 and T-47D breast carcinoma cell lines. Steroids were at  $10^{-8}$  M final concentration. Actin (not

regulated by steroid hormones) was used as a control gene. Note detection of three isoforms only in LNCaP.

Figure 40 shows the expression of the KLK-L5 gene in breast cancer (1-17) and normal (18) tissues. Note complete absence of expression in 12 cancer tissues. For isoforms see also Figure 38.

5 Figure 41 shows the full structure of a KLK-L6 nucleic acid molecule;

Figure 42 is a plot of hydrophobicity and hydrophilicity of KLK-L6 protein compared to prostate specific antigen (PSA).

10 Figure 43 shows an alignment of the deduced amino acid sequence of KLK-L6 with members of the kallikrein multigene family. (See SEQ.ID. NOs. 78-81, 83, 84). Dashes represent gaps to bring the sequences to better alignment.

Figure 44 is a dendrogram of the predicted phylogenetic tree for some serine proteases and other kallikrein proteins. Neighbor-joining/UPGMA method was used to align KLK-L6 with other serine proteases and members of the kallikrein gene family.

#### DETAILED DESCRIPTION OF THE INVENTION

15 In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See for example, Sambrook, Fritsch, & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y); DNA Cloning: A Practical Approach, Volumes I and II (D.N. Glover ed. 1985); Oligonucleotide Synthesis (M.J. Gait ed. 1984); Nucleic Acid Hybridization B.D. Hames & S.J. Higgins eds. (1985); Transcription and Translation B.D. Hames & S.J. Higgins eds (1984); Animal Cell Culture R.I. Freshney, ed. (1986); Immobilized Cells and enzymes IRL Press, (1986); and B. Perbal, A Practical Guide to Molecular Cloning (1984).

##### 1. Nucleic Acid Molecules of the Invention

25 As hereinbefore mentioned, the invention provides an isolated nucleic acid molecule having a sequence encoding a KLK-L Protein. The term "isolated" refers to a nucleic acid substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical reactants, or other chemicals when chemically synthesized. An "isolated" nucleic acid may also be free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5' and 3' ends of the nucleic acid molecule) from which the nucleic acid is derived. The term "nucleic acid" is intended to include DNA and RNA and can be either double stranded or single stranded. In an embodiment, a nucleic acid molecule encodes a KLK-L Protein comprising an amino acid sequence as shown in SEQ.ID.NO. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67, preferably a nucleic acid molecule comprising a nucleic acid sequence as shown in SEQ.ID.NO. 1, 13, 21, 43, 56, or 65.

35 The invention includes nucleic acid sequences complementary to a nucleic acid encoding a KLK-L Protein comprising an amino acid sequence as shown in SEQ.ID.NO. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67, preferably the nucleic acid sequences complementary to a full nucleic acid sequence shown in SEQ.ID.NO. 1, 13, 21, 43, 56, or 65.

The invention includes nucleic acid molecules having substantial sequence identity or homology to nucleic acid sequences of the invention or encoding proteins having substantial identity or similarity to the amino acid sequence shown in SEQ.ID.NO. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67. Preferably, the nucleic acids have substantial sequence identity for example at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, or 85% nucleic acid identity; more preferably 90% nucleic acid identity; and most preferably at least 95%, 96%, 97%, 98%, or 99% sequence identity. "Identity" as known in the art and used herein, is a relationship between two or more amino acid sequences or two or more nucleic acid sequences, as determined by comparing the sequences. It also refers to the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences. Identity and similarity are well known terms to skilled artisans and they can be calculated by conventional methods (for example see Computational Molecular Biology, Lesk, A.M. ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D.W. ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, A.M. and Griffin, H.G. eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G. Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J. eds. M. Stockton Press, New York, 1991, Carillo, H. and Lipman, D., SIAM J. Applied Math. 48:1073, 1988). Methods which are designed to give the largest match between the sequences are generally preferred. Methods to determine identity and similarity are codified in publicly available computer programs including the GCG program package (Devereux J. et al., Nucleic Acids Research 12(1): 387, 1984); BLASTP, BLASTN, and FASTA (Atschul, S.F. et al. J. Molec. Biol. 215: 403-410, 1990). The BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S. et al. NCBI NLM NIH Bethesda, Md. 20894; Altschul, S. et al. J. Mol. Biol. 215: 403-410, 1990).

Isolated nucleic acid molecules encoding a KLK-L Protein, and having a sequence which differs from a nucleic acid sequence of the invention due to degeneracy in the genetic code are also within the scope of the invention. Such nucleic acids encode functionally equivalent proteins (e.g., a KLK-L Protein) but differ in sequence from the sequence of a KLK-L Protein due to degeneracy in the genetic code. As one example, DNA sequence polymorphisms within the nucleotide sequence of a KLK-L Protein may result in silent mutations which do not affect the amino acid sequence. Variations in one or more nucleotides may exist among individuals within a population due to natural allelic variation. Any and all such nucleic acid variations are within the scope of the invention. DNA sequence polymorphisms may also occur which lead to changes in the amino acid sequence of a KLK-L Protein. These amino acid polymorphisms are also within the scope of the present invention.

Another aspect of the invention provides a nucleic acid molecule which hybridizes under stringent conditions, preferably high stringency conditions to a nucleic acid molecule which comprises a sequence which encodes a KLK-L Protein having an amino acid sequence shown in SEQ.ID.NO. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67. Appropriate stringency conditions which promote DNA hybridization are known to those skilled in the art, or can be found in Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C,



followed by a wash of 2.0 x SSC at 50°C may be employed. The stringency may be selected based on the conditions used in the wash step. By way of example, the salt concentration in the wash step can be selected from a high stringency of about 0.2 x SSC at 50°C. In addition, the temperature in the wash step can be at high stringency conditions, at about 65°C.

5 It will be appreciated that the invention includes nucleic acid molecules encoding a KLK-L Related Protein including truncations of a KLK-L Protein, and analogs of a KLK-L Protein as described herein. It will further be appreciated that variant forms of the nucleic acid molecules of the invention which arise by alternative splicing of an mRNA corresponding to a cDNA of the invention are encompassed by the invention. (See for example, splice variants of KLK-L5, SEQ.ID.NO. 58, 59, and 60.)

10 An isolated nucleic acid molecule of the invention which comprises DNA can be isolated by preparing a labelled nucleic acid probe based on all or part of a nucleic acid sequence of the invention. The labeled nucleic acid probe is used to screen an appropriate DNA library (e.g. a cDNA or genomic DNA library). For example, a cDNA library can be used to isolate a cDNA encoding a KLK-L Related Protein by screening the library with the labeled probe using standard techniques. Alternatively, a genomic DNA  
15 library can be similarly screened to isolate a genomic clone encompassing a gene encoding a KLK-L Related Protein. Nucleic acids isolated by screening of a cDNA or genomic DNA library can be sequenced by standard techniques.

An isolated nucleic acid molecule of the invention which is DNA can also be isolated by selectively amplifying a nucleic acid encoding a KLK-L Related Protein using the polymerase chain  
20 reaction (PCR) methods and cDNA or genomic DNA. It is possible to design synthetic oligonucleotide primers from the nucleotide sequence of the invention for use in PCR. A nucleic acid can be amplified from cDNA or genomic DNA using these oligonucleotide primers and standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. cDNA may be prepared from mRNA, by isolating total cellular mRNA by a variety of techniques,  
25 for example, by using the guanidinium-thiocyanate extraction procedure of Chirgwin et al., Biochemistry, 18, 5294-5299 (1979). cDNA is then synthesized from the mRNA using reverse transcriptase (for example, Moloney MLV reverse transcriptase available from Gibco/BRL, Bethesda, MD, or AMV reverse transcriptase available from Seikagaku America, Inc., St. Petersburg, FL).

An isolated nucleic acid molecule of the invention which is RNA can be isolated by cloning a  
30 cDNA encoding a KLK-L Related Protein into an appropriate vector which allows for transcription of the cDNA to produce an RNA molecule which encodes a KLK-L Related Protein. For example, a cDNA can be cloned downstream of a bacteriophage promoter, (e.g. a T7 promoter) in a vector, cDNA can be transcribed *in vitro* with T7 polymerase, and the resultant RNA can be isolated by conventional techniques.

Nucleic acid molecules of the invention may be chemically synthesized using standard techniques.  
35 Methods of chemically synthesizing polydeoxynucleotides are known, including but not limited to solid-phase synthesis which, like peptide synthesis, has been fully automated in commercially available DNA synthesizers (See e.g., Itakura et al. U.S. Patent No. 4,598,049; Caruthers et al. U.S. Patent No. 4,458,066; and Itakura U.S. Patent Nos. 4,401,796 and 4,373,071).

Determination of whether a particular nucleic acid molecule encodes a KLK-L Related Protein can be accomplished by expressing the cDNA in an appropriate host cell by standard techniques, and testing the expressed protein in the methods described herein. A cDNA encoding a KLK-L Related Protein can be sequenced by standard techniques, such as dideoxynucleotide chain termination or Maxam-Gilbert  
5 chemical sequencing, to determine the nucleic acid sequence and the predicted amino acid sequence of the encoded protein.

The initiation codon and untranslated sequences of a KLK-L Related Protein may be determined using computer software designed for the purpose, such as PC/Gene (IntelliGenetics Inc., Calif.). The intron-exon structure and the transcription regulatory sequences of a gene encoding a KLK-L Related  
10 Protein may be confirmed by using a nucleic acid molecule of the invention encoding a KLK-L Related Protein to probe a genomic DNA clone library. Regulatory elements can be identified using standard techniques. The function of the elements can be confirmed by using these elements to express a reporter gene such as the lacZ gene which is operatively linked to the elements. These constructs may be introduced into cultured cells using conventional procedures or into non-human transgenic animal models. In addition  
15 to identifying regulatory elements in DNA, such constructs may also be used to identify nuclear proteins interacting with the elements, using techniques known in the art.

In a particular embodiment of the invention, the nucleic acid molecules isolated using the methods described herein are mutant *klk-l* gene alleles. The mutant alleles may be isolated from individuals either known or proposed to have a genotype which contributes to the symptoms of for example, cancer (e.g.,  
20 breast, testicular, brain, colon, and prostate cancer). Mutant alleles and mutant allele products may be used in therapeutic and diagnostic methods described herein. For example, a cDNA of a mutant *klk-l* gene may be isolated using PCR as described herein, and the DNA sequence of the mutant allele may be compared to the normal allele to ascertain the mutation(s) responsible for the loss or alteration of function of the mutant gene product. A genomic library can also be constructed using DNA from an individual suspected  
25 of or known to carry a mutant allele, or a cDNA library can be constructed using RNA from tissue known, or suspected to express the mutant allele. A nucleic acid encoding a normal *klk-l* gene or any suitable fragment thereof, may then be labeled and used as a probe to identify the corresponding mutant allele in such libraries. Clones containing mutant sequences can be purified and subjected to sequence analysis. In addition, an expression library can be constructed using cDNA from RNA isolated from a tissue of an  
30 individual known or suspected to express a mutant *klk-l* allele. Gene products made by the putatively mutant tissue may be expressed and screened, for example using antibodies specific for a KLK-L Related Protein as described herein. Library clones identified using the antibodies can be purified and subjected to sequence analysis.

The sequence of a nucleic acid molecule of the invention, or a fragment of the molecule, may be  
35 inverted relative to its normal presentation for transcription to produce an antisense nucleic acid molecule. An antisense nucleic acid molecule may be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art.

## 2. Proteins of the Invention

An amino acid sequence of a KLK-L Protein comprises a sequence as shown in Tables 1 to 5 or SEQ.ID.NO. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67.

In addition to proteins comprising an amino acid sequence as shown in Tables 1 to 5 or SEQ.ID.NO. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67, the proteins of the present invention include  
5 truncations of a KLK-L Protein, analogs of a KLK-L Protein, and proteins having sequence identity or similarity to a KLK-L Protein, and truncations thereof as described herein (i.e. included in KLK-L Related Proteins). Truncated proteins may comprise peptides of between 3 and 70 amino acid residues, ranging in size from a tripeptide to a 70 mer polypeptide.

The truncated proteins may have an amino group (-NH<sub>2</sub>), a hydrophobic group (for example,  
10 carbobenzoxy, dansyl, or T-butyloxycarbonyl), an acetyl group, a 9-fluorenylmethoxy-carbonyl (PMOC) group, or a macromolecule including but not limited to lipid-fatty acid conjugates, polyethylene glycol, or carbohydrates at the amino terminal end. The truncated proteins may have a carboxyl group, an amido group, a T-butyloxycarbonyl group, or a macromolecule including but not limited to lipid-fatty acid conjugates, polyethylene glycol, or carbohydrates at the carboxy terminal end.

15 The proteins of the invention may also include analogs of a KLK-L Protein, and/or truncations thereof as described herein, which may include, but are not limited to a KLK-L Protein, containing one or more amino acid substitutions, insertions, and/or deletions. Amino acid substitutions may be of a conserved or non-conserved nature. Conserved amino acid substitutions involve replacing one or more amino acids of a KLK-L Protein amino acid sequence with amino acids of similar charge, size, and/or  
20 hydrophobicity characteristics. When only conserved substitutions are made the resulting analog is preferably functionally equivalent to a KLK-L Protein. Non-conserved substitutions involve replacing one or more amino acids of the KLK-L Protein amino acid sequence with one or more amino acids which possess dissimilar charge, size, and/or hydrophobicity characteristics.

One or more amino acid insertions may be introduced into a KLK-L Protein. Amino acid  
25 insertions may consist of single amino acid residues or sequential amino acids ranging from 2 to 15 amino acids in length.

Deletions may consist of the removal of one or more amino acids, or discrete portions from a KLK-L Protein sequence. The deleted amino acids may or may not be contiguous. The lower limit length of the resulting analog with a deletion mutation is about 10 amino acids, preferably 20 to 40 amino acids.

30 The proteins of the invention include proteins with sequence identity or similarity to a KLK-L Protein and/or truncations thereof as described herein. Such KLK-L Proteins include proteins whose amino acid sequences are comprised of the amino acid sequences of KLK-L Protein regions from other species that hybridize under selected hybridization conditions (see discussion of stringent hybridization conditions herein) with a probe used to obtain a KLK-L Protein. These proteins will generally have the same regions  
35 which are characteristic of a KLK-L Protein. Preferably a protein will have substantial sequence identity for example, about 30%, 35%, 40%, 45%, 50%, 60%, 65%, 70%, 75%, 80%, or 85% identity, preferably 90% identity, more preferably at least 95%, 96%, 97%, 98%, or 99% identity, and most preferably 98% identity with an amino acid sequence shown in Tables 1 to 5 or SEQ.ID.NO. 2, 3, 14, 22, 23, 44, 45, 57,

58, 59, 60, 66, or 67.

A percent amino acid sequence homology, similarity or identity is calculated as the percentage of aligned amino acids that match the reference sequence using known methods as described herein.

The invention also contemplates isoforms of the proteins of the invention. An isoform contains  
5 the same number and kinds of amino acids as a protein of the invention, but the isoform has a different molecular structure. Isoforms contemplated by the present invention preferably have the same properties as a protein of the invention as described herein.

The present invention also includes KLK-L Related Proteins conjugated with a selected protein, or a marker protein (see below) to produce fusion proteins. Additionally, immunogenic portions of a KLK-L Protein and a KLK-L Protein Related Protein are within the scope of the invention.  
10

A KLK-L Related Protein of the invention may be prepared using recombinant DNA methods. Accordingly, the nucleic acid molecules of the present invention having a sequence which encodes a KLK-L Related Protein of the invention may be incorporated in a known manner into an appropriate expression vector which ensures good expression of the protein. Possible expression vectors include but are not limited  
15 to cosmids, plasmids, or modified viruses (e.g. replication defective retroviruses, adenoviruses and adeno-associated viruses), so long as the vector is compatible with the host cell used.

The invention therefore contemplates a recombinant expression vector of the invention containing a nucleic acid molecule of the invention, and the necessary regulatory sequences for the transcription and translation of the inserted protein-sequence. Suitable regulatory sequences may be derived from a variety  
20 of sources, including bacterial, fungal, viral, mammalian, or insect genes (For example, see the regulatory sequences described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1990). Selection of appropriate regulatory sequences is dependent on the host cell chosen as discussed below, and may be readily accomplished by one of ordinary skill in the art. The necessary regulatory sequences may be supplied by the native KLK-L Protein and/or its flanking regions.

The invention further provides a recombinant expression vector comprising a DNA nucleic acid molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is linked to a regulatory sequence in a manner which allows for expression, by transcription of the DNA molecule, of an RNA molecule which is antisense to the nucleic acid sequence of a protein of the invention or a fragment thereof. Regulatory sequences linked to the antisense nucleic acid can be chosen  
25 which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance a viral promoter and/or enhancer, or regulatory sequences can be chosen which direct tissue or cell type specific expression of antisense RNA.  
30

The recombinant expression vectors of the invention may also contain a marker gene which facilitates the selection of host cells transformed or transfected with a recombinant molecule of the invention. Examples of marker genes are genes encoding a protein such as G418 and hygromycin which  
35 confer resistance to certain drugs,  $\beta$ -galactosidase, chloramphenicol acetyltransferase, firefly luciferase, or an immunoglobulin or portion thereof such as the Fc portion of an immunoglobulin preferably IgG. The markers can be introduced on a separate vector from the nucleic acid of interest.

The recombinant expression vectors may also contain genes which encode a fusion moiety which provides increased expression of the recombinant protein; increased solubility of the recombinant protein; and aid in the purification of the target recombinant protein by acting as a ligand in affinity purification. For example, a proteolytic cleavage site may be added to the target recombinant protein to allow separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the recombinant protein.

The recombinant expression vectors may be introduced into host cells to produce a transformant host cell. "Transformant host cells" include host cells which have been transformed or transfected with a recombinant expression vector of the invention. The terms "transformed with", "transfected with", "transformation" and "transfection" encompass the introduction of a nucleic acid (e.g. a vector) into a cell by one of many standard techniques. Prokaryotic cells can be transformed with a nucleic acid by, for example, electroporation or calcium-chloride mediated transformation. A nucleic acid can be introduced into mammalian cells via conventional techniques such as calcium phosphate or calcium chloride coprecipitation, DEAE-dextran-mediated transfection, lipofectin, electroporation or microinjection. Suitable methods for transforming and transfecting host cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks.

Suitable host cells include a wide variety of prokaryotic and eukaryotic host cells. For example, the proteins of the invention may be expressed in bacterial cells such as *E. coli*, insect cells (using baculovirus), yeast cells, or mammalian cells. Other suitable host cells can be found in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, CA (1991).

A host cell may also be chosen which modulates the expression of an inserted nucleic acid sequence, or modifies (e.g. glycosylation or phosphorylation) and processes (e.g. cleaves) the protein in a desired fashion. Host systems or cell lines may be selected which have specific and characteristic mechanisms for post-translational processing and modification of proteins. For example, eukaryotic host cells including CHO, VERO, BHK, HeLA, COS, MDCK, 293, 3T3, and WI38 may be used. For long-term high-yield stable expression of the protein, cell lines and host systems which stably express the gene product may be engineered.

Host cells and in particular cell lines produced using the methods described herein may be particularly useful in screening and evaluating compounds that modulate the activity of a KLK-L Related Protein.

The proteins of the invention may also be expressed in non-human transgenic animals including but not limited to mice, rats, rabbits, guinea pigs, micro-pigs, goats, sheep, pigs, non-human primates (e.g. baboons, monkeys, and chimpanzees) [see Hammer et al. (Nature 315:680-683, 1985), Palmiter et al. (Science 222:809-814, 1983), Brinster et al. (Proc Natl. Acad. Sci USA 82:4438-4442, 1985), Palmiter and Brinster (Cell. 41:343-345, 1985) and U.S. Patent No. 4,736,866]. Procedures known in the art may be

used to introduce a nucleic acid molecule of the invention encoding a KLK-L Related Protein into animals to produce the founder lines of transgenic animals. Such procedures include pronuclear microinjection, retrovirus mediated gene transfer into germ lines, gene targeting in embryonic stem cells, electroporation of embryos, and sperm-mediated gene transfer.

5           The present invention contemplates a transgenic animal that carries the *KLK-L* gene in all their cells, and animals which carry the transgene in some but not all their cells. The transgene may be integrated as a single transgene or in concatamers. The transgene may be selectively introduced into and activated in specific cell types (See for example, Lasko et al, 1992 Proc. Natl. Acad. Sci. USA 89: 6236). The transgene may be integrated into the chromosomal site of the endogenous gene by gene targeting. The transgene may be selectively introduced into a particular cell type inactivating the endogenous gene in that cell type (See  
10 Gu et al Science 265: 103-106).

          The expression of a recombinant KLK-L Related Protein in a transgenic animal may be assayed using standard techniques. Initial screening may be conducted by Southern Blot analysis, or PCR methods to analyze whether the transgene has been integrated. The level of mRNA expression in the tissues of  
15 transgenic animals may also be assessed using techniques including Northern blot analysis of tissue samples, *in situ* hybridization, and RT-PCR. Tissue may also be evaluated immunocytochemically using antibodies against KLK-L Protein.

          Proteins of the invention may also be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis (Merrifield, 1964, J. Am. Chem. Assoc. 85:2149-  
20 2154) or synthesis in homogenous solution (Houbenweyl, 1987, Methods of Organic Chemistry, ed. E. Wansch, Vol. 15 I and II, Thieme, Stuttgart).

          N-terminal or C-terminal fusion proteins comprising a KLK-L Related Protein of the invention conjugated with other molecules, such as proteins, may be prepared by fusing, through recombinant techniques, the N-terminal or C-terminal of a KLK-L Related Protein, and the sequence of a selected  
25 protein or marker protein with a desired biological function. The resultant fusion proteins contain KLK-L Protein fused to the selected protein or marker protein as described herein. Examples of proteins which may be used to prepare fusion proteins include immunoglobulins, glutathione-S-transferase (GST), hemagglutinin (HA), and truncated myc.

### 3.     Antibodies

30           KLK-L Related Proteins of the invention can be used to prepare antibodies specific for the proteins. Antibodies can be prepared which bind a distinct epitope in an unconserved region of the protein. An unconserved region of the protein is one that does not have substantial sequence homology to other proteins. A region from a conserved region such as a well-characterized domain can also be used to prepare an antibody to a conserved region of a KLK-L Related Protein. Antibodies having specificity for a KLK-L  
35 Related Protein may also be raised from fusion proteins created by expressing fusion proteins in bacteria as described herein.

          The invention can employ intact monoclonal or polyclonal antibodies, and immunologically active fragments (e.g. a Fab, (Fab)<sub>2</sub> fragment, or Fab expression library fragments and epitope-binding fragments

thereof), an antibody heavy chain, and antibody light chain, a genetically engineered single chain Fv molecule (Ladner et al, U.S. Pat. No. 4,946,778), or a chimeric antibody, for example, an antibody which contains the binding specificity of a murine antibody, but in which the remaining portions are of human origin. Antibodies including monoclonal and polyclonal antibodies, fragments and chimeras, may be prepared using methods known to those skilled in the art.

#### 4. Applications of the Nucleic Acid Molecules, KLK-L Related Proteins, and Antibodies of the Invention

The nucleic acid molecules, KLK-L Related Proteins, and antibodies of the invention may be used in the prognostic and diagnostic evaluation of cancer (e.g. breast, testicular, and prostate cancer) or other conditions, and the identification of subjects with a predisposition to cancer (Section 4.1.1 and 4.1.2). Methods for detecting nucleic acid molecules and KLK-L Related Proteins of the invention, can be used to monitor conditions including cancer, by detecting KLK-L Related Proteins and nucleic acid molecules encoding KLK-L Related Proteins. It would also be apparent to one skilled in the art that the methods described herein may be used to study the developmental expression of KLK-L Related Proteins and, accordingly, will provide further insight into the role of KLK-L Related Proteins. The applications of the present invention also include methods for the identification of compounds that modulate the biological activity of *KLK-L* or KLK-L Related Proteins (Section 4.2). The compounds, antibodies etc. may be used for the treatment of cancer (Section 4.3).

##### 4.1 Diagnostic Methods

A variety of methods can be employed for the diagnostic and prognostic evaluation of conditions including cancer (e.g. breast, testicular, and prostate cancer), and the identification of subjects with a predisposition to such conditions. Such methods may, for example, utilize nucleic acid molecules of the invention, and fragments thereof, and antibodies directed against KLK-L Related Proteins, including peptide fragments. In particular, the nucleic acids and antibodies may be used, for example, for: (1) the detection of the presence of *KLK-L* mutations, or the detection of either over- or under-expression of *KLK-L* mRNA relative to a non-disorder state or the qualitative or quantitative detection of alternatively spliced forms of *KLK-L* transcripts which may correlate with certain conditions or susceptibility toward such conditions; and (2) the detection of either an over- or an under-abundance of KLK-L Related Proteins relative to a non-disorder state or the presence of a modified (e.g., less than full length) KLK-L Protein which correlates with a disorder state, or a progression toward a disorder state.

The methods described herein may be performed by utilizing pre-packaged diagnostic kits comprising at least one specific *KLK-L* nucleic acid or antibody described herein, which may be conveniently used, e.g., in clinical settings, to screen and diagnose patients and to screen and identify those individuals exhibiting a predisposition to developing a disorder.

Nucleic acid-based detection techniques are described, below, in Section 4.1.1. Peptide detection techniques are described, below, in Section 4.1.2. The samples that may be analyzed using the methods of the invention include those which are known or suspected to express *KLK-L* or contain KLK-L Related Proteins. The samples may be derived from a patient or a cell culture, and include but are not limited to

biological fluids, tissue extracts, freshly harvested cells, and lysates of cells which have been incubated in cell cultures.

Oligonucleotides or longer fragments derived from any of the nucleic acid molecules of the invention may be used as targets in a microarray. The microarray can be used to simultaneously monitor the expression levels of large numbers of genes and to identify genetic variants, mutations, and polymorphisms. The information from the microarray may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

The preparation, use, and analysis of microarrays are well known to a person skilled in the art. (See, for example, Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995), PCT Application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662.)

#### **4.1.1 Methods for Detecting Nucleic Acid Molecules of the Invention**

The nucleic acid molecules of the invention allow those skilled in the art to construct nucleotide probes for use in the detection of nucleic acid sequences of the invention in samples. Suitable probes include nucleic acid molecules based on nucleic acid sequences encoding at least 5 sequential amino acids from regions of a KLK-L Protein, preferably they comprise 15 to 30 nucleotides. A nucleotide probe may be labeled with a detectable substance such as a radioactive label which provides for an adequate signal and has sufficient half-life such as  $^{32}\text{P}$ ,  $^3\text{H}$ ,  $^{14}\text{C}$  or the like. Other detectable substances which may be used include antigens that are recognized by a specific labeled antibody, fluorescent compounds, enzymes, antibodies specific for a labeled antigen, and luminescent compounds. An appropriate label may be selected having regard to the rate of hybridization and binding of the probe to the nucleotide to be detected and the amount of nucleotide available for hybridization. Labeled probes may be hybridized to nucleic acids on solid supports such as nitrocellulose filters or nylon membranes as generally described in Sambrook et al, 1989, Molecular Cloning, A Laboratory Manual (2nd ed.). The nucleic acid probes may be used to detect genes, preferably in human cells, that encode KLK-L Related Proteins. The nucleotide probes may also be useful in the diagnosis of cancer; in monitoring the progression of cancer; or monitoring a therapeutic treatment.

The probe may be used in hybridization techniques to detect genes that encode KLK-L Related Proteins. The technique generally involves contacting and incubating nucleic acids (e.g. recombinant DNA molecules, cloned genes) obtained from a sample from a patient or other cellular source with a probe of the present invention under conditions favorable for the specific annealing of the probes to complementary sequences in the nucleic acids. After incubation, the non-annealed nucleic acids are removed, and the presence of nucleic acids that have hybridized to the probe if any are detected.

The detection of nucleic acid molecules of the invention may involve the amplification of specific gene sequences using an amplification method such as PCR, followed by the analysis of the amplified molecules using techniques known to those skilled in the art. Suitable primers can be routinely designed



by one of skill in the art.

Genomic DNA may be used in hybridization or amplification assays of biological samples to detect abnormalities involving *klk-l* structure, including point mutations, insertions, deletions, and chromosomal rearrangements. For example, direct sequencing, single stranded conformational polymorphism analyses, heteroduplex analysis, denaturing gradient gel electrophoresis, chemical mismatch cleavage, and oligonucleotide hybridization may be utilized.

Genotyping techniques known to one skilled in the art can be used to type polymorphisms that are in close proximity to the mutations in a *klk-l* gene. The polymorphisms may be used to identify individuals in families that are likely to carry mutations. If a polymorphism exhibits linkage disequilibrium with mutations in a *klk-l* gene, it can also be used to screen for individuals in the general population likely to carry mutations. Polymorphisms which may be used include restriction fragment length polymorphisms (RFLPs), single-base polymorphisms, and simple sequence repeat polymorphisms (SSLPs).

A probe of the invention may be used to directly identify RFLPs. A probe or primer of the invention can additionally be used to isolate genomic clones such as YACs, BACs, PACs, cosmids, phage or plasmids. The DNA in the clones can be screened for SSLPs using hybridization or sequencing procedures.

Hybridization and amplification techniques described herein may be used to assay qualitative and quantitative aspects of *klk-l* expression. For example, RNA may be isolated from a cell type or tissue known to express *klk-l* and tested utilizing the hybridization (e.g. standard Northern analyses) or PCR techniques referred to herein. The techniques may be used to detect differences in transcript size which may be due to normal or abnormal alternative splicing. The techniques may be used to detect quantitative differences between levels of full length and/or alternatively splice transcripts detected in normal individuals relative to those individuals exhibiting cancer symptoms or other disease conditions.

The primers and probes may be used in the above described methods *in situ* i.e directly on tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections.

#### 4.1.2 Methods for Detecting KLK-L Related Proteins

Antibodies specifically reactive with a KLK-L Related Protein, or derivatives, such as enzyme conjugates or labeled derivatives, may be used to detect KLK-L Related Proteins in various samples (e.g. biological materials). They may be used as diagnostic or prognostic reagents and they may be used to detect abnormalities in the level of KLK-L Related Proteins expression, or abnormalities in the structure, and/or temporal, tissue, cellular, or subcellular location of a KLK-L Related Protein. Antibodies may also be used to screen potentially therapeutic compounds *in vitro* to determine their effects on cancer, and other conditions. *In vitro* immunoassays may also be used to assess or monitor the efficacy of particular therapies. The antibodies of the invention may also be used *in vitro* to determine the level of *KLK-L* expression in cells genetically engineered to produce a KLK-L Related Protein.

The antibodies may be used in any known immunoassays which rely on the binding interaction between an antigenic determinant of a KLK-L Related Protein and the antibodies. Examples of such assays are radioimmunoassays, enzyme immunoassays (e.g. ELISA), immunofluorescence, immunoprecipitation,

latex agglutination, hemagglutination, and histochemical tests. The antibodies may be used to detect and quantify KLK-L Related Proteins in a sample in order to determine its role in particular cellular events or pathological states, and to diagnose and treat such pathological states.

5 In particular, the antibodies of the invention may be used in immuno-histochemical analyses, for example, at the cellular and sub-subcellular level, to detect a KLK-L Related Protein, to localize it to particular cells and tissues, and to specific subcellular locations, and to quantitate the level of expression.

Cytochemical techniques known in the art for localizing antigens using light and electron microscopy may be used to detect a KLK-L Related Protein. Generally, an antibody of the invention may be labeled with a detectable substance and a KLK-L Related Protein may be localised in tissues and cells  
10 based upon the presence of the detectable substance. Examples of detectable substances include, but are not limited to, the following: radioisotopes (e.g.,  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{35}\text{S}$ ,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ), fluorescent labels (e.g., FITC, rhodamine, lanthanide phosphors), luminescent labels such as luminol; enzymatic labels (e.g., horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase, acetylcholinesterase), biotinyl groups (which can be detected by marked avidin e.g., streptavidin containing a fluorescent marker or enzymatic  
15 activity that can be detected by optical or calorimetric methods), predetermined polypeptide epitopes recognized by a secondary reporter (e.g., leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags). In some embodiments, labels are attached via spacer arms of various lengths to reduce potential steric hindrance. Antibodies may also be coupled to electron dense substances, such as ferritin or colloidal gold, which are readily visualised by electron microscopy.

20 The antibody or sample may be immobilized on a carrier or solid support which is capable of immobilizing cells, antibodies etc. For example, the carrier or support may be nitrocellulose, or glass, polyacrylamides, gabbros, and magnetite. The support material may have any possible configuration including spherical (e.g. bead), cylindrical (e.g. inside surface of a test tube or well, or the external surface of a rod), or flat (e.g. sheet, test strip). Indirect methods may also be employed in which the primary  
25 antigen-antibody reaction is amplified by the introduction of a second antibody, having specificity for the antibody reactive against KLK-L Related Protein. By way of example, if the antibody having specificity against a KLK-L Related Protein is a rabbit IgG antibody, the second antibody may be goat anti-rabbit gamma-globulin labeled with a detectable substance as described herein.

Where a radioactive label is used as a detectable substance, a KLK-L Related Protein may be  
30 localized by radioautography. The results of radioautography may be quantitated by determining the density of particles in the radioautographs by various optical methods, or by counting the grains.

#### 4.2 Methods for Identifying or Evaluating Substances/Compounds

The methods described herein are designed to identify substances that modulate the biological activity of a KLK-L Related Protein including substances that bind to KLK-L Related Proteins, or bind to  
35 other proteins that interact with a KLK-L Related Protein, to compounds that interfere with, or enhance the interaction of a KLK-L Related Protein and substances that bind to the KLK-L Related Protein or other proteins that interact with a KLK-L Related Protein. Methods are also utilized that identify compounds that bind to *KLK-L* regulatory sequences.

The substances and compounds identified using the methods of the invention include but are not limited to peptides such as soluble peptides including Ig-tailed fusion peptides, members of random peptide libraries and combinatorial chemistry-derived molecular libraries made of D- and/or L-configuration amino acids, phosphopeptides (including members of random or partially degenerate, directed phosphopeptide libraries), antibodies [e.g. polyclonal, monoclonal, humanized, anti-idiotypic, chimeric, single chain antibodies, fragments, (e.g. Fab, F(ab)<sub>2</sub>, and Fab expression library fragments, and epitope-binding fragments thereof)], and small organic or inorganic molecules. The substance or compound may be an endogenous physiological compound or it may be a natural or synthetic compound.

Substances which modulate a KLK-L Related Protein can be identified based on their ability to bind to a KLK-L Related Protein. Therefore, the invention also provides methods for identifying substances which bind to a KLK-L Related Protein. Substances identified using the methods of the invention may be isolated, cloned and sequenced using conventional techniques. A substance that associates with a polypeptide of the invention may be an agonist or antagonist of the biological or immunological activity of a polypeptide of the invention.

The term "agonist", refers to a molecule that increases the amount of, or prolongs the duration of, the activity of the polypeptide. The term "antagonist" refers to a molecule which decreases the biological or immunological activity of the polypeptide. Agonists and antagonists may include proteins, nucleic acids, carbohydrates, or any other molecules that associate with a polypeptide of the invention.

Substances which can bind with a KLK-L Related Protein may be identified by reacting a KLK-L Related Protein with a test substance which potentially binds to a KLK-L Related Protein, under conditions which permit the formation of substance-KLK-L Related Protein complexes and removing and/or detecting the complexes. The complexes can be detected by assaying for substance-KLK-L Related Protein complexes, for free substance, or for non-complexed KLK-L Related Protein. Conditions which permit the formation of substance-KLK-L Related Protein complexes may be selected having regard to factors such as the nature and amounts of the substance and the protein.

The substance-protein complex, free substance or non-complexed proteins may be isolated by conventional isolation techniques, for example, salting out, chromatography, electrophoresis, gel filtration, fractionation, absorption, polyacrylamide gel electrophoresis, agglutination, or combinations thereof. To facilitate the assay of the components, antibody against KLK-L Related Protein or the substance, or labeled KLK-L Related Protein, or a labeled substance may be utilized. The antibodies, proteins, or substances may be labeled with a detectable substance as described above.

A KLK-L Related Protein, or the substance used in the method of the invention may be insolubilized. For example, a KLK-L Related Protein, or substance may be bound to a suitable carrier such as agarose, cellulose, dextran, Sephadex, Sepharose, carboxymethyl cellulose polystyrene, filter paper, ion-exchange resin, plastic film, plastic tube, glass beads, polyamine-methyl vinyl-ether-maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon, silk, etc. The carrier may be in the shape of, for example, a tube, test plate, beads, disc, sphere etc. The insolubilized protein or substance may be prepared by reacting the material with a suitable insoluble carrier using known chemical or physical

methods, for example, cyanogen bromide coupling.

The invention also contemplates a method for evaluating a compound for its ability to modulate the biological activity of a KLK-L Related Protein of the invention, by assaying for an agonist or antagonist (i.e. enhancer or inhibitor) of the binding of a KLK-L Related Protein with a substance which binds with  
5 a KLK-L Related Protein. The basic method for evaluating if a compound is an agonist or antagonist of the binding of a KLK-L Related Protein and a substance that binds to the protein, is to prepare a reaction mixture containing the KLK-L Related Protein and the substance under conditions which permit the formation of substance-KLK-L Related Protein complexes, in the presence of a test compound. The test compound may be initially added to the mixture, or may be added subsequent to the addition of the KLK-L  
10 Related Protein and substance. Control reaction mixtures without the test compound or with a placebo are also prepared. The formation of complexes is detected and the formation of complexes in the control reaction but not in the reaction mixture indicates that the test compound interferes with the interaction of the KLK-L Related Protein and substance. The reactions may be carried out in the liquid phase or the KLK-L Related Protein, substance, or test compound may be immobilized as described herein. The ability of a  
15 compound to modulate the biological activity of a KLK-L Related Protein of the invention may be tested by determining the biological effects on cells.

It will be understood that the agonists and antagonists i.e. inhibitors and enhancers that can be assayed using the methods of the invention may act on one or more of the binding sites on the protein or substance including agonist binding sites, competitive antagonist binding sites, non-competitive antagonist  
20 binding sites or allosteric sites.

The invention also makes it possible to screen for antagonists that inhibit the effects of an agonist of the interaction of KLK-L Related Protein with a substance which is capable of binding to the KLK-L Related Protein. Thus, the invention may be used to assay for a compound that competes for the same binding site of a KLK-L Related Protein.

25 The invention also contemplates methods for identifying compounds that bind to proteins that interact with a KLK-L Related Protein. Protein-protein interactions may be identified using conventional methods such as co-immunoprecipitation, crosslinking and co-purification through gradients or chromatographic columns. Methods may also be employed that result in the simultaneous identification of genes which encode proteins interacting with a KLK-L Related Protein. These methods include probing  
30 expression libraries with labeled KLK-L Related Protein.

Two-hybrid systems may also be used to detect protein interactions *in vivo*. Generally, plasmids are constructed that encode two hybrid proteins. A first hybrid protein consists of the DNA-binding domain of a transcription activator protein fused to a KLK-L Related Protein, and the second hybrid protein consists of the transcription activator protein's activator domain fused to an unknown protein encoded by  
35 a cDNA which has been recombined into the plasmid as part of a cDNA library. The plasmids are transformed into a strain of yeast (e.g. *S. cerevisiae*) that contains a reporter gene (e.g. lacZ, luciferase, alkaline phosphatase, horseradish peroxidase) whose regulatory region contains the transcription activator's binding site. The hybrid proteins alone cannot activate the transcription of the reporter gene. However,

interaction of the two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is detected by an assay for the reporter gene product.

It will be appreciated that fusion proteins may be used in the above-described methods. In particular, KLK-L Related Proteins fused to a glutathione-S-transferase may be used in the methods.

5       The reagents suitable for applying the methods of the invention to evaluate compounds that modulate a KLK-L Related Protein may be packaged into convenient kits providing the necessary materials packaged into suitable containers. The kits may also include suitable supports useful in performing the methods of the invention.

#### 4.3 Compositions and Treatments

10       The proteins of the invention, substances or compounds identified by the methods described herein, antibodies, and antisense nucleic acid molecules of the invention may be used for modulating the biological activity of a KLK-L Related Protein, and they may be used in the treatment of conditions such as cancer (e.g. prostate, testicular, brain, uterine, thymus, ovarian, colon, ovarian, or breast cancer). Accordingly, the substances, antibodies, peptides, and compounds may be formulated into pharmaceutical  
15       compositions for administration to subjects in a biologically compatible form suitable for administration *in vivo*. By "biologically compatible form suitable for administration *in vivo*" is meant a form of the active substance to be administered in which any toxic effects are outweighed by the therapeutic effects. The active substances may be administered to living organisms including humans, and animals. Administration of a therapeutically active amount of a pharmaceutical composition of the present invention is defined as  
20       an amount effective, at dosages and for periods of time necessary to achieve the desired result. For example, a therapeutically active amount of a substance may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of antibody to elicit a desired response in the individual. Dosage regima may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies  
25       of the therapeutic situation.

      The active substance may be administered in a convenient manner such as by injection (subcutaneous, intravenous, etc.), oral administration, inhalation, transdermal application, or rectal administration. Depending on the route of administration, the active substance may be coated in a material to protect the substance from the action of enzymes, acids and other natural conditions that may inactivate  
30       the substance.

      The compositions described herein can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle. Suitable vehicles are described, for example, in Remington's Pharmaceutical Sciences (Remington's  
35       Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis, the compositions include, albeit not exclusively, solutions of the active substances in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

Based upon their homology to genes encoding kallikrein, nucleic acid molecules of the invention may be also useful in the treatment of conditions such as hypertension, cardiac hypertrophy, arthritis, inflammatory disorders, neurological disorders, and blood clotting disorders.

5 Vectors derived from retroviruses, adenovirus, herpes or vaccinia viruses, or from various bacterial plasmids, may be used to deliver nucleic acid molecules to a targeted organ, tissue, or cell population. Methods well known to those skilled in the art may be used to construct recombinant vectors which will express antisense nucleic acid molecules of the invention. (See, for example, the techniques described in Sambrook et al (supra) and Ausubel et al (supra)).

10 The nucleic acid molecules comprising full length cDNA sequences and/or their regulatory elements enable a skilled artisan to use sequences encoding a protein of the invention as an investigative tool in sense (Yousoufian H and H F Lodish 1993 Mol Cell Biol 13:98-104) or antisense (Eguchi et al (1991) Annu Rev Biochem 60:631-652) regulation of gene function. Such technology is well known in the art, and sense or antisense oligomers, or larger fragments, can be designed from various locations along the coding or control regions.

15 Genes encoding a protein of the invention can be turned off by transfecting a cell or tissue with vectors which express high levels of a desired KLK-L-encoding fragment. Such constructs can inundate cells with untranslatable sense or antisense sequences. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until all copies are disabled by endogenous nucleases.

20 Modifications of gene expression can be obtained by designing antisense molecules, DNA, RNA or PNA, to the regulatory regions of a gene encoding a protein of the invention, ie, the promoters, enhancers, and introns. Preferably, oligonucleotides are derived from the transcription initiation site, eg, between -10 and +10 regions of the leader sequence. The antisense molecules may also be designed so that they block translation of mRNA by preventing the transcript from binding to ribosomes. Inhibition may also be achieved using "triple helix" base-pairing methodology. Triple helix pairing compromises the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Therapeutic advances using triplex DNA were reviewed by Gee J E et al (In: Huber B E and B I Carr (1994) Molecular and Immunologic Approaches, Futura Publishing Co, Mt Kisco N.Y.).

30 Ribozymes are enzymatic RNA molecules that catalyze the specific cleavage of RNA. Ribozymes act by sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. The invention therefore contemplates engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding a protein of the invention.

35 Specific ribozyme cleavage sites within any potential RNA target may initially be identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once the sites are identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets

may also be determined by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Methods for introducing vectors into cells or tissues include those methods discussed herein and which are suitable for *in vivo*, *in vitro* and *ex vivo* therapy. For *ex vivo* therapy, vectors may be introduced  
5 into stem cells obtained from a patient and clonally propagated for autologous transplant into the same patient (See U.S. Pat. Nos. 5,399,493 and 5,437,994). Delivery by transfection and by liposome are well known in the art.

The nucleic acid molecules disclosed herein may also be used in molecular biology techniques that have not yet been developed, provided the new techniques rely on properties of nucleotide sequences that  
10 are currently known, including but not limited to such properties as the triplet genetic code and specific base pair interactions.

The invention also provides methods for studying the function of a polypeptide of the invention. Cells, tissues, and non-human animals lacking in expression or partially lacking in expression of a nucleic acid molecule or gene of the invention may be developed using recombinant expression vectors of the  
15 invention having specific deletion or insertion mutations in the gene. A recombinant expression vector may be used to inactivate or alter the endogenous gene by homologous recombination, and thereby create a deficient cell, tissue, or animal.

Null alleles may be generated in cells, such as embryonic stem cells by deletion mutation. A recombinant gene may also be engineered to contain an insertion mutation that inactivates the gene. Such  
20 a construct may then be introduced into a cell, such as an embryonic stem cell, by a technique such as transfection, electroporation, injection etc. Cells lacking an intact gene may then be identified, for example by Southern blotting, Northern Blotting, or by assaying for expression of the encoded polypeptide using the methods described herein. Such cells may then be fused to embryonic stem cells to generate transgenic non-human animals deficient in a polypeptide of the invention. Germline transmission of the mutation may  
25 be achieved, for example, by aggregating the embryonic stem cells with early stage embryos, such as 8 cell embryos, *in vitro*; transferring the resulting blastocysts into recipient females and; generating germline transmission of the resulting aggregation chimeras. Such a mutant animal may be used to define specific cell populations, developmental patterns and *in vivo* processes, normally dependent on gene expression.

The invention thus provides a transgenic non-human mammal all of whose germ cells and somatic  
30 cells contain a recombinant expression vector that inactivates or alters a gene encoding a KLK-L Related Protein. In an embodiment the invention provides a transgenic non-human mammal all of whose germ cells and somatic cells contain a recombinant expression vector that inactivates or alters a gene encoding a KLK-L Related Protein resulting in a KLK-L Related Protein associated pathology. Further the invention provides a transgenic non-human mammal which does not express a KLK-L Related Protein of the invention.  
35 In an embodiment, the invention provides a transgenic non-human mammal which does not express a KLK-L Related Protein of the invention resulting in a KLK-L Related Protein associated pathology. A KLK-L Related Protein pathology refers to a phenotype observed for a KLK-L Related Protein homozygous mutant.

A transgenic non-human animal includes but is not limited to mouse, rat, rabbit, sheep, hamster, dog, guinea pig, micro-pig, pig, cat, goat, and non-human primates, preferably mouse.

The invention also provides a transgenic non-human animal assay system which provides a model system for testing for an agent that reduces or inhibits a pathology associated with an KLK-L Related Protein, preferably a KLK-L Related Protein associated pathology, comprising:

- (a) administering the agent to a transgenic non-human animal of the invention; and
- (b) determining whether said agent reduces or inhibits the pathology (e.g. KLK-L Related Protein associated pathology) in the transgenic non-human animal relative to a transgenic non-human animal of step (a) which has not been administered the agent.

The agent may be useful in the treatment and prophylaxis of conditions such as cancer as discussed herein. The agents may also be incorporated in a pharmaceutical composition as described herein.

The activity of the proteins, substances, compounds, antibodies, nucleic acid molecules, agents, and compositions of the invention may be confirmed in animal experimental model systems. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the  $ED_{50}$  (the dose therapeutically effective in 50% of the population) or  $LD_{50}$  (the dose lethal to 50% of the population) statistics. The therapeutic index is the dose ratio of therapeutic to toxic effects and it can be expressed as the  $ED_{50}/LD_{50}$  ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred.

The following non-limiting examples are illustrative of the present invention:

## Examples

### Example 1

#### MATERIALS AND METHODS

##### Identification of positive PAC and BAC genomic clones from a human genomic DNA library

The sequence of PSA, KLK1, KLK2, NES1 and Zyme genes is already known. Polymerase chain reaction (PCR)-based amplification protocols have been developed which allowed generation of PCR products specific for each one of these genes. Using these PCR products as probes, labeled with  $^{32}P$ , a human genomic DNA PAC library and a human genomic DNA BAC library was screened for the purpose of identifying positive clones of approximately 100-150 Kb long. The general strategies for these experiments have been published elsewhere (14). The genomic libraries were spotted in duplicate on nylon membranes and positive clones were further confirmed by Southern blot analysis as described (14).

##### DNA sequences on chromosome 19

The Lawrence Livermore National Laboratory participates in the sequencing of the human genome project and focuses on sequencing chromosome 19. Large sequencing information on this chromosome is available at the website of the Lawrence Livermore National Laboratory (<http://www-bio.llnl.gov/genome/gemnome.html>).

Approximately 300 Kb of genomic sequences were obtained from that website, encompassing a region on chromosome 19q13.3 - 13.4, where the known kallikrein genes are localized. This 300 Kb of sequence is represented by 8 contigs of variable lengths. By using a number of different computer



A transgenic non-human animal includes but is not limited to mouse, rat, rabbit, sheep, hamster, dog, guinea pig, micro-pig, pig, cat, goat, and non-human primates, preferably mouse.

The invention also provides a transgenic non-human animal assay system which provides a model system for testing for an agent that reduces or inhibits a pathology associated with an KLK-L Related Protein, preferably a KLK-L Related Protein associated pathology, comprising:

- (a) administering the agent to a transgenic non-human animal of the invention; and
- (b) determining whether said agent reduces or inhibits the pathology (e.g. KLK-L Related Protein associated pathology) in the transgenic non-human animal relative to a transgenic non-human animal of step (a) which has not been administered the agent.

The agent may be useful in the treatment and prophylaxis of conditions such as cancer as discussed herein. The agents may also be incorporated in a pharmaceutical composition as described herein.

The activity of the proteins, substances, compounds, antibodies, nucleic acid molecules, agents, and compositions of the invention may be confirmed in animal experimental model systems. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the  $ED_{50}$  (the dose therapeutically effective in 50% of the population) or  $LD_{50}$  (the dose lethal to 50% of the population) statistics. The therapeutic index is the dose ratio of therapeutic to toxic effects and it can be expressed as the  $ED_{50}/LD_{50}$  ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred.

The following non-limiting examples are illustrative of the present invention:

## Examples

### Example 1

#### MATERIALS AND METHODS

##### Identification of positive PAC and BAC genomic clones from a human genomic DNA library

The sequence of PSA, KLK1, KLK2, NES1 and Zyme genes is already known. Polymerase chain reaction (PCR)-based amplification protocols have been developed which allowed generation of PCR products specific for each one of these genes. Using these PCR products as probes, labeled with  $^{32}P$ , a human genomic DNA PAC library and a human genomic DNA BAC library was screened for the purpose of identifying positive clones of approximately 100-150 Kb long. The general strategies for these experiments have been published elsewhere (14). The genomic libraries were spotted in duplicate on nylon membranes and positive clones were further confirmed by Southern blot analysis as described (14).

##### DNA sequences on chromosome 19

The Lawrence Livermore National Laboratory participates in the sequencing of the human genome project and focuses on sequencing chromosome 19. Large sequencing information on this chromosome is available at the website of the Lawrence Livermore National Laboratory (<http://www-bio.llnl.gov/genome/gemnome.html>).

Approximately 300 Kb of genomic sequences were obtained from that website, encompassing a region on chromosome 19q13.3 - 13.4, where the known kallikrein genes are localized. This 300 Kb of sequence is represented by 8 contigs of variable lengths. By using a number of different computer

programs, an almost contiguous sequence of the region was established as shown diagrammatically in Figure 1 and Figure 28. Some of the contigs were reversed as shown in Figure 1 in order to reconstruct the area on both strands of DNA.

By using the published sequences of PSA, KLK2, NES1 and Zyme and the computer software  
5 BLAST 2, using alignment strategies, the relative positions of these genes on the contiguous map were identified (Figure 28). These known genes served as hallmarks for further studies. An EcoRI restriction map of the area is also available at the website of the Lawrence Livermore National Laboratory. Using this restriction map and the computer program WebCutter (<http://www.firstmarket.com/cutter/cut2.html>), a restriction study analysis of the available sequence was performed to further confirm the assignment and  
10 relative positions of these contigs along chromosome 19. The obtained configuration and the relative location of the known genes are presented in Figure 1.

#### Gene prediction analysis

For exon prediction analysis of the whole genomic area, a number of different computer programs were used. All the programs were initially tested using known genomic sequences of the PSA, Zyme, and  
15 NES1 genes. The more reliable computer programs, GeneBuilder (gene prediction), GeneBuilder (exon prediction), Grail 2 and GENEID-3 were selected for further use.

#### Protein homology searching

Putative exons of the new genes were first translated to the corresponding amino acid sequences. BLAST homology searching for the proteins encoded by the exons of the putative new genes were  
20 performed using the BLASTP program and the Genbank databases.

### RESULTS

#### Relative position of PSA, KLK2, Zyme and NES1 on Chromosome 19

Screening of the human BAC library identified two clones which were positive for the Zyme gene (clones BAC 288H1 and BAC 76F7). These BACs were further analyzed by PCR and primers specific for  
25 PSA, NES1, KLK1 and KLK2. These analyses indicated that both BACs were positive for Zyme, PSA and KLK2 and negative for KLK1 and NES1 genes.

Screening of the human PAC genomic library identified a PAC clone which was positive for NES1 (clone PAC 34B1). Further PCR analysis indicated that this PAC clone was positive for NES1 and KLK1 genes and negative for PSA, KLK2 and Zyme. Combination of this information with the EcoRI  
30 restriction map of the region allowed establishment of the relative positions of these four genes. PSA is the most centromeric, followed by KLK2, Zyme and NES1. Further alignment of the known sequences of these genes with the 300 Kb contig enabled precise localization of all four genes and determination of the direction of transcription, as shown by the arrows in Figure 1. The KLK1 gene sequence was not identified on any of these contigs and appears to be further telomeric to NES1 (since it is co-localized on the same  
35 PAC as NES1).

#### Identification of new genes

A set of rules was used to consider the presence of a new gene in the genomic area of interest as follows:

1. Clusters of at least 3 exons should be found.
2. Only exons with high prediction score ("good" or "excellent" quality, as indicated by the searching programs) were considered for the construction of the putative new genes.
3. Exons predicted were reliable only if they were identified by at least two different exon prediction programs.

By using this strategy, eleven putative new genes were identified of which three were found on subsequent homology analysis to be known genes not previously mapped i.e. the human stratum corneum chymotrypsin enzyme (HSCCE), human neuropsin, and trypsin-like serine protease (TLSP). Their relative location is shown in Figure 1. The five genes all have variable homologies with known human or animal kallikrein proteins and/or other known serine proteases (depicted as KLK-L1, KLK-L2, KLK-L3, KLK-L4 and KLK-L5 in Figure 1 and KLK-L1 to KLK-L6 in Figure 28).

In Tables 1 to 5, the preliminary exon structure and partial protein sequence for each one of the newly identified genes is shown. In Table 6, some proteins are presented which appear, on preliminary analysis, to be homologous to the proteins encoded by the putative new genes. SEQ. ID. NOs. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, and 67 show amino acid sequences of KLK-L1-KLK-L6, and SEQ. ID. NOs. 1, 13, 21, 43, 56, and 65 show nucleic acid sequences of the genes encoding KLK-L1- KLK-L6.

## DISCUSSION

Prediction of protein-coding genes in newly sequenced DNA becomes very important after the establishment of large genome sequencing projects. This problem is complicated due to the exon-intron structure of the eukaryotic genes which interrupts the coding sequence in many unequal parts. In order to predict the protein-coding exons and overall gene structure, a number of computer programs were developed. All these programs are based on the combination of potential functional signals with the global statistical properties of known protein-coding regions (15). However, the most powerful approach for gene structure prediction is to combine information about potential functional signals (splice sites, translation start or stop signal etc.) together with the statistical properties of coding sequences (coding potential) along with information about homologies between the predicted protein and known protein families (16).

In mouse and rat, kallikreins are encoded by large multigene families and these genes tend to cluster in groups with a distance as small as 3.3 – 7.0 Kb (3). A strong conservation of gene order between human chromosome 19q13.1 – q13.4 and 17 loci in a 20-cM proximal part of mouse chromosome 7, including the kallikrein locus, has been documented (17).

In humans, only a few kallikrein genes were identified. In fact, only KLK1, KLK2 and KLK3 (PSA) are considered to represent the human kallikrein gene family (9). The work described herein provides strong evidence that a large number of kallikrein-like genes are clustered within a 300Kb region around chromosome 19q13.2 – q13.4. The three established human kallikreins (KLK1, KLK2, KLK3), Zyme and NES1, as well as the stratum corneum chymotryptic enzyme, neuropsin, and TLSP (trypsin-like serine protease) and another five new genes, KLK-L1 to KLK-L5, may constitute a large gene family. This will bring the total number of kallikrein or kallikrein-like genes in this region of chromosome 19 to thirteen.

The human stratum corneum chymotryptic enzyme (19), neuropsin (20) and trypsin-like serine

protease (TLSP) (21) are three previously characterized genes which have many structural similarities with the kallikreins and other members of the serine protease family. However, they have not been mapped in the past. Their precise mapping in the region of the kallikrein gene family indicates that these three genes, along with the ones that were newly identified, or are already known, constitute a family that likely  
5 originated by duplication of an ancestral gene. The relative localization of all these genes is depicted in Figure 1.

Kallikrein genes are a subfamily of serine proteases, traditionally characterized by their ability to liberate lysyl-bradykinin (kallidin) from kininogen (18). More recently, however, a new, structural concept has emerged to describe kallikreins. From accumulated sequence data, it is now clear that the mouse has  
10 many genes with high homology to kallikrein coding sequences (19-20). Richard and co-workers have contributed to the concept of a " kallikrein multigene family" to refer to these genes (21-22). This definition is not based much on specific enzymatic function of the gene product, but more on its sequence homology and their close linkage on mouse chromosome 7. In humans, only KLK1 meets the functional definition of a kallikrein. KLK2 has trypsin-like enzymatic activity and KLK3 (PSA) has very weak  
15 chymotrypsin-like enzymatic activity. These activities of KLK2 and KLK3 are not known to liberate biologically active peptides from precursors. Based on the newer definition, members of the kallikrein family include, not only the gene for the kallikrein enzyme, but also genes encoding other homologous proteases, including the enzyme that processes the precursors of the nerve growth factor and epidermal growth factor (8). Therefore, it is important to note the clear distinction between the enzyme kallikrein and  
20 a kallikrein or a kallikrein-like gene.

In carrying out the study only exons were considered which were predicted with "good" or "excellent" quality and only exons were considered which were predicted by at least two different programs. Moreover, the presence of a putative gene was only considered when at least three exons clustered coordinately in that region. Additional evidence that these new genes are indeed homologous to  
25 the known kallikreins and other serine proteases comes from comparison of the intron phases. As published previously (14), trypsinogen, PSA and NES1 have 5 coding exons of which the first has intron phase I (the intron occurs after the first nucleotide of the codon), the second has intron phase II (the intron occurs after the second nucleotide and the codon), the third has intron phase I and the fourth has intron phase 0 (the intron occurs between codons). The fifth exon contains the stop codon. The intron phases of the predicted  
30 new kallikrein-like genes follow these rules and are shown in the respective tables. Further support comes from the identification in the new genes, of the conserved amino acids of the catalytic domain of the serine proteases, as presented in Tables 1 - 5.

In order to test the accuracy of the computer programs, known genomic areas containing the PSA, Zyme and KLK2 genes were tested. Two of these programs (Grail 2 and GeneBuilder) were able to detect  
35 about 95% of the tested known genes. Matches with expressed sequence tag sequences (EST) can also be employed for gene structure prediction in the GeneBuilder program and this can significantly improve the power of the program especially at high stringency (e.g. >95% homology).

In mouse, ten of the kallikrein genes appear to be pseudogenes (9).

## Example 2

### PROSTASE/KLK-L1 in prostate and breast tissues

The fine mapping of the prostase/KLK-L1 gene and its chromosomal localization in relation to a number of other homologous genes also mapping to the same region are described. In addition, extensive  
 5 tissue expression studies were carried out that demonstrate that, in addition to prostate (which shows the highest expression), that prostase/KLK-L1 is also expressed in female breasts, testis, adrenals, uterus, colon, thyroid, brain, spinal cord and salivary glands. Furthermore, the gene is up-regulated by androgens and progestins in the breast carcinoma cell line BT-474.

### Materials and Methods

#### 10 DNA sequences on chromosome 19

Large DNA sequencing data for chromosome 19 is available at the web site of the Lawrence Livermore National Laboratory (LLNL) (<http://www-bio.llnl.gov/genome/genome.html>). Approximately 300 Kb of genomic sequence was obtained from that web site, encompassing a region on chromosome 19q13.3 - 13.4, where the known kallikrein genes are localized. This sequence is represented by 9 contigs  
 15 of variable lengths. By using the sequences of PSA, KLK2, NES1 and protease M and the alignment program BLAST 2 (37), the relative positions of these genes on the contiguous map were located.

### Gene prediction analysis

For exon prediction analysis of the whole genomic area, a number of different computer programs were used. Originally all these programs were tested using the known genomic sequences of the PSA,  
 20 protease M and NES1 genes. The most reliable computer programs GeneBuilder (gene prediction) (<http://l25.itba.mi.cnr.it/~webgene/genebuilder.html> ) GeneBuilder (exon prediction) [<http://l25.itba.mi.cnr.it/~webgene/genebuilder.html>] , Grail 2 [<http://compbio.ornl.gov> ], and GENEID-3 [<http://apolo.imim.es/geneid.html>] were selected for further use.

### Protein homology searching

25 Putative exons of the newly identified gene were first translated to the corresponding amino acid sequences. BLAST homology searching for the proteins encoded by the exons were performed using the BLASTP program and the GenBank databases (37).

### Searching expressed sequence tags (ESTs)

Sequence homology searching was performed using the BLASTN algorithm (37) on the National  
 30 Center for Biotechnology Information web server (<http://www.ncbi.nlm.nih.gov/BLAST/>) against the human EST database (dbEST). Clones with > 95% homology were obtained from the I.M.A.G.E. (38) consortium through Research Genetics Inc, Huntsville, AL and from The Institute for Genomic Research (TIGR) (<http://WWW.TIGR.ORG/tdb/tdb.html>) (Table 7). Clones were propagated, purified and then sequenced from both directions with an automated sequencer, using insert-flanking vector primers.

#### 35 Breast cancer cell line and stimulation experiments

The breast cancer cell line BT-474 was purchased from the American Type Culture Collection (ATCC), Rockville, MD. BT-474 cells were cultured in RPMI media (Gibco BRL, Gaithersburg, MD) supplemented with glutamine (200 mmol/L), bovine insulin (10 mg/L), fetal bovine serum (10%),

antibiotics and antimycotics, in plastic flasks, to near confluency. The cells were then aliquoted into 24-well tissue culture plates and cultured to 50% confluency. 24 hours before the experiments, the culture media were changed into phenol red-free media containing 10% charcoal-stripped fetal bovine serum. For stimulation experiments, various steroid hormones dissolved in 100% ethanol were added into the culture media, at a final concentration of  $10^{-8}$  M. Cells stimulated with 100% ethanol were included as controls. The cells were cultured for 24 hours, then harvested for mRNA extraction.

#### Reverse transcriptase polymerase chain reaction

Total RNA was extracted from the breast cancer cells using Trizol reagent (Gibco BRL) following the manufacturer's instructions. RNA concentration was determined spectrophotometrically. 2 µg of total RNA was reverse transcribed into first strand cDNA using the Superscript™ preamplification system (Gibco BRL). The final volume was 20 µl. Based on the combined information obtained from the predicted genomic structure of the new gene and the EST sequences, two gene-specific primers were designed (Table 8), PCR was carried out in a reaction mixture containing 1 µl of cDNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 200 µM dNTPs (deoxynucleoside triphosphates), 150 ng of primers and 2.5 units of AmpliTaq Gold DNA polymerase (Roche Molecular Systems, Branchburg, NJ, USA) on a Perkin-Elmer 9600 thermal cycler. The cycling conditions were 94°C for 9 minutes to activate the Taq Gold DNA polymerase, followed by 43 cycles of 94°C for 30 s, 63°C for 1 minute and a final extension at 63°C for 10 min. Equal amounts of PCR products were electrophoresed on 2% agarose gels and visualized by ethidium bromide staining. All primers for RT-PCR spanned at least 2 exons to avoid contamination by genomic DNA.

#### Tissue expression of KLK-L1

Total RNA isolated from 26 different human tissues was purchased from Clontech, Palo Alto, CA. cDNA was prepared as described above for the tissue culture experiments and used for PCR reactions with the primers described in Table 8 (SEQ. ID. Nos 5-12). Tissue cDNAs were amplified at various dilutions.

#### Cloning and sequencing of the PCR products

To verify the identity of the PCR products, they were cloned into the pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The inserts were sequenced from both directions using vector-specific primers, by an automated DNA sequencer.

### Results

#### Identification of the prostate/KLK-L1 gene

The exon prediction strategy of the 300Kb DNA sequences around chromosome 19q13.3 - q13.4 identified a novel gene with a structure reminiscent of a serine protease. The major features of this gene were its homology, at the amino acid and DNA level, with other human kallikrein genes; the conservation of the catalytic triad (histidine, aspartic acid, and serine), the number of exons and the complete conservation of the intron phases.

#### EST sequence homology search

EST sequence homology search of the putative exons obtained from the gene prediction programs (as described above) against the human EST database (dbEST) revealed five expressed sequence tags

(ESTs) with >95 % identity to the putative exons of the gene (Table 7). Positive clones were obtained and the inserts were sequenced from both directions. Alignment was used to compare between the EST sequences and the exons predicted by the computer programs, and final selection of the exon-intron splice sites was made according to the EST sequences. Furthermore, many of the ESTs were overlapping, further ensuring the accuracy of the data.

The coding sequence of the klk-L2 gene is shown in SEQ. ID. NO. 1 and GenBank Accession # AF135023. The exons of the gene are as follows: exon 1 (939-999); exon 2 (2263-2425); exon 3 (2847-3097); exon 4 (3181-3317); and exon 5 (4588-4740). The amino acid sequence of KLK-L2 proteins are shown in SEQ. ID. Nos. 2 and 3.

#### 10 Mapping and chromosomal localization of prostate /KLK-L1 gene

Alignment of the prostate/ KLK-L1 sequence and the sequences of other known kallikrein genes within the 300 Kb area of the contigs constructed at the Lawrence Livermore National Laboratory enabled precise localization of all genes and to determine the direction of transcription, as shown in Figure 2. The distance between PSA and KLK2 genes was calculated to be 12,508 bp. The prostate/KLK-L1 gene is 15 26,229 bp more telomeric to KLK2 and transcribes in the opposite direction. The zyme gene is about 51 Kb more telomeric to the prostate gene and transcribes in the same direction. The human stratum corneum chymotryptic enzyme gene, the neuropsin gene and the NES 1 gene are all further telomeric to zyme and all transcribe in the same direction as zyme.

#### Tissue expression of the prostate/KLK-L1 gene

20 The tissues that express the prostate/KLK-L1 gene were assessed by RT-PCR. The experiments were performed at various dilutions of the cDNAs to obtain some information about the relative levels of expression. RT-PCR for actin was used as a positive control and RT-PCR for the PSA cDNA was used as another positive control with tissue restricted specificity. Positive ESTs for prostate/KLK-L1 were used as controls for the PCR procedure. The PSA gene was found to be highly expressed in the prostate, as 25 expected, and to a lower extent in mammary and salivary glands as also expected from recent literature reports (24, 25). Very low expression of PSA in the thyroid gland, trachea and testis was also found, a finding that accords with recent RT-PCR data by others (26).

The tissue expression of prostate/KLK-L1 is summarized in Table 9 and Figure 3. This protease is primarily expressed in the prostate, testis, adrenals, uterus, thyroid, colon, central nervous system and 30 mammary tissues, and, at much lower levels in other tissues. The specificity of the RT-PCR procedure was verified for prostate/KLK-L1 by cloning the PCR products from mammary, testicular and prostate tissues and sequencing them. One example with mammary tissue is shown in Figure 4. All cloned PCR products were identical in sequence to the cDNA sequence reported for the prostate/KLK-L1.

#### Hormonal regulation of the prostate/KLK-L1 gene

35 The steroid hormone receptor-positive breast carcinoma cell line BT-474 was used as a model system to evaluate whether prostate/KLK-L1 expression is under steroid hormone regulation. As shown in Figure 5, the controls worked as expected i. e., actin positivity without hormonal regulation in all cDNAs, only estrogen up-regulation of the pS2 gene and up-regulation of the PSA gene by androgens and

progestins. Prostase/KLK-L1 is up-regulated primarily by androgens and progestins, similarly to PSA. This up-regulation was dose-dependent and it was evident at steroid hormone levels  $\geq 10^{-10}$  M.

## DISCUSSION

The KLK3 gene encodes for PSA, a protein that currently represents the best tumor marker available (24). Since in rodents there are so many kallikrein genes, the restriction of this family to only 3 genes in humans was somewhat surprising. More recently, new candidate kallikrein genes in humans have been discovered, including NES1 (13) and zyme/protease M/neurosin (10-12). The known kallikreins and the newly discovered kallikrein-like genes share the following similarities: (a) they encode serine proteases (b) they have five coding exons (c) they share significant DNA and protein homologies with each other (d) they map in the same locus on chromosome 19q13.3-q13.4, a region that is structurally similar to an area on mouse chromosome 7, where all the mouse kallikrein genes are localized (e) they appear to be regulated by steroid hormones. Prostase/KLK-L1 is a member of the same family since these common characteristics are also shared by the newly discovered gene.

The exact localization of the KLK-L1 gene and its position in relation to other genes in the area (Figure 2) was determined. Prostase/KLK-L1 lies between KLK2 and zyme.

Irwin et al. (27) have proposed that the serine protease genes can be classified into five different groups according to intron position. The established kallikreins (KLK1, KLK2, and PSA), trypsinogen and chymotrypsinogen belong to a group that has: (1) an intron just downstream from the codon for the active site histidine residue, (2) a second intron downstream from the exon containing the codon for the active site aspartic acid residue, and (3) a third intron just upstream from the exon containing the codon for the active site serine residue. As seen in Figure 6, the genomic organization of prostase/KLK-L1 gene is very similar to this group of genes. The lengths of the coding parts of exons 1-5 are 61, 163, 263, 137 and 153 bp, respectively, which are close or identical to the lengths of the exons of the kallikrein genes and also, similar or identical to those of other newly discovered genes in the same chromosomal region like the NES1(14), zyme/protease M/neurosin (10-12) and neuropilin (28) genes.

The sensitive RT-PCR protocol reveals that the KLK-L1 enzyme is expressed in prostatic tissue and it is also expressed in significant amounts in other tissues, including testis, female mammary gland, adrenals, uterus, thyroid, colon, brain, lung and salivary glands (Figure 3 and Table 9). The specificity of the RT-PCR primers was verified by sequencing the obtained PCR products, with one example shown in Figure 4 (SEQ.ID.NO. 4). Tissue culture studies with the breast carcinoma cell line BT-474 further confirm not only the ability of these cells to produce prostase/KLK-L1 but also its hormonal regulation (Figure 5).

An interesting theme is now developing involving the group of homologous genes on chromosome 19q13.3(PSA, KLK2, prostase, zyme, and NES1). The combined data suggest that all of them are expressed in prostate and breast tissues, and all of them are hormonally regulated. All these genes may be part of a cascade pathway that plays a role in cell proliferation, differentiation or apoptosis by regulating (positively or negatively) growth factors or their receptors or cytokines, through proteolysis (30). Also interesting is the linkage of locus 19q13 to solid tumors and gliomas (31) which raises the possibility that some of the genes in the region may be disrupted by rearrangements.



The KLK-L1 gene encodes for a serine protease that shows homology with other members of the kallikrein gene family and maps to the same chromosomal location. Many structural features of the kallikreins are conserved in prostase/KLK-L1. The precise mapping of this gene between the two known genes KLK2 and zyme is presented. It is further demonstrated that prostase/KLK-L1 is expressed in many tissues, in addition to the prostate, including the female breast. This gene is also herein referred to as 'prostase'. It has been further demonstrated, using breast carcinoma cell lines, that prostase/KLK-L1 can be produced by these cells and that its expression is significantly up-regulated by androgens and progestins. Based on information for other homologous genes in the area (PSA, zyme, and NES1), prostase/KLK-L1 may be involved in the pathogenesis and/or progression of prostate, breast and possibly other cancers.

### Example 3

#### IDENTIFICATION OF THE KLK-L2 GENE

##### Materials and Methods

##### DNA sequence on chromosome 19

Sequencing data of approximately 300Kb of nucleotides on chromosome 19q13.3-q13.4 was obtained from the web site of the Lawrence Livermore National Laboratory (LLNL) (<http://www-bio.llnl.gov/genome/genome.html>). This sequence was in the form of 9 contigs of different lengths. A restriction analysis study of the available sequences was performed using the "WebCutter" computer program (<http://www.firstmarket.com/cutter/cut2.html>) and with the aid of the EcoRI restriction map of this area (also available from the LLNL web site) an almost contiguous stretch of genomic sequences was constructed. The relative positions of the known kallikrein genes: PSA (GenBank accession # X14810), KLK2 (GenBank accession # M18157), and zyme (GenBank accession # U60801) was determined using the alignment program BLAST 2 (37).

##### New Gene Identification

A number of computer programs were used to predict the presence of putative new genes in the genomic area of interest. These programs were initially tested using the known genomic sequences of the PSA, protease M and NES1 genes. The most reliable computer programs GeneBuilder (gene prediction) (<http://l25.itba.mi.cnr.it/~webgene/genebuilder.html>) GeneBuilder (exon prediction) (<http://l25.itba.mi.cnr.it/~webgene/genebuilder.html>), Grail 2 (<http://compbio.ornl.gov>) and GENEID-3 (<http://apollo.imim.es/geneid.html>) were selected for further use.

##### Expressed sequence tag (EST) searching

The predicted exons of the putative new gene were subjected to homology search using the BLASTN algorithm (37) on the National Center for Biotechnology Information web server (<http://www.ncbi.nlm.nih.gov/BLAST/>) against the human EST database (dbEST). Clones with > 95% homology were obtained from the I.M.A.G.E. consortium (38) through Research Genetics Inc, Huntsville, AL (Table 10). The clones were propagated, purified and sequenced from both directions with an automated sequencer, using insert-flanking vector primers.

##### Rapid amplification of cDNA ends (5' RACE)

According to the EST sequence data and the predicted structure of the gene, two gene-specific primers were designed (R1 & R2) (Table 11). Two rounds of RACE reactions (nested PCR) were performed with 5µl Marathon Ready™ cDNA of human testis (Clontech, Palo Alto, CA, USA) as a template. The reaction mix and PCR conditions were conducted according to the manufacturer's recommendations. In brief, denaturation was done for 5 min at 94°C followed by 94° C for 5 sec followed by 72°C for 2 min for 5 cycles, then 94°C for 5 sec followed by 70° C for 2 min for 5 cycles then 94°C for 5 sec followed by 65°C for 2 min for 30 cycles for the first reaction and 25 cycles for the nested PCR reaction.

#### **Tissue expression**

Total RNA isolated from 26 different human tissues was purchased from Clontech, Palo Alto, CA. cDNA was prepared as described below for the tissue culture experiments and used for PCR reactions with the primers described in Table 11 (SEQ. ID. Nos 9-12, 15-20). Tissue cDNAs were amplified at various dilutions.

#### **Breast cancer cell line and hormonal stimulation experiments**

The breast cancer cell line BT-474 was purchased from the American Type Culture Collection (ATCC), Rockville, MD. Cells were cultured in RPMI media (Gibco BRL, Gaithersburg, MD) supplemented with glutamine (200 mmol/L), bovine insulin (10 mg/L), fetal bovine serum (10%), antibiotics and antimycotics, in plastic flasks, to near confluency. The cells were then aliquoted into 24-well tissue culture plates and cultured to 50% confluency. 24 hours before the experiments, the culture media were changed into phenol red-free media containing 10% charcoal-stripped fetal bovine serum. For stimulation experiments, various steroid hormones dissolved in 100% ethanol were added into the culture media, at a final concentration of  $10^{-8}$  M. Cells stimulated with 100% ethanol were included as controls. The cells were cultured for 24 hours, then harvested for mRNA extraction

#### **Reverse transcriptase polymerase chain reaction**

Total RNA was extracted from the breast cancer cells using Trizol reagent (Gibco BRL) following the manufacturer's instructions. RNA concentration was determined spectrophotometrically. 2 µg of total RNA was reverse-transcribed into first strand cDNA using the Superscript™ preamplification system (Gibco BRL). The final volume was 20 µl. Based on the combined information obtained from the predicted genomic structure of the new gene and the EST sequences, two gene-specific primers were designed (Table 11) and PCR was carried out in a reaction mixture containing 1 µl of cDNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 200 µM dNTPs (deoxynucleoside triphosphates), 150 ng of primers and 2.5 units of AmpliTaq Gold DNA polymerase (Roche Molecular Systems, Branchburg, NJ, USA) on a Perkin-Elmer 9600 thermal cycler. The cycling conditions were 94°C for 9 minutes to activate the Taq Gold DNA polymerase, followed by 43 cycles of 94°C for 30 s, 63°C for 1 minute and a final extension at 63°C for 10 min. Equal amounts of PCR products were electrophoresed on 2% agarose gels and visualized by ethidium bromide staining. All primers for RT-PCR spanned at least 2 exons to avoid contamination by genomic DNA.

To verify the identity of the PCR products, they were cloned into the pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The inserts were sequenced from both directions using vector-specific primers, with an automated DNA sequencer.

#### Structure analysis

5 Multiple alignment was performed using the Clustal X software package available at: <ftp://ftp.ebi.ac.uk/pub/software/dos/clustalw/clustalx/> (clustalx1.64b.msw.exe) and the multiple alignment program available from the Baylor College of Medicine (BCM), Houston, TX, USA ([kiwi.imgen.bcm.tmc.edu:8808/search-launcher/launcher/html](http://kiwi.imgen.bcm.tmc.edu:8808/search-launcher/launcher/html)). Phylogenetic studies were performed using the Phylip software package available at: <http://evolution.genetics.washington.edu/phylip/getme.html>. Distance matrix analysis  
10 was performed using the "Neighbor-Joining/UPGMA" program and parsimony analysis was done using the "Protpars" program. Hydrophobicity study was performed using the BCM search launcher programs (<http://dot.imgen.bcm.tmc.edu:9331/seq-search/struc-predict.html>). Signal peptide was predicted using the "SignalP" server (<http://www.cbs.dtu.dk/services/signal>). Protein structure analysis was performed by "SAPS" (structural analysis of protein sequence) program (<http://dot.imgen.bcm.tmc.edu:9331/seq-search/struc-predict.html>).  
15

#### RESULTS

Computer analysis of the genomic sequence predicted a putative new gene consisting of four exons. This gene was detected by all programs used and all exons had high prediction scores. EST sequence homology search of the putative exons against the human EST database (dbEST) revealed nine  
20 expressed sequence tag (EST) clones from different tissues with >95 % identity to the putative exons of the gene (Table 10). Positive clones were obtained and the inserts were sequenced from both directions. The "Blast 2 sequences" program was used to compare the EST sequences with the predicted exons, and final selection of the exon-intron splice sites was done according to the EST sequences. The presence of many areas of overlap between the various EST sequences allowed further verification of the structure of  
25 the new gene. The coding sequence of the gene is shown in SEQ. ID. NO. 13 and GenBank Accession #AF135028. The 3' end of the gene was verified by the presence of poly A stretches that are not present in the genomic sequence at the end of two of the sequenced ESTs. One of the sequenced ESTs revealed the presence of an additional exon at the 5' end. The nucleotide sequence of this exon matches exactly with the genomic sequence. To further identify the 5' end of the gene, 5' RACE was performed but no additional  
30 sequence could be obtained. However, as is the case with other kallikreins, the presence of further upstream untranslated exon(s) could not be excluded. The amino acid sequence of KLK-L2 is shown in SEQ. ID. No. 14.

#### Mapping and chromosomal localization of the KLK-L2 gene

35 Alignment of KLK-L2 gene and the sequences of other known kallikrein genes within the 300 Kb area of interest enabled precise localization of all genes and determination of the direction of transcription, as shown by the arrows in Figure 8. The PSA gene was found to be the most centromeric, separated by 12,508 base pairs (bp) from KLK2, and both genes are transcribed in the same direction (centromere to telomere). The prostase/KLK-L1 gene is 26,229 bp more telomeric and transcribes in the opposite

direction, followed by KLK-L2. The distance between KLK-L1 and KLK-L2 is about 35 Kilobases (Kb). The zyme gene is 5,981 bp more telomeric and the latter 3 genes are all transcribed in the same direction (Figure 8).

#### **Structural characterization of the KLK-L2 gene and its protein product**

5           The KLK-L2 gene, as presented in Figure 7, is formed of 5 coding exons and 4 intervening introns, spanning an area of 9,349 bp of genomic sequence on chromosome 19q13.3-q13.4. The lengths of the exons are 73, 262, 257, 134, and 156 bp, respectively. The intron/exon splice sites (mGT....AGm) and their flanking sequences are closely related to the consensus splicing sites (-mGTAAGT ...CAGm-) (32). The presumptive protein coding region of the KLK-L2 gene is formed of 879 bp nucleotide sequence encoding  
10 a deduced 293-amino acid polypeptide with a predicted molecular weight of 32 KDa. There are two potential translation initiation codons (ATG) at positions 1 and 25 of the predicted first exon (numbers refer to SEQ. ID. NO. 13 and GenBank Accession #AF135028). It is assumed that the first ATG will be the initiation codon, since : (1) the flanking sequence of that codon (GCGGCCATGG) matches closely with the Kozak consensus sequence for initiation of translation (GCC A/G CCATGG) (33) and is exactly the  
15 same as that of the homologous zyme gene. At this initiation codon, the putative signal sequence at the N-terminus is similar to other trypsin-like serine proteases (prostase and EMSP) (Figure 9). The cDNA ends with a 328 bp of 3' untranslated region containing a conserved poly adenylation signal (AATAAA) located 11 bp up-stream of the poly A tail ( at a position exactly the same as that of the zyme poly A tail)(11).

A hydrophobicity study of the KLK-L2 gene shows a hydrophobic region in the N-terminal region  
20 of the protein (Figure 10), suggesting that a presumed signal peptide is present. By computer analysis, a 29-amino acid signal peptide is predicted with a cleavage site at the carboxyl end of Ala<sup>29</sup>. For better characterization of the predicted structural motif of the KLK-L2 protein, it was aligned with other members of the kallikrein multi-gene family, (Figure 9), and the predicted signal peptide cleavage site was found to match with the predicted signal cleavage sites of zyme (11), KLK1(1), KLK2 (8), and KLK-L1. Also,  
25 sequence alignment supports, by analogy, the presence of a cleavage site at the carboxyl end of Ser<sup>66</sup>, which is the exact site predicted for cleavage of the activation peptide of all the other kallikreins aligned in Figure 9. Interestingly, the starting amino acid sequence of the mature protein (I I N G (S) D C ) is conserved in the prostase and enamel matrix serine proteinase 1 (EMSP) genes. Thus, like other kallikreins, KLK-L2 is likely also synthesized as a preproenzyme that contains an N-terminal signal peptide (prezymogen)  
30 followed by an activation peptide and the enzymatic domain.

The presence of aspartate (D) in position 239 suggests that KLK-L2 will possess a trypsin-like cleavage pattern like most of the other kallikreins (e.g., KLK1, KLK2, TLSP, neuropsin, zyme, prostase, and EMSP) but different from PSA which has a serine (S) residue in the corresponding position, and is known to have a chymotrypsin like activity (Figure 9). The dotted region in Figure 9 indicates an 11-amino  
35 acid loop characteristic of the classical kallikreins (PSA, KLK1, and KLK2) but not found in KLK-L2 or other members of the kallikrein-like gene family (11).

#### **Homology with the kallikrein multi-gene family**

The mature 227-amino acid sequence of the predicted protein was aligned against the GenBank

database and the known kallikreins using the "BLASTP" and "BLAST 2 sequence" programs. KLK-L2 is found to have 54% amino acid sequence identity and 68% similarity with the enamel matrix serine proteinase 1 (EMSP1) gene, 50% identity with both trypsin like serine protease (TLSP) and neuropsin genes and 47%, 46%, and 42% identity with trypsinogen, zyme, and PSA genes, respectively. The multiple alignment study shows that the typical catalytic triad of serine proteases is conserved in the KLK-L2 gene (H<sup>108</sup>, D<sup>153</sup>, and S<sup>245</sup>) and, as the case with all other kallikreins, a well conserved peptide motif is found around the amino acid residues of the catalytic triad [i.e., histidine (WLLTAAHC), serine(GDSGGP), and aspartate(DLMLI) ] (10, 11).

Twelve cysteine residues are present in the putative mature KLK-L2 protein, ten of them are conserved in all the serine proteases that are aligned in Figure 9, and would be expected to form disulphide bridges. The other two cysteines (C<sup>178</sup> and C<sup>279</sup>) are not found in PSA, KLK1, KLK2 or trypsinogen, however, they are found in similar positions in prostase, EMSP1, zyme, neuropsin, and TLSP genes and are expected to form an additional disulphide bond. Twenty nine "invariant" amino acids surrounding the active site of serine proteases have been described (39). Of these, twenty-six are conserved in KLK-L2. One of the non-conserved amino acids (Ser<sup>210</sup> instead of Pro) is also found in prostase and EMSP1 genes, the second (Leu<sup>103</sup> instead of Val) is also found in TLSP gene, and the third (Val<sup>174</sup> instead of Leu) is also not conserved in prostase or EMSP1 genes. According to protein evolution studies, each of these amino acid changes represents a conserved evolutionary substitution to a protein of the same group (39).

#### Evolution of the KLK-L2 gene

To predict the phylogenetic relatedness of the KLK-L2 gene with other serine proteases, the amino acid sequences of the kallikrein genes were aligned together using the "Clustal X" multiple alignment program and a distance matrix tree was predicted using the Neighbor-joining/UPGMA method (Figure 10). Phylogenetic analysis separated the classical kallikreins (KLK1, KLK2, and PSA) and grouped the KLK-L2 with KLK-L1, EMSP1, and TLSP (40, 41).

#### Tissue expression of the KLK-L2 gene

As shown in Table 12 and Figure 11, the KLK-L2 gene is primarily expressed in the brain, mammary gland, and testis but lower levels of expression are found in many other tissues. In order to verify the RT-PCR specificity, the PCR products were cloned and sequenced.

#### Hormonal regulation of the KLK-L2 gene

A steroid hormone receptor positive breast cancer cell line (BT-474) was used as a model to verify whether the KLK-L2 gene is under steroid hormone regulation. PSA was used as a control known to be upregulated by androgens and progestins and pS2 as an estrogen upregulated control. The results indicate that KLK-L2 is up-regulated by estrogens and progestins (Figure 12).

#### Expression of KLK-L2 in Ovarian Tissues

KLK-L2 is up-regulated (overexpressed) in ovarian tumors (Figure 13).

#### Discussion

With the aid of computer programs for gene prediction and the available EST database, a new gene, named KLK-L2 (for kallikrein like gene 2) was identified. The 3' end of the gene was verified by the

presence of "poly A" stretches in the sequenced ESTs which were not found in the genomic sequence, and the start of translation was identified by the presence of a start codon in a well conserved consensus Kozak sequence.

As is the case with other kallikreins, the KLK-L2 gene is composed of 5 coding exons and 4  
5 intervening introns and, except for the second coding exon, the exon lengths are comparable to those of other members of the kallikrein gene family (Figure 6). The exon-intron splice junctions were identified by comparing the genomic sequence with the EST sequence and were further confirmed by the conservation of the consensus splice sequence (-mGT.....AGm-) (32), and the fully conserved intron phases, as shown in Figure 6. Furthermore, the position of the catalytic triad residues in relation to the different exons is also  
10 conserved (Figure 6). As is the case with most other kallikreins, except PSA and HSCCE, KLK-L2 is more functionally related to trypsin than to chymotrypsin (34). The wide range of tissue expression of KLK-L2 should not be surprising since, by using the more sensitive RT-PCR technique instead of Northern blot analysis, many kallikrein genes were found to be expressed in a wide variety of tissues including salivary gland, kidney, pancreas, brain, and tissues of the reproductive system (uterus, mammary gland, ovary, and  
15 testis) (34). KLK-L2 is highly expressed in the brain. Another kallikrein, neuropsin, was also found to be highly expressed in the brain and has been shown to have important roles in neural plasticity in mice (35). Also, the zyme gene is highly expressed in the brain and appears to have amyloidogenic potential (11). Taken together, these data point to a possible role of KLK-L2 in the central nervous system.

It was initially thought that each kallikrein enzyme has one specific physiological substrate.  
20 However, the increasing number of substrates, which purified proteins can cleave *in vitro*, has led to the suggestion that they may perform a variety of functions in different tissues or physiological circumstances. Serine proteases encode protein cleaving enzymes that are involved in digestion, tissue remodeling, blood clotting etc., and many of the kallikrein genes are synthesized as precursor proteins that must be activated by cleavage of the propeptide. The predicted trypsin-like cleavage specificity of KLK-L2 makes it a  
25 candidate activator of other kallikreins or it may be involved in a "cascade" of enzymatic reactions similar to those found in fibrinolysis and blood clotting (36).

In conclusion, a new member of the human kallikrein gene family, KLK-L2 was characterized. This gene is hormonally regulated and it is mostly expressed in the brain, mammary gland and testis. KLK-L2 may be useful as a tumor marker.

#### 30 Example 4

##### Materials and methods

##### Strategy for new gene discovery

Sequencing data of approximately 300 kb, around chromosome 19q13.3-q13.4, was obtained from the web site of the Lawrence Livermore National Laboratory (LLNL) (<http://www-bio.llnl.gov/genome/genome.html>). Different computer programs were used for putative new gene prediction, as previously  
35 described.

##### RT-PCR for KLK-L3 cDNA

Total RNA isolated from 26 different human tissues was purchased from Clontech, Palo Alto, CA.

cDNA was prepared as described below and used for PCR amplification. A primer set (L3-F1 and L3-R1) was used to identify the presence of the gene in tissues, and the reverse primer (L3-R1) was used with another primer (L3-F2) to amplify and clone the full cDNA of the gene. These primer sequences are shown in Table 13 (SEQ. ID. Nos. 9-12, 24-26). Tissue cDNAs were amplified at various dilutions.

5 **Reverse transcriptase polymerase chain reaction.**

2 µg of total RNA was reverse-transcribed into first strand cDNA using the Superscript™ preamplification system (Gibco BRL, Gaithersburg, MD). The final volume was 20 µl. Based on the combined information obtained from the predicted genomic structure of the new gene and the EST sequence, two gene-specific primers (L3-F1 and L3-R1) were designed (Table 13, SEQ. ID. Nos. 9-12, 24-26) and PCR was carried out in a reaction mixture containing 1 µl of cDNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 200 µM dNTPs (deoxynucleoside triphosphates), 150 ng of primers and 2.5 units of AmpliTaq Gold DNA polymerase (Roche Molecular Systems, Branchburg, NJ, USA) on a Perkin-Elmer 9600 thermal cycler. The cycling conditions were 94°C for 9 minutes, followed by 43 cycles of 94°C for 30 s, 63°C for 1 minute, and a final extension at 63°C for 10 minutes. Equal amounts of PCR products were electrophoresed on 2% agarose gels and visualized by ethidium bromide staining. All primers for RT-PCR spanned at least 2 exons to avoid contamination by genomic DNA.

**Breast cancer cell line and hormonal stimulation experiments**

The breast cancer cell line BT-474 was purchased from the American Type Culture Collection (ATCC), Rockville, MD. Cells were cultured in RPMI media (Gibco BRL, Gaithersburg, MD) supplemented with glutamine (200 mmol/L), bovine insulin (10 mg/L), fetal bovine serum (10%), antibiotics and antimycotics, in plastic flasks, to near confluency. The cells were then aliquoted into 24-well tissue culture plates and cultured to 50% confluency. 24 hours before the experiments, the culture media were changed into phenol red-free media containing 10% charcoal-stripped fetal bovine serum. For stimulation experiments, various steroid hormones dissolved in 100% ethanol were added into the culture media, at a final concentration of 10<sup>-8</sup> M. Cells stimulated with 100% ethanol were included as controls. The cells were cultured for 24 hours, then harvested for total RNA extraction by the Trizol method (Gibco-BRL). cDNA was prepared and amplified as described above. Control genes (PSA, pS2, and actin) were amplified as previously described herein.

**Cloning and sequencing of the PCR products.**

To verify the identity of the PCR products, they were cloned into the pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The inserts were sequenced from both directions using vector-specific primers, with an automated DNA sequencer.

**Identification of positive PAC and BAC genomic clones from human genomic DNA libraries**

The PCR product generated with primer set Z1S and Z1AS (Table 14, SEQ.ID.NOS. 27-42), was purified and then labeled with <sup>32</sup>P by the random primer method (Sambrook, supra) and used as a probe to screen a human genomic DNA BAC library, spotted in duplicate on nylon membranes, for identification of positive clones. The filters were hybridized in 15% formamide, 500 mM Na<sub>2</sub>HPO<sub>4</sub>, 7% SDS, 1% BSA (w/v) at 65°C overnight, then washed sequentially with 2X SSC, 1X SSC, 0.2X SSC, containing 0.1% SDS

at 65°C, and then exposed to X-ray film as described (Sambrook, supra). Positive clones were obtained, plated on selective LB medium, and then a single colony was transferred into LB broth for overnight cultures. A PAC clone positive for NES1 was identified by a similar methodology as described elsewhere (14). PAC and BAC libraries were constructed by de Jong and associates (42). Purification of BAC and

5 PAC DNA was done by a rapid alkaline lysis miniprep method, which is a modification of the standard Qiagen-Tip method. Positive clones were further confirmed by Southern blot analysis as described (Sambrook, supra).

#### **5' Rapid amplification of cDNA ends (5' RACE)**

According to the EST sequences and the computer-predicted structure of the KLK-L3 gene, two

10 gene specific primers were designed. Two rounds of RACE reactions (nested PCR) were performed with 5µl Marathon Ready™ cDNA of human testis (Clontech) as a template. The reaction mix and PCR conditions were selected according to the manufacturer's recommendations. Positive bands were gel-purified using Qiagen Gel Purification kits according to manufacturer's recommendations.

#### **Gene-specific amplification of other genes from genomic DNA**

15 According to the published sequence of prostatic specific antigen (PSA), human renal kallikrein (KLK1), human glandular kallikrein (KLK2), normal epithelial cell-specific 1 gene (NES1), KLK-L1, KLK-L2 and zyme genes, gene-specific primers were designed for each of these genes (Table 14) and developed polymerase chain reaction (PCR)-based amplification protocols which allowed us to generate specific PCR products with genomic DNA as a template. The PCR reactions were carried out as described above but by

20 using an annealing/extension temperature of 65°C.

#### **Structure analysis studies.**

Multiple alignment was performed using the clustal X software package available at: [ftp://ftp.ebi.ac.uk/pub/software/dos/clustalw/clustalx/\(clustalx1.64b.msw.exe\)](ftp://ftp.ebi.ac.uk/pub/software/dos/clustalw/clustalx/(clustalx1.64b.msw.exe)) and the multiple alignment program available from the Baylor College of Medicine (BCM) search launcher

25 (kiwi.imgen.bcm.tmc.edu:8808/search-launcher/launcher/html). Phylogenetic studies were performed using the Phylip software package available from: (<http://evolution.genetics.washington.edu/phylip/getme.html>). Distance matrix analysis was performed using the "Neighbor-Joining/UPGMA" program and parsimony analysis was done using the "Promoters" program. Hydrophobicity study was performed using the BCM search launcher programs (<http://dot.imgen.bcm.tmc.edu:9331/seq-search/struc-predict.html>). Signal peptide was predicted using the SignalP WWW server (<http://www.cbs.dtu.dk/services/signal>). Protein structure analysis was performed by SAPS (structural analysis of protein sequence) program

30 (<http://dot.imgen.bcm.tmc.edu:9331/seq-search/struc-predict.html>).

#### **Results:**

#### **Construction of a contiguous map of the human kallikrein locus on chromosome 19q13.3-q13.4**

35 Sequence information around the human chromosome 19q13.3-q13.4 locus (the proposed kallikrein locus) is available at the Lawrence Livermore National Laboratory web site. Sequences of approximately 300 kb in length were obtained. These sequences were in the form of contigs of different lengths. A restriction analysis study of the contigs was performed using various computer programs. With



the aid of the EcoRI restriction map of this area which is also available at the LLNL web site, the relative positions of these contigs was defined in relation to each other. Some contigs were overlapping, enabling construction of a contiguous segment; however, three gaps were present. <BLAST> analysis of these segments against the GenBank database (37) enabled the precise location of two classical kallikreins, namely PSA and KLK2 to be defined. Other newly discovered serine proteases were localized which are homologous with the kallikrein genes, namely protease M/zyme/neurosin (10, 11, 12), human stratum corneum chymotryptic enzyme ( HSSCE) (55), neuropsin (28), normal epithelial cell-specific 1 gene ( NES1) (13), trypsin-like serine protease ( TLSP) (GenBank accession # AF164623), KLK-L1 (SEQ.ID.NO. 1) and KLK-L2 (SEQ.ID.NO. 13). The gaps in the 300 kb genomic sequence were partially filled as follows:

- (a) The margins of the first gap were found to contain the 5' and 3' ends of the KLK2 gene; this gap was filled with the genomic structure of the KLK2 gene (GenBank Accession # M18157).
- (b) The margins of the third gap (gaps are numbered from centromere to telomere) were found to have the 3' and 5' ends of the zyme gene mRNA sequence; thus, a radiolabeled probe specific for the zyme gene was used to screen a human BAC library and two positive clones were obtained. Restriction analysis was performed, followed by Southern blotting and a fragment containing the zyme gene was obtained and sequenced, thus filling this gap.
- (c) The second gap (between KLK-L1 and KLK-L2 genes) still exists and the EcoRI restriction map of this area was used to approximately define its length (Figure 14).

Further support for the relative locations of these genes was obtained by performing PCR reactions with gene-specific primers to screen genomic DNA clones. The most centromeric group of genes (PSA, KLK2, KLK-L1, KLK-L2 and zyme ) were found to be clustered in one genomic BAC clone, and the next group (HSCCE, neuropsin, KLK-L3 and NES1) were found to be clustered together in another clone, as expected from the data of Figure 14.

#### **Cloning of the KLK-L3 gene**

A putative new gene, formed of three exons, was predicted by computer analysis of the genomic sequence. The predicted exons were subjected to sequence homology search against the human EST database (dbEST) and revealed an EST clone (GenBank accession # AA583908) which exhibited 99% homology with the putative gene. This EST was obtained, purified and sequenced and the sequence was aligned by BLAST software (37) against the genomic area that contains the putative gene. An additional exon, downstream of the predicted structure, was identified. The 3' end of the gene was verified by: (a) The presence of the serine residue (S) of the catalytic triad in a well-conserved region. This highly conserved motif (GDSGGP) always occurs at the beginning of the last exon in all known kallikreins. (b) The presence of a stop codon that is in frame with the predicted amino acid sequence. (c) The presence of a 19-poly A stretch at the end of the EST that was not found in the genomic sequence.

To verify the accuracy of the cDNA sequence of the gene, PCR reactions were performed using gene-specific primers for the first and last exons of the predicted structure of the gene (L3-F2 and L3-R1) with cDNA isolated from different human tissues as putative templates. A positive band of the expected

size was isolated from testis cDNA and fully sequenced. Its sequence was aligned by BLAST against the genomic sequence to unequivocally define the exon/intron boundaries. For further characterization of the 5' end of the gene, 5'RACE reaction was performed using Marathon Ready cDNA from testis as a template. This allowed identification of an additional exon that contains the start codon and 5' untranslated region.

5 The full sequence of the gene is shown in SEQ. ID. NO. 21 (GenBank Accession # AF135026) and the amino acid sequences of KLK-L3 proteins are shown in SEQ. ID. Nos. 22 and 23.

**Structural characterization of the KLK-L3 gene:**

As shown in Figure 15, the KLK-L3 gene is formed of 5 coding exons and 4 intervening introns, although, as with other kallikreins, the presence of further upstream untranslated exon(s) could not be ruled out (14, 28). All of the exon /intron splice sites conform to the consensus sequence for eukaryotic splice sites (32). The gene further follows strictly the common structural features of the human kallikrein multigene family, as described below.

10

The predicted protein-coding region of the gene is formed of 753 bp, encoding a deduced amino acid polypeptide with a predicted molecular weight of 27.5 kDa. A potential translation initiation codon is found at position 28 of the predicted first exon (numbers of nucleotides refer to SEQ. ID. NO. 21 or GenBank Accession # AF135026. This codon does not match well with the consensus Kozak sequence (33), however, it has a purine at position (-3) which occurs in 97% of vertebrate mRNAs (43), and it is almost identical to the sequence of the zyme gene flanking the start codon. It should also be noted that most kallikreins do not have the consensus G nucleotide in position (+4).

15

Nucleotides 6803-6808 (AGTAAA) closely resemble a consensus polyadenylation signal (44) and are followed by a stretch of 19 poly A nucleotides not found in genomic DNA, after a space of 14 nucleotides. No other potential polyadenylation signals were discernable in the 3' untranslated region, suggesting that the above motif is indeed the polyadenylation signal. The same polyadenylation signal motif was predicted for the KLK1 and KLK2 genes.

20

Although the KLK-L3 protein sequence is unique, comparative analysis revealed that it is highly homologous to other members of the kallikrein multigene family. KLK-L3 shows 40% protein identity with the TLSP gene product and 38% and 33% identity with the KLK-L2 and KLK1 proteins, respectively. Hydrophobicity analysis revealed that the amino-terminal region is quite hydrophobic (Figure 16), consistent with the possibility that this region may harbor a signal sequence, analogous to other serine proteases. Computer analysis of the amino acid sequence of KLK-L3 predicted a cleavage site between amino acids 19 and 20 (GWA-DT). Sequence alignment (Figure 17) also revealed a potential cleavage site (Arg<sup>22</sup>), at a site homologous to other serine proteases (lysine (K) or arginine (R) is present in most cases). Several evenly distributed hydrophobic regions throughout the KLK-L3 polypeptide are consistent with a globular protein, similar to other kallikreins and serine proteases. The dotted region in Figure 17 indicates an 11-amino acid loop characteristic of the classical kallikreins (PSA, KLK1, and KLK2) but not found in KLK-L3 or other members of the kallikrein multi-gene family (11, 41).

25

30

35

Twenty nine "invariant" amino acids surrounding the active site of serine proteases have been described. Of these, twenty-six are conserved in KLK-L3. One of the unconserved amino acids (Ser<sup>168</sup>

instead of Pro) is also found in prostase, KLK-L2 and enamel matrix serine proteinase (EMSP1) genes. The second (Leu<sup>58</sup> instead of Val) is also found in TLSP and KLK-L2 genes, and the third is Ala<sup>26</sup> instead of Gly. According to protein evolution studies, each of these changed amino acids represents a conserved evolutionary change to a protein of the same group (45). Twelve cysteine residues are present in the putative mature KLK-L3 protein, ten of them are conserved in all the serine proteases that are aligned in Figure 17, and would be expected to form disulphide bridges. The other two (C<sup>136</sup> and C<sup>238</sup>) are not found in PSA, KLK1, KLK2 or trypsinogen; however, they are found in similar positions in prostase, HSCCE, zyme neuropsin, and TLSP genes and are expected to form an additional disulphide bond.

To predict the phylogenetic relatedness of the KLK-L3 gene with other serine proteases, the amino acid sequences of the kallikrein genes were aligned together using the "Clustal X" multiple alignment program and a distance matrix tree was predicted using the Neighbor-joining/UPGMA method (Figure 18). Phylogenetic analysis separated the classical kallikreins (KLK1, KLK2, and PSA) and grouped KLK-L3 with TLSP, neuropsin, zyme, HSCCE and prostase/KLK-L1, consistent with previously published studies (11, 41).

#### **Tissue expression and hormonal regulation of the KLK-L3 gene**

As shown in Figure 19, the KLK-L3 gene is primarily expressed in thymus, testis, spinal cord, cerebellum, trachea, mammary gland, prostate, brain, salivary gland, ovary and skin (the latter two tissues are not shown in the figure). Lower levels of expression are seen in fetal brain, stomach, lung, thyroid, placenta, liver, small intestine, and bone marrow. No expression was seen in uterus, heart, fetal liver, adrenal gland, colon, spleen, skeletal muscle, pancreas, and kidney. In order to verify the RT-PCR specificity, representative PCR products were cloned and sequenced. Figure 20 shows that KLK-L3 gene is regulated by steroid hormones in the human breast cancer cell line BT-474.

#### **DISCUSSION**

A human kallikrein gene locus has been defined, and the first detailed map describing the relative positions of the kallikreins and other kallikrein-like genes has been constructed (Figure 14). This map is consistent with previous reports on the localization of the classical kallikreins and the approximate mapping of some new kallikreins by radiation hybrid and FISH techniques (9, 14, 67). It should be noted, however, that the lengths of certain segments of this map (as depicted in Figure 14) are dependent on the EcoRI restriction map of the area and are measured in terms of approximate kb units. Also, the measure of intervals between genes may change slightly in the future, since some kallikreins may have extra 5'exon(s) that have not as yet been identified. Kallikreins with verified 5'-untranslated exons include NES1 (14), zyme, and neuropsin (35). This map is also directional; it indicates that PSA and KLK2 genes are transcribed in the same direction (centromere to telomere) and that the rest of the kallikrein-like genes are transcribed in the reverse direction (Figure 14).

An early report indicated that KLK1 is located approximately 31 kb centromeric to PSA (9). The map described extends only 24 kb centromeric to PSA, and for this reason, KLK1 was not precisely localized. Thus, the exact location of the KLK1 gene is still to be defined from linear chromosome 19 sequencing data. The possibility still exists that this locus is extended further, and that other kallikrein-like

genes may be located upstream of PSA or downstream from TLSP.

Traditionally, kallikreins are characterized by their ability to liberate lysyl-bradykinin (kallidin) from kininogen (2). In humans, only KLK1 meets this "functional" definition. KLK2 and KLK3 are assigned to the same family based on the strong structural similarities of the genes and proteins and the close localization of these genes on the same chromosomal region (20). More recently, a new structural concept has emerged to describe kallikreins. Richards and co-workers introduced the concept of a "kallikrein multigene family" in mice, to refer to these genes (20, 21). This definition is not based much on the specific enzymatic function of the gene product, but more on its sequence homology and its close linkage on mouse chromosome 7.

Irwin et al. (27) proposed that the serine protease genes can be classified into five different groups according to intron position as discussed above. The results indicate the presence of some more common structural features that are found in all kallikreins (including the newly identified KLK-L3 gene): (1) All genes are formed of 5 coding exons and 4 intervening introns (with the possibility that some genes may have extra 5' untranslated exon(s) (24, 31, 35) (Figure 21). (2) The exon lengths are usually comparable. (3) The intron phases are always conserved (I-II-I-0) (see Figure 21 for description of intron phases). (4) These genes are clustered in the same chromosomal region, apparently without any intervening non kallikrein-like genes (Figure 14). Thus, all the recently identified serine proteases that are present in this region (zyme, HSCCE, neuropsin, NES1, prostase/KLK-L1, KLK-L2 and TLSP), together with the newly identified kallikrein-like gene (KLK-L3), could be considered members of the expanded human kallikrein multigene family.

The chromosomal band 19q13 is nonrandomly rearranged in a variety of human solid tumors including ovarian cancers (46), and the currently available data indicate that the kallikrein gene locus is related to many malignancies. At least three kallikrein genes (PSA, zyme and NES1) are down regulated in breast cancer (10, 13, 47, 48), and NES1 appears to be a novel tumor suppressor gene (29). Furthermore, PSA exhibits potent antiangiogenic activity (49). It is possible that some of these kallikreins are involved in a cascade pathway, similar to the coagulation or apoptotic process, whereby pro-forms of proteolytic enzymes are activated and then act upon downstream substrates. Such activity was found for the KLK2 gene product which acts upon and activates pro PSA (50, 51).

The expanded human kallikrein gene family has similar number of members as the rodent family of genes. Some new compelling data have raised the possibility that at least some of these genes behave as tumor suppressors (29), as negative regulators of cell growth (52), as antiangiogenic (49) and apoptotic (53) molecules. The paramount diagnostic value of some members is also well-established (24, 54). For these reasons, it is important to check all members of this family of genes as potential diagnostic or prognostic markers or as candidate therapeutic targets.

The newly identified KLK-L3 gene is expressed in many tissues, including skin, thymus, central nervous system, breast, prostate, and testis. The wide range of tissue expression of KLK-L3 should not be surprising since, by using the more sensitive RT-PCR technique, many kallikrein genes were found to be expressed in a wide variety of tissues. For example, PSA, KLK2, prostase/KLK-L1, and KLK-L2 are now

known to be expressed in breast and many other tissues (30, 54).

Like many other kallikreins, KLK-L3 is regulated by steroid hormones but in a more complex fashion than PSA and KLK2 which are up-regulated by androgens and progestins (71). In the breast carcinoma cell line studied, KLK-L3 appears to be up-regulated by progestins > estrogens > androgens (Figure 20).

### Example 5

#### Materials and Methods

##### DNA sequence on chromosome 19 and prediction of new genes

Sequencing data of approximately 300Kb of nucleotides, around chromosome 19q13.3-q13.4, was obtained from the web site of the Lawrence Livermore National Laboratory (LLNL) (<http://www.llnl.gov/genome/genome.html>) and an almost contiguous stretch of genomic sequences was constructed. A number of computer programs were used to predict the presence of putative new genes in this genomic area.

##### Expressed sequence tag (EST) searching

The predicted exons of the putative new gene were subjected to homology search using the BLASTN algorithm (37) on the National Center for Biotechnology Information web server (<http://www.ncbi.nlm.nih.gov/BLAST/>) against the human EST database (dbEST). Clones with > 95% homology were obtained from the I.M.A.G.E. consortium (38) through Research Genetics Inc, Huntsville, AL. The clones were propagated, purified and sequenced from both directions with an automated sequencer, using insert-flanking vector primers.

##### Rapid amplification of cDNA ends (3' RACE)

According to the EST sequence data and the predicted structure of the gene, two gene-specific primers were designed and two rounds of RACE reactions (nested PCR) were performed with 5µl Marathon Ready™ cDNA of human testis (Clontech, Palo Alto, CA, USA) as a template. The reaction mix and PCR conditions used were according to the manufacturer's recommendations.

##### Tissue expression

Total RNA isolated from 26 different human tissues was purchased from Clontech. cDNA was prepared as described below, and used for PCR reactions with different sets of primers (Table 15, SEQ.ID.NO.s. 46-55, 9-12). Tissue cDNAs were amplified at various dilutions.

##### Breast cancer cell line and hormonal stimulation experiments

The breast cancer cell line BT-474 was purchased from the American Type Culture Collection (ATCC), Rockville, MD. Cells were cultured in RPMI media (Gibco BRL, Gaithersburg, MD) supplemented with glutamine (200 mmol/L), bovine insulin (10 mg/L), fetal bovine serum (10%), antibiotics and antimycotics, in plastic flasks, to near confluency. The cells were then aliquoted into 24-well tissue culture plates and cultured to 50% confluency. 24 hours before the experiments, the culture media were changed into phenol red-free media containing 10% charcoal-stripped fetal bovine serum. For stimulation experiments, various steroid hormones dissolved in 100% ethanol were added into the culture media, at a final concentration of  $10^{-8}$  M. Cells stimulated with 100% ethanol were included as controls.

The cells were cultured for 24 hours, then harvested for mRNA extraction.

#### **Reverse transcriptase polymerase chain reaction**

Total RNA was extracted from the breast cancer tissues and cell lines using Trizol™ reagent (Gibco BRL) following the manufacturer's instructions. RNA concentration was determined spectrophotometrically. 2 µg of total RNA was reverse-transcribed into first strand cDNA using the Superscript™ preamplification system (Gibco BRL). The final volume was 20 µl. Based on the combined information obtained from the predicted genomic structure of the new gene and the EST sequences, two gene-specific primers were designed (L4-F1 and L4-R1, see Table 15, SEQ.ID.NOs. 46 and 47) and PCR was carried out in a reaction mixture containing 1 µl of cDNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 200 µM dNTPs (deoxynucleoside triphosphates), 150 ng of primers and 2.5 units of AmpliTaq Gold DNA polymerase (Roche Molecular Systems, Branchburg, NJ, USA) on a Perkin-Elmer 9600 thermal cycler. The cycling conditions were 94°C for 9 minutes to activate the Taq Gold DNA polymerase, followed by 43 cycles of 94°C for 30 s, 63°C for 1 minute and a final extension at 63°C for 10 min. Equal amounts of PCR products were electrophoresed on 2% agarose gels and visualized by ethidium bromide staining. All primers for RT-PCR spanned at least 2 exons to avoid contamination by genomic DNA.

To verify the identity of the PCR products, they were cloned into the pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The inserts were sequenced from both directions using vector-specific primers, with an automated DNA sequencer.

#### **Normal and malignant breast tissues**

Normal breast tissues were obtained from women undergoing reduction mammoplasties. Breast tumor tissues were obtained from female patients at participating hospitals of the Ontario Provincial Steroid Hormone Receptor Program. The normal and tumor tissues were immediately frozen in liquid nitrogen after surgical resection and stored in this manner until extracted. The tissues were pulverized with a hammer at dry ice temperature and RNA was extracted as described above, using Trizol reagent.

#### **Structure analysis**

Multiple alignment was performed using the Clustal X software package available at: [ftp://ftp.ebi.ac.uk/pub/software/dos/clustalw/clustalx/\[clustalx1.64b.msw.exe\]](ftp://ftp.ebi.ac.uk/pub/software/dos/clustalw/clustalx/[clustalx1.64b.msw.exe]) and the multiple alignment program available from the Baylor College of Medicine (BCM), Houston, TX, USA [[kiwi.imgen.bcm.tmc.edu:8808/search-launcher/launcher/html](http://kiwi.imgen.bcm.tmc.edu:8808/search-launcher/launcher/html)]. Phylogenetic studies were performed using the Phylip software package available at: <http://evolution.genetics.washington.edu/phylip/getme.html>. Distance matrix analysis was performed using the "Neighbor-Joining/UPGMA" program and parsimony analysis was done using the "Protpars" program. Hydrophobicity study was performed using the BCM search launcher programs [<http://dot.imgen.bcm.tmc.edu:9331/seq-search/struc-predict.html>]. Signal peptide was predicted using the "SignalP" server [<http://www.cbs.dtu.dk/services/signal>]. Protein structure analysis was performed by the "SAPS" (structural analysis of protein sequence) program [<http://dot.imgen.bcm.tmc.edu:9331/seq-search/struc-predict.html>].

#### **Results**

### Cloning of the KLK-L4 gene

Computer analysis of the genomic sequence around chromosome 19 q13.3-q13.4 predicted a putative new gene formed of at least 3 exons. To experimentally verify the existence of this gene, the putative exons were subjected to sequence homology search against the human expressed sequence tag (EST) database (dbEST), and four EST clones with > 97% homology were identified (Table 16). All ESTs were cloned from testicular tissue. These clones were obtained and inserts were sequenced from both directions. Sequences were then compared with the computer-predicted structure and final selection of the intron/exon splice sites was made according to the EST sequences.

As shown in Figure 22, three ESTs match almost perfectly with the predicted 3 exons (exons 3, 4, 5) of the gene and one EST matches perfectly with predicted exons 3 and 5. However, each of the ESTs extends further upstream with different exonic patterns, suggesting the presence of different splice variants.

Attempts to translate these clone sequences demonstrated the presence, in some ESTs, of interrupting stop codons in all three possible reading frames. A homology search of the three common exons against the GenBank database revealed a cDNA sequence from the German Human Genome Project. This clone has an identical exon 2 as the long form of KLK-L4 gene [this form will be described below] but has an extended exon 3 that ends with a stop codon (Figure 22). This clone was isolated from uterine tissue and is translated by software into a truncated protein product of 196 amino acids which is followed by a 3' untranslated region [GenBank accession # AL050220].

Screening of cDNAs from 26 different tissues by RT-PCR, using gene-specific primers for exons 3 and 5 [L4-F1 and L4-R1] (Table 15 & Figure 22) revealed that this gene is expressed in many tissues. Four tissues that show the highest level of expression [salivary gland, mammary gland, prostate, and testis] (Figure 23) and uterus [the EST clone AL050220 was isolated from this tissue] were selected for identification of the full structure of the gene. Different PCR reactions were performed using one reverse primer (L4-R1) together with each of the forward primers located in upstream exons that were found in the different EST clones [primers L4-B, L4-D, L4-E] (Table 15 & Figure 22). The PCR reactions were performed under different experimental conditions, using the EST clones as positive controls, and the PCR products were sequenced. None of these forms were found in any of the tissues, except in testis where all three forms were found.

By RT-PCR of the KLK-L4 gene using primers L4-R1 and L4-F1, it was found that the gene is expressed in a wide variety of tissues (Figure 23). In order to obtain the structural forms that exist in these tissues, a homology study was performed. Aligning the predicted polypeptide of the KLK-L4 gene with all other kallikreins and kallikrein-like genes, suggested, by homology, that at least two more exons should be present upstream of the predicted three exons. The genomic fragment upstream of the third exon was subjected to further computer analysis for gene prediction, and exon 2 was identified based on: a) a consensus exon/intron splice site b) preservation intron phase II after this exon, in agreement to intron phases of all other known kallikreins c) presence of the histidine residue of the catalytic triad (H<sup>76</sup>) surrounded by a well-conserved peptide motif [see below] just before the end of this exon d) comparable exon length to other kallikrein genes. A potential first exon was also predicted from the upstream genomic

sequence, based on the preserved intron phase (phase I), and the existence of an in-frame start codon that is located at a comparable distance [in relation to other kallikreins] from the end of this exon. To verify this predicted structure, a PCR reaction was performed using one reverse primer (L4-R1) together with another forward primer that is located in the predicted first exon (primer L4-X1) (Table 15 & Figure 22).

5 Two main PCR bands were obtained from the tissues examined; the expected 819 bp band (predominant) and an additional minor band of about 650 bp (Figure 24). Cloning and sequencing of these two bands revealed that the gene exists in two main forms in these tissues; the long form [SEQ. ID. No. 43 or GenBank Accession No. AF135024] and another form [referred to as the short KLK-L4 variant] that utilizes an upstream alternative splice donor site, located inside exon 3, thus creating an mRNA product

10 that that is 214 bp shorter. This alternative splice site causes frame-shifting of the coding region that will generate a predicted stop codon at the beginning of exon 4, giving rise to a truncated protein product that does not contain the serine residue of the catalytic triad (Figures 24 and 25).

Aligning the long KLK-L4 form with the ESTs (Figure 22) demonstrated that all ESTs utilize a different splice donor site located 80 bp downstream from the end of exon 3. These additional 80 bp

15 contain an in-frame stop codon at nucleotide position 5505 which will lead to the formation of a shorter polypeptide product. They also utilize an alternative polyadenylation signal located at position 8706 [numbers refer to SEQ. ID. No. 43 or or GenBank Accession No. AF135024]. The clone from the German Genome Project utilizes another splice donor site that is located further downstream, inside intron 3, and ends up with a poly A tail without having a fourth or fifth exon. The same stop codon (position 5505) will

20 be in-frame, and therefore, a truncated protein product is predicted to be formed (Figure 22).

In order to obtain the 3' end of the gene, a 3'RACE reaction was performed, and an additional 375 bp fragment of 3' untranslated region, downstream from PCR primer L4-R1, was obtained. This fragment was further confirmed to be present in all tissues tested, by performing a PCR reaction using primers L4-F1 and L4-R3 (Table 15 & Figure 22). This fragment ends with a putative polyadenylation signal variant

25 (TATAAA).

#### **Structural characterization of the KLK-L4 gene and its protein product**

The long form of the KLK-L4 gene is presented in Figure 25 (SEQ.ID.NO. 43). KLK-L4 is formed of five coding exons and four intervening introns, spanning an area of 8,905 bp of genomic sequence on chromosome 19q13.3-q13.4. The lengths of the coding regions are 52, 187, 269, 137 and 189

30 bp, respectively. The predicted protein coding region of the gene is formed of 831 bp, encoding a deduced 277-amino acid protein with a predicted molecular mass of 30.6 kDa (Figure 25). The intron/exon splice sites (mGT....AGm, where m is any base) and their flanking sequences are in agreement with the consensus splice site sequence. A potential translation initiation codon is present at position 45 of the predicted first exon [numbers refer to SEQ. ID. No. 43]. The cDNA extends at least 382 bp further downstream from the

35 stop codon and a putative polyadenylation signal (TATAAA) is present at the end of this region (Figure 25).

Hydrophobicity analysis revealed that the amino-terminal region is quite hydrophobic (Figure 26), consistent with the possibility that this region may harbor a signal sequence, analogous to other serine



proteases. Figure 26 also shows the presence of several evenly distributed hydrophobic regions throughout the KLK-L4 polypeptide, which are consistent with a globular protein, similar to other serine proteases (13). Computer analysis of the amino acid sequence of KLK-L4 predicted a cleavage site between amino acids 20 and 21 (GVS-QE). Sequence homology with other serine proteases (Figure 27) predicted another potential cleavage site (Lys25) in close proximity. Most other kallikreins are activated by cleavage after arginine or lysine. Thus, the protein product is very likely to be a secreted protein. The dotted region in Figure 27 indicates an 11-amino acid loop characteristic of the classical kallikreins (PSA, KLK1, and KLK2) which is not found in KLK-L4 or other members of the kallikrein multi-gene family (11,13, 35).

Amino acid sequences for KLK-L4 proteins are shown in SEQ.ID.NO. 44 and 45.

Sequence analysis of eukaryotic serine proteases indicates the presence of twenty nine invariant amino acids (39). Twenty eight of them are conserved in the KLK-L4 protein and the remaining amino acid (Q182 instead of P) is not conserved among all other kallikreins (Figure 27). Ten cysteine residues are present in the putative mature KLK-L4 protein. These are conserved in all the serine proteases that are aligned in Figure 27, and would be expected to form disulphide bridges. The presence of aspartate (D) in position 239 suggests that KLK-L4 will possess a trypsin-like cleavage pattern, similarly to most of the other kallikreins [e.g., KLK1, KLK2, TLSP, neuropsin, zyme, prostase, and EMSP] but different from PSA which has a serine (S) residue in the corresponding position, and is known to have chymotrypsin like activity (Figure 27) (2,40).

#### Mapping and chromosomal localization of the KLK-L4 gene

Alignment of the KLK-L4 gene and the sequences of other known kallikrein genes within the 300 Kb area of interest [the human kallikrein gene family locus], enabled precise localization of all known genes and to determine the direction of transcription, as shown by the arrows in Figure 28. The PSA gene lies between KLK1 and KLK2 genes and is separated by 13, 319 base pairs (bp) from KLK2, and both genes are transcribed in the same direction (centromere to telomere). All other kallikrein-like genes are transcribed in the opposite direction. KLK-L4 is 13 kb centromeric from KLK-L6 [SEQ.ID.NO. 65], and 21 kb more telomeric to KLK-L5 [SEQ. ID. NO. 56].

#### Homology with the kallikrein multi-gene family

Alignment of the amino acid sequence of the KLK-L4 protein (long form) against the GenBank database and the known kallikreins, using the BLAST algorithm (37), indicated that KLK-L4 has 51% amino acid sequence identity with the TLSP and zyme genes, 49% identity with KLK-L2 and 47% and 45% identity with PSA and KLK2 genes, respectively. Multiple alignment study shows that the typical catalytic triad of serine proteases is conserved in the KLK-L4 gene (H<sup>108</sup>, D<sup>153</sup>, and S<sup>245</sup>) and, as is the case with all other kallikreins, a well conserved peptide motif is found around the amino acid residues of the catalytic triad [i.e. histidine (WLLTAAHC), serine (GDSGGP), and aspartate (DLMLI)] (Figure 27) (1, 11, 13, 35).

In addition, several other residues were found to be fully or partially conserved among the human kallikrein gene family, as further shown in Figure 27. To predict the phylogenetic relatedness of the KLK-L4 gene with other serine proteases, the amino acid sequences of the kallikrein genes were aligned together using the "Clustal X" multiple alignment program and a distance matrix tree was predicted using the Neighbor-

joining/UPGMA method (Figure 29). Phylogenetic analysis separated the classical kallikreins (KLK1, KLK2, and PSA) and grouped KLK-L4 with zyme, TLSP, KLK-L3, neuropsin, and NES1 genes, consistent with previously published studies (41) and indicating that this group of genes probably arose from a common ancestral gene by duplication.

#### 5 Tissue expression and hormonal regulation of the KLK-L4 gene

As shown in Figure 23, the KLK-L4 gene is primarily expressed in mammary gland, prostate, salivary gland and testis, but, as is the case with other kallikreins, lower levels of expression are found in many other tissues. In order to verify the RT-PCR specificity, the PCR products were cloned and sequenced.

10 A steroid hormone receptor-positive breast cancer cell line (BT-474) was used as a model, to verify whether the KLK-L4 gene is under steroid hormone regulation. PSA was used as a control gene, known to be up-regulated by androgens and progestins and pS2 as an estrogen up-regulated control gene in the same cell line. Preliminary results indicate that KLK-L4 is up-regulated by progestins and androgens and to a lower extent by estrogens (Figure 30).

#### 15 Expression of KLK-L4 in breast cancer tissues and cell lines

To characterize the extent and frequency of expression of the KLK-L4 gene in breast tumors, cDNA derived from 3 normal and 19 malignant breast tissues and 3 breast cancer cell lines was used. The data were interpreted by comparison of band intensities. Out of the 19 tumors, KLK-L4 gene expression was undetectable in 7, lower than normal tissues in 9, comparable to the normal tissues in 1, and higher than  
20 normal tissues in 2 tumors. Without hormonal stimulation, the BT-474 and T-47D cell lines had no detectable KLK-L4 mRNA, while the MCF-7 cell line was positive. These preliminary results suggest that this gene is down-regulated in the majority (16/19) of breast tumors.

#### Discussion

The established kallikreins (KLK1, KLK2, and PSA), trypsinogen and chymotrypsinogen belong  
25 to a group that has: (1) an intron just downstream from the codon for the active site histidine residue, (2) a second intron downstream from the exon containing the codon for the active site aspartic acid residue, and (3) a third intron just upstream from the exon containing the codon for the active site serine residue. Figure 31 shows that KLK-L4 meets the above mentioned criteria; moreover, is located in close proximity to other kallikrein genes on the chromosomal locus 19q13.3-q13.4 (Figure 28).

30 The preliminary findings, supporting that the KLK-L4 gene may be down-regulated in a subset of breast cancers, is not surprising. There is now growing evidence that many of the kallikreins and kallikrein-like genes that are clustered in the same chromosomal region (Figure 28) are related to malignancy. PSA is the best marker for prostate cancer so far (24). A recent report provided evidence that PSA has antiangiogenic activity, and that this activity may be related to its function as a serine protease  
35 (49). This study suggested that other serine proteases, including new members of the kallikrein multigene family of enzymes, should also be evaluated for potential antiangiogenic activity (49). Recent reports suggest that hK2 (encoded by the KLK2 gene) could be another useful diagnostic marker for prostate cancer (57, 58). NES1 appears to be a tumor suppressor gene (29). The protease M gene was shown to

be differentially expressed in primary breast and ovarian tumors (10), and the human stratum corneum chymotryptic enzyme has been shown to be expressed at abnormally high levels in ovarian cancer (59).

Another recently identified kallikrein-like gene, located close to KLK-L4 and tentatively named tumor-associated, differentially expressed gene-14 (TADG14) [an alternatively spliced form of neuropsin, see Figure 28] was found to be overexpressed in about 60% of ovarian cancer tissues (59). Also, prostate/KLK-L1, another newly discovered kallikrein-like gene, is speculated to be linked to prostate cancer (41). Thus, extensive new literature suggests multiple connections of many kallikrein genes to various forms of human cancer.

The removal of intervening RNA sequences (introns) from the pre-messenger RNA in eukaryotic nuclei is a major step in the regulation of gene expression (60). RNA splicing provides a mechanism whereby protein isoform diversity can be generated and the expression of particular proteins with specialized functions can be restricted to certain cell or tissue types during development (60). The sequence elements in the pre-mRNA at the 5' and 3' splice sites in metazoans have very loose consensus sequence; only the first and the last two bases (GT..AG) of the introns are highly conserved (Sambrook, supra). These sequences cannot be the sole determinants of splice site selection, since identical, but not ordinarily active, consensus sequences can be found within both exons and introns of many eukaryotic genes. Other protein factors and sequences downstream of the splice sites are also involved.

The existence of multiple splice forms is frequent among kallikreins. Distinct RNA species are transcribed from the PSA gene, in addition to the major 1.6-kb transcript (61). Several distinct PSA transcripts have been described by Reigman et al (7). Interestingly, one of these clones lacks the 3' untranslated region and the first 373 nucleotides of the open reading frame, and has an extended exon that contains a stop codon, a pattern that is comparable with some alternative forms of the KLK-L4 cDNA, as described here (Figure 22). Heuze et al., reported the cloning of a full-length cDNA corresponding to a 2.1 kb PSA mRNA. This form results from the alternative splicing of intron 4 and lacks the serine residue that is essential for catalytic activity (61). Also, Reigman et al reported the identification of two alternatively spliced forms of the human glandular kallikrein 2 (KLK2) gene (62). A novel transcript of the tissue kallikrein gene (KLK1) was also isolated from the colon (63). Interestingly, this transcript lacks the first two exons of the tissue kallikrein gene, but the last three exons were fully conserved, a pattern that is similar to the findings with some ESTs containing parts of the KLK-L4 gene (Figure 22). Neuropsin, a recently identified kallikrein-like gene, was found to have two alternatively spliced forms, in addition to the major form (59, 64). Here, the cloning of the KLK-L4 gene is described and the identification of a number of alternative mRNA forms. These forms may result from alternative splicing (Sambrook, supra), retained intronic segment (7), or from the utilization of an alternative transcription initiation site (63). Because the long form of KLK-L4 and the major alternative splice variant [short KLK-L4 variant] (Figure 24) have an identical 5' sequence required for translation, secretion and activation, it is possible to assume that both mRNAs encode for a secreted protein (61).

In order to investigate the relative predominance of the long KLK-L4 and related forms, cDNA from various tissues was amplified by PCR. Although, in general, it is difficult to use PCR for quantitative

comparisons between mRNA species, in this experiment, [mRNAs of comparable sizes, using one set of primers under identical conditions], such a comparison is reasonable (62). In all five normal tissues examined [breast, prostate, testis, salivary gland and uterus] the long form of KLK-L4 was the predominant, with minimal level of expression of the short form (Figure 24).

5       The presence of alternatively spliced forms may be related to malignancy. Recent literature suggests that distinct molecular forms of PSA could be expressed differently by malignant versus benign prostate epithelium (65). Aberrant PSA mRNA splicing in benign prostatic hyperplasia, as opposed to prostate cancer, has been described by Henttu et al (66). In addition, it has been recently postulated that different prostatic tissues potentially harboring occult cancer could account for the presence of various  
10       forms of PSA (65).

### Example 6

#### Materials and Methods

##### DNA sequence on chromosome 19

Sequencing data of approximately 300Kb of nucleotides on chromosome 19q13.3-q13.4 was  
15       obtained from the web site of the Lawrence Livermore National Laboratory (LLNL) (<http://www-bio.llnl.gov/genome/genome.html>). This sequence was in the form of 9 contigs of different lengths. Restriction enzyme analysis, long PCR strategies, followed by DNA sequencing, BAC and PAC library screening and end sequencing of selected clones, were used to construct a contiguous genomic region, representing the complete human kallikrein gene locus.

##### 20       New gene identification

A number of computer programs were used to predict the presence of putative new genes within the contiguous genomic area of interest. The ability of these programs for predicting new genes was first examined by using the genomic sequences of the known kallikreins as testing parameters. The most reliable computer programs; GeneBuilder (gene prediction) (<http://l25.itba.mi.cnr.it/~webgene/genebuilder.html>),  
25       GeneBuilder (exon prediction) (<http://l25.itba.mi.cnr.it/~webgene/genebuilder.html>), Grail 2 (<http://compbio.ornl.gov>), and GENEID-3 (<http://apolo.imim.es/geneid.html>) were selected for further use.

##### Expressed sequence tag (EST) searching

The predicted exons of the putative new gene were subjected to homology search using the BLASTN algorithm (37) on the National Center for Biotechnology Information web server (<http://www-ncbi.nlm.nih.gov/BLAST/>) against the human EST database (dbEST). A clone with > 95% homology was  
30       obtained from the I.M.A.G.E. consortium (38) through Research Genetics Inc, Huntsville, AL. This clone was propagated, purified and sequenced from both directions with an automated sequencer, using insert-flanking vector primers.

##### Rapid amplification of cDNA ends (RACE)

35       According to the EST sequence and the predicted structure of the gene, two sets of gene-specific primers were designed for 5' and 3' RACE reactions. Two rounds of RACE reactions (nested PCR) were performed for each type of RACE with 5µl Marathon Ready™ cDNA of human testis and prostate (Clontech, Palo Alto, CA, USA) as templates. The reaction mix and PCR conditions were selected

according to the manufacturer's recommendations. In brief, the initial denaturation was for 5 min at 94°C, followed by 94°C for 5 s and 72°C for 2 min, for 5 cycles; then, 94°C for 5 s and 70°C for 2 min, for 5 cycles; then, 94°C for 5 s and 65°C for 2 min for 30 cycles for the first reaction and 25 cycles for the nested PCR reaction.

## 5 Tissue expression

Total RNA isolated from 26 different human tissues was purchased from Clontech, Palo Alto, CA. cDNA was prepared as described below for the tissue culture experiments and used for PCR reactions. After aligning all known kallikrein genes, two primers (KLK-L5-R1 and KLK-L5-F1) (Table 17, SEQ.ID.NO. 61-64, 9-12, and Figure 32) were designed from areas with relatively low homology. Tissue  
10 cDNAs were amplified at various dilutions. Due to the high degree of homology between kallikreins, and to exclude non-specific amplification, PCR products were cloned and sequenced.

### Normal and malignant breast tissues

Normal breast tissues were obtained from women undergoing reduction mammoplasties. Breast tumor tissues were obtained from female patients at participating hospitals of the Ontario Provincial Steroid  
15 Hormone Receptor Program. The normal and tumor tissues were immediately frozen in liquid nitrogen after surgical resection and stored in this manner until extracted. The tissues were pulverized with a hammer under liquid nitrogen and RNA was extracted as described below, using Trizol reagent.

### Breast and prostate cancer cell lines and hormonal stimulation experiments

The breast cancer cell lines BT-474 and T-47D, and the LNCaP prostate cancer cell line were  
20 purchased from the American Type Culture Collection (ATCC), Rockville, MD. Cells were cultured in RPMI media (Gibco BRL, Gaithersburg, MD) supplemented with glutamine (200 mmol/L), bovine insulin (10 mg/L), fetal bovine serum (10%), antibiotics and antimycotics, in plastic flasks, to near confluency. The cells were then aliquoted into 24-well tissue culture plates and cultured to 50% confluency. 24 hours before the experiments, the culture media were changed into phenol red-free media containing 10% charcoal-stripped fetal bovine serum. For stimulation experiments, various steroid hormones dissolved in 100%  
25 ethanol were added into the culture media at a final concentration of  $10^{-8}$  M. Cells stimulated with 100% ethanol were included as controls. The cells were cultured for 24 hours, then harvested for mRNA extraction.

### Reverse transcriptase polymerase chain reaction (RT-PCR)

Total RNA was extracted from the cell lines or tissues using Trizol reagent (Gibco BRL)  
30 following the manufacturer's instructions. RNA concentration was determined spectrophotometrically. 2 µg of total RNA was reverse-transcribed into first strand cDNA using the Superscript™ preamplification system (Gibco BRL). The final volume was 20 µl. Based on the combined information obtained from the predicted genomic structure of the new gene and the EST sequences, two gene-specific primers were  
35 designed (KLK-L5-F1 and KLK-L5-R1) (Table 17) and PCR was carried out in a reaction mixture containing 1 µl of cDNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 200 µM dNTPs (deoxynucleoside triphosphates), 150 ng of primers and 2.5 units of AmpliTaq Gold DNA polymerase (Roche Molecular Systems, Branchburg, NJ, USA) on a Perkin-Elmer 9600 thermal cycler. The cycling

conditions were 94°C for 9 minutes to activate the Taq Gold DNA polymerase, followed by 43 cycles of 94°C for 30 s, 63°C for 1 minute and a final extension step at 63°C for 10 min. Equal amounts of PCR products were electrophoresed on 2% agarose gels and visualized by ethidium bromide staining. All primers for RT-PCR spanned at least 2 exons to avoid contamination by genomic DNA.

- 5 To verify the identity of the PCR products, they were cloned into the pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The inserts were sequenced from both directions using vector-specific primers, with an automated DNA sequencer.

#### Structure analysis

- Multiple alignment was performed using the Clustal X software package available at:  
10 <ftp://ftp.ebi.ac.uk/pub/software/dos/clustalw/clustalx/> (clustalx1.64b.msw.exe) and the multiple alignment program available from the Baylor College of Medicine (BCM), Houston, TX, USA ([kiwi.imgen.bcm.tmc.edu:8808/search-launcher/launcher/html](http://kiwi.imgen.bcm.tmc.edu:8808/search-launcher/launcher/html)). Phylogenetic studies were performed using the Phylip software package available at: <http://evolution.genetics.washington.edu/phylip/getme.html>. Distance matrix analysis was performed using the "Neighbor-Joining/UPGMA" program and parsimony analysis was done using  
15 the "Protpars" program. Hydrophobicity study was performed using the BCM search launcher programs (<http://dot.imgen.bcm.tmc.edu:9331/seq-search/struc-predict.html>). Signal peptide was predicted using the "SignalP" server (<http://www.cbs.dtu.dk/services/signal>). Protein structure analysis was performed by "SAPS" (structural analysis of protein sequence) program (<http://dot.imgen.bcm.tmc.edu:9331/seq-search/struc-predict.html>).

## 20 RESULTS

### Identification of the KLK-L5 gene

- Computer analysis of the genomic area of interest (300Kb around chromosome 19q13.3-q13.4) predicted a putative gene comprised of at least three exons. Screening of the human expressed sequence tag (EST) database revealed an EST clone (GenBank Accession #394679) with 99% homology with the  
25 predicted exons. This clone was obtained, purified, and sequenced. The full-length sequence of the EST was compared with the genomic area containing the putative new gene and showed 100% homology with certain areas (exons), which were separated by introns. This alignment indicated that the new gene was comprised of 7 exons. Sequence homology comparisons and phylogenetic analysis revealed that this new gene is structurally similar to known kallikreins and other serine proteases (see below). Since four other  
30 new kallikrein-like genes were discovered in this area, this gene was named KLK-L5 (for kallikrein-like gene 5). Attempts to translate the coding region in all three possible reading frames indicated that only one reading frame will produce a full-length polypeptide chain without interrupting in-frame stop codons. Further support for the correctness of this reading frame was obtained by demonstrating that only this frame will preserve the three amino acid residues necessary for serine protease activity (catalytic triad) and the  
35 conserved motifs around them. An in-frame methionine start codon was found in the second exon. This start codon falls within a typical consensus Kozak sequence (CCACCATGG) (33). Thus, the gene will have at least one 5' untranslated exon, similarly to other kallikrein-like genes [e.g. zyme, the normal epithelial cell-specific 1 gene (NES1) (14), and neuropsin (35)]. 5' and 3' RACE reactions were performed in order to

obtain the 5' and 3' ends of the gene. No more sequence was obtained by 5' RACE. However, 3' RACE enabled identification of the 3' untranslated region of the gene. The additional sequence ends with a poly-A stretch that does not exist in the genomic structure, thus marking the 3' end of the gene and the start of the poly-A tail.

## 5 Splice variants of the KLK-L5 gene

Homology analysis of the KLK-L5 gene with other kallikreins revealed the presence of an additional 3' exon, an observation that has not been reported for any other member of the kallikrein multigene family. Furthermore, two different PCR bands were obtained with the 3' RACE. Sequencing of these bands revealed that this gene has at least two splice forms at its 3' end; one form in which the last exon is a single continuous fragment, and another form in which the last exon is split into two exons, with an intervening intron. In order to identify the full structure of other possible splice variants of the gene, PCR was performed using two primers (L5-F2 and L5-R2) (Table 17 and Figure 32). cDNA from 26 different tissues were used as templates and the reaction was performed under different experimental conditions (annealing temperature,  $MgCl_2$  concentration). Three distinct bands were observed in many tissues. These bands were excised, gel-purified, and sequenced. As shown in Figure 32, the KLK-L5 gene was found to have 3 molecular forms:

1) One form (referred to, from now on, as the "classical" form) represents a typical kallikrein-like serine protease with five coding exons and four intervening introns (Figure 32). As is the case with some other kallikreins, a 5' untranslated exon is also present, and the possibility of further upstream untranslated exon(s) could not be excluded. Exons 1, 2 and 3 were present at the aforementioned EST. The start codon is present in the second exon (numbers refer to SEQ.ID.NO. 56 or GenBank Accession # AF135025). The stop codon is located in the sixth exon, followed by a 3' untranslated region, and a typical polyadenylation signal (AATAAA) is located 16 bp before the poly-A tail (Figure 33). This form of KLK-L5 spans a genomic length of 5,801 bp on chromosome 19q13.3-q13.4. The lengths of the coding regions of the exons are 37, 160, 260, 134, and 156 bp, respectively (Figures 33 and 34). The predicted protein-coding region is formed of 747 bp, encoding a deduced 248-amino acid protein with a predicted molecular mass of 26.7 kDa. The intron/exon splice sites (GT....AG) and their flanking sequences are in agreement with the consensus splice site sequence.

2) The second mRNA form, encoding the KLK-L5-related protein-1, is an alternatively spliced form in which the last exon is split into two separate exons with an additional intervening intron (Figure 32). This splitting of the last exon results in the utilization of another stop codon at position 9,478, thus creating a deduced 254-amino acid protein that is 6 amino acids longer than the "classical" KLK-L5 form and its carboxyterminal end is different in sequence by 19 amino acids (Figure 32). This variant has a predicted molecular mass of 27.1 kDa (for base numbering please see SEQ.ID.NO. 56 and GenBank Accession # AF135025).

3) The third mRNA form, encoding for KLK-L5-related protein-2, is similar to the classical form except that the fourth exon is missing (Figure 32). This leads to frame shifting of the coding region, and an earlier in-frame stop codon will be encountered at position 9,180. The protein-coding region of this form

consists of 336 bp, encoding for a predicted 111-amino acid protein with a molecular mass of 12 kDa. This protein will lack both the serine and aspartate residues characteristic of serine proteases.

Amino acid sequences for KLK-L5 proteins are shown in SEQ. ID. NOs. 57 to 60.

#### Structural analysis of the classical KLK-L5 gene

5 Figure 35 shows a comparative hydrophobicity analysis of the KLK-L5 and the prostate-specific antigen (PSA) proteins. The amino terminal regions of both genes are quite hydrophobic, indicating that this region of KLK-L5 is possibly harboring a signal peptide analogous to PSA. Figure 35 also shows the presence of several evenly distributed hydrophobic regions throughout the KLK-L5 polypeptide, which are consistent with a globular protein, similar to other serine proteases (13). Figure 36 shows the alignment of  
10 KLK-L5 protein with another 10 members of the same gene family. The dotted region in Figure 36 indicates an 11-amino acid loop characteristic of the classical human kallikreins (PSA, hK1 and hK2) but not found in KLK-L5 protein or other members of the kallikrein multigene family (11, 13, 35). Sequence analysis of eukaryotic serine proteases indicates the presence of twenty nine invariant amino acids (39). Twenty eight of them are conserved in the KLK-L5 polypeptide and the remaining amino acid (S156  
15 instead of P) is not conserved among all other kallikreins (Figure 36). Twelve cysteine residues are present in the putative mature KLK-L5 protein, ten of them are conserved in all kallikreins, and the remaining two (C133, and C235 ) are present in most of the other kallikrein-like proteins but not in the classical kallikreins and they are expected to form an additional disulphide bridge (Figure 36).

The presence of aspartate (D) at position 194 suggests that KLK-L5 will possess a trypsin-like  
20 cleavage pattern, similarly to most of the other kallikreins (e.g., hK1, hK2, TLSP, neuropsin, zyme, prostase, and EMSP) but different from PSA, which has a serine (S) residue in the corresponding position, and is known to have chymotrypsin like activity (Figure 36) (54).

#### Homology with other members of the kallikrein multigene family

Although the protein encoded by the KLK-L5 gene is unique, it has a high degree of homology  
25 with the other kallikrein-like genes. The KLK-L5 protein (classical form) has 48% amino acid sequence identity and 57% overall similarity with neuropsin, 46% identity with the normal epithelial cell-specific 1 gene product (NES1) and 38% identity with both PSA and hK2 proteins. Multiple alignment shows that the typical catalytic triad of serine proteases is conserved in the KLK-L5 protein (H<sup>62</sup>, D<sup>108</sup>, and S<sup>200</sup>) (Figures 33 and 36). In addition, a well-conserved peptide motif is found around the amino acid residues  
30 of the catalytic triad as is the case with other serine proteases [i.e., histidine (VLTAAHC), serine (GDSGGP), and aspartate (DLRLL)] (11, 12) (Figure 36). Figure 36 also shows other amino acid residues that are completely conserved between kallikreins and kallikrein-like proteins. To predict the phylogenetic relatedness of the KLK-L5 protein with other serine proteases, the amino acid sequences of the kallikrein proteins were aligned together using the "Clustal X" multiple alignment program and a distance matrix tree  
35 was predicted using the Neighbor-joining/UPGMA and Protpars parsimony methods. Figure 37 shows the phylogenetic analysis which separated the classical kallikreins (hK1, hK2, and PSA) and clustered KLK-L5 with NES1 and neuropsin proteins in a separate group away from other serine proteases, consistent with previously published studies (27, 41) and indicating that this group of genes probably arose from a common



ancestral gene, by gene duplication.

#### **Tissue expression and hormonal regulation of the KLK-L5 gene**

As shown in Figure 38, the KLK-L5 gene is primarily expressed in the salivary gland, stomach, uterus, trachea, prostate, thymus, lung, colon, brain, breast and thyroid gland, but, as is the case with other kallikreins, lower levels of expression are found in some other tissues (testis, pancreas, small intestine, spinal cord). In order to verify the RT-PCR specificity, the PCR products were cloned and sequenced. The three splice forms of the gene were expressed in most of these tissues. However, the relative abundance of each form was different among tissues (Figure 38).

In order to investigate whether the KLK-L5 gene is under steroid hormone regulation, two breast cancer cell lines (BT-474 and T-47D) and a prostate cancer cell line (LNCaP) were used as models. In LNCaP cells, the gene was up-regulated only by androgen and progestin. Only in this cell line all 3 isoforms were expressed. In BT-474 cells, KLK-L5 was found to be up-regulated, at the mRNA level, by estrogen and androgen, and to a lesser extent by the progestin. The rank of potency was estrogen>androgen>progestin. However, the rank of potency for the T-47D cell line was androgen>progestin>estrogen. In both of these cell lines, only the short isoform (related protein-2) was present (Figure 39).

#### **KLK-L5 is down regulated in breast cancer**

Expression of the KLK-L5 gene, at the mRNA level, was compared between seventeen breast cancer tissues and one normal breast tissue, by RT-PCR. The gene is not expressed at all in 12 tumors (Figure 40). In all breast tissues (normal and malignant) the short isoform (related protein-2) was predominant, with the exception of one tumor, which expressed only the classical form (Figure 40, lane 8). These results should be interpreted as preliminary, since the number of tumors and normal tissues tested is relatively small.

#### **Mapping and chromosomal localization of the KLK-L5 gene**

The knowledge of extensive genomic sequence on chromosome 19q13.3-q13.4 enabled the precise localization of 14 kallikrein-like genes and determination of the direction of transcription, as shown by the arrows in Figure 28. Only PSA and KLK2 transcribe from centromere to telomere; the rest of the genes are transcribed in the reverse direction. The KLK1 gene was found to be the most centromeric, and the KLK-L6 gene the most telomeric (KLK-L6; SEQ.ID. NO.65). KLK-L5 is 21.3 Kb centromeric to KLK-L4 (SEQ.ID.NO. 43) and 1.6 kb more telomeric to the trypsin-like serine protease gene (TLSP) (Figure 28).

#### **DISCUSSION**

As shown in Figure 34, kallikreins are characterized by the following common structural features: (a) All genes are formed of 5 coding exons and 4 intervening introns [some genes may have extra 5' untranslated exon(s)] (14, 35). (b) The exon lengths are usually comparable. (c) The intron phases are always conserved (I-II-I-0) (see legend of Figure 34 for definition of intron phases). (d) These genes are clustered in the same chromosomal region, without any intervening non-kallikrein-like genes (Figure 28). (e) The histidine residue of the catalytic triad of serine proteases is located near the end of the second coding exon; the aspartate residue in the middle of the third coding exon; and serine at the beginning of the

fifth coding exon. As shown in Figure 34, all these criteria apply to the newly identified KLK-L5 gene. Thus, KLK-L5 should be considered a new member of the kallikrein multigene family.

Serine proteases and kallikreins are synthesized as "preproenzymes" that contain an N-terminal signal peptide (pre-zymogen), followed by a short activation peptide and the enzymatic domain (41, 54).  
5 PreproPSA has 24 additional residues that constitute the pre-region (signal peptide, 17 residues), and the propeptide (7 residues) (67). The signal peptide directs the protein to and across the endoplasmic reticulum (ER). In the ER, the signal peptide is removed and the resulting proPSA is transported to the plasma membrane, where it is secreted. The hydrophobicity study (Figure 35) indicates that the amino terminal region of the KLK-L5 protein is harboring a signal peptide. Also, computer analysis of the amino acid  
10 sequence of KLK-L5 predicted a cleavage site between amino acids 17 and 18 (SQA-AT). Thus, the protein product is very likely a secreted protein.

The presence of alternatively spliced forms is not a unique feature of the KLK-L5 gene; several other kallikreins are known to be expressed in various alternatively spliced forms. In addition to the major 1.6-kb transcript, several RNA species are transcribed from the PSA gene (61). Furthermore, others (69,  
15 70) have described several PSA isoforms. Retained introns and loss of complete exons have been reported in some of these forms. In addition, Riegman et al. reported the identification of two alternatively spliced forms of the human glandular kallikrein (KLK2) gene (62) and Liu et al. isolated three alternative forms of the same gene (68). A novel transcript of the tissue kallikrein gene was isolated from the colon (63). Neuropsin, a recently identified kallikrein-like gene, was found to have two alternatively spliced forms in  
20 addition to the major form (35, 64). Here, the cloning of the classical kallikrein form and two unique splice forms of the KLK-L5 gene are described. Because the classical form and the splice forms all have the same 5' sequence required for translation, secretion and activation as do other kallikreins, i.e. a 5' leader sequence, a signal peptide, and a proregion, it is reasonable to assume that all three mRNA forms should produce a secreted protein. Preliminary findings identifying forms of KLK-L5 predominant in certain  
25 tissues are presented in Figures 35 and 40.

The preliminary results indicate that KLK-L5 is up-regulated by steroid hormones in breast and prostate cancer cell lines (Figure 39). These results are not surprising, since many other kallikrein genes are also regulated by steroid hormones. The differences in the rank of potency of steroid hormones among different cell lines could be attributed to differences in the abundance of the steroid hormone receptors  
30 between them as described elsewhere.

In conclusion, a new member of the human kallikrein gene family, KLK-L5, has been characterized which maps to the human kallikrein locus (chromosome 19q13.3-q13.4). This gene has two related splice forms in addition to the main form. KLK-L5 is expressed in a variety of tissues, appears to be down-regulated in breast cancer and its expression is influenced by steroid hormones. Since a few other  
35 kallikreins are already used as valuable tumour markers, KLK-L5 may also find a similar clinical application.

#### Example 7

Using the Materials and Methods substantially as set out in Example 6, the present inventors

identified another novel gene of the kallikrein multigen family referred to as KLK-L6. The full structure of the KLK-L6 gene is shown in Figure 41. Exons 1, 2, 3, 4, 5, 6, and 7 are at nucleic acids 1172-1281; 2561-2695; 2781-2842, 3714-3885; 5715-5968; 6466-6602; and 7258-7520. The nucleic acid sequence of the KLK-L6 gene is also shown in SEQ.ID.NO. 65 and amino acid sequences for the KLK-L6 protein are shown in SEQ.ID. Nos. 66 and 67. (See also GenBank Accession # AF161221).

Figure 42 shows a comparative hydrophobicity analysis of KLK-L6 and the prostate-specific antigen (PSA). The amino terminal regions of both genes are quite hydrophobic indicating that this region of KLK-L6 is possibly harboring a signal peptide analogous to PSA

Multiple alignment of KLK-L6 was carried out using the Clustal X software program as described herein (Figure 43).

To predict the phylogenetic relatedness of the KLK-L6 protein with other serine proteases, the amino acid sequences of the kallikrein proteins were aligned together using the "Clustal X" multiple alignment program and a distance matrix tree was predicted using the Neighbor-joining/UPGMA and Protpars parsimony methods. Figure 44 shows the phylogenetic analysis which separated the classical kallikreins (hK1, hK2, and PSA) and placed KLK-L6 in a separate group.

Having illustrated and described the principles of the invention in a preferred embodiment, it should be appreciated to those skilled in the art that the invention can be modified in arrangement and detail without departure from such principles. All modifications coming within the scope of the following claims are claimed.

All publications, patents and patent applications referred to herein are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

**FULL CITATIONS FOR REFERENCES REFERRED TO IN THE SPECIFICATION**

1. Evans BAE, Yun ZX, Close JA, Tregear GW, Kitamura N, Nakanishi S, et al. Structure and chromosomal localization of the human renal kallikrein gene. *Biochemistry* 1988;27:3124-3129.
2. Clements JA. The glandular kallikrein family of enzymes: Tissue-specific and hormonal regulation. *Endocr Rev* 1989;10:393-419.
3. Evans BA, Drinkwater CC, Richards RI. Mouse glandular kallikrein genes: Structure and partial sequence analysis of the kallikrein gene locus. *J Biol Chem* 1987;262:8027-8034.
4. Drinkwater CC, Evans BA, Richards RI. Kallikreins, kinins and growth factor biosynthesis. *Trends Biochem Sci* 1988b;13:169-172.
- 10 5. Ashley PL, MacDonald RJ. Tissue-specific expression of kallikrein-related genes in the rat. *Biochemistry* 1985;24:4520-5427.
6. Gerald WL, Chao J, Chao L. Sex dimorphism and hormonal regulation of rat tissue kallikrein mRNA. *Biochim Biophys Acta* 1986;867:16-23.
7. Riegman PHJ, Vlietstra RJ, van der Korput JAGM, Romijn JC, Trapman J. Characterization of the prostate-specific antigen gene: A novel human kallikrein-like gene. *Biochem Biophys Res Commun* 1989;159:95-102.
- 15 8. Schedlich LJ, Bennetts BH, Morris BJ. Primary structure of a human glandular kallikrein gene. *DNA* 1987;6:429-437.
9. Riegman PH, Vlietstra RJ, Suurmeijer L, Cleutjens CBJM, Trapman J. Characterization of the human kallikrein locus. *Genomics* 1992;14:6-11.
- 20 10. Anisowicz A, Sotiropoulou G, Stenman G, Mok SC, Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. *Mol Med* 1996;2:624-636.
11. Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson M, et al. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. *J Biol Chem* 1997;272:25135-25142.
- 25 12. Yamashiro K, Tsuruoka N, Kodama S, Tsujimoto M, Yamamura Y, Tanaka T, et al. Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. *Biochim Biophys Acta* 1997;1350:11-14.
13. Liu XL, Wazer DE, Watanabe K, Band V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. *Cancer Res* 1996;56:3371-3379.
- 30 14. Luo L, Herbrick J-A, Scherer SW, Beatty B, Squire J, Diamandis EP. Structural characterization and mapping of the normal epithelial cell-specific 1 gene. *Biochem Biophys Res Commun* 1998;247:580-586.
- 35 15. Milanesi L, Kolchanov N, Rogozin I, Kel A, Titov I. Sequence functional inference. In: "Guide to human genome computing", ed. M.J. Bishop, Academic Press, Cambridge, 1994, 249-312.
16. Burset M, Guigo R. Evaluation of gene structure prediction programs. *Genomics* 1996;34:353-367.

17. Nadeau J, Grant P, Kosowsky M. Mouse and human homology map. *Mouse Genome* 1991;89:31-36.
18. Schachter M. Kallikreins (kininogenases) - a group of serine proteases with bioregulatory actions. *Pharmacol Rev* 1980;31:1-17.
- 5 19. Morris BJ, Catanzaro DF, Richards RI, Mason AJ, Shine J. Kallikrein and renin: Molecular biology and biosynthesis. *Clin Sci* 1981;61:351s-353s.
20. Richards RI, Catanzaro DF, Mason AJ, Morris BJ, Baxter JD, Shine J. Mouse glandular kallikrein genes. Nucleotide sequence of cloned cDNA coding for a member of the kallikrein arginyl ester-peptidase group of serine proteases. *J Biol Chem* 1982;257:2758-2761.
- 10 21. Van Leeuwen BH, Evans BA, Tregear GW, Richards RI. Mouse glandular kallikrein genes. Identification, structure and expression of the renal kallikrein gene. *J Biol Chem* 1986; 261:5529-5535.
22. Evans BA, Richards RI. Genes for the  $\alpha$  and  $\gamma$  subunits of mouse nerve growth factor. *EMBO J* 1985; 4:133-138.
- 15 23. Rogozin IB, Milanese L, Kolchanov NA. Gene structure prediction using information on homologous protein sequence. *Comput Applic Biosci* 1996;12:161-170.
24. Diamandis, E.P. Prostate specific antigen-its usefulness in clinical medicine. *Trends Endocrinol. Metab.*, 9: 310-316, 1998.
25. Diamandis, E. P., Yu H., and Sutherland, D.J. Detection of prostate-specific antigen  
20 immunoreactivity in breast tumours. *Breast Cancer Res.Treat.*, 32: 301-310, 1994
26. Ishikawa, T., Kashiwagi, H., Iwakami, Y., et al. Expression of  $\alpha$ -fetoprotein and prostate specific antigen genes in several tissues and detection of mRNAs in normal circulating blood by reverse transcriptase-polymerase chain reaction. *Jpn. J. Oncol.*, 28:723-728, 1998.
- 25 27. Irwin, D.M., Robertson, K.A., and MacGillivray, R.T. *J.Mol.Biol.*212:31-45, 1988.
28. Yoshida, S., Taniguchi, M., Hirata, A., and Shiosaka, S. Sequence bovine prothrombin gene. *J. Mol. Biol.*, 212: 31-45, 1988.
29. Goyal, J., Smith, K.M., Cowan, J.M., et al. The role of NES1 serine protease as a novel tumor suppressor. *Cancer Res.*, 58: 4782-4786, 1998.
- 30 30. Diamandis, E.P., and Yu, H. New biological functions of prostate specific antigen? *J. Clin. Endocrinol. Metab.*, 80 : 1515-1517, 1995.
31. Reifenberger, J., reifenberger, G., Liu, L., James, C.D. et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. *Am. J. Pathol.*,145: 1175-90, 1994.
- 35 32. Iida, Y. (1990). Quantification analysis of 5'-splice signal sequence in mRNA precursors. Mutations in 5'-splice signal sequence of human  $\beta$ -globin gene and  $\beta$ -thalassemia. *J. Theor. Biol.* 145: 523-533.
33. Kozak, M. (1991). An analysis of vertebrate mRNA sequences: Intimations of translational

- control. *J. Cell Biol.* 115: 887-892.
34. Clements, J. (1997). The molecular biology of the kallikreins and their roles in inflammation. *In*: S. Farmer (ed.), *The kinin system*, pp. 71 -97. New York: Academic Press.
  35. Yoshida, S., Taniguchi, M., Hirata, A., and Shiosaka, S. (1998). Sequence analysis and expression  
5 of human neuropsin cDNA and gene. *Gene* 213 :9-16.
  36. Takayama, T. K., Fujikawa, K., Davie, E. W. (1997). Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. *J. Biol. Chem.* 272: 21582-21588.
  37. Altschul, S.F. et al., *Nucleic Acids Res.* 25: 3389-3402, 1997.
  - 10 38. Lennon, G. et al, *Genomics* 33: 151-152, 1996.
  39. Dayhoff, M. O., *Natl. Biomed. Res. Found.* 5 (Suppl 3) 79-81, 1998.
  40. Simmer, J.P., et al, *J. Dent. Res.* 77:377-386, 1998.
  41. Nelson, P.S. et al, *PNAS* 96: 3114-3119, 1999.
  42. Osoegawa, K. et al, *Genomics* 52: 1-8, 1999.
  - 15 43. Kozak, M., *Nucleic Acid Res.* 15: 8125-8148, 1987.
  44. Proudfoot, N.J. and Brownlee, C.G., *Nature* 263: 211-214, 1976.
  45. Miyata, T. et al, *J. Mol Evol.* 12: 219-236, 1979.
  46. Mitelman, F., *Catalog of Chromosome Aberrations in Cancer*, 5<sup>th</sup> ed. Wiley-Liss, New York, pp. 3067-3198.
  - 20 47. Yu, H. et al, *Clin. Cancer res.* 4: 1489-1497, 1998.
  48. Sauter, E.R., *Cancer Epidemiol. Biomarkers Prev.* 5:967-970, 1996.
  49. Fortier, A.H. et al, *J. Natl. Cancer Inst.* 91: 1635-1640, 1999.
  50. Kumar, A., 1998, *Cancer res.* 57: 3111-3114, 1997.
  51. Lovgren, J. *Biochem. Biophys. Res. Commun.* 238: 549-555, 1987.
  - 25 52. Lai, L.C. et al, *Int. J. Cancer* 66: 743-746, 1996.
  53. Balbay, M.D. et al, *Proc. Amer. Assoc. Cancer Res.* 40: 225-226, 1999.
  54. Rittenhouse, H.G. et al *Crit. Rev. Clin. Lab. Sci.* 35: 275-368, 1998.
  55. Hansson, L et al, *J. Biol. Chem.* 269: 19420-19426, 1994.
  56. Stephenson, S. et al *J. Biol. Chem.* 27: 23210-23214, 1999.
  - 30 57. Stenman, U.H. *Clin. Chem.* 45: 753-754, 1999.
  58. Black, M.H., *Clin. Chem.* 45: 790-799, 1999.
  59. Underwood, L.J. et al, *Cancer Res.* 59:4435-4439, 1999.
  60. Adams, M.D. et al, *Curr. Opin. Cell Biol.* 8:331-339, 1996.
  61. Heuze, N. et al, *cancer Res.* 59: 2820-2824, 1999.
  - 35 62. Riegman, P.H., *Mol. Cell Endocrinol.* 76: 181-190.
  63. Chen, L.M. *Braz. J. Med. Biol Res.* 27: 1829-1838, 1994.
  64. Mitsui, S. et al, *Eur. J. Biochem.* 260:627-634.
  65. Baffa, R., *Urology*, 47:795-800,1996.

66. Henttu, P. et al, *Int. J. Cancer* 45: 654-660, 1990.
67. McCormack, R.T. et al, *Urology* 45: 729-744, 1995.
68. Liu, X.F., et al, *Biochem. Biophys. Res. Commun.* 264:833-839, 1999.
69. Riegman, P.H. et al, *Biochem. Biophys. Res. Commun.* 155: 181-188, 1988.
- 5 70. Lundwall, A. and H. Lilja, *FEBS Lett.* 214: 317-322, 1987.
71. Zarghami, N. et al, *Br. J. Cancer* 75: 579-88, 1997.

TABLE 1. Predicted exons of the putative gene KLK-L1. The translated protein sequences of each exon (open reading frame) are shown.

Exon No. <sup>1</sup>	Putative coding region <sup>2</sup>	No. of bases	Translated protein sequence	EST match <sup>3</sup>	Intron phase <sup>4</sup>	Stop codon <sup>5</sup>	Catalytic triad <sup>6</sup>	Exon prediction program <sup>7</sup>
	From(bp)	To (bp)						
2	2263	2425	SLVSGSCQIINGEDCSPHSQPWQAALVMENELFCSGV LVHPQWVLSAAHCFQ	+	II	-	H	A,B,D
3	2847	3109	NSYTI <del>GLGLH</del> SL <del>EA</del> DQEPGQSMVEASLSVRHPEYNRPL LANDLMLIKLDES <del>V</del> SESDTIRISISIASQCPTAGNSCLVSG WGLLANGELT	+	I	-	D	A,B,C,D
4	3180	3317	GRMPTVLQCVNVSVVSEEVCSKLYDPLYHPSMFCAGG GQDKDSCN	+	0	-		A,B,C,D
5	4588	4737	GD <del>SG</del> GPLICNGYLQGLVSFGKAPCGQGVGPGVYTNLC KFEWIEKTVQAS	+	-	+	S	A,B,C

1. Conventional numbering of exons in comparison to the five coding exons of PSA, as described in Ref. 14.

2. Nucleotide numbers refer to the related contig

3. (+) = >95% homology with published human EST sequences.

4. Intron phase: 0 = the intron occurs between codons; I = the intron occurs after the first nucleotide of the codon; II = the intron occurs after the second nucleotide of the codon.

5. (+) denotes the exon containing the stop codon.

6. H = histidine, D = aspartic acid, S = serine. The amino acids of the catalytic triad are bold and underlined.

7. A = GeneBuilder (gene analysis), B = GeneBuilder (exon analysis), C = Grail 2,

D = GENEID-3



TABLE 2. Predicted exons of the putative gene KJK-L2. The translated protein sequences of each exon (open reading frame) are shown.

Exon No. <sup>1</sup>	Putative coding sequence <sup>2</sup> From(bp) To(bp)	No. of bases	Translated protein sequence	EST match <sup>3</sup>	Intron phase <sup>4</sup>	Stop codon <sup>5</sup>	Catalytic triad <sup>6</sup>	Exon prediction program <sup>7</sup>
1	15,361 15,433	73	MATARPPWMVLCALITALLGVT	+	I	-	-	-
2	17,904 18,165	262	EHVLANNVSCDHPSTVPSGNSQDLGAGAGEDARSDDSSRIIN GSDCDMHTQPWQAALLLRPNQLYCGAVLVHPQWLLTAAHCRK K	+	II	-	H	A,B,C,D
3	18,903 19,159	257	VFRVRLGHYSLSPVYESGQQMFQGVKSIPIHPGYSHPGHSNDLMLI KLNRRIRPTKDVRRPINVSSHCPASAGTKCLVSGWGTTKSPQ	+	I	-	D	C,D
4	19,245 19,378	134	VHFPKVLQCLNISVLSQKRCEDAYPRQIDDTMFCAGDKAGRDSC Q	+	0	-	-	B,C
5	24,232 24,384	153	GDGGPVVCGNGSLQGLVSWGDYPCARPNNRPGVYTNLCKFTKWI QETIQANS	+	-	+	S	A,B,C

\* All footnotes same as Table 1

TABLE 3. Predicted exons of the putative gene KLK-L3. The translated protein sequences of each exon (open reading frame) are shown

Exon No. <sup>1</sup>	Putative coding region <sup>2</sup> From(bp) To(bp)	No. of bases	Translated protein sequence	EST match <sup>3</sup>	Intron phase <sup>4</sup>	Stop codon <sup>5</sup>	Catalytic triad <sup>6</sup>	Exon prediction program <sup>7</sup>
1	70,473 70,584	112	VHFPTPNHRGGPMEEEGDGMAYHKEALDACTFQDP	-	I	-	-	A,B,C,D
2	70,764 70,962	199	ACSSLTPLSLIPTPGHGWADTRAIGAEECRPNSQPWQAGLF HLTRLFCGATLISDRWLLTAHCRK	+	II	-	H	A,B,C,D
3	73,395 73,687	293	PLTSEACPSRYLWVRLGEHLWKWEGPEQLFRVTDFFPH GFNKDLSANDHNDIMLRLPRQARLSPA VQPLNLSQTCV SPGMQCLISGWGA VSSPK	+	I	-	D	A,B,C,D
4	76,305 76,441	137	ALFPVTLCANISILENKLCHWAYPGHISDSMLCAGLWEG GRGSCQ	+	0	-	-	A,B,C,D
5	76,884 77,633	749	GDGGPLVCNGTLAGVSSGGAEPCSRPRRPAVYTSVCHYL DWIQEIMEN	-	-	+	S	A,B

\* All footnotes same as Table 1

TABLE 4. Predicted exons of the putative gene KLK-L4. The translated protein sequences of each exon (open reading frame) are shown

Exon No. <sup>1</sup>	Putative coding region <sup>2</sup> From(bp) To(bp)	No. of bases	Translated protein sequence	EST match <sup>3</sup>	Intron phase <sup>4</sup>	Stop codon <sup>5</sup>	Catalytic triad <sup>6</sup>	Exon prediction program <sup>7</sup>
2	24,945 25,120	176	ESSKVLNTNGTSGFLPGGYTCFPHSQPWQAALLVQGRLL CGGLVHPKWVLTAAHCLKE	+	II	-	H	C
3	25,460 25,728	269	GLKVYLGKHALGRVEAGEQVREVVHSIPHPYRRSPTHL NHDHIMLLELQSPVQLTGYIQTPLSHNNRLTPGTTCTRV SGWGTTTSPQ	+	I	-	D	A,B,C,D
4	26,879 27,015	137	VNYPKTLQCANIQLRSDECRQVYPGKITDNMLCAGTKE GGKDSCE	+	0	-	-	A,B,C,D
5	28,778 28,963	189	GDGGPLVCNRTLGVISWGDFFCGQPDPRPGVYTRVSRY VLWIRETIKKYETQQKWLGPO	+	.	+	S	A,B,C

\* All footnotes same as Table 1

TABLE 5. Predicted exons of the putative gene KLK-L5. The translated protein sequences of each exon (open reading frame) are shown.

Exon No. <sup>1</sup>	Putative coding region <sup>2</sup> From(bp) To(bp)	No. of bases	Translated protein sequence	EST match <sup>3</sup>	Intron phase <sup>4</sup>	Stop codon <sup>5</sup>	Catalytic triad <sup>6</sup>	Exon prediction program <sup>7</sup>
2	1588 1747	160	LSQAATPKIFNGTECGRNSQPWQVGLFEGTSLRCGGV LIDHRWVL TAAHCSG	-	II	-	H	A,B,C
3	3592 3851	260	SRYWVRLGEHLSQLDWTQIRHSGFSVTHPGVYLGAS TSHEHDLRLRLPVRVTSSVQPLPLPNDCATAGTEC HVSQWGITNHPR	+	I	-	D	A,B,C,D
4	4806 4939	134	NPFPDLLQCLNLSIVSHATCHGVYPGRITSNMVCAGG VPGQDACQ	+	0	-	-	A,B,C,D

\* All footnotes same as Table 1

TABLE 6. Homology between the predicted amino acid sequences of the newly identified putative genes and protein sequences deposited in Genbank

No.	Gene identity	Homologous known protein	Identity% (number of amino acids)
1	KLK-L1	• Human stratum corneum chymotryptic enzyme	44(101/227)
		• Rat kallikrein	40( 96/237)
		• Mouse glandular kallikrein K22	39( 94/236)
		• Human glandular kallikrein	38( 93/241)
		• Human prostatic specific antigen	37( 91/241)
		• Human protease M	37( 87/229)
2	KLK-L2	• Human neuropsin	48(106/219)
		• Human stratum corneum chymotryptic enzyme	47(103/216)
		• Human protease M	45( 99/219)
		• Human trypsinogen I	45(100/221)
		• Rat trypsinogen	44( 98/220)
3	KLK-L3	• Human neuropsin	44(109/244)
		• Rat trypsinogen 4	39( 95/241)
		• Human protease M	38( 98/253)
		• Human glandular kallikrein	37( 94/248)
		• Human prostatic specific antigen	36( 89/242)
4	KLK-L4	• Human protease M	52(118/225)
		• Human neuropsin	51(116/225)
		• Mouse neuropsin	51(116/226)
		• Human glandular kallikrein	48(113/234)
		• Human prostatic specific antigen	47(108/227)
5	KLK-L5	• Human neuropsin	44( 81/184)
		• Rat trypsinogen I	42( 76/178)
		• Rat trypsinogen II	42( 75/178)
		• Human protease M	41( 73/178)

- 72 -

**Table 7.** Expressed sequence tags with >95% homology to exons of the prostate/KLK-L1 gene.

GenBank #	Source	Tissue	homologous exons
AA551449	I.M.A.G.E.	prostate	3,4,5
AA533140	I.M.A.G.E.	prostate	4,5
AA503963	I.M.A.G.E.	prostate	5
AA569484	I.M.A.G.E.	prostate	5
AA336074	TIGR	endometrium	2,3

**Table 8.** Primers used for reverse transcription-polymerase chain reaction (RT-PCR) analysis of various genes.

Gene	Primer name	Sequence <sup>1</sup>	Product size (base pairs)
Protease (KLK-L1)	RS	TGACCCGCTGTACCACCCCA	278
	RAS	GAATTCCTCCGCAGGATGT	
pS2	PS2S	GGTGATCTGCGCCCTGGTCCT	328
	PS2AS	AGGTGTCCGGTGGAGGTGGCA	
PSA	PSAS	TGCGCAAGTTCACCCTCA	754
	PSAAS	CCCTCTCCTTACTTCATCC	
Actin	ACTINS	ACAATGAGCTGCGTGTGGCT	372
	ACTINAS	TCTCCTTAATGTCACGCACGA	

1. All nucleotide sequences are given in the 5'→3' orientation.

Table 9. Tissue expression of prostate/CLK-LI by RT-PCR analysis

Expression level			
High	medium	low	No Expression
Prostate	Mammary gland	Salivary glands	Stomach
Testis	Colon	Lung	Heart
Adrenals	Spinal cord	Brain	Spleen
Uterus		Bone marrow	Placenta
Thyroid		Thymus	Liver
		Trachea	Pancreas
		Cerebellum	Kidney
			Fetal brain
			Fetal liver
			Skeletal muscle
			Small intestine



**Table 10.** EST clones with >95% homology to exons of KLK-L2

GENBANK #	Tissue of Origin	I.M.A.G.E. ID	Homologous exons
W73140	Fetal heart	344588	4,5
W73168	Fetal heart	344588	3,4,5
AA862032	Squamous cell carcinoma	1485736	4,5
AI002163	Testis	1619481	3,4,5
N80762	Fetal lung	300611	5
W68361	Fetal heart	342591	5
W68496	Fetal heart	342591	5
AA292366	Ovarian tumor	725905	1,2
AA394040	Ovarian tumor	726001	5

Table 11. Primers used for reverse transcription polymerase chain reaction (RT-PCR) analysis.

Gene	Primer name	Sequence <sup>1</sup>	Product size (base pairs)
KLK-L2	KS	GGATGCTTACCCGAGACAGA	342
	KAS	GCTGGAGAGATGAACATTCT	
pS2	PS2S	GGTGATCTGCGCCCTGGTCCT	328
	PS2AS	AGGTGTCCGGTGGAGGTGGCA	
PSA	PSAS	TGCGCAAGTTCACCCTCA	754
	PSAAS	CCCTCTCCTTACTTCATCC	
Actin	ACTINS	ACAATGAGCTGCGTGTGGCT	372
	ACTINAS	TCTCCTTAATGTACGCACGA	
KLK-L2	R1	CCGAGACGGACTCTGAAAACCTTCTTCC	
	R2	TGAAAACCTTCTTCTCCTGCAGTGGGCGGC	

1. All nucleotide sequence are given in the 5' 3' orientation.

**Table 12.** Tissue expression of KLK-L2 by RT-PCR analysis.

sion level			
high	Medium	low	No Expression
Brain	Salivary gland	Uterus	Stomach
Mammary gland	Fetal brain	Lung	Adrenal gland
Testis	Thymus	Heart	Colon
	Prostate	Fetal liver	Skeletal muscle
	Thyroid	Spleen	
	Trachea	Placenta	
	Cerebellum	Liver	
	Spinal cord	Pancreas	
		Small intestine	
		Kidney	
		Bone marrow	

TABLE 13 . Primers used for reverse transcription polymerase chain reaction (RT-PCR) analysis.

Gene	Primer name	Sequence <sup>1</sup>
KLK-L3	L3-F1	CATGCAGTGTCTCATCTCAG
	L3-F2	CATGGAGGAGGAAGGAGATG
	L3-R1	CTTCGGCCTCTCTTGGTCTT
PSA	PSAS	TGCGCAAGTTCACCCTCA
	PSAAS	CCCTCTCCTTACTTCATCC
Actin	ACTINS	ACAATGAGCTGCGTGTGGCT
	ACTINAS	TCTCCTTAATGTCACGCACGA

1. All nucleotide sequence are given in the 5' → 3' orientation.

TABLE 14. Primers used for gene-specific PCR amplification of the kallikrein genes using DNA as a template.

Primer name	Sequence <sup>1</sup>	Coordinates	GenBank accession #	Gene name
Z1S Z1AS	GACCCTGACATGTGACATCTA GCCACTGCCTGATGGAGACTG	979-999 1422-1402	U62801	Zyme
GL3-F1 LL3-R1	AACATCAGCATCCTGGAGAA CTTCGGCCTCTCTTGGTCTT	7324-7343 8051-8060	AF135026	KLK-L3
L2-1 L2-2	GGGTCAGAGCTGCAGAGAAG GGGCCTGTCGTCTGCAATGG	11104-11123 11522-11541	AF135028	KLK-L2
KLK-L1	ATGGCCACAGCAGGAAATCC GGTCACTTGTCTGCGCAGAC	1411-1430 1990-2019	AF113141	KLK-L1
PS PAS	CCCAACCCTGTGTTTTTCTC GGCCCTCCTCCCTCAGA	3634-3653 4143-4118	M33105	PSA <sup>2</sup>
K1S K1AS	ATCCCTCCATTCCCATCTTT CACATACAATTCTCTGGTTC	2-22 324-30	M18157	KLK1 <sup>3</sup>
K2S K2AS	AGTGACACTGTCTCAGAATT CCCCAATCTCACCAGTGCAC	131-150 580-561	AF024605	KLK2 <sup>4</sup>
NS NAS	GCTTCCCTACCGCTGTGCT CACTCTGGCAAGGGTCCTG	552-570 763-744	AF055481	NES1 <sup>5</sup>

1. all nucleotide sequences are given in the 5' → 3' orientation

2. prostate specific antigen

3. human renal kallikrein

4. human glandular kallikrein

5. normal epithelia cell-specific 1 gene.

TABLE 15. Primers used for reverse transcription polymerase chain reaction (RT-PCR) analysis.

Gene	Primer name	Sequence <sup>1</sup>
KLK-L4	L4-F1	AACTCTACAATGTGCCAACA
	L4-R1	TTATTGTGGGCCCTTCAACC
	L4-R3	GGATGGTCCATTTATAGGAC
	L4-A	AGGCTGCCCTACTAGTGCAA
	L4-B	ATATTGCCTAGGTGGATGTG
	L4-D	AAGACTTCAAGGAGCCAAGC
	L4-E	GACCCTTCACCTCCCAAAT
	L4-X1	CTAGTGATCGCCTCCCTGAC
pS2	PS2S	GGTGATCTGCGCCCTGGTCCT
	PS2AS	AGGTGTCCGGTGGAGGTGGCA
PSA	PSAS	TGCGCAAGTTCACCCTCA
	PSAAS	CCCTCTCCTTACTTCATCC
Actin	ACTINS	ACAATGAGCTGCGTGTGGCT
	ACTINAS	TCTCCTTAATGTCACGCACGA

1. All nucleotide sequence are given in the 5'→3' orientation.

TABLE 16. EST clones with &gt;95% homology to exons of KLK-L4

GenBank #	Tissue of origin	I.M.A.G.E. ID
AA399955 AA401397	Testis	743113
AA846771	Testis	1392889
AI002101	Testis	1619045
AI032327	Testis	1644236

TABLE 17. Primers used for reverse transcription polymerase chain reaction (RT-PCR) analysis.

Gene	Primer name	Sequence <sup>1</sup>
KLK-L5	KLK-L5-F1	TCAGCCAGGCAGCCACACCG
	KLK-L5-R1	TTGGTGATGCCCCAGCCTGA
	L5-F2	CCACACCGAAGATTTTCAAT
	L5-R2	GCCCCTCCTTCATTTATA
PSA	PSAS	TGCGCAAGTTCACCCTCA
	PSAAS	CCCTCTCCTTACTTCATCC
Actin	ACTINS	ACAATGAGCTGCGTGTGGCT
	ACTINAS	TCTCCTTAATGTCACGCACGA

1. All nucleotide sequence are given in the 5'→3' orientation.



We Claim:

1. An isolated KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6 nucleic acid molecule of at least 30 nucleotides which hybridizes to SEQ ID NO. 1, 13, 21, 43, 56, or 65, respectively, or the complement of SEQ ID NO. 1, 13, 21, 43, 56, or 65, under stringent hybridization conditions
2. An isolated nucleic acid molecule which comprises:
  - (i) a nucleic acid sequence encoding a protein having substantial sequence identity with an amino acid sequence of a KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6 protein as shown in SEQ.ID.NO. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67, respectively;
  - (ii) a nucleic acid sequence encoding a protein comprising an amino acid sequence of a KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6 protein as shown in SEQ.ID.NO. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67, respectively;
  - (iii) nucleic acid sequences complementary to (i);
  - (iv) a degenerate form of a nucleic acid sequence of (i);
  - (v) a nucleic acid sequence capable of hybridizing under stringent conditions to a nucleic acid sequence in (i), (ii) or (iii);
  - (vi) a nucleic acid sequence encoding a truncation, an analog, an allelic or species variation of a protein comprising an amino acid sequence of a KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6 protein as shown in SEQ.ID.NO. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67, respectively; or
  - (vii) a fragment, or allelic or species variation of (i), (ii) or (iii).
3. A purified and isolated nucleic acid molecule of the invention comprises:
  - (i) a nucleic acid sequence comprising the sequence of SEQ.ID.NO. 1, 13, 21, 43, 56, or 65 wherein T can also be U;
  - (ii) nucleic acid sequences complementary to (i), preferably complementary to the full nucleic acid sequence of SEQ.ID.NO. 1, 13, 21, 43, 56, or 65;
  - (iii) a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid of (i) or (ii) and preferably having at least 18 nucleotides; or
  - (iv) a nucleic acid molecule differing from any of the nucleic acids of (i) to (iii) in codon sequences due to the degeneracy of the genetic code.
4. An isolated nucleic acid molecule which encodes a protein which binds an antibody of a KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6 protein.
5. A regulatory sequence of an isolated nucleic acid molecule as claimed in any of the preceding claims fused to a nucleic acid which encodes a heterologous protein.
6. A vector comprising a nucleic acid molecule of any of the preceding claims.
7. A host cell comprising a nucleic acid molecule of any of the preceding claims.

8. An isolated KLK-L1 protein comprising an amino acid sequence of SEQ. ID. NO. 2 or 3.
9. An isolated KLK-L2 protein comprising an amino acid sequence of SEQ. ID. NO. 14.
10. An isolated KLK-L3 protein comprising an amino acid sequence of SEQ. ID. NO. 22 or 23.
11. An isolated KLK-L4 protein comprising an amino acid sequence of SEQ. ID. NO. 44 or 45.
- 5 12. An isolated KLK-L5 protein comprising an amino acid sequence of SEQ. ID. NO. 57, 58, 59, or 60.
13. An isolated KLK-L6 protein comprising an amino acid sequence of SEQ. ID. NO. 66 or 67.
14. An isolated protein having at least 65% amino acid sequence identity to an amino acid sequence of SEQ. ID. NO. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67.
15. A method for preparing a protein as claimed in any of the preceding claimd comprising:
  - 10 (a) transferring a vector as claimed in claim 6 into a host cell;
  - (b) selecting transformed host cells from untransformed host cells;
  - (d) culturing a selected transformed host cell under conditions which allow expression of the protein; and
  - (e) isolating the protein.
- 15 16. A protein prepared in accordance with the method of claim 15.
17. An antibody having specificity against an epitope of a polypeptide as claimed in claim 8, 9, 10, 11, 12, or 13.
18. An antibody as claimed in claim 17 labeled with a detectable substance and used to detect the protein in biological samples, tissues, and cells.
- 20 19. A probe comprising a sequence encoding a protein as claimed in claim 8, 9, 10, 11, 12, or 13, or a part thereof.
20. A method of diagnosing and monitoring conditions mediated by a protein as claimed in claim 8, 9, 10, 11, 12, or 13, by determining the presence of a nucleic acid molecule encoding the protein as claimed in any of the preceding claims or determining the presence of the protein.
- 25 21. A method as claimed in claim 20 wherein the condition is cancer.
22. A method for identifying a substance which associates with a protein as claimed in claim 8, 9, 10, 11, 12, or 13 comprising (a) reacting the protein with at least one substance which potentially can associate with the protein, under conditions which permit the association between the substance and protein, and (b) removing or detecting protein associated with the substance, wherein detection of associated protein and substance indicates the substance associates with the prtoein.
- 30 23. A method for evaluating a compound for its ability to modulate the biological activity of a protein as claimed in claim 8, 9, 10, 11, 12, or 13 comprising providing a known concentration of the protein with a substance which associates with the protein and a test compound under conditions which permit the formation of complexes between the substance and protein, and removing and/or detecting complexes.
- 35 24. A method for detecting a nucleic acid molecule encoding a protein comprising an amino acid sequence of SEQ. ID. NO. 2, 3, 14, 22, 23, 44, 45, 57, 58, 59, 60, 66, or 67 in a biological sample comprising the steps of:

- 85 -

- (a) hybridizing a nucleic acid molecule of claim 2 to nucleic acids of the biological sample, thereby forming a hybridization complex; and
- (b) detecting the hybridization complex wherein the presence of the hybridization complex correlates with the presence of a nucleic acid molecule encoding the protein in the biological sample.
- 5
25. A method as claimed in claim 24 wherein nucleic acids of the biological sample are amplified by the polymerase chain reaction prior to the hybridizing step.
26. A method for treating a condition mediated by a protein as claimed in claim 8, 9, 10, 11, 12, or 13 comprising administering an effective amount of an antibody as claimed in claim 17 or a substance or compound identified in accordance with a method claimed in claim 22 or 23.
- 10
27. A method as claimed in claim 26 wherein the condition is cancer.
28. A composition comprising one or more of a nucleic acid molecule or protein claimed in any of the preceding claims, or a substance or compound identified using a method as claimed in any of the preceding claims, and a pharmaceutically acceptable carrier, excipient or diluent.
- 15
29. Use of one or more of a nucleic acid molecule or protein claimed in any of the preceding claims, or a substance or compound identified using a method as claimed in any of the preceding claims in the preparation of a pharmaceutical composition for treating a condition mediated by a protein as claimed in any of the preceding claims.
- 20
30. A transgenic non-human mammal which does not express a KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6 protein as claimed in claim 8, 9, 10, 11, 12, or 13, respectively, resulting in a KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6 protein associated pathology, respectively.
- 25
31. A transgenic animal assay system which provides a model system for testing for an agent that reduces or inhibits an a KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6 protein associated pathology comprising
- (a) administering the agent to a transgenic non-human animal as claimed in claim 26; and
- (b) determining whether said agent reduces or inhibits a KLK-L1, KLK-L2, KLK-L3, KLK-L4, KLK-L5, or KLK-L6 protein associated pathology in the transgenic non-human animal relative to a transgenic non-human animal of step (a) which has not been administered the agent.

30

FIGURE 1






FIGURE 2



3/51


FIGURE 3



**FIGURE 4**

TGACCCGCTG TACCACCCCA GCATGTTCTG CGCCGGCGGA GGGCAAGACC  
AGAAGGACTC CTGCAACGGT GACTCTGGGG GGCCCCTGAT CTGCAACGGG  
TACTTGCAGG GCCTTGTGTC TTTCGGAAAA GCCCGTGTG GCCAAGTTGG  
CGTGCCAGGT GCCTACACCA ACCTCTGCAA ATTCACTGAG TGGATAGAGA  
AAACCGTCCA GGCCAGTTAA CTCTGGGGAC TGGGAACCCA TGAAATTGAC  
CCCCAAATAC ATCCTGCGGA AGGAATTC


## FIGURE 5





6/51


FIGURE 6



## FIGURE 7

(ATG)GCTACAGCAAGACCCCCCTGGATGTGGGTGCTCTGTGCTCTGATCACAGCCT  
 M A T A R P P W M W V L C A L I T A  
 TGCTTCTGGGGGTCACAGgttaaccaga ----- intron 1-----tcccag  
 L L L G V T  
 AGCATGTTCTCGCCAACAATGATGTTTCTGTGACCACCCCTCTAACACCGTGCCC  
 E H V L A N N D V S C D H P S N T V P  
 TCTGGGAGCAACCAGGACCTGGGAGCTGGGGCCGGGAAGACGCCCCGGTCGGAT  
 S G S N Q D L G A G A G E D A R S D  
 GACAGCAGCAGCCGCATCATCAATGGATCCGACTGCGATATGCACACCCAGCCGT  
 D S S S R I I N G S D C D M H T Q P  
 GGCAGGCCGCGCTGTTGCTAAGGCCCAACCAGCTCTACTGCGGGGCGGTGTTGGT  
 W Q A A L L L R P N Q L Y C G A V L V  
 GCATCCACAGTGGCTGCTCACGGCCGCCCACTGCAGGAAGAAgtgagtgga-----  
 H P Q W L L T A A H C R K K  
 ----- intron 2-----tcttcctcagAGTTTTCAGAGTCCGTCT  
 V F R V R L  
 CGGCCACTACTCCCTGTCAACAGTTTATGAATCTGGGCAGCAGATGTTCCAGGGG  
 G H Y S L S P V Y E S G Q Q M F Q G  
 GTCAAATCCATCCCCACCCTGGCTACTCCCACCCTGGCCACTCTAACGACCTCAT  
 V K S I P H P G Y S H P G H S N D L M  
 GCTCATCAAAGTGAACAGAAGAATTCGTCCCACTAAAGATGTCAGACCCATCAAC  
 L I K L N R R I R P T K D V R P I N  
 GTCTCCTCTCATTGTCCCTCTGCTGGGACAAAGTGCTTGGTGTCTGGCTGGGGGAC  
 V S S H C P S A G T K C L V S G W G T  
 AACCAAGAGCCCCCAAGgtgagtgaccaggt ----- intron 3-----tgacag  
 T K S P Q  
 TGCACTTCCCTAAGGTCCTCCAGTGCTTGAATATCAGCGTGCTAAGTCAGAAAAG  
 V H F P K V L Q C L N I S V L S Q K R  
 GTGCGAGGATGCTTACCCGAGACAGATAGATGACACCATGTTCTGCGCCGGTGAC  
 C E D A Y P R Q I D D T M F C A G D  
 AAAGCAGGTAGAGACTCCTGCCAGgtgaggacacc----- intron 4-----  
 ag  
 K A G R D S C Q  
 GGTGATTCTGGGGGGCCTGTGGTCTGCAATGGCTCCCTGCAGGGACTCGTGTCTCT  
 G D S G G P V V C N G S L Q G L V S  
 GGGGAGATTACCCTTGTGCCCCGCCCAACAGACCGGTGTCTACACGAACCTCTG  
 W G D Y P C A R P N R P G V Y T N L C  
 CAAGTTCACCAAGTGGATCCAGGAAACCATCCAGGCCAACTCCTGAGTCAATCC  
 CA  
 K F T K W I Q E T I Q A N S  
 GGACTCAGCACACCGGCATCCCCACCTGCTGCAGGGACAGCCCTGACACTCCTTT  
 CAGACCCCTCATTCCTTCCCAGAGATGTTGAGAATGTTTCATCTCTCCAGCCCCTGAC  
 CCCATGTCTCTCTGGACTCAGGGTCTGCTTCCCCACATTGGGCTGACCGTGTCTCT  
 CTAGTTGAACCCTGGGAACAATTTCCAAAACCTGTCCAGGGCGGGGGTTGCGTCTC  
 AATCTCCCTGGGGCACTTTTCATCTCAAGCTCAGGGCCCATCCCTTCTCTGCAGCT  
 CTGACCCAAATTTAGTCCCAGAAATAAACTGAGAAG

FIGURE 8




## FIGURE 9

protease	MATAGNPWGWLGL----	YLILGVAGSLVSG-----	26
EMSP	MATAGNPWGWLGL----	YLILGVAGSLVSG-----	26
KLK-L2	MATARPPMMWVLCALITALLGVTEHVLANNVSCDHPSNTVPSSGNQDLGAGAGEDARS		60
zyme	-----MKKLM-----	VVLSLIAAAWA-----	16
neuropsin	-MGRPRPRAAKTW-----	MFLLLLGCAWAGH-----	S 26
TLSP	-----MRILQ-----	LILLALATGLVG-----	17
PSA	-----MWVPVVF-----	LTLSVTWIGAAPL-----	20
KLK2	-----MWDLVLS-----	IALSVGCTGAVPL-----	20
KLK1	-----MWFLVLC-----	LALSLGGTGAAPP-----	20
trypsinogen	-----MNPLLI-----	LTFVAAALAAPFD-----	19
↑			
protease	--SCSQIINGEDCSPHSQPWQAALVM-ENELFCSGVLVHPQWVLSAAHCFQNSYTIGLGL		83
EMSP	--SCSQIINGEDCSPHSQPWQAALVM-ENELFCSGVLVHPQWVLSAAHCFQNSYTIGLGL		83
KLK-L2	DDSSSRIINGSDCMHTQPWQAALLRPNQLYCGAVLVHPQWLLTAACHCKKPVFRVRLGH		120
zyme	-EEQNKLVHGGPCDKTSHPYQAALYT-SGHLCCGGVLHPLWVLTAAHCKKPNLQVFLGK		74
neuropsin	RAQEDKVLGGHECQPHSQPWQAALFQ-GQQLCCGGVLVGGWVLTAAHCKKPKYTVRLGD		85
TLSP	--GETRIIKGFCECKPHSQPWQAALFE-KTRLLCGATLIAPRWLLTAACHCKPKYIVHLGQ		74
PSA	--ILSRIVGGWECEKHSQPWQVLVAS-RGRAVCGGVLVHPQWVLTAAHCKIRNKSIVILLGR		77
KLK2	--IQSRIVGGWECEKHSQPWQVAVYS-HGWAHCGGVLVHPQWVLTAAHCKKNSQVWLGR		77
KLK1	--IQSRIVGGWECEKHSQPWQAALYH-FSTFQCGGILVHRQWVLTAAHCKISDNQYLWLGR		77
trypsinogen	--DDDKIVGGYNCEENSVPYQVSLNS--GYHFCGGSLINEQWVVSAGHCYKSRIVRLGE		75
↑			
protease	HSLEADQEPGSQMVEASLSVRHPEYN----	RP-----LLANDLMLIKLDESVS-ESDT	131
EMSP	HSLEADQEPGSQMVEASLSVRHPEYN----	RP-----LLANDLMLIKLDESVS-ESDT	131
KLK-L2	YSLSPVYESGQMFQGVKSIHPHGYSG----	HP-----GHSNDLMLIKLNRRIR-PTKD	168
zyme	HNLRO-RESSQEQQSSVRAVIHPDY----	DAA-----SHDQDMLLRLARPAK-LSEL	121
neuropsin	HSLQN-KDGPEQEIPVVSQSIHPHCYN-SSDVE-----	DHNHDLMLLQLRDQAS-LGSK	135
TLSP	HNLQK-EEGCEQTRTATESFPHPGFNNSLPNK-----	DHRNDIMLVKMASPVS-ITWA	125
PSA	HSLFH-PEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDSSHDMLLRLSEPAP-LTDA		135
KLK2	HNLFE-PEDTGQVRVPVSHSFPHPLYNMSLLKHQSLRPFEDSSHDMLLRLSEPAK-ITDV		135
KLK1	HNLFD-DENTAQFVHVSESFPHPGFNMSLLENHTRAEDYSHDMLLRLTEPADTITDA		136
trypsinogen	HNIEV-LEGNEQFINAAKIIRHPQYDRKTLNN-----	DIMLIKLSRAV-INAR	122
-----+			
protease	IRSISIASQCPTAGNSCLVSGWGGLLANG--	RMPTVLQCVNVSVVSEEVCSKLYDPLYHPS	189
EMSP	IRSISIASQCPTAGNSCLVSGWGGLLANG--	RMPTVLQCVNVSVVSEEVCSKLYDPLYHPS	189
KLK-L2	VRPINVSSHCPASAGTKCLVSGWGTTKSPQVHFPPKVLQCLNISVLQKRCEDAYPRQIDDT		228
zyme	IQPLPLERDCSANTTSCHILGWGKTADG--	DFPDITQCAIHLVSRECEHAYPGQITQN	179
neuropsin	VKPISLADHCTQPGQKCTVSGWGTVTSPRENFPTLNCAEVKIFPQKKCEDAYPGQITDG		195
TLSP	VRPLTLSSRCVTAGTSCLSISGWGSTSSPQLRLPHTLRANITIIHQKCNAYPGNITDT		185
PSA	VKVMDLPTQEPALGTTTCYASGWSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQKVTKF		195
KLK2	VKVLGLPTQEPALGTTTCYASGWSIEPEEFLRPRSLQCVSLHLLSNDMCAVSEKVTDF		195
KLK1	VKVVELPTEPEVSGTCLASGWSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTF		196
trypsinogen	VSTISLPTAPPATGTCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKITSN		182
protease	MFCAGGGHDQKDSNGDSGGFLICNGYLQGLVSFGKAPCGQVGPVGYTNLCKFTEWIEK		249
EMSP	MFCAGGGHDQKDSNGDSGGFLICNGYLQGLVSFGKAPCGQVGPVGYTNLCKFTEWIEK		249
KLK-L2	MFCAG-DKAGRDSCQGDSGGFVVCNGLVSGWDYPCARPNRPGVYTNLCKFTKWIQE		287
zyme	MLCAGDEKYGKDSQGDSGGFLVCGDHLRGLVSWGNIPCGSKEKPGVYTNVCRYTNWIQK		239
neuropsin	MVCAGSSK-GADTCQGDSGGFLVCDGALQGITSWGSDPCGRSDKPGVYTNICRYLDWIKK		254
TLSP	MVCASVQEGGKDSQGDSGGFLVCNQSLQGIISWGDPCAITRKPGVYTKVCKYVDWIQE		245
PSA	MLCAGRWTGGKSTCSGDSGGFLVCNGVLQGITSWGSEPCALPERPSLYTKVHYRKWIKD		255
KLK2	MLCAGLWTGGKDTCSGDSGGFLVCNGVLQGITSWGSEPCALPEKPAVYTKVHYRKWIKD		255
KLK1	MLCVGHLEGGKDTCSGDSGGFLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLVYKWIWED		256
trypsinogen	MFCVGFLEGGKDSQGDSGGFVVCNGVLQGVTSWG-DGCAQKNKPGVYTKVYNYVKWIKN		241


10/51

FIGURE 10

(A)




(B)




11/51

FIGURE 11



12/51

## FIGURE 12



# FIGURE 13







FIGURE 14



## FIGURE 15

CACTGGACGGGTGCACGTTTCAGGATCCAGGTGCCAGGGGTCAATG AAG CTG GGA  
 CTC M K L G L  
 CTC TGT GCT CTG CTC TCT CTG CTG GCA Ggtga... intron 1 ..ccag GG CAT  
 GGC L C A L L S L L A G H  
 TGG GCA GAC ACC CGT GCC ATC GGG GCC GAG GAA TGT CGC CCC AAC TCC  
 CAG W A D T R A I G A E E C R C N S  
 Q  
 CCT TGG CAG GCC GGC CTC TTC CAC CTT ACT CGG CTC TTC TGT GGG GCG  
 ACC P W Q A G L F H L T R L F C G A T  
 CTC ATC AGT GAC CGC TGG CTG CTC ACA GCT GCC CAC TGC CGC AAG  
 CCgtga..... L I S D R W L L T A A H C R K P  
 intron 2 .....gcag G TAT CTG TGG GTC CGC CTT GGA GAG CAC CAC CTC TGG AAA  
 Y L W V R L G E H H L W K  
 TGG GAG GGT CCG GAG CAG CTG TTC CGG GTT ACG GAC TTC TTC CCC CAC  
 CCT W E G P E Q L F R V T D F F P H P  
 GGC TTC AAC AAG GAC CTC AGC GCC AAT GAC CAC AAT GAT GAC ATC ATG  
 CTG G F N K D L S A N D H N D D I M L  
 ATC CGC CTG CCC AGG CAG GCA CGT CTG AGT CCT GCT GTG CAG CCC CTC  
 AAC I R L P R Q A R L S P A V Q P L N  
 CTC AGC CAG ACC TGT GTC TCC CCA GGC ATG CAG TGT CTC ATC TCA GGC  
 TGG L S Q T C V S P G M Q C L I S G W  
 GGG GCC GTG TCC AGC CCC AAG Ggtat..... intron ..acag CG CTG TTT CCA  
 GTC G A V S S P K A L F P  
 V  
 ACA CTG CAG TGT GCC AAC ATC AGC ATC CTG GAG AAC AAA CTC TGT CAC  
 TGG T L Q C A N I S I L E N K L C H W  
 GCA TAC CCT GGA CAC ATC TCG GAC AGC ATG CTC TGT GCG GGC CTG TGG  
 GAG A Y P G H I S D S M L C A G L W E  
 GGG GGC CGA GGT TCC TGC CAG Ggtga..... intron ..acag GGT GAC TCT GGG  
 GGC G G R G S C Q G D S G  
 G  
 CCC CTG GTT TGC AAT GGA ACC TTG GCA GGC GTG GTG TCT GGG GGT GCT  
 GAG P L V C N G T L A G V V S G G A E

## FIGURE 15 (CONT'D)


CCC TGC TCC AGA CCC CGG CGC CCC GCA GTC TAC ACC AGC GTA TGC CAC  
TAC

P C S R P R R P A V Y T S V C H Y

CTT GAC TGG ATC CAA GAA ATC ATG GAG AAC (TGA)  
L D W I Q E I M E N

GCCCCGCGCCACGGGGGCACCTTGGAAGACCAAGAGAGGGCCGAAGGGGCACGGGGTA  
GGGGGTTCTCGTAGGGTCCCAGCCTCAATGGTTCCCGCCCTGGACCTCCAGCTGCCCTG  
ACTCCCCTCTGGACACTAAGACTCCGCCCCTGAGGCTCCGCCCCCTCACGGGTCAAGCA  
AGACACAGTCGCGCCCCCTCGGAACGGAGCAGGGACACGCCCTTCAGAGCCGTCTCTAT  
GACGTCACCGACAGCCATCACCTCCTTCTTGGAACAGCACAGCCTGTGGCTCCGCCCCA  
AGGAACCACTTACACAAAATAGCTCCGCCCCTCGGAACCTTTGCCAGTGGGACTTCCCC  
TCGGGACTCCACCCCTTGTGGCCCCGCTCCTTACCAGAGATCTCGCCCCTCGTGATGT  
CAGGGGCGCAGTAGCTCCGCCCACGTGGAGCTCGGGCGGTGTAGAGCTCAGCCCTTGTG  
GCCCCGTCTGGGCGTGTGCTGGGTTTGAATCCTGGCGGAGACCTGGGGGGAATTGAG  
GGAGGGTCTGGATACCTTTAGAGCCAATGCAACGGATGATTTTTTCAGTAAACGGGGAAA  
CCTCA

17/51

**FIGURE 16**

## FIGURE 17

PSA -----MWVPVFLTSLVTWIGAAPLI-LSRIVGGWECEKHSQPWQVLVASRGRAVC  
 KLK2 -----MWDVLVLSIALSVGCTGAVPLI-QSRIVGGWECEKHSQPWQVAVYSHGWAHC  
 KLK1 -----MWFLVLCLALSLGGTGAAPPI-QSRIVGGWECEKHSQPWQAAALYHFSTFQC  
 trypsinogen -----MNPLLILTFVAAALAAPFDD-DDKIVGGYNCENSVPYQVSLNS-GYHFC  
 KLK-L3 -----MKLGLLCLALLSLLAGHGWA--DTRAIGAEECRPNSQPWQAGLFHLTRLFC  
 TLSP -----MRI-LQLILLALATGLVGG--ETRIIKGFCECKPHSQPWQAAALFEKTRLLC  
 neuropsin -MGRPRPRAAKTWMFLLLLLGGAWAGHSRAQ-EDKVLGGHECQPHSQPWQAAALFQGGQLLC  
 zyme -----MKK--LMVVLSLIAAAWAE-EQNKLVHGGPCDKTSHPYQAALYTSGLLCC  
 HSCCE ---MARSLLLPLQILLLSLALETAGEEAQG--DKIIDGAPCARGSHPWQVALLSGNQLHC  
 prostase ---MA-TAGNPWGWLGLYLILGVAGSLVSGSCSQIINGEDCSPHSQPWQAAALVMENELFC

♦

PSA GGVLVHPQAVLTAAHCIIRNKSVILLGRHSLFHPEDT-GQVFQVSHSFPHPLYDMSLLKNR  
 KLK2 GGVLVHPQAVLTAAHCLKKNQVWLGRHNLFEEDT-GQRPVSHSFPHPLYNMSLLKHQ  
 KLK1 GGILVHRQAVLTAAHCIISDNYQLWLRHNLFDENT-AQFVHVSESFPHPGFNMSLLENH  
 trypsinogen GGSLINECAVVSAGHCYKSRIOVRLGEHNIIEVLEGN-EQFINAAKIRHPQYDRKTLNN-  
 KLK-L3 GATLISDRALLTAAHCKRPYLWVRLGEHHLWKWEGP-EQLFRVTDFFPHPGFNKDLNAN-  
 TLSP GATLIAPRALLTAAHCKLPRIYVHLGQHNLOKEEGC-EQTRTATESFPHPGFNNSLPNK-  
 neuropsin GGVLVGGNAVLTAAHCKKPKYTIVRLGDHSLQNKDGP-EQEIPVVQSIHPGYNSSD-VE-  
 zyme GGVLVHPQAVLTAAHCKKPNLQVFLGKHNLRQESS-QEQSSVRAVIHPDYDAAS----  
 HSCCE GGVLVNERAVLTAAHCKMNEYTVHLGSDTLGDRR---AQRIKASKSFRHPGYSTQT---  
 prostase SGVLVHPQAVLTAAHCFQNSYITIGLGLHSLEADQEPGSMVEASLSVRHPEYNRPLLAN-

PSA FLRPGDDSSHDLMLRLRLSEPAE-LTDAVKVMDLPTQEPALGTTTCYASGWGSIPEEFLLTP  
 KLK2 SLRPEDESSHDLMLRLRLSEPAK-ITDVVKVLGLPTQEPALGTTTCYASGWGSIPEEFLLRP  
 KLK1 TRQADEDYSHDLMLRLRLTEPADTITDAVKVVELPTEPEVGSTCLASGWGSIPEENFSFP  
 trypsinogen -----DIMLIKLSRAV-INARVSTISLPTAPPATGKCLISGWGNTASSGADYP  
 KLK-L3 -----DHNDDIMLIRLPRQAR-LSPAVQPLMNSQTCVSPGMQCLISGWGAVSSPKALFP  
 TLSP -----DHRNDIMLVKMASPVS-ITWAVRPLTLSSRCVTAGTSCILSGWGSTSSPQLRLP  
 neuropsin -----DHNDDIMLQLRLDQAS-LGSKVKPISLADHCTQPGQKCTVSGWGTVTSPRENFP  
 zyme -----HDQDIMLIRLARPAP-LSELIQPLPLERDCSANTTSCHILGWGKTADG--DFP  
 HSCCE -----HVNDDIMLVKLNSQAR-LSSMVKVRLPSRCEPPGTTCTVSGWGTSTSPDVTFP  
 prostase -----DIMLIKLDSEVS-ESDTIRISIASQCPTAGNSCLVSGWGLLANG--RMP

PSA KKLQCVDLHVISNDVCAQVHPQKVTKFMCLCAGRWTGGKSTCSGDSGGPLVCNGVLQGIT  
 KLK2 RSLQCVSLHLLSNDMCARAYSEKVTFFMLCAGLWTGGKDTCCGDSGGPLVCNGVLQGIT  
 KLK1 DDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCCGDSGGPLMCDGVLQGVTS  
 trypsinogen DELQCLDAPVLSQAKCEASYPGKITSNMFCVGFLEGGKDSQCGDSGGPLVCNGVLQGVTS  
 KLK-L3 VTLQCANISILENKLCHWAYPGHISDSMLCAGLWEGGRGSCCGDSGGPLVCNGTLAGVVS  
 TLSP HTLRANITIIIEHQKCEANYPGNITDTMVCASVQEGGKDSQCGDSGGPLVCNQSLQGIIS  
 neuropsin DTLNCAEVKIFPQKKCEDAYPGQITDGMVCAGSSKG-ADTCQCGDSGGPLVCDGALQGIT  
 zyme DTIQCAIYIHLVSREECEHAYPGQITQNMCLCAGDEKYGKDSQCGDSGGPLVCGDHLRGLVS  
 HSCCE SDLMCVDVKLISPQDCTKVYKDLLENSMLCAGIPDSKKNACNGDSGGPLVCRGTLOGLVS  
 prostase TVLQCVNVSVVSEEVCSKLYDPLYHPSMFCAGGHDQKDSNCGDSGGPLICNGYLQGLVS

PSA WGSEPCALPERPSLYTKVHYRKWIKDTIVANP  
 KLK2 WGPEPCALPEKPAVYTKVHYRKWIKDTIAANP  
 KLK1 WGYVPCGTPNKPVSVAVRVLSYVKWIEDTIAENS  
 trypsinogen WG-DGCAQKNKPGVYTKVYNYVKWIKNTIAANS  
 KLK-L3 GGAEPCSRPRRPAVYTSVCHYLDWIEIMEN--  
 TLSP WGQDPCAITRKPGVYTKVCKYVDWIEIMKNN-  
 neuropsin WGSDFCGRSDKPGVYTNICRYLDWIKKIIGSKG  
 zyme WGNIPCGSKEKPGVYTNVCRYTNWIKTIQAK-  
 HSCCE WGTFFCGQPNDPGVYTVCKFTKWINDTMKKHR  
 prostase FGKAPCGQVGPVYTNLCKFTIEWIEKTVQAS-

19/51

FIGURE 18





FIGURE 19



21/51

## FIGURE 20






FIGURE 21






FIGURE 22




24/51

## FIGURE 23



25/51

FIGURE 24



26/51  
FIGURE 25


TCAGGCCCCGCCCCGCCCTGCCCTCCCCTCCCGATCCCGGAGCC ATG TGG CCC CTG GCC  
M W P L A  
CTA GTG ATC GCC TCC CTG ACC TTG GCC TTG TCA GGA G...gtaaga.... intron 1 ..... ttaccag  
L V I A S L T L A L S G  
GT GTC TCC CAG GAG TCT TCC AAG GTT CTC AAC ACC AAT GGG ACC AGT GGG TTT  
G V S Q E S S K V L N T N G T S G F  
CTC CCA GGT GGC TAC ACC TGC TTC CCC CAC TCT CAG CCC TGG CAG GCT GCC  
L P G G Y T C F P H S Q P W Q A A  
CTA CTA GTG CAA GGG CGG CTA CTC TGT GGG GGA GTC CTG GTC CAC CCC AAA  
L L V Q G R L L C G G V L V H P K  
TGG GTC CTC ACT GCC GCA CAC TGT CTA AAG GA gtatgt ..... intron 2..... cacag G GGG  
W V L T A A H C L K E G  
CTC AAA GTT TAC CTA GGC AAG CAC GCC CTA GGG CGT GTG GAA GCT GGT GAG  
L K V Y L G K H A L G R V E A G E  
CAG GTG AGG GAA GTT GTC CAC TCT ATC CCC CAC CCT GAA TAC CGG AGA AGC  
Q V R E V V H S I P H P E Y R R S  
CCC ACC CAC CTG AAC CAC GAC CAT GAC ATC ATG CTT CTG GAG CTG CAG TCC  
P T H L N H D H D I M L L E L Q S  
CCG GTC CAG CTC ACA GGC TAC ATC CAA ACC CTG CCC CTT TCC CAC AAC AAC CGC  
P V Q L T G Y I Q T L P L S H N N R  
CTA ACC CCT GGC ACC ACC TGT CGG GTG TCT GGC TGG GGC ACC ACC ACC AGC  
L T P G T T C R V S G W G T T T S  
CCC CAG G gtatgcac... intron 3..... tcccc ag TG AAT TAC CCC AAA ACT CTA CAA TGT GCC  
P Q V N Y P K T L Q C A  
AAC ATC CAA CTT CGC TCA GAT GAG GAG TGT CGT CAA GTC TAC CCA GGA AAG  
N I Q L R S D E E C R Q V Y P G K  
ATC ACT GAC AAC ATG TTG TGT GCC GGC ACA AAA GAG GGT GGC AAA GAC TCC  
I T D N M L C A G T K E G G K D S  
TGT GAG gtatgca... intron 4..... aactcag GGT GAC TCT GGG GGC CCC CTG GTC TGT AAC  
C E G D S G G P L V C N  
AGA ACA CTG TAT GGC ATC GTC TCC TGG GGA GAC TTC CCA TGT GGG CAA CCT  
R T L Y G I V S W G D F P C G Q P  
GAC CGG CCT GGT GTC TAC ACC CGT GTC TCA AGA TAC GTC CTG TGG ATC CGT  
D R P G V Y T R V S R Y V L W I R

## FIGURE 25 (CONT'D)

GAA ACA ATC CGA AAA TAT GAA ACC CAG CAG CAA AAA TGG TTG AAG GGC CCA  
E T I R K Y E T Q Q Q K W L K G P

CAA (TAA) AAGTTGAGAAATGTACCGGCTTCCATCCTGTCACCATGACTTCCTCAC  
Q

ATGGTCTGCTTAGCCCTTCTCTGCTCCTTATTCCCAGTGTTCCATTTGAACCAGTGATCCATGTC  
CTGAAAAATGCTCAATCTCAGCTAACATTCCATGTTTCAGAAGCATTTCAGGCACTGCCAGGCT  
TGCAGTCTCCCAGATGTTGCATCCCTGAAACATCTCAACAACCTGAATGTCCCAACCCAGACA  
ATGGCCCAGGTCTCTCAACTTCATCAGTGTGGCTTCTATGAGCCCAGATCACCACCTGAACGT  
TCTGTCTGTGGCACATTCTTAAATATTTCCATCAGCCCATCTCAACAATATATGTCCTTATAAAT  
GGACCATCCTTGACA

**FIGURE 26**

## FIGURE 27


1	KLK-L1/protease	15 16	30 31	45 46	60 61	75 76	90
2	EMSP	---MATAGN	PWGFLG---	YLIL	GVAG---	---SLVSG---	IINGEDCSPHSQPWQ
3	KLK-L2	---MATAGN	PWGFLG---	YLIL	GVAG---	---SLVSG---	IINGEDCSPHSQPWQ
4	PSA	---MATARP	PWMVLCALITALL	GVTEHVLANDVSCD	HPSNTVPVSGSNQDLG	AGAGEDARSDDSSR	IINGSDCDMHTQPWQ
5	KLK2	---MWVPVVF---	LTLSV	TWIG---	---AAPLI---	---L---	IUGWECEKHSQPWQ
6	KLK1	---MWFLVLC---	LALSU	GGTG---	---AAPLI---	---Q---	IUGWECEKHSQPWQ
7	trypsinogen	---MNPLLI---	LTFVA	AALA---	---APFDD---	---D---	IUGGYNCEENSVPYQ
8	zyme/protease M	---MKKLMV---	VLSL	IAAA---	---WAEQNK---	---LNTNGTSGF---	LHVGPGCDKTSHPYQ
9	KLK-L4	---MW	PLALVIA---	SLTL	ALSG---	---GVSESSKV---	LPGGYTCFPHSQPWQ
10	TLSP	---MR	ILQILLALATGLVG	GETR---	---I---	---IKGFECKPHSQPWQ	---IKGFECKPHSQPWQ
11	neuropsin	---MGRPREPA	AKTWMFLLLGGAWA	GHSR---	---AQEDK---	---VLGHECQPHSQPWQ	---VLGHECQPHSQPWQ
12	NES1	MRAPHLHLSAASGAR	ALAKLLPLMLAQLWA	AEAA---	---LLPQN---	---DTRLDP	EAYGAPCARGSQPWQ
91	protease	105 106	120 121	135 136	150 151	165 166	180
2	EMSP	AALVM-ENELFCSGV	LVPQV---	NSYTTGLGLHLSLEAD	QEPGQMVSEASLSVR	HPEYNRPILLAN---	---DMLIKLD
3	KLK-L2	AALVM-ENELFCSGV	LVPQV---	NSYTTGLGLHLSLEAD	QEPGQMVSEASLSVR	HPEYNRPILLAN---	---DMLIKLD
4	PSA	AALLRPNQLYCGAV	LVPQV---	KVFRVLGHVLSLV	YESGQMFQGVKSIP	HPOYSHPHGNSN---	---DMLIKLN
5	KLK2	VAVYS-RGRAVCGGV	LVPQV---	IR	NKSVLLGRHSLFHP	-EDTGQVQVSHSP	HPLIDMSLLKNRFLR
6	KLK1	VAVYS-RGRAVCGGV	LVPQV---	IR	NKSVLLGRHSLFHP	-EDTGQVQVSHSP	HPLIDMSLLKNRFLR
7	trypsinogen	AALYH-FSTFQCGGI	LVPQV---	IS	DNYQLWGLRHNLFPD	-ENTAGFVHVSESP	HGFNMSLLENHTRQ
8	zyme	VSLNS-GYHFCGGS	LINEG---	VEG---	SNQVRLGHEHNIYL	-EGNEQFINAAKIIR	HPQYDRKTLAN---
9	KLK-L4	AALYT-SCHLLCGGV	LHPLE---	PKK	PNLOVFLGKHNLRQ	---HPDYDAA---	---SHDQDINRFLA
10	TLSP	AALLV-QGRLLCGGV	LVPQV---	PKK	EGLKYLGLGHALGRV	-EAGEQVREVVHSIP	HPEYRSPTHL---
11	neuropsin	AALFE-KTRLLCGAT	LIAPR---	PKK	PRYIVHLGQHLOKE	-EGCEQTRTATESPP	HPGFNNSLPNK---
12	NES1	AALFO-GQQLLCGGV	LVGNN---	PKK	PKYTVRLGHSLOKQ	-DGPEQEIPVQOSIP	HPCYNSD-VE---
		VSLFN-GLSFHCAGV	LVDQS---	PKK	KPLMARVGGDHLHLL	Q--GEQLRRTTRSVV	HPKYHOGS-GPILPR
181	protease	195 196	210 211	225 226	240 241	255 256	270
2	EMSP	ESVS-ESDITIRISIS	ASQCPTAG-NSCLVS	GWGLLANG--	RMPTV	LQCVNVSVVSEEVCS	KLYDPLVHPNMFACG
3	KLK-L2	ESVS-ESDITIRISIS	ASQCPTAG-NSCLVS	GWGLLANG--	RMPTV	LQCVNVSVVSEEVCS	KLYDPLVHPNMFACG
4	PSA	RRIR-PTKDVVRPINV	SSHCPSAG-TKCLVS	GWGTTKSPQVHFPKV	LOCLINISLVSKRCE	DAYPRQIDDTMFCAG	DKAG-RDSCQDSEGG
5	KLK2	EPAE-LTDAVKVMDL	PTQEPALG-TTCVAS	GWGSTEPEEFLTPKK	LQCVDLHVISNDVCA	QVHPQKVTXFMFLCAG	RWTGGKSTCSQDSEGG
6	KLK1	EPAE-LTDAVKVMDL	PTQEPALG-TTCVAS	GWGSTEPEEFLTPKK	LQCVDLHVISNDVCA	QVHPQKVTXFMFLCAG	RWTGGKSTCSQDSEGG
7	trypsinogen	EPADTITDAVKVVEL	PTQEPALG-TTCVAS	GWGSTEPEEFLTPKK	LQCVDLHVISNDVCA	QVHPQKVTXFMFLCAG	RWTGGKSTCSQDSEGG
8	zyme	SRAP-INARVSTISL	PTAPPATG-TKCLIS	GWGNTASSGADYDE	LQCLDAPVLSQAKCE	ASYPGKITSNMFCVG	FLEGGKDSQDSEGG
9	KLK-L4	RPAP-LSELIQPLPL	ERDCSANT-TSCHIL	GWGKTADG--	DFPDT	IQCAYIHLVSREECE	HAYPGQITQNMFLCAG
10	TLSP	SPVQ-LTGYIQTPL	SHNNRLTPGTTCRVS	GWGTTSPQVNYRPT	LRCANITIIHQKCE	QVYPGKITDNMLCAG	TKEGGKDSCEGHQDSEGG
11	neuropsin	SPVS-ITWAVRPLTL	SSRCVTAG-TSCLIS	GWGTTSSPQLRLPHT	LRCANITIIHQKCE	QVYPGKITDNMLCAG	TKEGGKDSCEGHQDSEGG
12	NES1	DQAS-LGSKVKPISL	ADHCTQPG-QKCTVS	GWGTVTSPENF PDT	LNCAEVKIFPQKCE	DAYPGQITDGMVACG	SSKG-ADTCQDSEGG
		RPVVP-GPRVRLAQL	PYRCAQPG-DQCQVA	GWGTTAARRVKYKNG	LTCSSITILSPKECE	VFPYGVVNNMICAG	LDRG-ODPCQDSEGG



FIGURE 27 (CONT'D)

1	prostate	271	285	286	300	301	315	316	330	331
2	EMSP	PHI	GYLQGLVSFG	KAPCGQVGVP	GVVYTN	LCKFTWIEKTVQAS	---	---	---	---
3	KLK-L2	PHI	GYLQGLVSFG	KAPCGQVGVP	GVVYTN	LCKFTWIEKTVQAS	---	---	---	---
4	PSA	HVF	GSLOGLVSWG	DYPCARPNRPG	VVYTN	LCKFTWIEKTVQAS	S	---	---	---
5	KLK2	HVF	GSLOGLVSWG	DYPCARPNRPG	VVYTN	LCKFTWIEKTVQAS	S	---	---	---
6	KLK1	HVF	GSLOGLVSWG	DYPCARPNRPG	VVYTN	LCKFTWIEKTVQAS	S	---	---	---
7	trypsinogen	HVF	GSLOGLVSWG	DYPCARPNRPG	VVYTN	LCKFTWIEKTVQAS	S	---	---	---
8	zyme	HVF	GSLOGLVSWG	DYPCARPNRPG	VVYTN	LCKFTWIEKTVQAS	S	---	---	---
9	KLK-L4	HVF	GSLOGLVSWG	DYPCARPNRPG	VVYTN	LCKFTWIEKTVQAS	S	---	---	---
10	TLSP	HVF	GSLOGLVSWG	DYPCARPNRPG	VVYTN	LCKFTWIEKTVQAS	S	---	---	---
11	neuropsin	HVF	GSLOGLVSWG	DYPCARPNRPG	VVYTN	LCKFTWIEKTVQAS	S	---	---	---
12	NES1	HVF	GSLOGLVSWG	DYPCARPNRPG	VVYTN	LCKFTWIEKTVQAS	S	---	---	---

FIGURE 28



## FIGURE 29

```

          +-----TLSP
        +----4
          !
        +-----KLK-L3
      +-13
      ! ! +-----neuropsin
      ! +-12
+-14      +-----NES1
! !
! ! +-----zyme
! +-11
!      +-----KLK-L4
!
!      +-----PSA
!      +---2
! +-----3 +---KLK2
! !
! !      +-----KLK1
-15-10
! ! +-----trypsinogen I
! ! !
! ! ! +-----complement factor D
! +-9      +---6
! ! +---7 +-----granzyme A
! ! !
! +-8 +-----cathepsin G
! !
!      +-----chymotrypsin
!
!      +protease/KLK-L1
! +-----1
+----5      +EMSP
!
+-----KLK-L2

```


33/51  
**FIGURE 30**

FIGURE 31






FIGURE 32



## FIGURE 33

GCAGGTAGGTGGACGGAGAGATAGCAGCGACGAGGACAGGCCAAACAGTGACAGCCACG  
TAGAGGATCTGGCAGACAAAGAGACAAGGTGAGAAGGAG gtagg.....Intron 1.....  
.....tgacactccccag ACTTTGGAAGTGACCCACC ATG  
M  
GGG CTC AGC ATC TTT TTG CTC CTG TGT GTT CTT G gtgagttctcccg  
G L S I F L L L C V L  
gagcagggagagggca..... Intron 2 .....cctgtctgtctccag GG CTC  
G L  
AGC CAG GCA GCC ACA CCG AAG ATT TTC AAT GGC ACT GAG TGT GGG  
S Q A A T P K I F N G T E C G  
CGT AAC TCA CAG CCG TGG CAG GTG GGG CTG TTT GAG GGC ACC AGC  
R N S Q P W Q V G L F E G T S  
CTG CGC TGC GGG GGT GTC CTT ATT GAC CAC AGG TGG GTC CTC ACA  
L R C G G V L I D H R W V L T  
GCG GCT CAC TGC AGC GGC AG gtaagtccttcc.....intron3.....  
A A H C S G S  
.ccgtcgccaccggcag C AGG TAC TGG GTG CGC CTG GGG GAA CAC AGC  
R Y W V R L G E H S  
CTC AGC CAG CTC GAC TGG ACC GAG CAG ATC CGG CAC AGC GGC TTC  
L S Q L D W T E Q I R H S G F  
TCT GTG ACC CAT CCC GGC TAC CTG GGA GCC TCG ACG AGC CAC GAG  
S V T H P G Y L G A S T S H E  
CAC GAC CTC CGG CTG CTG CGG CTG CGC CTG CCC GTC CGC GTA ACC  
H D L R L L R L R L P V R V T  
AGC AGC GTT CAA CCC CTG CCC CTG CCC AAT GAC TGT GCA ACC GCT  
S S V Q P L P L P N D C A T A  
GGC ACC GAG TGC CAC GTC TCA GGC TGG GGC ATC ACC AAC CAC CCA  
G T E C H V S G W G I T N H P  
CGG A gtaaggggcccaggccagg.....intron 4 .....  
R  
.gaccctgcagcacgcacgtgttctctctccag AC CCA TTC CCG GAT CTG CTC  
N P F P D L L  
CAG TGC CTC AAC CTC TCC ATC GTC TCC CAT GCC ACC TGC CAT GGT  
Q C L N L S I V S H A T C H G  
GTG TAT CCC GGG AGA ATC ACG AGC AAC ATG GTG TGT GCA GGC GGC  
V Y P G R I T S N M V C A G G  
GTC CCG GGG CAG GAT GCC TGC CAG gtgagcc..... Intron 5 .....  
V P G Q D A C Q  
.aaacagaaataagatgtctccttgttcagacagtacttctcttcccttccag GGT  
G  
GAT TCT GGG GGC CCC CTG GTG TGT GGG GGA GTC CTT CAA GGT CTG  
D S G G P L V C G G V L Q G L  
GTG TCC TGG GGG TCT GTG GGG CCC TGT GGA CAA GAT GGC ATC CCT  
V S W G S V G P C G Q D G I P  
GGA GTC TAC ACC TAT ATT TGC AA(G TAT GTG GAC TGG ATC CGG ATG  
G V Y T Y I C K Y V D W I R M  
ATC ATG AGG AAC AAC TGA CCTGTTCTCCACCTCCACCCCACTTAACTT  
I M R N N  
GGGTACCCCTCTGGCCCTCAGAGCACCACCAATATCTCCTCCATCACTTCCCTAG) CTCCAC  
TCTTGTGTGGCCTGGGAACCTTCTTGGAACTTTAACTCCTGCCAGCCCTTC TAA GACCCACG  
AGCGGGGTGAGAGAAGTGTGCAATAGTCTGGAATAAATATAAATGAAGGAGGGGC

FIGURE 34






**FIGURE 35**



Figure 36 cont'd

1	PSA	271	285	286	300	301	
2	hk2	SLXTKVHHYRKWKD	TIVANP	-----	---	---	261
3	hk1	AVYTKVHHYRKWKD	TIAANP	-----	---	---	261
4	prostase	SVAVRVLSYVKWIED	TIAENS	-----	---	---	262
5	zyme	GVYTNLCKFTENIEK	TVQAS	-----	---	---	254
6	TLSP	GVYTNVCRYTNNIQK	TIQAK	-----	---	---	244
7	KLK-L4	GVYTKVCKYVDWIQE	TMKNN	-----	---	---	250
8	NES1	GVYTRVSRVVLHIRE	TIRKYETQQQKWLKG	PQ	---	---	277
9	KLK-L5	AVYTIQICKYNSWINK	VIRSN	-----	---	---	276
10	neuropsin	GVYTIYICKYVDWIRM	INRNN	-----	---	---	248
		GVYTNICRYLDNKKK	IIGSKG	-----	---	---	260

41/51




**FIGURE 37**

FIGURE 38




43/51

## FIGURE 39



44/51

# FIGURE 40



45/51  
FIGURE 41

ATCGTGTAAAT	CACCGCCACA	TCCAGTGCAA	AGCTGATTCTG	TCACCACAGA	GCAGCTCCCT
CCTGCCACCC	CATCCCTGGG	TCCCAAGAGA	ACCCTTTCTT	AAAAGAGGGA	GTTCTTGACG
GGTGTGGTGG	CTCATGCCTG	TAATCCTTGC	ACTTTGGGAG	GCCAAGGAGG	GTGGATCATT
TGAGGTCAGG	AGTTTGAGAC	CAGACTGGCC	AACATGGTGA	AACCCTGTCT	TTACTAAAAA
TACAAAAAAA	TGAGCGGGGC	ATGGTGGTGG	GTGCCTATAG	CCCCAGCTAC	TCAGGAGGCT
GAGGCAGGAG	AATGAGGTGA	ACCCAGGAGG	CAGAGGTTGC	AGTGAGCCGA	GATTGAGCCA
CTGCACTCCA	GCCGGGGCTA	AAGAGTGAGA	CTCTGTCTCA	AAAAAAAAAA	AAAGAAAAAG
AAAAAAGAA	AAAAAATAA	AATAAATAAA	TAAATAAAAT	AAATTTAAAA	ATTTAAAAAT
AAAGAGGGGG	TTCTTGTTGT	GATGCCGAGC	CTGAACCAAG	GCAGAGGAGG	CCGGGAAGGC
TTCCCAAGGC	CTTCAGCTCA	AAGCAGGGAG	GCCCATAGTT	AAACAGAAAC	AGTTCAGGAA
TCACAGAAAG	GCACCTGGGG	AGAGATGGGT	GTGTGGCTCC	AGATGCAGGT	GCCCAGACAG
TGCGTCCCCA	GGTGATACAGA	CAGACCCAGG	CCAAGCTCCA	GCTCAAAGAG	CCAGCCTAGG
GGGGTGCCGA	GGTGAGGGGA	GGCTGAGTCA	GGCTGAGGCC	GGGGAACAGT	TGGGGTAGCC
AAGGGAGGCA	AGCAGCCTCC	TGAGTCACCA	CGTGGTCCAG	GTACGGGGCT	GCCCAGGCCC
AGAGACGGAC	ACAAGCACTG	GGGAATTTAA	GGGGCTAGGG	GAGGGGCTGA	GGAGGGTAGG
CCCTCCCCCA	AATGAGGATG	GAACCCCTCC	AACCTCAGAA	CCCCCTGCA	GGCTGGCCAG
AATCCTTCCC	CATCTCATTC	ACTCTGTCTC	TCCTGCTCTC	TGCCGTCTCC	TATTTTGAAT
TTCCAACCCC	GTCTGTAAAG	ACTGTCTTTC	TGTCTCTGAA	TCTCTGTCCC	CTTCTCTTTC
TGGGTCTCTC	TCCCTCTCCC	TCTGGGTCTC	TGTCCCCCTC	TCTGGGTCTC	TGTCACTCTC
TCTTTGCATC	TCCAGCTCTC	ACTTTGTCTC	<u>TGCACCTAGC</u>	<u>AGATCCCAAG</u>	<u>CTGGGGAATG</u>
<u>CCAGTTCTGG</u>	<u>CACCAACCTT</u>	<u>CCTGTCTCCCT</u>	<u>GCTGGGGCCT</u>	<u>CTGCTCCCCC</u>	<u>ATCTCTCAGG</u>
<u>AGTCGAAAGT</u>	<u>GAGAAAGCAA</u>	<u>GGTGGGCAGC</u>	<u>TCTGTCTCCAG</u>	<u>GTCCAGGTAT</u>	<u>CTCCCGCCCA</u>
CCTCCTGCCC	GTCTCTATC	CCACCCCTCC	TCTCCATCTC	TCCCTGGCGC	TGCCATCTCT
CATCTAGGCC	TCCGTCTCCT	CTGTCAATGT	CCCCATCCCC	TGTAGGTGCC	CATCCTTCCC
GTCTCCCCCT	TGCCATCGGC	CTGCCTGTCC	CATCCTCTTT	CTCCCACCAT	GTCCCGTTCT
CTTCCACGTC	TCATGCCCGC	ACTGCCCTCA	TCATCATCGC	TGTTGTTCTG	TGTGTGTTTG
TGGTGAGTGC	CGCATGGTGG	GGGCGTCTCG	GCCTCTCTCC	TCTCTCTCCA	CTGTTTTCTC
TTTCTGTGTG	TCTGTTTCCA	TTCTATCTCC	ACCTTCTTCC	CTCCGTCTTT	TGCTTTTCTA
TCTCCACTTC	TCCACACCCC	TCTCTCCCTG	CGTCTCTGTG	TCTCCCTCTT	CCTCTGTCTT
GTTTTTTTTC	CACCGTCTGC	CTCTTCTGTT	CCCTGTCACTA	TCCAACCTCC	ACCGGTTTCT
CCAGCTCTCT	CCTCAGTTCC	TTCTCTCATG	AGCACACCTG	CCTCTGTGCT	CGTATTCCCTG
GACTCCTCTC	TCTCCACTGT	CATATCTTCT	CATTCAATTT	CCCAGTCTCT	CTCTGTCTCT
TGCTCTCCCC	CTCTCTCTCA	CTCTGTCTCT	GTCTCTCTCT	TTCTCTCTCT	CTCTGTGTGT
CTCTCTGTCT	GGCTCTCTCT	CTGTCTCTCT	TCTCATCTCT	CTCTCTCTCT	CCCCCCGTC
ACCTGTCTCT	TGTCTCTCTC	TGTCTGTGTG	TCTCTCTGTC	TTTCTCTCTC	TCCATCTCTC
TCTGTCTCTC	TCTCTCTCTC	TCTCTCTCTC	CCTCTCTCCC	TCCTCCCGTG	ACTCCCTCTC
TCAGTCCATC	TCTTCTCTCC	TCTCTCAGCC	CCTTCGTGCC	CTTTCTCTCTG	AACTCCCCCA
CCCTGGTTTC	CTGACTCCAC	CACCTAGATCC	ACCACCTCCA	GCAACTGGGA	ACCCTCCCCCT
GCCCACCCCTG	CCCTGGGGTC	CCCTCCCAGG	ATTCCCTTCTA	GATTATAGCA	TCTTCCCTGG
GCGGGTTCTC	ATGAACAATT	GTGGCTGCTT	TTTTGGCCAG	ACAGGGGAGG	GAGGGGATGG
GATCAGGGAG	TCCTGGAATG	GGAACCTAGGC	AATAAAAAAA	AAAAAATGTC	AGAAGCAGGG
CGGCGGGAGG	TGGGGGAGG	GCCAGCTGTC	CTTACCAGGG	ATAAAAGGCT	TTGCCAGTGT
GACTAGGAAG	AGAGACACCT	CCCTCCTTTC	CTTCATCAAG	<u>ACATCAAGGA</u>	<u>GGGACCTGTG</u>
<u>CCCTGTCTCA</u>	<u>CATCCTCCCA</u>	<u>CCTGCCGCCC</u>	<u>GCAGAGCCTG</u>	<u>CAGGCCCCGC</u>	<u>CCCCCTCGTC</u>
<u>TCTGGTCCCT</u>	<u>ACCTCTCTGC</u>	<u>TGTGTCTTCA</u>	<u>TGTCCCTGAG</u>	<u>GGTCTTGGGC</u>	<u>TCTGGGTAAAG</u>
TGCCCTTTCG	TGTCTCTGCC	TCTCAGCCCC	CGGTTCTGTT	GAAGGTTCCCT	TCTCTCTCAC
TTTTTCTCTG	CATTTGACAG	<u>GACCTGGCCC</u>	<u>TCAGCCCCCTA</u>	<u>AAATGTTCCCT</u>	<u>CCTGCTGACA</u>
<u>GCACTTCAAG</u>	<u>TCCTGGCTAT</u>	<u>AGGTAAGAGA</u>	<u>ACGGTTGGGT</u>	<u>ATGACACAAG</u>	<u>GGGTCCCCCT</u>
GGAGACTCTG	AGAAGAGATG	GGGATGGGTC	CTTGGGGCCC	CTGGATGCTC	ATGGTGACCT
CATAAGAAAG	AGCAGGGAGT	GGTTTGGGGG	TCATGGTGGG	GGAACGTGCT	GGAGGCCTAA
ATTCTTAGTT	GTGGAGGTGC	TAGGGAATTG	TGGGGCCGGG	GAGAGAGGTG	TTTATAAGGT
CTGGTGCAAA	ATACATAAGG	AATCTTAGGG	AACATATTAG	TCCTGAGTGG	GTATAGCAG
AAAGATCACG	GGGCTCTACC	TGACTGTGTT	AGGAAAGAAA	CAATGTCAGA	AAGATGTTTT
GTTGTCTAGAG	GGAAGGTGGA	GAAGGATGAT	GGGATGGCGG	GATCGTGGCA	TGGGGTGGCG
GGATCCTGGC	ATGGGTGTGT	GAGGTGGATG	GGGGCAAGTG	TGGGGCAAGA	GATGGCGGAT
CCTTGGGGTC	CCACTGAGTG	GGAACGTTGG	GGAGGAGACA	GGGAGGTCCT	TGAATGTGTT
GGGGAAGGAC	TCATTGGGGG	GAAATGTGGC	ATATTTTCGAG	AAGTGATCAC	AGAAATTATG
GGAGCATAGA	GCTAAGGGTC	GATAGTGTAG	CAAGGCCCTG	GATAAGGTGG	CCACGGCACA
AAATAAGAGA	TGCTACGGAG	GTGACTTGGG	AGGTGAGTCA	GAAAGCTCTC	CGTGCTGGGG



## FIGURE 41 (CONT'D)

CAATAACGGG	GTCAATATTG	GGCATGTCTC	ACCCTGGGTG	GGACAGATAG	AGGCGGGCAG
TTTAGGGGTT	AGACCAAAG	GAAGGGGATT	TGTCAGTTTT	GGAATCCTAC	AAACTTGTGG
AGTGGAGAGT	GTTTGCTCAT	CTACTTTCCC	CACCCAATCC	TGTCCACTCC	<b>TAGCCATGAC</b>
<b>ACAGAGCCAA</b>	<b>GAGGATGAGA</b>	<b>ACAAGATAAT</b>	<b>TGGTGGCCAT</b>	<b>ACGTGCACCC</b>	<b>GGAGCTCCCA</b>
<b>GCCGTGGCAG</b>	<b>GCGGCCCTGC</b>	<b>TGGCGGGTCC</b>	<b>CAGGCGCCGC</b>	<b>TTCTCTGCG</b>	<b>GAGGCGCCCT</b>
<b>GCTTTCAGGC</b>	<b>CAGTGGGTCA</b>	<b>TCACTGCTGC</b>	<b>TCACTGCGGC</b>	<b>CGCCCGTAAG</b>	<b>TGACCCCTC</b>
CCCTGTCCCT	GTACCTAGTG	AATTCCAGAG	TCTAAAGCCC	TAGAGCTGAG	CTGAGAACCT
GGATCTCTGT	ATAGAACCCA	ATGTAGTGGC	TGGCTCCTGG	TTTGAGGTCT	AGAGAAGAGC
CTGGAACAAA	AACACAGCTC	GGGATGTGGG	CTCCTCCATA	AATCTCGAAC	TCAGCATAGG
TTCTGAAAGC	AGATGGGCAG	CTTGGAACCC	ATGGACCTGC	TGAGAACCGA	ACATCTGATC
CAGTGATTCT	TCCAGAGGCC	ACACATTACA	TCGAGACCAA	GCTTAGCCCA	TTCCAGATTG
GTGGCTGAAT	TCAGGACCCC	GTCTACATTC	AGAACTCAG	GACACTACGT	AGAACTCAGA
GCCCCAGTTCA	GGACCTGCAG	TCTAGCCATA	AATCCAGAAC	TAGAACGCTG	CTCACAGCTG
GAACATACAA	CTCTAAGAAT	AGAGGCAAAA	CCTGGAGGCT	GTTTCACACC	CAAGGTTTAG
TTCAGAGTCT	AGTCTATAGC	TCCGCTATGA	GCAGACTTCA	ACCCAGTGTT	TGAATCCCAG
AATGTGGCGG	GTGCGGTGGC	TCATGCCTAT	AATCCTAGCA	CTTTGGGATG	CTGAGGCAGG
CAGATCACCT	GAGGTCAGGA	GTTCGAGACC	AGCCTGAGCA	ACATAGAGAA	ACCTGTCTC
TACTAAAAAT	GCAAAATTAG	CCAGGCATGG	TGGCACATGC	CTGTAATCCC	AGCCACTCGG
GAGGCTGAGG	CAGGAGAATC	ACTTGAACCT	GGGAGGCGGA	GTTTGCAGTG	AGTCAAGATC
GCACCATTGC	ACTCCAGGCT	AGGCAACAAG	AGCGAAATC	CATATCAATC	AATCAATCAA
TAAATCCCA	GAATCAGATC	CTAATCAGAA	GCCCCATATA	AAACCTAGAC	CCCTCCTAAA
TTCTAGATCT	GAACCTACAA	CCCAGACCCC	AGCCAAGAGG	TCAAAATGCC	TATAAGCCAT
ATCTATGCCA	TAAACAGGTC	AGTCTAGAAC	CTAGAGATCA	AAGCTCAGGC	CAGAGTCTAG
AATATAAAGG	CCAGAATGCA	AACCAGACTC	TAGAATCTTG	GATCCGGGCC	ATAACCTAGA
GCTCCAACTA	GAACCCAGAG	CCCAACCTGA	GGTCAAGGGC	TAGGGCCAGA	GTCCAGAACC
AAGAGCCCTA	TAATCCAATA	TGAAACAGAC	CTGTAGAGGC	TGGGTGCGGT	GGCTCACGCC
TGTAATCCCA	GCACTTTGGG	AGGCTGAGGC	GGGAGAATCA	CTTGAACCTG	GAGTTGGAGG
TCGAGAGTGA	GCTGAGATCG	TGCCACTGCA	CTCCAGCCTA	GGTGACAGAG	CGAGACTCCA
TCACAAAAAA	AAAATAAATA	AATAAATCAA	GTCATAATCC	AGGTTCGATC	TAGAATCCTG
ATCTTGAAT	AGAGTCAAAA	GTTTAAGATC	TCTAGAACTC	AGAACCAGG	CTAGAAACAG
AATGCTGCC	ACTCCGGAAT	ATCAGTTCCG	ATTTAGAGCC	TAGACTCATA	ACGCAGTTTC
GCTTAGGACT	CAATGCACCG	AGCCAGCAC	AGACCCTGGC	ACGAGGCCAA	GCTCTCCCAA
TCATCACCTT	CTTCCCAAGC	CAGGAGCTGG	AGCCCAGCCC	AAGAGCGGAA	GGAGAGGCAG
CTGGGGCTGG	GCCGAGAGAA	TGCCCTGGCC	ATGGGGAAGG	GCACAGGAGG	CCAAGAATGC
TCGGCCTGCA	GTTAGTGAGA	AGCAGGCTAG	ACCTCGGGGA	AGACTCGTCA	CCCGGCCAGG
GAACCGGGCT	GGAGGGTGGG	GAGGAGTCTC	TGGCTCAGAC	CCTGAGCAGC	GCTTCTCTTG
GGGGTCGTGG	CCAGGATCCT	<b>TCAGGTTGCC</b>	<b>CTGGGCAAGC</b>	<b>ACAACCTGAG</b>	<b>GAGGTGGGAG</b>
<b>GCCACCCAGC</b>	<b>AGGTGCTGCG</b>	<b>CGTGGTTCGT</b>	<b>CAGGTGACGC</b>	<b>ACCCCAACTA</b>	<b>CAACTCCCGG</b>
<b>ACCCAGGACA</b>	<b>ACGACCTCAT</b>	<b>GCTGCTGCAG</b>	<b>CTACAGCAGC</b>	<b>CCGCACGGAT</b>	<b>CGGGAGGGCA</b>
<b>GTCAGGCCCCA</b>	<b>TTGAGGTCAC</b>	<b>CCAGGCCTGT</b>	<b>GCCAGCCCCG</b>	<b>GGACCTCCTG</b>	<b>CCGAGTGTCA</b>
<b>GGCTGGGGAA</b>	<b>CTATATCCAG</b>	<b>CCCCATCGGT</b>	<b>GAGGACTCCT</b>	<b>GCGTCTTGGA</b>	<b>AAGCAGGGGA</b>
CTGGGCCTGG	GCTCCTGGGT	CTCCAGGAGG	TGGAGCTGGG	GGGACTGGGG	CTCCTGGGTC
TGAGGGAGGA	GGGGCTGGGC	CTGGACTCCT	GGGTCTGAGG	GAGGAGGGGG	CTGAGGCCTG
GACTCCTGGG	TCTCAAGGAG	GAGGAGCTGG	GCCTGGACTC	ATACGTCTGA	GGGAGGAGGG
GCTGGAGCCT	GGACTCCTGG	GTCTCAAGGA	GGAGGGGCTG	GGCCTGGACT	TCTGGGTCTG
AGGGAGGAGG	GGCTGGGGAC	CTGGACTCCC	GGGTCTGAGG	GAGGAGGGAC	TGGGGGTCTG
GACTCCTGGG	TCTGAGGGAG	GAGGGGCTGG	GGGCCTGGAC	TCCTGGGTCT	GAGGGAGGAG
GTGCTGGGGC	TGGACTCCTG	GGTGGAAGG	AGGAGGGGCT	GGGGGCTGG	ACCCTTGGGT
CTTATGGGAG	GGTAGACCCA	GTTATAACCC	TGCAGTGTCC	CCCAGCCAGG	<b>TACCCCGCCT</b>
<b>CTCTGCAATG</b>	<b>CGTGAACATC</b>	<b>AACATCTCCC</b>	<b>CGGATGAGGT</b>	<b>GTGCCAGAAG</b>	<b>GCCTATCCTA</b>
<b>GAACCATCAC</b>	<b>GCCTGGCATG</b>	<b>GTCTGTGCAG</b>	<b>GAGTTCCTCA</b>	<b>GGGCGGGAAG</b>	<b>GACTCTTGTC</b>
<b>AGTAAGGCC</b>	<b>CAGGATGGGA</b>	<b>GCTGTGGTAG</b>	<b>GGATTATTG</b>	<b>GGACTGGGAT</b>	<b>TTAAGCAAAT</b>
GATGTCAGGA	GCATGGAAGT	CTGCAGAGGT	CTTCAGAAGA	GAGTGAACCG	CAGGCACAGA
GAGATTCCGA	TAGCCAGGCC	ACCCTGCTTC	CTAGCCCTGT	GCCCCCTGGG	TAATGGACTC
AGAGCATTCA	TGCCTCAGTT	TCCTCATCTG	TCAGGTGGGA	GTAACCTCT	TAGGGTAGTT
GGTGAATGG	GATGAGGCAG	GTTGGGGAAA	GATCGCAGAG	TGGCCTCTGC	TCATATGGGT

## FIGURE 41 (CONT'D)

CTGGGAAAGG	CTGTGCTGAG	GCTTCTAGAA	ATCTTAATGC	ATCCTTGAGG	GAGGCAGAGA
TGGGGAAATA	GAAAAAGAGA	GACACACAAA	TGTTCTACAG	TTGGAGCGAA	CAGAGAGGGG
CCTGGTGAGA	TTCAAGGGAC	AGGCAGGTGC	ACACAGAGAC	AGAGCCAGAC	CCAGCGGAGA
GGGAAGGAAG	TGCCCCGACC	TCCGGGGCTG	AGACCTCAGA	GCTGGGGCAG	GACTGTGTCC
CTAACTGTCC	ACCAGTGTCT	CTGCCTGTCT	CCCTGTGTCT	GCTTCTCGGG	TTCTCTGTGC
CATGGTGGCT	CTGGCTACCT	GTCCATCAGT	GTCTCCATT	CTGTTCCCTC	CCCTCAGGGT
<b>GACTCTGGGG</b>	<b>GACCCCTGGT</b>	<b>GTGCAGAGGA</b>	<b>CAGCTCCAGG</b>	<b>GCCTCGTGTC</b>	<b>TTGGGGAATG</b>
<b>GAGCGCTGCG</b>	<b>CCCTGCCTGG</b>	<b>CTACCCCGGT</b>	<b>GTCTACACCA</b>	<b>ACCTGTGCAA</b>	<b>GTACAGAAGC</b>
<b>TGGATTGAGG</b>	<b>AAACGATGCG</b>	<b>GGACAAATGA</b>	<b>TGGTCTTCAC</b>	<b>GGTGGGATGG</b>	<b>ACCTCGTCAG</b>
<b>CTGCCCAGGC</b>	<b>CCTCCTCTCT</b>	<b>CTACTCAGGA</b>	<b>CCCAGGAGTC</b>	<b>CAGGCCCCAG</b>	<b>CCCCTCCTCC</b>
<b>CTCAGACCCA</b>	<b>GGAGTCCAGG</b>	CCCCAGCCCC	CTCCTCCCTC	AGACCCGGGA	GTCCAGGCCC
CCAGCCCTC	CTCCCTCAGA	CCCAGGAGTC	CAGGCCCCAG	CCCCTCCTCC	CTCAGACCCG
GGAGTCCAGG	CCCCCAGCCC	CTCCTCCCTC	AGACCCAGGA	GTCCAGGCCC	CAGTCCCTCC
TCCCTCAGAC	CCAGGAGTCC	AGGCCCCCAG	CCCCTCCTCC	CTCAGACCCA	GGAATCCAGG
CCCAGCCCTC	CTCCTCTCAG	ACCCAGGAGC	CCAGTCCCC	CAGCCCCTCC	TCCTTGAGAC
CCAGGAGTCC	AGGCCCAGCC	CCTCCTCCCT	CAGACCCAGG	AGCCCCAGTC	CCCAGCATCC
TGATCTTTAC	TCCGGCTCTG	ATCTCTCCTT	TCCCAGAGCA	GTTGCTTCAG	GCGTTTCTC
CCCACCAAGC	CCCCACCCTT	GCTGTGTAC	CATCACTACT	CAAGACCGGA	GGCACAGAGG
GCAGGAGCAC	AGACCCCTTA	AACCGGCATT	GTATTCCAAA	GACGACAATT	TTTAACACGC
TTAGTGTCTC	TAAAAACCGA	<b>ATAAATAATG</b>	<b>ACAATAAAAA</b>	TGGAATCATC	CTAAATTGTA
TTCATTCATC	CATGTGTTTA	CTTTTATTTT	TTTGAGACAA	GGTCTTGCTC	AGTCTCCTGG
TGAAATGCTG	TAACGCAATC	ATAGCTCACT	GCAACCGTGA	CCTCCTGGGC	TCCAGTGATC
CTCTTACCTC	AGCCTCCCGA	GTAGCTGGGA	CCACAGGTGC	CCGTCACCAT	GCCCCGCTAC
TTTTTAAATT	TTGTGTAGAG	ATGAGGTTTC	CCTGTGTTGC	TCAGGCTGGT	CTCGAACACC
TGACCCCAAG	CAATCCGCC	ACGTCGGTTT	CCCAAAGTGC	CGGGATTGCA	GGCGTGAGCT
GCCCGCCCCA	GCCTTATCCA	TCCAATTAAT	GACTTCAAGA	AACATGTACA	CAGTGGCCCC
ACCATGCCAA	GCCAGGAGCT	GTGTACTGAC	AAGTGGCTGC	CTCCCTCTTT	GCGTGTTTTT
CCTTGGGAGT	CCCCCGTCCA	CCCCACTGTA	TCAGGTTTCT	AGACGGAAAC	ACCTCAGCCC
TGCAGAGTGA	CCTTGAGCAT	GACTGCCTTC	TACCAGCCTC	CTCCCTGGAG	CCCCTGTGGT
CCAGGGTAGG	GAACTAAGTG	CCTTGTTTCC	TGGAAAATTC	TATGCAAATG	AAGATGTCTT
CATTTTCCTA	ATCAGATCTC	AGGTGAGGAG	AGTTGAGTTA	ATCACAGGCT	TCAGTTCCTG
CCCAGGCAAA	GCCCTTCTCT	CATTTTATTA	ATTTATTTCC	ACTCTTCATC	TCTGGCTCTG
TCCCCCTCCC	TCCCCACAGG	CACCGACATA	AATGGCTTTG	AGTGCCCTGC	ATCCTTGGA
AACAAGGCAG	TGTCACAGTG	TACTGTTTCT	AATTACATG	AAACCATTGT	GTTAGGAATC
TCATTCTCTT	TCTTACTTTT	ACTCATCAAC	AGCTATTGAG	CACCTACTAC	GGGCCAGGCA
TTGGTCTATT	TATTAGGCAC	CTGCTATACA	CCAGGCATTG	TTCTGGGTGC	TGGAGGAAGA
ACTGTGAGCA	AGCCAGTCAG	AATCCCTGCC	CTCACAGAAC	TTATATTCTA	GCAGGAGATG
ACAGACAAGA	AGCCATAAAC	ATAATTTTAA	AATAAAGCAG	AGTCCCTATG	AGTAACGAGG
TCAATAAACT	TGGGCTGGGC	GGCAGGCCCA	ATGTGTGCCA	GGGCCAGCTC	ATACATGCTC
GCAAGAGTCT	ACCAGCAAAT	TTTCAGGAAT	TTTCGAGAACC	AGTTGCTAAA	TGCAGCCATC
ATTAAAAATT	AAATTACATA	AGCGTATAAT	TACATAATTG	ATTAAAAAAA	TTGTCAGTAA
ATACTCAAAA	CTCAACTGTT	GCTAATTATT	TCAACTAATA	CCTATGCTTG	GGAGTGAGAT
ATGTCTCTTG	TACTACGTCT	GTAATGATGA	GTTTCTGCAC	ACCTCTTTCC	AACTCCCCAA
CTCTGTCTGC	ACCAGTAGCT	TGACAATAGC	CAAAGAAGAA	GTATTTACTG	CAGTGAATTT
GAAAAACACT	ATAGATAGGG	CTTTGCCGGA	CAGTCATTGC	TAAACCTTTA	CCAGGCACCC
TTGGATGGGT	CTGCCCTGGG	ATGACCTCAT	GATCTTAGTG	TCTGTCTTCT	CAAAGTTCTG
TGCTTGGATA	CTGCAGAGTA	TAGCTAAAAT	AGAATGTTGT	ACTCACCTTA	TGTTCTATGG
GGACAGCACA	GTATTGGGGA	ACCCTAAGGT	GGCAGGTCTG	GGACATGCAC	GAAAGATTGC
TGGGAAGTAG	AGGCTCCCTC	CTTTTCCTCA	TCCTCCCAAC	CCATCCTCCA	GTGTCTGGTA
ACCACCATTTC	TACTCTCTGC	TTCTAAGAGT	CTGAGTTTTT	TAGATTTTCA	ATGTAAGTGA
GATCATGCAG	TAATTGTCAT	TCTGTGTCTG	ACCTATTTCA	CTTAACACAG	TGTCCTCCCG
GTCCATCCAT	GTTGTACAAA	ATGACAGGAT	TTCTTTCTTT	TATAAGGCAG	AATAATATTA
AATTATACTG	ATACTAATAT	ATTACATTTT	CTTTATCCAT	TCATCCATCA	ACAGACACAT

48/51



**FIGURE 42**



FIGURE 43(CONT'D)

181.	195	196	210	211	225	226	240	241	255	256	270
1 PSA	LGTTTCYASGWGSIETP	EEFLTPKPKLQCVDLH	VISNDVCAQVHPQKV	TKFMLCAGRWTGGKS	TCSGDSSGGLVVCNGV	LQGITSWG-SEPCAL					236
2 hK2	LGTTTCYASGWGSIETP	EEFLRPRSLQCVSLH	LLSNDMCARAYSEKV	TEFMLCAGLWTGGKD	TCGGDSSGGLVVCNGV	LQGITSWG-PEPCAL					236
3 hK1	VGSTCLASGWGSIETP	ENFSFPDDLQCVDLK	ILPNDCKKAHVQKV	TDFMLCVGHLEGGKD	TCVGDSSGGLMCDGV	LQGVTSWG-YVPCGT					237
4 HSCCE	PGTTCTVSGWGTTS	PDVTFPSDLMCDVVK	LISPDQCTKVYKDLL	ENSMCAGIDPSKKN	ACNGDSSGGLVVCNGV	LQGVTSWG-TFPCGQ					228
5 zyme	NTTSCILGWGKTAD	--GDFPDTIQCAIYH	LVSRECEHAYPGQI	TQNMLCAGDEKYGKD	SCQGDSSGGLVVCNGV	LRGLVSWG-NIPCGS					220
6 KLK-L6	PGTSCRVSOGWTISS	PIARYPASLQCVNIN	ISPDEVQCKAYPRTI	TPGMVCAGVPQGGKD	SCQGDSSGGLVVCNGV	LRGLVSWG-MERCAL					227
7 TLSP	AGTSCILSGWGSTSS	PQLRLPHTLRCANIT	ILIEHQKCNAYPGNI	TDTMVCASVQEGGKD	SCQGDSSGGLVVCNGV	LQGIISWG-QDFCAI					226
8 KLK-L4	PGTTCRVSGWGTTTS	PQVNYPKTLQCANIQ	LRSDCECRQVYPGKI	TDNMLCAGTKEGGKD	SCEGDSGGPLVVCNRT	LYGIVSWG-DFFCGQ					241
9 NES1	PGDQCQVAGWGTTAA	RRVKYNKGLTCSSIT	ILSPKECEVFYPGVV	TNNMICAGLDR-GQD	PCQSDSSGGLVVCNGV	LQGIISWG-DFFCGQ					252
10 KLK-L5	AGTECHVSGWGITNH	PRNPFDDLQCLNLS	IVSHATCHGVYPGRI	TSNMVCAGGVP-GQD	ACQGDSSGGLVVCNGV	LQGLVSWG-SVGPCCGQ					224
11 neurops.in	PGQKCTVSGWGTVTS	PRENFPDTLNCAEVK	IFPQKKCEDAYPGQI	TDGMVCAGSSK-GAD	TCQGDSSGGLVVCNGV	LQGIISWG-SDPCGR					235
12 prostate	AGNSCLVSGWGLLAN	--GRMPTVTLQCVNVS	VVSEEVCSKLYDPLY	HPSMFCAGGGHDQKD	SCNGDSSGGLVVCNGV	LQGLVSWG-KAPCGQ					230
271	285	286	300	301	315	316	330	331	345	346	360
1 PSA	PERPSLYTKVVHYRK	WIKDTIVANP-----			261						
2 hK2	PERPAVYTKVVHYRK	WIKDTIAANP-----			261						
3 hK1	PNKPSAVRVLVYVK	WIEDTIAENS-----			262						
4 HSCCE	PNDPGVYTVCKFTK	WINDTMKKHR-----			253						
5 zyme	KEKPGVYTNVCRYTN	WIKDTIQAK-----			244						
6 KLK-L6	PGYPGVYTNLCCKYRS	WIEETMRDK-----			251						
7 TLSP	TRKPGVYTKVCKYVD	WIKETMKN-----			250						
8 KLK-L4	PDRPGVYTVRSRYVL	WIRETKRYETQOQK	WLKGPQ		277						
9 NES1	AQHPAVYTVQICKYMS	WINKVIRSN-----			276						
10 KLK-L5	DGIPGVYTYICKYVD	WIRMIMRNN-----			248						
11 neurops.in	SDKPGVYTNICRYLD	WIKKIIGSKG-----			260						
12 prostate	VGVPGVYTNLCCKFTE	WIEKTVQAS-----			254						

**FIGURE 44**

## Sequence Listing

SEQ.ID. NO. 1

KLK-LI na

```
1 tatctcatga gagagaataa gaacatgaaa agagaaagaa tgagagagag
agagagaaaag
61 aaaaaggaga gtggagtcta ggatctgggc aggggtctcc tccctgggtc
cctagaccct
121 gctgccagcc ccttctgggc cccaaccac tgcttggtca gatttgaggc
agcctgagag
181 agttgagctg gaagtttgca gcacctgacc cctggaacac atcccctggg
ggcaggccag
241 ccaggctga ggatgcttat aagccccaag gagggccctg cggaggcagc
aggctggagc
301 tcagcccagc agtggaatcc aggagcccag aggtggccgg gtaagaggcc
tggtgggtccc
361 ccactaaaag cctgcagtgt tcatgatcca actctcccta cagctccatg
tcgctggatt
421 ctacgctctc gtgccttctg tctccacatc tctctagaca gatctctcac
tgtctctagt
481 taggagtcac tgtctctagt taggggtctc tctgtctctc tgaatctata
tctccatgtc
541 taactctcag actgtctctg aggatatctc tcaagcactc tgtctctccg
gctctgattc
601 tctgtgtgtc ttccctccat gcttgtttgt ggggtggctag acaccatctc
tccccattca
661 cagatggcta gatgctttct ctaaactttc ctttctacct agttctctct
ctctctcttt
721 tcccatctct ctctctcttt ttctctctca gtctctaaat ctgtctctct
aggttctggg
781 tccatggatg ggagaggggg tagatggtct aggcctcttg ctacctata
acgtcccaga
841 gggaagaaag ggaggggaca agagagggat ggagagactt gggctgaaga
tccccagaca
901 cggctaagtc tcagtcctca tcccagggtg ctgacgtgat ggccacagca
ggaaatccct
961 ggggctgggt cctgggggtac ctcatccttg gtgtcgcagg tatctgagta
tgcgtgtgtg
1021 tgtctgtccg tgcttggggg cacagtgttt gttaatgttc aggtgtgact
cagtgtcctc
1081 ttgcttgtga ctgcaaagct gcctgtgaga cggtagcgtg ttatccgtcc
gccatggctg
1141 tgcccctgca- actccttgta tcgtggtaaa tttgtgtgtg gcagtgtgcc
tgggtgtgtg
1201 gttgtacctg tgagactctg acagtttgtg cctctgaata tctgggtggag
tgacaacagt
1261 gtaatgatga tatggggaca ggggaagccg aggggtgcagg agatttgtgt
tcctggggcg
1321 tgatccattg ctgggaatct gtgcctgctt cctgggtctt cagtccctgag
atccccctct
1381 cccatcccca aggaactcac ctacaggac tataaacgg tgttttgggtg
tgcatgggct
1441 tgtggcttgg tgtgactgtg ggcaaggctg ggagaggata ggagtgactc
ggcgcaggac
1501 cgactctttg agcatcagtc tgccgagaca agtgaccga tccttgctcc
cagcaacaac
1561 tccaccccct gagctttaat tcaccccgaa ggacccgac ctaccgctat
gagcctagac
```

1621 tctctctgttg aaccctctct gaccgtggct ttgcaccgag atggcaccag  
tctcacctcc  
1681 agagctcacc ccagagccct gactccgccc cagaagccct ggtcccacct  
tctgagactg  
1741 cctctagcca taaccagct cttgaagcct tgatggcgcc cctgcgctgt  
aaccccaacc  
1801 ctaggagcac tgatcccgcc ttctcagccc acccccatgc cctgactctc  
ctcccaggag  
1861 ccttgactac cctgaatccc tgaccaggct cctgcaccgt gatcaccgcc  
cctgggagcc  
1921 ctaggcctat atcctggacc agcccctgaa gctccgatca tgacccttgc  
accataaacc  
1981 cacccccagg agccctgggt ccgccccctg ggcccgcgcc cagccctgac  
tcggcccccc  
2041 aagagtccctg actgctcctg aagccctgac cacgccccctg ctcggtaacc  
cctcccccaa  
2101 gagccctggg ccgcctcct gagcccgctc ccagccctga ctccgccccg  
aggagccctg  
2161 actgctcctg aacctctgac cacgccccctg ctcggtaagc ccacccccag  
gaaccctggg  
2221 ccgcctcct ggtcccgatc ccacccctga ctccgcccctc aggatctctc  
gtctctggta  
2281 gctgcagcca aatcataaac ggcgaggact gcagcccgca ctgcgagccc  
tggcaggcgg  
2341 cactgggtcat ggaaaacgaa ttgttctgct cgggcgtcct ggtgcatccg  
cagtgggtgc  
2401 tgtcagccgc aactgtttc cagaagttag tgtagaggta gggggagtgg  
gcagggcctg  
2461 ggtccggggg cggggcctaa tatcaggctc atcttggggg gctcaggggg  
aaacagcggg  
2521 gaaggctctg ggaggaggac ggaatgagcc tggatccggg gagcccagag  
ggaagggctg  
2581 ggaggcgga atcttgcttc ggaaggactc agagagccct gacttgaat  
ctcagcccag  
2641 tgctgagtct ctagtgaact aaggcaagtt cttgtccctg aatttttgtg  
aatgaggatt  
2701 tgagaccatg gttaagtagc tcttaggggtg ttagcgaag aggggtgggt  
tggggttagg  
2761 agatggggat gggaatgggg ttgaagatga gaatggagggt aaggatgtag  
ttgccacaaa  
2821 actgacctgc cctccgtggc ccacagctcc tacaccatcg ggctgggcct  
gcacagtctt  
2881 gagccgacc aagagccagg gagccagatg gtggaggcca gcctctccgt  
acggcaccca  
2941 gagtacaaca gacccttgct cgctaacgac ctcatgctca tcaagttgga  
cgaatccgtg  
3001 tccgagtctg acaccatccg gagcatcagc attgcttcgc agtgccctac  
cgccgggaac  
3061 tcttgccctg tttctggctg gggctctgctg gcgaacgggtg agctcacggg  
tgtgtgtctg  
3121 cctcttcaa ggaggtctc tggccagtcg cgggggctga cccagagctc  
tgctccag  
3181 gcagaatgcc taccgtgctg cagtgcgtga acgtgtcggg ggtgtctgag  
gaggtctgca  
3241 gtaagctcta tgaccgctg taccacccca gcatgttctg cgccggcgga  
gggcaagacc  
3301 agaaggactc ctgcaacgtg agagagggga aaggggaggg caggcgactc  
agggaagggt  
3361 ggagaagggg gagacagaga cacacagggc cgcatggcga gatgcagaga  
tgagagaga



3421 cacagggaga cagtgacaac tagagagaga aactgagaga aacagagaaa  
taaacacagg  
3481 aataaagaga agcaaaggaa gagagaaaca gaaacagaca tggggaggca  
gaaacacaca  
3541 cacatagaaa tgcagttgac cttccaacag catggggcct gagggcggtg  
acctccaccc  
3601 aatagaaaat cctcttataa cttttgactc cccaaaaacc tgactagaaa  
tagcctactg  
3661 ttgacgggga gccttaccaa taacataaat agtcgattta tgcatacggt  
ttatgcattc  
3721 atgatatacc tttgttgga ttttttgata tttctaagct acacagttcg  
tctgtgaatt  
3781 tttttaaatt gttgcaactc tcctaaaatt tttctgatgt gtttattgaa  
aaaatccaag  
3841 tataagtgga cttgtgcagt tcaaaccagg gttgttcaag ggtcaactgt  
gtaccagag  
3901 ggaaacagtg acacagattc atagaggtga aacacgaaga gaaacaggaa  
aatcaagac  
3961 tctacaaaga ggctgggcag ggtggctcat gcctgtaatc ccagcacttt  
gggaggcgag  
4021 gcaggcagat cacttgaggt aaggagttca agaccagcct ggccaaaatg  
gtgaaatcct  
4081 gtctgtacta aaaatacaaa agttagctgg atatggtggc aggcgcctgt  
aatccagct  
4141 acttgggagg ctgaggcagg agaattgctt gaatatggga ggcagaggtt  
gaagtgaatt  
4201 gagatcacac cactatactc cagctggggc aacagagtaa gactctgtct  
caaaaaaaaa  
4261 aaaaaaaaaag actttacaaa gagatgcaga gacactgaga cagataaaca  
agccacaaag  
4321 gagacaaagg agagacagac aaacagaaac agacagacca caagcccaag  
agaagcagcc  
4381 agcattcagg acataggaca tcgggaagca ggattagatg aagtcaggga  
tctggaatgg  
4441 gacttccaac agatatgttg ctgggctatg ttgttattga tgatggttct  
gtctttgttt  
4501 ctcagtetca tttagttcct tttgagccc atatccattt ccacctctct  
gtgttttgaa  
4561 ttctgactct cctctcttc acaacagggt gactctgggg ggccttgat  
ctgcaacggg  
4621 tacttgagg gccttggtgc tttcggaaaa gcccgtgtg gccaaagttg  
cgtgccaggt  
4681 gtctacacca acctctgcaa attcactgag tggatagaga aaaccgtcca ggccagttaa

SEQ.ID. NO. 2

KLK-L1

SLVSGSCSQIINGEDCSPHSQPWQAALVMENELFCSGVLVHPQWVLSAAHCF  
QNSYTI GLGLHSLEADQEPGSQMVEASLSVRHPEYNRPLLANDLMLIKLDES  
V  
SESDTIRSIASQCPTAGNSCLVSGWGLLANGELTGRMPTVLQCVNVS  
V  
SE  
EVCSKLYDPLYHPSMFCAGGGQDQKDSCNGDSGGPLICNGYLQGLVSFGKAP  
CGQVGVPGVYTNLCKFTEWIEKTVQAS

SEQ.ID. NO. 3

KLK-L1

MATAGNPWGWFLGYLILGVAGSLVSGSCSQIINGEDCSPHSQPWQAALVME  
NELFCSGVLVHPQWVLSAAHCFQNSYTIGLGLHSLEADQEPGSQMVEASLSV  
RHPEYNRPLLANDLMLIKLDES VSESDTIRSISIASQCPTAGNSCLVSGWGLLA  
NGRMPTVLQCVNVSVVSEEVCSKLYDPLYHPSMFCAGGGQDQKDS CNGDSG  
GPLICNGYLQGLVSFGKAPCGQVGVPGVYTNLCKFTEWIEKTVQAS

SEQ.ID. NO. 4

Figure 4 Sequence

TGACCCGCTG TACCACCCCA GCATGTTCTG CGCCGGCGGA  
GGGCAAGACC AGAAGGACTC  
CTGCAACGGT GACTCTGGGG GGGCCCTGAT CTGCAACGGG  
TACTTGCAGG GCCTTGTGTC  
TTTCGGAAAA GCGCCGTGTG GCCAAGTTGG CGTGCCAGGT  
GCCTACACCA ACCTCTGCAA  
ATTCAGTGA TGGATAGAGA AAACCGTCCA GGCCAGTTAA  
CTCTGGGGAC TGGGAACCCA  
TGAAATTGAC CCCCAAATAC ATCCTGCGGA AGGAATTC

SEQ.ID. NO. 5

Table 8 Sequence

TGACCCGCTGTACCACCCCA

SEQ.ID. NO. 6

Table 8 Sequence

GAATTCCTTCCGCAGGATGT

SEQ.ID. NO. 7

Table 8 Sequence

GGTGATCTGCGCCCTGGTCCT

SEQ.ID. NO. 8

Table 8 Sequence

AGGTGTCCGGTGGAGGTGGCA

SEQ.ID. NO. 9

Table 8 Sequence

TGCGCAAGTTCACCCTCA

SEQ.ID. NO. 10

Table 8 Sequence

CCCTCTCCTTACTTCATCC

SEQ.ID. NO. 11

Table 8 Sequence

ACAATGAGCTGCGTGTGGCT

SEQ.ID. NO. 12

Table 8 Sequence

TCTCCTTAATGTCACGCACGA

SEQ.ID. NO. 13

KLK-L2 na

```
1 gggcccagag tgaaggcaag agaaggagtt gagagctccc tctgcaaagt
ggcttgagtc
61 tcccctgcct aaaatgcagg gagagggagg cagaaagaca gggaagagga
aggggtgggg
121 aagaaagaga gagagagaga gagacagaat aacacaacta cagaaacaca
gagagaacac
181 acagagagcc tgggacacag ggacacacag agtcagagag aaaagagaag
atagagaaaag
241 acacaaatgg agacacagag gtgtaaagaa agagagatta acagagtccc
agatacacgc
301 aaaggggcag aagcacagtt ttcagggtgg tgtctatgat catcttcttt
tttttttttt
361 tttttttttt tttttgagac ggagtctcgc tctgtcgccc aggctggagt
gcagtggcgg
421 gatctcggt cactgcaagc tccgcctccc gggttcacgc cattctctg
cctcagcctc
481 ccaagtagct gggactacag gcgcccgcga ctacgcccgg ctaatttttt
tgtattttta
541 gtagagacgg ggtttcacgc ttttagccgg gatggcctcg atctcctgac
ctcgtgatcc
601 gccgcctcg gcctcccaaa gtgctgggat tacaggcgtg agccaccgcg
cccggccatg
661 atcatcttct tgactatgct gatgtgacaa gtacctaaag ccatcagact
ctacccttta
721 aatatgcagt ttgggccagg caccgtggct catgcctgta attccagcac
tttgggaggc
781 agaggtgggt gaatcacttg aggccaggag tttgagacca gcctggccaa
catggtgaaa
841 ctctgtcttt actaaaaaaaa aaaaaaaaaa aaaaaaatc agccgggtgt
cgtggggcac
901 acctgtaatc ccagctatgc tggaggctga ggcacgagag tcacttgaac
cctggaggcg
```

961 gaggttgacag tgggcccaga tcacatcacc gccctccagc ctgggcgaca  
gagcaagact  
1021 ctgtctcaaa taaataaata aacaaacgaa caagcagttt gttgtacctt  
agttatatct  
1081 aaaaaaaaaa tgctgtcaac aaatagagca gaagtgaat aaaggaaaat  
aatgggcca  
1141 agaactctaa ggtatatattg acaaatcatt cagaaccttt aaaaaagaaa  
gaatcacaga  
1201 ggcataagaaa gacagggagg aacagggaga cagaaacacc tgtggcccaa  
ggagaacaaa  
1261 acaaggctcc taagacagac aggaggagag agagagagag tgagtgaagag  
acagacagag  
1321 aaaaagacag agagagagag acagagacag agagacagag aggcgagagg  
gatagaaaga  
1381 gagagagggg tggagagaga cacgagatat tgagagagac tcagaaagat  
agccgagggg  
1441 gaaccacaga gagatggaag aagactctga gaaaaaacca gagacaaaga  
tggaagagg  
1501 agtatcgagg gtgaacagac agtgggtggaa tgagcaaat gcagagaaga  
aagcaagcaa  
1561 tccaggcgcc aagaatagtg acccagagtt ggtgagaagc cagatcctta  
aggctggggg  
1621 aggcagggaa ggggctggcc tggcttcagg agaccctcc ccattctccg  
ggccagggag  
1681 gtagggagtg acattccgga ctgggtggg ggtgctctgg ggggtggagat  
agggggagca  
1741 ggaggagcta ttgctaaggc ccgataggca cctcattgcc cgggaatgtg  
ccccagggag  
1801 cagtgggtgg ttataactca ggcccggtgc ccagagccca ggaggaggca  
gtggccagga  
1861 aggcacaggc ctgagaagtc tgcggctgag ctgggagcaa atccccacc  
ccctacctgg  
1921 gggacagggc aagtgaagc tgggtgagggg ggtcagcag gcagggaagg  
agaggtgtct  
1981 gtgcgtcctg caccacatc tttctctgtc ccctccttgc cctgtctgga  
ggctgctaga  
2041 ctctatctt ctgaattcta tagtgctgg gtctcagcg agtgccgatg  
gtggcccgtc  
2101 cttgtggttc ctctctacct ggggaaataa ggtaggggag ggaggggaag  
tggtttaagg  
2161 gctccccgga tcgctgggc ctcccaacc tctgacattc cccatccagg  
tgcagcgcc  
2221 atggctacag caagacccc ctggatgtgg gtgctctgtg ctctgatcac  
agccttgctt  
2281 ctgggggtca caggtaacca gaactctggg gtgggagggg tgtgggattg  
ggaggactgt  
2341 ctctgcggca ctagagcgcc tgtccctgg ggaactgtgt gagcctgggc  
atgactcgg  
2401 gaccgggtga atgtgagtct ctgtctgtac ttgtggttgt gcgatcgat  
gtggccctgt  
2461 gactgccacg gtgtgtgtcg gggaggggga tgccttttcc catatcaggt  
gactgtgcgg  
2521 caggtggcac tgaccctttg aggtgtgtg tgtggttttg tgattgtgtg  
tgcatttaag  
2581 attgtgtgtg gctccacagc tgtgtgggtg aatgcatgta gactggggg  
tgttactgt  
2641 gtgtttggct gtgtgtgggt acttggcatt gtatatgact gcaggtatct  
gcagttcctg  
2701 tccctgaggt cccgggattg cgtgcaacaa aagtggcat caccatggaa  
agctgtgact

2761 gtgtgctgct tgcaggcgat tatgtgattg tggctgagtg tgacgttatg  
gatgcccgtg  
2821 tttgtgaccg tgtgactacc tgaagctctg tgtaggggtg actgtatgtg  
actgtgtgtg  
2881 tctgtgtgag gccgtgtaaa tgctactgta tgtgtgatgg tgcagctgtg  
tgtctggagt  
2941 ttctgtctct gcctggaggg atagagggtg caggggtagc tatctctggg  
agatgggtgc  
3001 caggtgactg acttgacgtg tgtgcctgtg tgcagaagag tatgtggcag  
tctgaacatc  
3061 tgtgcacaca cggcactctgt gcgtggcact gagacactgt ggatgagggg  
gtgcgatccc  
3121 gctaggctgc ccgggagcgt gtgtacctgg agacagagct gtatgttagc  
tgcacctgtg  
3181 gaggcaacat gggcgtgtct gcagaactgc gtgcgtgctt ggctgttact  
gctgtttgtg  
3241 gcgtgggttct tggggtgagt tctgtaatga tgggtgggtgcc agggccatca  
gcaagggtaa  
3301 gaaccaggcc gggcgcggtg gctcacgcct gtaatcccag ccccttgagg  
ggccgaggca  
3361 ggcggatcac ctgaggtcgg gagatcgagg ccagcctgac caacatggag  
aaccctgtct  
3421 ctactaaaaa tacaaaaaat tagctggtgt ggtggcgctg gcctgtaatc  
ccagctactc  
3481 gggagactgg ggcagaaaaa tcgcttgaac ccgggaggtg gaggttgcgg  
tgagccgaga  
3541 tcgcgccatt gcaactccagc ctgggcaaca agagcgaaac tccgtctcga  
aagaaaaaaa  
3601 gaaaaaaaaa agggtaagaa ccagtgaatg ggcacgggag gactgatgat  
ggagtggggc  
3661 atgcatgtag tctgtaggtc tgtgtgtgag aggaggagat tgacaggatt  
gagaaggcat  
3721 gttttcatct gagaattcag aaacctaggc ctgctcttcc cctccatgtg  
gccccctaag  
3781 ctgagccctt ctttctctgg cctgctttcg gaacctagc tccgcccatt  
agctctgacc  
3841 ccacctcctt tcttcaacca cgccccagg ccagactcta gtggaccccc  
cctaaggcca  
3901 cacccttttg ggccaggctc cacccttat tctgtgggta ccttctagaa  
cccccttcaa  
3961 agtcagagct tttttttttt tttttttgga gacagtcttg ctctctctcc  
caggctggag  
4021 tgcagtggcg tgatctcggc tcaactgcaac ctctgcctcc caggttcaag  
tgattctcgt  
4081 gcctccacct cctgagtagc tgggattaca ggtgcgcgcc accacgcctg  
gctaattttt  
4141 gtgtcttttag tagagacagg gtttcacctt gttggccagg ctggtctcaa  
actccaacc  
4201 tcaggatgat cggccacctc ggccctccag agtgctgggg ttacaggcgt  
gagccaccgc  
4261 cccagccca aagtcagagc tctttatagg agactctaac atgtaaccct  
gacctggcc  
4321 ctaactaagt caattccaaa ccccttctg cctccagccc tgacccact  
cactgaggcc  
4381 tgacccact tcttgagacc agttccatcc ctaaagccct ggtctccctc  
ccatcccccag  
4441 gctccagccc ccacagcttt ggcactacc ctgagcttgt ccaggaatcc  
tgtaccaat  
4501 ttaccctca catgtagttc tagccaattc caggaatctg tgaggctccag  
ttagagtcca

4561 gtaaccctac ctgagcctgg gctctgtcct tgagcttgag cctgggcttg  
agaggtgcca  
4621 ctcttattct ccaggccctg cccctgcccc ctcagcatgt cagacacca  
ccctctagct  
4681 ggtctggcct cttgagtctg aaaccaccc ccagcccaag ccccgctct  
gagccccgcc  
4741 caaccattt tccgttccca gagcatgttc tcgccaacaa tgatgtttcc  
tgtgaccacc  
4801 cctctaacac cgtgccctct gggagcaacc aggacctggg agctggggcc  
ggggaagacg  
4861 cccggtcgga tgacagcagc agccgcatca tcaatggatc cgactgcgat  
atgcacaccc  
4921 agccgtggca ggcgcgctg ttgctaaggc ccaaccagct ctactgcggg  
gcggtgttgg  
4981 tgcattccaca gtggctgctc acggccgccc actgcaggaa gaagtgagt  
ggagttccaa  
5041 gaggaggggt ggtggggacg gggaagtggg ggtgggggtg ggggaagtggg  
ggtgggggtg  
5101 tcatggaggt gagggtggtt ggggacgggg aagtgggggtt gggggtgtca  
tggaaggtga  
5161 gggttgggtg ggatgggttg gggatgtggg agcaggagga ggtcgagttg  
gggataggac  
5221 taaggatgga gttttgcggg ggagcaaggt gggaggatga ggttgagag  
gggagagtgt  
5281 tgtggtaggg aatgggaagg agccaaggat gggttggatt tggggttagg  
agcatatatt  
5341 tggtgaatgg tttgggatgg aggtggaatt gggattggct ttagaattgg  
gggtgggtga  
5401 aaatcgggct ggggtggaaa tgaagatagc atggagatag ggttgagatt  
gggagcagat  
5461 atagaatgaa ggatggggat tggagttttg ggtgggggtg gagatggtt  
gatttgggct  
5521 tgagaatgca tatggtgatg gcttctgggt agggaaagaa ttagggttgg  
gaatgggatg  
5581 ggtttggaat tgtgactggg atggggacag gcatgggatt ggagaccaag  
aggagttga  
5641 ggatgggttg gggaccgggg gtggggatgg ggggtgggct ggggctgggt  
gtgggggttg  
5701 gattggcggt ggacgtggag atagagatca gggttggttg tgacctgccc  
catcttctc  
5761 agagttttca gagtccgtct cggccactac tccctgtcac cagtttatga  
atctgggcag  
5821 cagatgttcc aggggggtcaa atccatcccc caccctggct actcccaccc  
tggccactct  
5881 aacgacctca tgctcatcaa actgaacaga agaattcgtc ccactaaaga  
tgtcagaccc  
5941 atcaacgtct cctctcattg tccctctgct gggacaaagt gcttgggtgc  
tggtggggg  
6001 acaaccaaga gcccccaagg tgagtgtcca ggttcttctt gataccgacc  
catctctgcc  
6061 gccttccatc tttctccact tctcattgtg ttctgtttg acagtgcact  
tccctaagg  
6121 cctccagtgc ttgaatatca gcgtgctaag tcagaaaagg tgcgaggatg  
cttaccgag  
6181 acagatagat gacaccatgt tctgcgccgg tgacaaagca ggtagagact  
cctgccagg  
6241 gaggacacct ctctttattc agcagatata cactgagtgc caactcggt  
acatggagcg  
6301 ttgcaaatt ctgagaatcc agcaattgcc aagacagtca ggaccctgt  
tctcacagag

6361 ctcataccct agagtagtgg tgttttagtag aaataatgct gagctgctta  
tgtcatttcc  
6421 agtttttttag tagccacatt aaaacaggta aaaaaggctg ggcgcagtg  
ctcacacctg  
6481 taatcccagc actttgggag gctgaggcag gcagatcacc tttggtcagg  
agtttgagac  
6541 tagcctggcc aacatggcga aactctgtct ctaaaaaaaa atacaaaaat  
tagcctggca  
6601 tgggtggcggg cgctgtaat ctgagctgct caggaggccg agacacaaga  
atcacttaaa  
6661 cccaggaggt ggagggtgca gtgagctgag atcgtgccac tcaactcaac  
ctgggagaca  
6721 gagtgaact tttgtctcaa aaagaaaaaa aaaaacaagt aaaaaagaaa  
cagggtgaagt  
6781 taactttaat aacccaatgt atcccaaata caatcatttc aaagtgaat  
taatataaaa  
6841 caattatgaa tgagatactt tacattcttt tcttgttttc atattaagtc  
tttgaaagtg  
6901 agtatatatg ttatgctgac agcacatctc aatttggaact agctacattt  
cagggtgctca  
6961 gtagccacat gtggctagca gttactgtat tggatggcac ggatctagag  
ggaaagatca  
7021 gggctgtttt gtatgggttg gcaggttgtg cactgcataa agataccata  
tctaataggg  
7081 gcactccgtg ttacagatgt cagttttggc agttttcagg cgtgtggtag  
ttaagtgtct  
7141 tgtttcaaca aaatctgtaa tatgacagtt ttctagcaag tgctggtaaa  
atatcttgag  
7201 gaaggaaaag agaaatctgg taggtatttt tacaagagaa tatttaatac  
aggggattaa  
7261 ttgcaaagct gctggaaggc ctggagggaac aaagttaaaa aataaaaaac  
tctgtggtca  
7321 agaactctgca taaatagggc aatttcagag agtggtaaaag gttaaccca  
aaataaaaca  
7381 tggtttttagg atagtaaaca ataagggcca atattcaaaa aggtggtcag  
gggagcctcc  
7441 ttggagaggt ggcatttgag cagagaatgg atgacacaaa gaagctaaac  
tcgtgaagtt  
7501 taaggggaaa gaaaaggcac gtgcaaaggc cctgaggcag taaggaattt  
ggctgattca  
7561 aagaagaaga ggaaaccaat gcaactggag aacaaaagtg ggggcaacag  
tagaaagtga  
7621 cgctggaggt gtaggcaggg gcgaatgctc tgcaagtatt tcttggtcac  
caacacagag  
7681 cttccctatg ttctaattga agctgtatct gttgaggaag acagaattta  
aaatcaaact  
7741 gttacatcaa ccagcacct tctctgtatt caggctcca agggatctag  
aaggacgtaa  
7801 gttacaagc tctcattagc aggggtgtgtg tttcaacagt agttaggaag  
ctggggattc  
7861 aggagtactc cagtcccatg gctatgaaaa gctccccca aattgtacaa  
acctgacaaa  
7921 tgcaacacct cccagctct cccattttct tctctgtgcc ctgggtgtgg  
gggggtgggt  
7981 tgcgaggggg aaaactttta acagaagaaa gcacatctcg gccgggcgtg  
gtggctcaca  
8041 cctgtaatcc caacactttg ggaggccgag gcgggtggat cactagggtca  
ggagatggag  
8101 accatcctgg ctgacacggt gaaaccctgt ctctactaaa aacacaaaaa  
attagccggg

8161 cgtggtggca ggcgcctgta gtcccagcta ctcgaggaggc tgaggcagga  
gaatggcctg  
8221 aaccgggag gcggaacttg cagtgcgagc aggttgcacc actgcactcc  
agcctgggca  
8281 acacagtgcg actccgtctc aaaaaaaaaa aaagaaaaga aaagaaatca  
catctcattc  
8341 aagtgggtggc atttaaaact atttagcctt tctgtaggca aggttagtat  
cttgtttttc  
8401 cagacctcaa ggtgtttttt tgtttgtttt ttcataccgg tgtgtggtct  
gggtgtggcc  
8461 actaaaagct acaagcaaga aataataaca actacaacaa tactaatacc  
aatagtataa  
8521 aaataatagc atctggctaa ttgctggaca ctgttttaag tggtttgcac  
gcctcagctc  
8581 attaaactcat ttacctgtta ttattggccc tattttacaa acaaggagcc  
aaggctcaga  
8641 gcagtttaact aacagcctct caaaagaaac tctgcagaga tattaattt  
aaaaataat  
8701 gagagaaatt aaaccacaag aaagttgaaa ttagaggta caggcagcta  
agcttgtttg  
8761 ctttgaaaca gtgtctgcta ctgggaaaaa ggcaagtctt ggctttccta  
ataattgata  
8821 ccaggactct gtaattcata ttttgcacgc atgtaagtaa gaaatgaagc  
cgggtgcaat  
8881 ggcacatgcc agtaatccca gcactctggg agactgaagt gggaagatca  
cttgagctca  
8941 ggagttcaag accagcctgg gcaactaaaa attaaaaaaa taaaaatact  
aattgttttt  
9001 atttttagtag attttattca taccacttac atcattattg tagtatgtac  
atattttatt  
9061 cttttctttt cttttctttt cttttttgag acggagtctc gctctgtcac  
ccaggctgga  
9121 gtgcaatggc accatatcag ctcaactgcag catgcgcctc ctgggttcaa  
gcatttcttc  
9181 cacctcagcc tccaagtag ctgggataac aggcacccac caccatgcct  
ggctattttt  
9241 ttttttccgt agagatgggg ttccaccatg ttggccaggc tggctctgaa  
ctcctgacct  
9301 ccagtgcctc gcctgcctcg gcctcccaaa ttgctggtat tacagggtgtg  
agccaccgtg  
9361 cccagggtggg agatagacat ttctctctac ctcaaacaga ggtccactca  
agctactttt  
9421 ctttttcttc ataaatatta gccgagtggc tttttgcac caggaaatgg  
tccagggtgct  
9481 gtggatatgg catcaggcaa aacagaccaa aaacttcctg ccgctgtggc  
ctcatgttcc  
9541 ccaagtggaa gacaggcaat aaagagatag ataaatatgt agtaaattaa  
aaaaaaaaa  
9601 aattagccgg gtgtgggtggc ttgcacctgt agttccagct acttgggagg  
ctgagggtggg  
9661 agaattgctt gagcccaaac gtttgaggct gcggttaagcc atgactgcac  
tgctgcactc  
9721 cagacagcag cctgggtgac aaagcaagac gtttttgtca .gaaagaaaaa  
aaaaagagac  
9781 gaagggagga aggagagaga aaggaaggaa ggaaggagaa agaaaggaa  
gaaggagaaa  
9841 gaaaggaagg aaggaaggag aaagaaagga agaaagagaa agaaagaaaa  
agaaagaaag  
9901 aaagaagaaa gaaaagagag aggaaggaag gaaagaagga aaagagggaa  
aaaaatgact



9961 gttgaagagc agtgagtatt attataggag ggtaattata gggaggtatg  
gggaattgaa  
10021 gacaggaaac acaaattagt ccaagcgaat ggatttctat tgggagtgat  
tctgccccta  
10081 gaagacactg gcaataccag gagacatttt tggttgtcac aactatatgg  
aggggcatta  
10141 ctggcaacta atggatagat gccaaagtgtg ctgttcaaca tgctatgatg  
cacacggcag  
10201 gcctccacaa caaaccatta tccagcttca gatgccaca gtgccagat  
cgaggaaccc  
10261 tcatccaggg gctgagaacc gtatttttgc agaagggagg tataaggatg  
ggttggtgga  
10321 gaatggggaa ggaaggtgtg tgtccagtaa gagaaataag gcctgcacag  
gctggagggg  
10381 agagtgagag agaaagggag gcgagagat acacgatgag ggagacaggc  
tggaacagaa  
10441 agtagagacg aagattcgag atgtggagag gaagggtcac agaccccccc  
gaaatgatgt  
10501 gtggacaaca ggaatctgga agaggaagat ggagtggaga gtgacaaatg  
gggtctaaag  
10561 gttgaacttg gaggccaggc atggtggctc acgcctgtaa tcccaacact  
ttggaggctg  
10621 aggtgggcga atcacttgag gccaggagt tgcagaccagc ctggccaaca  
tggtgaaacc  
10681 ccgtctctac aaaaaaata caaaaaatta gccgggtgtg gtgatggaca  
cctgtagtca  
10741 cagctacttg ggaggctgag gcaggagaat tgcttgaacc cgggagatgg  
aggctgcagt  
10801 gagctgaggt caggccactg cgctccaacc tgggcaacag agtaagactc  
catctcaaaa  
10861 aaaaaaaagc tggatttgga gtgaaatatt aataacattc tccctctctc  
tccttttgcc  
10921 tgtgtctcca tctctgtctt tttctgcatt tottcatctc tgtactttcc  
atctctgtgt  
10981 gtctgttccc atctgcttct ccatctatgg gcattctctg gtctctcatg  
tctccttctg  
11041 cccactttgc cacatctctg cctctctcat gcccccttt ctctcctgca  
gggtgattct  
11101 ggggggcctg tggctgcaa tggtccctg cagggactcg tgtcctgggg  
agattaccct  
11161 tgtgcccggc ccaacagacc ggggtgtctac acgaacctct gcaagttcac  
caagtggatc  
11221 caggaaacca tccaggccaa ctctgagtc atcccaggac tcagcacacc  
ggcatcccca  
11281 cctgctgcag ggacagccct gacactcctt tcagaccctc attccttccc  
agagatgttg  
11341 agaatgttca tctctccagc cctgacccc atgtctcttg gactcagggt  
ctgcttcccc  
11401 cacattgggc tgaccgtgtc tctctagttg aaccctggga acaatttcca  
aaactgtcca  
11461 gggcgggggt tgcgtctcaa tctccctggg gcactttcat cctcaagctc  
agggccatc  
11521 ccttctgc agctctgacc caaatttagt ccagaaata aactgagaag

SEQ.ID. NO. 14

KLK-L2 aa

MATARPPWMWVLCALITALLLGVT EHVLANNDVSCDHPSNTVPSGSNQDLG

AGAGEDARSDDSSSRIINGSDCDMHTQPWQAALLLRPNQLYCGAVLVHPQW  
LLTAAHCRKKVFRVRLGHYSLSPVYESGQMFQGVKSIPHPGYSHPGHSNDL  
MLIKLNRIRPTKDVVRPINVSSHCPASAGTKCLVSGWGTTKSPQVHFVKVLQCL  
NISVLSQKRCEDAYPRQIDDTMFCAGDKAGRDSCQGDSGGPVVCNGSLQGL  
VSWG DYPCARPNRPGVYTNLCKFTKWIQETIQANS

SEQ.ID. NO. 15

Table 11

GGATGCTTACCCGAGACAGA

SEQ.ID. NO. 16

Table 11

GCTGGAGAGAGATGAACATTCT

SEQ.ID. NO. 17

Table 11

GGTGATCTGCGCCCTGGTCCT

SEQ.ID. NO. 18

Table 11

AGGTGTCCGGTGGAGGTGGCA

SEQ.ID. NO. 19

Table 11

CCGAGACGGACTCTGAAAACCTTCTTCC

SEQ.ID. NO. 20

Table 11

TGAAAACCTTCTTCTCCTGCAGTGGGCGGC

SEQ.ID. NO. 21

KLK-L3

1 cttgaaccca ggaggcagag gttgcagtga gctgagatcg cgccactgta  
cttcagcctg  
61 ggtgtcagag caatactccg ttttggaata caaacaacaa aacaacaaa  
caaaaaacag

121 atggagcaac tgagagaggt cttgtgactt gccc aaagtc acacacctca  
tcactaatca  
181 cacctaataca ttgagatttg gacacacatg gttcagttcc agagtccatg  
ctccaaacca  
241 tgacgacaca gtgagagaac attcaagggg agcccagacc cagcttcata  
accaggcctg  
301 tgagcaggag aaagtggaag ggatcgtaag tgcccagggg aggcaaagat  
ggactctgcc  
361 tgaggatctc agagatttcc tggaggaggg agaattgagg ttgggtgttg  
aaggatgagt  
421 gggagttcac caggaaaaga aggatatgga gaaagacatt cactcattca  
atgaacatct  
481 cctgaggact tctgcaagcc ctgttccgcc tggaaacgggg tgatgctggg  
acacagagat  
541 gagtcagacc tgggcccagc cctccagaag ctgtccacct ggtgagaagg  
aatgatgagg  
601 agagaggcag ggaggatggg gtgatggaag ggacaatggg gtggggggca  
gggagatgga  
661 tgaaaaaat atatagcaaa tgttctcagg atttggaaca gatcaggatg  
tattaagaga  
721 gagcacaggg cacttgctac ctggaagggt gggcacctgg gtccttgggt  
gggtggagccg  
781 tggggaaggg ggcaggttat gacaagagtg ggttaatcca gatggaacca  
gatttctcaa  
841 cattctagga gagggccttg tccttgtggg aagaggccca aatccccagg  
gcagggaagg  
901 ttctgcaagg tgtgtaaacc tgtgcagctg cctgtggtct ctgcctcact  
ccacctggat  
961 ttccctcaat ctttcccggt ttctgtctcc tcctcccact cctcctctca  
tcttgggtcc  
1021 ttctgtgect gtacctccct ctctttgtat cttttgctct tgtgtctgag  
tcctgactct  
1081 gtcttccacc cctgcctcc tttctgggtg gtccccctgc acatccctcc  
agcctgccgt  
1141 gggagggttg tctctgcaca ccactgcttt atccaaaata aacctgtgc  
accccaggac  
1201 cttaggcttc aaggatctcc ctcttttcc aggacacaaa agattctgta  
tctttagacc  
1261 taaggatgatg aggaatgagg tctccactc tgaagacccc agaggaggtg  
cccacaacct  
1321 ctccacaccc ccagcactcc tcctccattc agtcaagctc tggcccagca  
agccgccagt  
1381 tcatcccaaa aggggggtcc ccctgcactt acctcctctc ccaaggcccc  
tgtcacagcc  
1441 ccagggcttc cccctcccc aggtacattt cccaaccocg attaatacaca  
ggggcgggcc  
1501 catggaggag gaaggagatg gcatggctta ccataaagaa gcactggacg  
ccgggtgcac  
1561 gttccaggat ccagggtgcc aggggtcatg aagctgggac tcctctgtgc  
tctgtctct  
1621 ctgctggcag gtgaggctcc caggctgggt gccccttcac ggctgtacta  
aggtcacctt  
1681 gctcttccct cccatcccag gcttctgcct cctgccctct aggcttctca  
gcatectctc  
1741 cctgccctcc cagcctgtct ttogetgacc cttttgtccc tcatccccac  
cccaggcat  
1801 ggctgggcag acaccctgc catcggggcc gaggaatgtc gcccacactc  
ccagccttg  
1861 caggccggcc tcttccacct tactcggtct ttctgtgggg cgacctcat  
cagtgaccgc

1921 tggctgctca cagctgcccc ctgccgcaag ccgtgagtga cccagggctgg  
ccatgctggg  
1981 gagggacaga ggctgggggt caggagaggg tgaggggtgc tttaggccag  
aagtgcggag  
2041 cctccacttc tgataccaca agttcaactc ttagaagtag gaagggtagc  
ctcccaaadc  
2101 ctaaaattct agagaccagc aatatctcat ttgagaagtc taagattcga  
aacttaggct  
2161 cttcgaatcc gagactgacc cagagaaaac cagaatcgta gaatcctaaa  
atcttgaatt  
2221 tatgaaattc tgcaatagcc tcagcaaatt ttagaatcat agattcgcag  
actattagaa  
2281 tcttagcagt ctgggtcagc actgcccaga ggaattatga tgccagccac  
atgtgtaagt  
2341 ttaaatttct ggtggacaca tttaaaaaat aaggaatgag taaaattaat  
tctaatagat  
2401 ttaacttgac atacccaaaa acttattttg acatgtaac aatttttaaa  
tacgtatgaa  
2461 cgatacagtt tacttttgtt ttggtactaa gcctttgaaa tctgttctgt  
attttacaca  
2521 catagcctgt taaaaaatgg actagccaca tttcaagtgt tcaatagcca  
taatggctag  
2581 tgtgatccta gaatcttaaa ttcagagctt tctagattca ttgaatattg  
aaactcacag  
2641 tactagaatc tttgattcac agtatcctag aatattgaga ttcagataat  
tctgtagtct  
2701 taaactatct gaatcccaga ctcttaaatt tctaaggtta tagatttata  
gaatgatgac  
2761 attctagtct ttcttttttt tttttttttt tttttttgag acagagtctc  
cctctatctc  
2821 ccaggctgga gtgcagtggc acaatctcag ctactgcaa cctctgcctc  
tcgggttcaa  
2881 gcaattctcc tgcctcagcc tcctgagtag ctgggattac aggtatgcac  
caccatgcca  
2941 ggctattttt tttttttttt ttttttttagt agagacgggg gtttcacat  
attggccagg  
3001 ctggtcttga actcctgacc ttgtgatctg cccgcctcgg cctcccaag  
tgctgggatt  
3061 acaggcgtga gccaccgcgc ccagccaaaa ttctagtctt tttgtcctag  
aacattaaaa  
3121 ttctatgttc aaatcttaga ttaattcag ataatgtag aatcctggag  
tttttttgat  
3181 ccagggggaat ctggaatgtt agaactcttg attcataaaa ctctaaacct  
tgagcctcta  
3241 gattctagaa tcatggataa tagtgtgtcg gaatctgaga attctagaat  
cttaggttct  
3301 gggcattcta atagtatcct ggaatccacc tgatgcagga atcctctctc  
cattgcctct  
3361 gaaaagtgac catccatact gttccaattt tcttccctcc atgagtaaag  
cactgattgt  
3421 ggtaagagat gctgtgtggg aatttcccat catgcattgc tccatgatgg  
aacctcctt  
3481 aacttaagcc tatacatcag actgggagaa cgatgttcag atttcagccg  
aaagtgaagc  
3541 aggagaaatg cagagatatg aaggtggaag agagtgagag gcaggggga  
ggtaggggga  
3601 tgaagggatg taggggtgag gactactttt ccagatccag agccaagaca  
gcaagaatga  
3661 cagagagaga cagacacaga tgtttctggt tccccaacct tgaattcgca  
gtcattagcc

3721 tgctgcctaa tgtcagaggt cagaggctgg ggaatggact tgtcatcccc  
gaaaggatcc  
3781 cagctgtcta gggcatggac cagaaatgaa acaagtgcgc tgagactgtg  
gtgagggtt  
3841 aaggtttagac accaggaaga catgcattga aggggtgaagg atatgataga  
caggaaaagc  
3901 tgaggccaga gatgaccccc aatttgggga ttttccatat cccatcccct  
ttcatacaca  
3961 cgcacacgta tacacacaca ccacttagac atacagagcc gctcccacag  
aagccaccag  
4021 acctgtgggg gcaggggtgg ggcggttgtt atgtggtagg tgggggtcccc  
cgtgcccaca  
4081 ccgttcctag ggacccaagt caccaccaag gctccagggt agtagggagg  
aaggtggctc  
4141 actcagcctg ggactaggag cgggggtttt gtggggagag ctacaaagat  
ggagacacac  
4201 aaaacatcag agtggggacc agggaccag aggaggtgtg tgcctcgctt  
aaaatcacag  
4261 taccctgggc cagacataga tgatgagggt gcagagaggg tgtgtggctt  
gcagagggtc  
4321 acacagcacc ctgatggaca ggaaaagagg gctggggctg aaaggacttt  
tacctttccc  
4381 ccagcttgac ctctgaggcc tgtcccagca ggtatctgtg ggtccgcctt  
ggagagcacc  
4441 acctctggaa atgggagggt ccggagcagc tgttccgggt tacggacttc  
ttccccacc  
4501 ctggcttcaa caaggacctc agcgccaatg accacaatga tgacatcatg  
ctgatccgcc  
4561 tgcccaggca ggcacgtctg agtctctgtg tgcagcccct caacctcagc  
cagacctgtg  
4621 tctccccagg catgcagtgt ctcatctcag gctggggggc cgtgtccagc  
cccaagggtg  
4681 tgacctggcc cagaactctc tctgaaactt gctccctcac cctctgtct  
ctgccttttc  
4741 atctctgtct tctccttttc tctctctct ctctctctgt cagtctatct  
atctgccaat  
4801 cgatatattt aaccaaatat aagatgctag catttttaag atgtgccatt  
atctcatgaa  
4861 ctgcgaagaa gtggaagaag gaggaggagg agaagaaaaa aaggaggagg  
aggaaagatc  
4921 ccattagatc ccattgatta tataacacca ttttctggaa gacacattct  
aatttcagag  
4981 tgtttgtttg tttgtttgtt tgtttgttt tgagacaggg tctcgctttg  
ttgtcaggc  
5041 tggagtgcag cgggtgtgatc acggctcatt gcagctttga actcctgggc  
tcaagtgatc  
5101 ctctcgctc aacctcccaa gtagctggga ttacagatat gcaccaccac  
atcccacacc  
5161 ggggtcattt ttttattatt tattattatt attattatta tctttttttt  
tgtattttta  
5221 gtagagacag aggtttcacc atattggcca ggtggtctc aaattcctga  
cctgggtgatc  
5281 tgcccgctt ggactcccaa agtgctggga aaacaggcat gagccactgc  
accagccaa  
5341 aattctagtc ttttttaaatt ctagtcatat cttagattta attcagataa  
tgttagaatc  
5401 ctggagtttt ttgatccagg ggaatctgga atgttagaat cttggattca  
taaaactcta  
5461 aacgttgagc ctctagattc tagaatcatg gatactagtg tgtcagaatc  
tgagaattct

5521 agaatcttag attctgggca ttctaatagt atcctggaat ccacctgatg  
caggaatcct  
5581 ctctccattg cctctgaaaa gtgaccatcc atactgttcc aattttcttc  
cctccatgaa  
5641 taaagcactg attctggtaa aagatgctgg gtgggaattt cccatcatgc  
attgctocat  
5701 gatgggacct cctttaactt aagccttatg ctaaaaattt ttattatttt  
tagcaaagat  
5761 gaggtcttgc tatgttgtcc aggctagtct caaactcctg gcctcccaaa  
gtgctgagat  
5821 tacaagtgtg agccactgta cctggcccag agatgtttaa atgtgaaatg  
cgttcatctt  
5881 agaatgggaa taagaccatg tctctcagag tcacggatca ctgaccatt  
agccaaattg  
5941 ggtcagtgga ttggaaaaac agtctgaatt tgttgctgcc aatatctaaa  
acttggaag  
6001 ttttatacaa aagccagggt tctggattca cctgaaaaag tttgaagaac  
tcacattccc  
6061 aaaatagcaa gcattgggct gagtcaatgg aggctgcccc cttcagccaa  
gataagttct  
6121 ctgattcact ccaatggacc caaatggctc ctgtctccct gcacagcccc  
cgccccgac  
6181 ttctgtttac caattctgtt tatcatatcc cttgatgcat cggagcctgc  
acccatgtct  
6241 tatatagatg cacatgtgta ttatatatcc atatccacat ctatactgac  
tacactgtat  
6301 ctggtatctc tgtctatgtc tctgtctcca tcagtgacca tcttcctgca  
aatctcttct  
6361 cttttatctc actgccttca ttccaccctc tgaggctctgg gtctttttct  
attctttttt  
6421 tttttttttt taagagactg agtcttgctc ttgttgccca ggctggagtg  
cagtgggtgtg  
6481 atctcggctc actgcaacct ccacctcctg ggttttaagt gatcctcctg  
cctcagcctc  
6541 ccgagtagct gggactacag gtgtgcaaca gcatgcccag ctgatttttt  
gtattttcag  
6601 tagagacgga gtttcacat gttggccagg atggtctcaa tctcttgacc  
ttgtgatccg  
6661 cccgcctcag cctcccaaag tgctagggag ttatatatgc atctcctctt  
atctcttggc  
6721 tctctgcatg catctttctg tttctcttcc ttccctttctt tttttttttt  
tttttttttt  
6781 tttttttttt ttttttgaga cggagtcttg ctctgtctcc caggctggag  
tgcaagtacc  
6841 agtctcggct cactgcaacc tccacctccc aggttcaagt gattctcgtg  
cctcagcctc  
6901 ccgagtagct gggattacag gcgcctgcca ccatgcctgg ctaatttttg  
tatatttagc  
6961 agagatgggg tttcaccatg ttggctgggc tgggtctcaa ctctgacct  
caagcgatcc  
7021 gccggcctcg gcctccaaaa cactgggatt acaggcatga gccacggtgc  
ccggccagcc  
7081 tctctctcta cttggccctc ttccctcttg tctccatttg tttctcttgt  
gtgctatgac  
7141 tgtctgtctg tcaactgtctc ttgtctctat ctttgagagt cctaaatgtg  
gtccattgg  
7201 tcctttggaa aagctgcagg gaggactcag ggcagtgggg tgctgagtgt  
gttgagaca  
7261 gttgcagatc cttgacagtt ctcttcctg acagegctgt ttccagtcac  
actgcagtgt

7321 gccaacatca gcatacctgga gaacaaactc tgtcactggg cataccctgg  
acacatctcg  
7381 gacagcatgc tctgtgcggg cctgtgggag gggggccgag gttcctgcc  
ggtgagacct  
7441 tactctgggg aaaatgaggc tgtcctgcc agttttctag gatttagggg  
agcagagggg  
7501 tcggccccc gcttcctgg gtcaaaatga gaaggagact gggatacctg  
gttcctggga  
7561 gaggacggga ccagggcctg gactccttag tgtaaaagag aaaaggctctg  
gaggtccaga  
7621 cttctggatc tacaggagga gtgggctggg cgtccagagt ctgagtcctc  
ggggaggagg  
7681 aggttaggtc ctgcggggag gtgggccctc tgagctttta ctccctgggtc  
tgaggaagaa  
7741 gaggctggag atggaggact ctcgatgtt ggaggaggaa ggggctgggg  
cctttctggg  
7801 agggaggaag tggcccggtt aattgtcatg aacagagtgg cctaacagtt  
cctctgccct  
7861 tctctcgcgt acagggtgac tctgggggcc ccctggtttg caatggaacc  
ttggcaggcg  
7921 tgggtgtctg ggggtgctgag ccctgtctca gaccccgcg ccccgagtc  
tacaccagcg  
7981 tatgccacta ccttgactgg atccaagaaa tcatggagaa ctgagcccg  
gcgccacggg  
8041 ggcaccttg aagaccaaga gaggccgaag ggcacggggt agggggttct  
cgtaggggtc  
8101 cagcctcaat ggttcccgcc ctggacctcc agctgcctg actccctct  
ggacactaag  
8161 actccgcccc tgaggctccg cccctcaccg aggtcaagca agacacagtc  
gcgccccctc  
8221 ggaacggagc agggacacgc ccttcagagc cgtctctat gacgtcaccg  
acagccatca  
8281 cctccttctt ggaacagcac agcctgtggc tccgccccaa ggaaccactt  
acacaaaata  
8341 gctccgcccc tcggaacttt gccagtgagg acttccccctc gggactccac  
cccttggtggc  
8401 cccgcctcct tcaccagaga tctcgccct cgtgatgtca gggcgagtc  
agctccgccc  
8461 acgtggagct cgggcggtgt agagctcagc cccttggtggc cccgtcctgg  
gcgtgtgctg  
8521 ggtttgaatc ctggcggaga cctgggggga aattgaggga ggggtctggat  
accttttagag  
8581 ccaatgcaac ggatgatttt tcagtaaacc cgggaaacct ca

SEQ. ID. NO. 22

KLK-L3

VHFPTPINHRGGPMEEEGDGMA YHKEALDAGCTFQDPACSSLTPLSLIPTPGH  
GWADTRAIGAE ECRPNSQPWQAGLFHLTRLFCGATLISDRWLLTAAHCRKPL  
TSEACPSRYLWVRLGEHHLWKWEGPEQLFRVTDFFPHPGFNKDLSANDHND  
DIMLIRLPRQARLSPAVQPLNLSQTCVSPGMQCLISGWGAVSSPKALFPVTLQ  
CANISILENKLCHWAYYPGHISDSMLCAGLWEGGRGSCQGDSSGGPLVCNGTLA  
GVVSGGAEPCSRPRRPAVYTSVCHYLDWIQEIMEN

SEQ. ID. NO. 23

KLK-L3

MKLGLLCALLSLLAGHWADTRAIGAEECRPNSQPWQAGLFHLTRLFCGAT  
LISDRWLLTAAHCRKPYLWVRLGEHHLWKWEGPEQLFRVTDFPHPGFNKD  
LSANDHNDDIMLIRLPRQARLSPA VQPLNLSQTCVSPGMQCLISGWGAVSSPK  
ALFPVTLQCANISILENKLCHWAYYPGHISDSMLCAGLWEGGRGSCQGDSGGP  
LVCNGTLAGVVSGGAEPSCRPRRPAVYTSVCHYLDWIQEIMEN

SEQ. ID. NO. 24

Table 13

CATGCAGTGTCTCATCTCAG

SEQ. ID. NO. 25

Table 13

CATGGAGGAGGAAGGAGATG

SEQ. ID. NO. 26

Table 13

CTTCGGCCTCTCTTGGTCTT

SEQ. ID. NO. 27

Table 14

GACCCTGACATTGGACATCTA

SEQ. ID. NO. 28

TABLE 14

GCCACTGCCTGATGGAGACTG

SEQ. ID. NO. 29

TABLE 14

AACATCAGCATCCTGGAGAA

SEQ. ID. NO. 30



TABLE 14

CTTCGGCCTCTCTTGGTCTT

SEQ. ID. NO. 31

TABLE 14

GGGTCAGAGCTGCAGAGAAG

SEQ. ID. NO. 32

TABLE 14

GGGCCTGTCGTCTGCAATGG

SEQ. ID. NO. 33

TABLE 14

ATGGCCACAGCAGGAAATCC

SEQ. ID. NO. 34

TABLE 14

GGTCACTTGTCTGCGCAGAC

SEQ. ID. NO. 35

TABLE 14

CCCAACCCTGTGTTTTTCTC

SEQ. ID. NO. 36

GGCCCTCCTCCCTCAGA

SEQ. ID. NO. 37

TABLE 14

ATCCCTCCATTCCCATCTTT

SEQ. ID. NO. 38

TABLE 14

CACATACAATTCTCTGGTTC

SEQ. ID. NO. 39

TABLE 14

AGTGACACTGTCTCAGAATT

SEQ. ID. NO. 40

TABLE 14

CCCCAATCTCACCAGTGCAC

SEQ. ID. NO. 41

TABLE 14

GCTTCCCTACCGCTGTGCT

SEQ. ID. NO. 42

TABLE 14

CACTCTGGCAAGGGTCCTG

SEQ. ID. NO. 43

KLK-L4 NA

1 caggaggttg cacactgttc ctcccacctc gccactgcac cccaccaag  
gatggaattg  
61 gaggcggggg gcagattcca gggtcagggc tgtcaagagt gaatgaggcg  
aggagacatt  
121 caggagcaga gaggtttcag acgcggaggt tccgggcacg ccctcaacac  
cccccttcacc  
181 ttctcctcag gccccgcccc ccctgccctc ccctcccgat cccggagcca  
tgtggccccct  
241 ggccttagtg atgcctccc tgaccttggc cttgtcagga ggtaagaatg  
cgcgggggtg  
301 gaggcgcggc ggccattcgg gacaatggta ggaggggtca ggccggaggg  
ggagggggcg  
361 tgggagccgc gagctccgc ccccgccac tcggggcgg gtccagtggg  
gacagctcag  
421 agctcttctt gcttgtccct gggtgacctg gtttcccggc tgaggttggc  
cctccgaccc  
481 cagacccttc acctccaaa ataccctcgc agcagcccct cccgcgttca  
aggcttcttg  
541 tcctctctgg aaagctgaaa gacatgggtt cgcgtcctga cgctgccgct  
ttgagccagt  
601 agcctagcag ctgctttgtg cctaaattgt tttcatctgg aaaatgggct  
taatctataa

661 gtgcttacca gagaagggtca ctgtgaatat tgaaacgagg taatgcgctg  
agccttcagt  
721 atgtcgcagg tagaagggtac ttgaaagtta gccacttagc cgttattact  
ttattagtag  
781 ttttcctttt tttttttttt tttttttttg agatggaacc ttgctctgtc  
tcccaggctg  
841 gaaggcagtg gcacgatctt ggcttactga aacctccgcc tcccgggttg  
aagcgattct  
901 cctgcctcag cctcccaggt agctgggatt acaggcgccc gccaccacgc  
ccaactaatt  
961 tttgtatttt cagcagagac ggggtttcgc catgttggtt aggctggctt  
cgaacttcta  
1021 acttcaagta gcccgcgtca gcctcccaaa gtgccaggat tacaggcatg  
agccaccgag  
1081 cccggcctct agtattctgt cttcactctc agccccttcc agaaccttct  
agattgttat  
1141 tttaatcctt ggggtgacct caaacctatg tgacctcacc ccaaattggt  
agtccttaag  
1201 atccttatgg atctttccca tctttccctg ccgttgtagg caggttctct  
ggaaaccccc  
1261 ttcattgaatc atttattcat tcaacaaaca gctattaaac accggccact  
gtgctgggtg  
1321 ctgtacaagc agagacacag tccctgctct cagcacctgg agtctagcgg  
ggacagacgc  
1381 agatgttatt caaacaatta tccaaataat tagttaataa ttatcttgac  
atgaggtgaa  
1441 gacttcaagg agccaagcca ggggcctaga gatgtaatgg cggttccccg  
accagaggcc  
1501 ttcccaaagg gcttgaccct tgagccaaga cctgaaaaag gagggatctg  
tggttgacctg  
1561 gcacctggca ccatccttgg cctgaagggtg ggggtggcttt tctcctctgg  
cgacactccc  
1621 tggattcatg cccgtgccac tcctgagtgc cacaccctag gctaggagac  
ccacacgcta  
1681 cgccttgtgg agtcctcaac aacctggcga ggtaggtgca ttgtaattac  
tccaatttca  
1741 tggcagagaa acctaggact caaagacaga aggctcctgc tccaatgaca  
ccggcgatgc  
1801 ctgagtcaga atcctaatac aggttggttt cctgtccat atcctggact  
tgaggctctg  
1861 aaaaccattt ttataacttt tgacctaatc atttgcttaa agttagcttt  
ttttcttctt  
1921 ttttactca aacaaaagca tgttcaactt tatattactg tcctgaatag  
agaatagaat  
1981 tctttgtcat aaatagaagg taaggaagga aataaatcct gcacaatgaa  
aagaaaataa  
2041 tatgtttatt gggttggacc acctgaaatt gctgatactt gacccttttt  
gaccttccta  
2101 aaacaacttt tgcagatggg tcagtgtaat aaatgttagg tggcctgatg  
aggcttctgt  
2161 gtctccttgg ctttgaaaag tgagctcagt gaggattagg gaggtgttaa  
aaccatatta  
2221 gcaccatcct gagactttat ccttgacaaa atcagggttta aaagagaact  
ggatgctggg  
2281 tcagcgtctg agtgtcgat ttaacgttac ttaaacttca tctctctacc  
atctaaaatg  
2341 atcctgtgct caccgacaac ttctgtccct aactgcaaac cactgagcta  
atccaactgc  
2401 ttgccctgta gttggggaaa ctagctaggg aggcagaggg acctcctgtt  
gtagctaata

2461 attaataata acatttccca ctgactgagt gctctccatg ccacctgctg  
tgctgcacgg  
2521 tttgaaatgc aggatcatct tgaattcttc aactgcgcaa tgagagatga  
actattactt  
2581 tttctacttg acagctgggg aaactgaggc tggtgatttg cataaggtea  
cacagtcaca  
2641 aaatggcatg catgttcagg attggattct ccctgtccca cggaccctg  
ctgtgctttc  
2701 aatgccagac acagtgcctg gcacacacag cttttattta ttgagcccc  
attgtgtgcc  
2761 aggcgctgtg ttaggtcctg ggaatatggc actgaataaa gcagttaagg  
tgccgtgtgt  
2821 caatggagct tacagtcaaa gtggagagat ttttaaaaac gaatacatc  
aaatgtgaag  
2881 agaaatgaat agcaatcatt gttctgatga agaccaactg gaagaatgta  
atgggggagg  
2941 agtcgggacc aggagagtca acattagacc aggtgggtcag ggaaggcctt  
tctgaagagg  
3001 agacatttga gctgacctct cagaattaag aaggaccacg acatacaacc  
tctaaattct  
3061 gagggtcatc cagtagaata ttccatatat gtatatatga aatattctat  
atctgtgctg  
3121 tccaattatc cactagcccc ttcaggctat tgaacatttg aaatatggct  
ggtgtgactt  
3181 aagaactgaa tttttaattt agttttactt cattttaatt agtttaaat  
taaatagcca  
3241 catgtagcta gtggctacca tattaacaa cataggctcag gagaaaggac  
tgtgcagaga  
3301 gaggaaatag caagtataaa atgtctagta tgggggcatc caagatgatt  
taaattcttc  
3361 ttttctttaa atgcctgggtg tgtttgaaga acaggcccat gaggctggac  
tagaggaagt  
3421 cagaagaaag aggttggaga tgggttcaaa gaggctggca agggccagac  
agcacagagt  
3481 cctgcacacc ttgggaaggc tttttggatt ttattttaaa gaaagttgag  
cctgggaaca  
3541 acatctgact ttctttgttt gaagagtcct cagcctactt tgagaagact  
ggatcggagg  
3601 gatgtaaaag tggaaggatt taggttaatg ttgtagtcac ttgggctaca  
gaagatgggg  
3661 catggaccaaa gatggtggca gaagtgtgga gataactgga tatttgggag  
ataaaaacaa  
3721 taggaactgg ttgtgagtga tgaaggaaag aagagaagca aagatgactc  
ccaggtttgg  
3781 ggctgagcac tgagggtggga aatactggag cgaacagttt tgattgagaa  
gaatcaagtt  
3841 gggaatacaa agcttaagat gcctgtaagg catccaaatc aacagtgttt  
gagttttgag  
3901 cttaaagaag agttcagggc tggagatgat tagcctatag ctggtattta  
aagccatgga  
3961 ggcaaccagt atatatgcag tgaaaggata gagagatggg tggaaagatg  
attggatgga  
4021 tgcatggatg gatatatgga tagatggatg gatggatggt tggattggat  
ggatggatgg  
4081 atggatggat ggatggatgg atggatggat ggatgaataa atggaccagt  
ggatggaggg  
4141 acagatgagt ggatggatgg ttggatggat ggatggatgg atggatggat  
agatggttag  
4201 atgactacct aaatggatga atggatagat ggatgagtag acggatggac  
aaatcaatag

4261 gatgaatggg ggatggatga ttggatagat tgatggatag atattgccta  
ggtggatgtg  
4321 taggtcagtc tcacttctac ctctgaaat ccatcttctg gtagaatgat  
ataaaaaatg  
4381 catgtggaga gaaagtcagg ctctgctta cctatcagca acatcctcat  
tttgtgaact  
4441 cttctgttaa cccccagtg aggatttgg acttcctgag aaaataatgt  
caccctttg  
4501 ccctaattca tctccacttg gtcaagaata gcaactgcc taggtcggca  
aattcatctt  
4561 cagttccttg tcaccaggg caataatccg acccttacc caaaccaga  
aaccacaacc  
4621 ccagggctcc tctgccccct ggatcccagt tttctaaca tctctcttct  
ttaccagggtg  
4681 tctcccagga gtctccaag gttctcaaca ccaatgggac cagtgggtt  
ctcccagggtg  
4741 gctacacctg cttccccac tctcagccct ggcaggctgc cctactagt  
caagggcggc  
4801 tactctgtgg gggagtctg gtccaccca aatgggtcct cactgccgca  
cactgtctaa  
4861 aggagtatgt gggggccggg ggagcatggg gtagggatga gaatgggact  
gggattgtgg  
4921 atggggtaga gttggatttg aggatggagt tggagttagg gttggggatg  
gacatgggag  
4981 tgagaatgag gtttgggtt gagatatggg gattgggtat gggaatagaa  
tcaaagtagg  
5041 ggatttggat gggattgaag ttgaggatgg gggagatgta tttggagatg  
aggaaggtag  
5101 gatggagaag aagttaggtt ggggatggga agagggtggg gctgggatgg  
ggatggaaat  
5161 gggctcatct tctttcctaa ccaccttctt tctgcacca cagggggctc  
aaagtttacc  
5221 taggcaagca cgccctaggg cgtgtggaag ctggtgagca ggtgagggaa  
gttgtccact  
5281 ctatcccca cctgaatac cggagaagcc ccaccacct gaaccacgac  
catgacatca  
5341 tgcttctgga gctgcagtc ccggtccagc tcacaggcta catccaaacc  
ctgcccctt  
5401 cccacaaca ccgcctaacc cctggcacca cctgtcgggt gtctggctgg  
ggcaccacca  
5461 ccagcccca gggatgcac ccacacagg ggctgaggc cccataggag  
tggctggga  
5521 aacaggggca gagatgggag ggaaggctg aggtagggtt ctttatatat  
aaaaatataa  
5581 ataagtaa ataatatat atttaaagt agctgtatcc tttatataaa  
tataaattca  
5641 tgaatatata aaaatatgag tatataaatt catgaatata tagaaatata  
aatagatcta  
5701 atatatgaat atattatatg atgtatatta tgtattatat agtaatataa  
ttatatatta  
5761 tacaaaaagt atacaaatta aatgtatttt ataaattata aaatttatca  
attatgtatt  
5821 ttaaatatgt atttctgcat aatgtatata ttatatataa tctatattta  
aattatatat  
5881 tataaatgta ttttataaat gtatacatat atatatatat atactgtaaa  
tgaattttat  
5941 catttataat atataaatca tacatataaa atgtttatat ttctataatt  
tataaaatgt  
6001 ttaatatatt aaatatgggt attaatgaaa tgtctaataa ttcaatgtaa  
taattaattc

6061 tatatcatta cttagtaagt ataatacatt atatatgtga atataaagtt  
gatgtatata  
6121 ccgacaagag ccccttgcac ctccctagca atccctgact ctctcccagc  
ctcatgtttg  
6181 tatctttctc ctcaacatgc cctgtctctc ttccctaccat tctatccaac  
tctcccgtaa  
6241 ctcttcccat cccgttccct gcttttccca tctttaattc tctatttctg  
accatctccc  
6301 tattccaaact cctctctccc aactttctct ccccaaccgt ggctccacca  
ctctccttat  
6361 caaccttcca ttctcttgtc ccttccctcc ttgtccttcc ctccactttt  
ctcctcatct  
6421 ctcccttctg ctctctccca tgtccctcca tattttctgt acttccgttg  
ctttaccag  
6481 ataggtgtc atctcttctc ccacttttct ctcccatct caattttcta  
tctactcttt  
6541 acccattcaa ctgcctatt tcaccttcat cccatattct atccaggtcg  
gataccttag  
6601 accttctctt tcttctcccc agtgaattac cccaaaactc tacaatgtgc  
caacatccaa  
6661 ctctgctcag atgaggagtgc tcgtcaagtc taccaggaa agatcactga  
caacatgttg  
6721 tgtgccggca caaaagaggg tggcaaagac tctgtgagg tgaggccggg  
aggctgggtg  
6781 gtgccttggc caggatagaa agccagaatg gaagtgcag atgctgggga  
aaaagctttg  
6841 tttccagcct taggggaacc aatctttata agatacaatg tcccctcaca  
taggaggtca  
6901 agacaaaaag ggtaccag ggatggcagg aataattcat cataagcccc  
agctttgact  
6961 gagggtgtgc caagatccct gtgttgagat gcataaaggt tgggtattctt  
tcaattgtga  
7021 gtgatagaca accaactcaa actggcttaa acaaaatgca ggcttttgta  
actgaaaatc  
7081 caggttgtct ggcttttagc acagatggat ccaggatgc aaattgtgtg  
tttggaattc  
7141 tgtctttctt ttaactctca gctcttctt attctgtttt ggcttcattc  
tcggttagat  
7201 tcttcccatg acaagatggc cccagcagct ttgagcttac atcctaccct  
ctaggcaacc  
7261 ctattagaaa gagaacctct cttttccaat agttcacaca aaagtcttaa  
gcatgattct  
7321 cactaggctg acctaatgca tgtgtcttga gccatcactc caccagagct  
gtgggattct  
7381 ctgatgggac aagcctgagt cacatagtta actgtgggtg ctggagaggg  
gcagggacaa  
7441 actgcatgga ttggaagtgg agaagggcag ttccccaat gaaaaaatca  
ggagaggctg  
7501 ttacaaaaat aaggggaaat ggccaagtac agtagttcat gcctgtaatc  
ccagcacttt  
7561 gggaggctga ggtgagagga ttacttgagc ccaggagttt gagaccagcc  
tgggcaacat  
7621 agtgagactc tgtctctaca aaaagaaaaa aaagttttta aattagccag  
gtgtgggtgga  
7681 gtacaactgc agtcctagtt actcgggagg ctgaggcaga aggactattt  
gaaccagga  
7741 gttcaaggct gcagtgggt atgatcatgc cactgcactc cagcctgggt  
gatagagcaa  
7801 ggcctgtct ctaaaacaaa aagaaataaa tagagcaaga cactgtctct  
aataaataaa

7861 taaataaaaa tttaaaaatg aatgtttaat tttttaaaaa taagaggaaa  
tggatactac  
7921 atgagcaaaa aatagccttc atcaataaag aagttgagat tggattcagt  
gagaaaagagt  
7981 atgatactat attaatagata tgtgccttga tcgattagtg atgtctgcct  
tgggccagg  
8041 aagagaaata gacttacacg tgtgttgcac accctgcca gatatgaatg  
ggttcactca  
8101 atagtgaagag acacaaatga gccttaaata ggagcagggt cagctggtgt  
ggggcagggt  
8161 gtgatttagt accagggaaa caaaaatggg tatgaagtaa gttgttacca  
ttttaatgaa  
8221 actgaggaac agagaaaaac acagaaattt ctctgtgtct ctctttctct  
gggcctatct  
8281 ctgtctttct gtccctatct ctgtctcttg ctgtctgtcc ctctgtgttt  
gtcttcttgt  
8341 ctgtttctca ctgtcttcat tgccttctct cacactgtgt gtgtctgact  
ctgcctctct  
8401 gagtctcctt ctctgtgtgt gtctctctcc atctttcact ctctccccac  
acctcctgt  
8461 ccctgccttg tttagcccca gcaaggacc acctctctct ctctttcttt  
ccccaactca  
8521 gggtgactct gggggccccc tggctgttaa cagaacactg tatggcatcg  
tctcctgggg  
8581 agacttccca tgtgggcaac ctgaccggcc tgggtgtctac acctgtgtct  
caagatacgt  
8641 cctgtggatc cgtgaaacaa tccgaaaata tgaaaccag cagcaaaaat  
ggttgaagg  
8701 cccacaataa aagttgagaa atgtaccggc ttccatcctg tcaccatgac  
ttctcacat  
8761 ggtctgttta gcccttctct gctccttatt ccagtggtc cattgaacc  
agtgatccat  
8821 gtcctgaaaa atgctcaatc tcagctaaca ttccatgttt cagaagcatt  
caggcactgc  
8881 caggcttgca gtctcccaga tgttgcaccc ctgaaacatc tcaacaacct  
gaatgtccca  
8941 acccagacaa tggcccagggt ctctcaactt catcagtgtg gcttctatga  
gcccagatca  
9001 ccacctgaac gttctgtctg tggcacattc ttaaataatt ccatcagccc  
atctcaacaa  
9061 tatatgtcct ataaatggac catccttgac aacatcctct aactcttcaa  
gtatttattc  
9121 aatgccagta tccatagacct tctatttttt gactcaaga aggctctaga  
ctcccatgat  
9181 agttcatcct gaaaatatct tcttatgccc acaatcttct gccctgacaa  
cattctgtgt  
9241 acctctgtga ctaccacag ctaacattgg atcctcagaa tatttcattc  
tcacactgtt  
9301 atgggtgtct cagaagtccc aaccaacct acatcccaca ttcttccaat  
acccacctc  
9361 tgccaacatt cctctctga atcaatggca ccctagtctc tagagttata  
gggttcagta  
9421 taccaaagggt tcttcttgcc tgaactttat tgtctaccaa atattccgtc  
ttgtatcccc  
9481 tccatgaaca tccttgggtca gtgtcccttg ctgttacatc tttgtgcatg  
accctaaaat  
9541 gtagtgcaaa tccttgcttt ggacaagtta taaaactcac agtctctgtg  
ctttctcatc  
9601 tgtaaaatgg gttcataatt ttttttaatt gtaacattat tacaagaata  
aatgtcaagc

9661 atttactact attattatatt gcatggttcc cataaaatat taccttagaa  
tgtaataaac  
9721 agcccttcga atttgcagag tgtccaaaaa aagtgttgca ctgatttatt  
ttcctcagga  
9781 gacatttctt cagtgttgac tatgtgcaag cactctcttg ggtgttgta  
aatatagttt  
9841 atttactcaa caaatatttg tacctatcaa gagccaggca ctgttgaga  
gacaagtgat  
9901 aaccaatgag ttaaacagat aaaaacttct gcccttgtag aacttacatt  
cttttcaaga  
9961 agtctccata acaatgaata aagaaatagg ctgtcaggtg gtgctgcaag  
ccatagcaag  
10021 aaatgaaaca agggccatat gtggtagctc atgcctgtaa taccaacact  
gggaggccaa

SEQ.ID.NO. 44

KLK-L4 AA

ESSKVLNTNGTSGFLPGGYTCFPHSQPWQAALLVQGRLLCGGVLVHPKWVL  
TAAHCLKEGLKVYLKGKHALGRVEAGEQVREVVHSIPHPEYRRSPTHLNHDH  
DIMLLELQSPVQLTGYIQTLP LSHNNRLTPGTT CRVSGWGTTTSPQVNYPKTL  
QCANIQLRSDEECRQVYPGKITDNMLCAGTKEGGKDSCEGDSGGPLVCNRTL  
YGIVSWGDFPCGQPDRPGVYTRVSRYVLWIRETIRKYETQQQKWLKGPQ

SEQ.ID.NO. 45

KLK-L4 AA

MWPLALVIASLTALSGGVSQESSKVLNTNGTSGFLPGGYTCFPHSQPWQAA  
LLVQGRLLCGGVLVHPKWVLTAAHCLKEGLKVYLKGKHALGRVEAGEQVRE  
VVHSIPHPEYRRSPTHLNHDHDIMLLELQSPVQLTGYIQTLP LSHNNRLTPGTT  
CRVSGWGTTTSPQVNYPKTLQCANIQLRSDEECRQVYPGKITDNMLCAGTKE  
GGKDSCEGDSGGPLVCNRTLYGIVSWGDFPCGQPDRPGVYTRVSRYVLWIRE  
TIRKYETQQQKWLKGPQ

SEQ.ID.NO. 46

Table 15

AACTCTACAATGTGCCACA

SEQ.ID.NO. 47

Table 15

TTATTGTGGGCCCTTCAACC

SEQ.ID.NO. 48

Table 15



GGATGGTCCATTTATAGGAC

SEQ.ID.NO. 49

Table 15

AGGCTGCCCTACTAGTGCAA

SEQ.ID.NO. 50

Table 15

ATATTGCCTAGGTGGATGTG

SEQ.ID.NO. 51

Table 15

AAGACTTCAAGGAGCCAAGC

SEQ.ID.NO. 52

Table 15

GACCCTTCACCTCCCAAAT

SEQ.ID.NO. 53

Table 15

CTAGTGATCGCCTCCCTGAC

SEQ.ID.NO. 54

Table 15

GGTGATCTGCGCCCTGGTCCT

SEQ.ID.NO. 55

Table 15

AGGTGTCCGGTGGAGGTGGCA

SEQ.ID.NO. 56

KLK-L5 na

1 attgagggg gatcccagca ggtcccattt gttcagattc ttctgggcct  
ttctgtgttg  
61 catttcttcc tctgcaggac acctgtcaca tgagggtctt caggggaaaa  
ggaattctag  
121 tgtctgtgac tgcttcaaag gagaagtaag gggagaggag aggaaagcag  
gaggaggttg  
181 gagagaacct ctgtttcctg aggtcttcca atctccttca gctcaaagca  
ctcagcatgc  
241 tgaagttcca gactctgggc tatcacgttc tgacatgcaa cacaggcaac  
acccagctc  
301 catccagctt tctccaaaag cacaggcatg acgtcatatg gtgacaaaca  
cccttgtcca  
361 aaggaagccc ataggatag ctaattctag attcaciaaat actctagagg  
aactcacaca  
421 atgggatggg ccagtgcacc acacagagta tgaggcctcc caccttggtt  
gaatatcttt  
481 ttcttttttt tctttttttt tttttttgag acggagtctc actctgtcac  
ccaggctgga  
541 gtgcagtggc tcatctcgg ctcactgcaa cctctgcctc ccaggttcaa  
gtgattctcc  
601 tgccctagcc tctggagtag ctggaattac aggtgcccac caccacaact  
ggctaatttt  
661 tgtattttta gtagagacga gggccacca tgttgaccag gcttgtctcg  
aactcctggt  
721 ctcaagtgat ctgcccacct cggcctagtg ctgggattac agacgtgagt  
caccagccc  
781 ggccccacct tggttaaatt tctgaaaatc atttggtaaa gtgaggacc  
ctccagctga  
841 gacactgcca ggaaacagct attgagtctc ttagcaccca cagcattaa  
acaaacccaa  
901 aacatttttag gcctcgttga gttctggagg caaaatattc ctcatctaca  
aatttatttt  
961 attttatttt ttaataaaag ttattattat ttttttttat agagagacag  
ggtcttgcctc  
1021 tgtgaccag actagagtgc agtgggtgta ccatgggttca ctgcagcctc  
cacctcctgg  
1081 gctcaagcga tctcccacc tcagcctgcc aagtagctgg gaccacaggt  
atgcccctcc  
1141 ccagggctaa ctttttttta ctttttggg agatgaggtc tcactatggt  
gcccagctg  
1201 gtcttttttt tttttttttt tttttttgag acgggagtgc aggctggagt  
gcccagctg  
1261 gagtgcagtg gcacaatcat aactcactgc agcctcaaac tcctggggctc  
aagtatcct  
1321 ccacctcag cctcccat aactaggact acaggcctgt gtcaccataa  
tgccctgtta  
1381 atttttttag tttttgttg tagaaacagg gtctcactat gttaccag  
ctggcctcta  
1441 actcctggcc tcaatccatc ctccatctc aacctccaa agtgctagga  
ttatagccac  
1501 gagccaccat gcccgcccc atacttatat ttacttgtag tgagaacact  
taaaccctac  
1561 tcggtcagta attttcaagt acacaataca ttgttactaa ctatatacat  
ggtattttta  
1621 atttgcata atgtctctta aaatcagcga gcccgctta tttttgtat  
tcaattttat  
1681 tggatataaa ttccacatca gtaaacctga ttctcttaaa aatctacaca  
gaaaaaaaaa  
1741 aagagagaga ggttgagttg ggtagttgtt ggtatttttg tttttgttc  
tttgcttatt

1801 cagttgaggt ttattgtaaa acttgacacc agaaaaagga agaagtggcg  
tttttgtgct  
1861 gtgagcgtgt gacgtgtgtc ctttccagag aaaggacagt catggtgctt  
ttttatcctc  
1921 tctgccccaa gaaggaaagc tcttaacagc cagcaggagg ctttgtaggg  
accagcgta  
1981 tcaacgccag tcgcgctgac caatgatgag ttaaagcagt taggtcgttt  
ctaagagcaa  
2041 atcaaaagct aaggttctgt gattctgaaa atgagacacg gacagagact  
ggagaccag  
2101 agagaaagtg aaggactaaa agacagtcac aggggtgggag tttgctctcc  
tctgttttgt  
2161 tctgggtttt tttgtttgtt tgtgcgtctt gtctgaccgc tttctttttt  
tttctttttc  
2221 tttctttttt tttttttttt ttttgagatg gagtcttgct ctgccccca  
ggctggagt  
2281 cgggtggcaca atctcggctc actgcaagct ccgcctccca cgttcaaggg  
attctcctgc  
2341 ctcagcctcc cgagcagctg ggattacagg catgcaccac cacactcagc  
taatttttgt  
2401 atttttagta gagatggggt ttcaccatat tgaccaggct ggtcttgaac  
tcctggcgtc  
2461 aagtgacttg cccgcctcgg cctcccaaag tggtgggatt acaggcgtga  
gccaccgcgc  
2521 ctggccctga ctgcttttct ccttggtttg tttgtcaatc ccccttctc  
tgagccgaat  
2581 tccctttttg ttctcatttt ctctctctgt cccctctctc tctcttctt  
tctctcttc  
2641 cattcctcct agatgaagca aaaactcaga taaaccagca cagaggccag  
gtatggtggc  
2701 tcacacctgt aatcccggca ctttggggag ccaaggcagg cagggtgctt  
gaggccagga  
2761 gttcaagacc agcctggccc acatggtgaa acccgtctc tactaaaaat  
acaaaaatta  
2821 gccggacatg gtggcacgtg cctgtaatcc cagggtactca agagggtggag  
gttgacgtga  
2881 gcgagatca cagccctgca ctccagcctg ggtgacagag cgagactcca  
tctcaaaacg  
2941 aaaaacaaaa aacagcacia agttcccttg tcctgtgact cattctctct  
ctctctttct  
3001 accatttctc ctccctgtg tctttttttt ttctctctgt gggttttatt  
taagcaatag  
3061 aagttcttag caaagaaaaa ctttatggaa ttagattgat ccacttcata  
tgtacatata  
3121 tgaactcagt tcagaaactc tcttctaccc ctgcctgac acctatttgg  
aagtctgttc  
3181 cttcaactct tcttctcttt ctgggactct ttctagcttg ggcttcctgc  
ccctcccgtc  
3241 cactctcctg ctttcacagc ctctccttcc cctgcccct cccctgcact  
gcatggggat  
3301 gggccccagg tgtccaaggt ctccccaccc tcctttgtca ctggagtcag  
gattagaacc  
3361 cagctcccta gtcaccttga gtcacagtc ctggggctgc tgacgggctt  
gcagaggaga  
3421 gagggagtgg ggctgggtct tcccaccctg ggtcctttcc tccttcccca  
ctccgtttag  
3481 ctgtaaagct caattaagtg tgattagctg agaagagttt ctgcagaatt  
agagcacgcc  
3541 ccaccctgt cttcgtggtc cccttccctt aaccggaaa ctggatgggc  
caggacaaaag

3601 agagttaaga gctttgtcag tggctctgtct ggagcgacag atggaaggaa  
agggaccggt  
3661 tgagcaacat gacaggtggc tgaggagcca ggtgcagagt ggtagagttg  
gctggcggag  
3721 tggccagcac atgagaagac aggcaggtag gtggacggag agatagcagc  
gacgaggaca  
3781 ggccaaacag tgacagccac gtagaggatc tggcagacaa agagacaagg  
tgagaaggag  
3841 gtaggcgact gccaatgagg gagtgcacac caggggagca ggtagagaga  
ggacaagcag  
3901 gtcacccctt tggtagacctt caaagagaag cagagagggc agaggtgggg  
ggcacaggga  
3961 aagggtgacc tctgagattc cctttttccc ccagactttg gaagtgaccc  
accatggggc  
4021 tcagcatctt tttgtcctg tgtgttcttg gtgagttctc ccggagcagg  
gagagggcag  
4081 gactgcgact ggatcccttc acccccatga ggaggcccca ccacctccc  
catctcagct  
4141 ctggccccca gcctggtggg gaggaggaga ggggctttct ctgtgcctcc  
atttacctgc  
4201 agctctcagg gtactgtctc cctcggcttc cctattttt tgatccctct  
tcccttctgt  
4261 cctctctga atctctgtct ctccatttcc ctctatgtg taagcatctt  
tctccctggg  
4321 tgtctttgat gtttcatggg ctttttctat cactgggtct ctctctctt  
ctctctctt  
4381 ctggtctctc tttctctctc ctctctctg cctgtttctc tctctcactc  
tgtgtgtctc  
4441 tccatctctg tatcttttct tctctctctc gacctatgcc cctgtctgtc  
tccagggtc  
4501 agccaggcag ccacaccgaa gattttcaat ggactgagt gtgggcgtaa  
ctcacagccg  
4561 tggcaggtgg ggctgtttga gggcaccagc ctgcgctgcg ggggtgtcct  
tattgaccac  
4621 aggtgggtcc tcacagcggc tctactgcagc ggcaggtaag tcccttctctg  
gggtgggcga  
4681 agggaggact atgggaaggc aagcgctggg ggtaggatca caagggaggg  
tggtgcccac  
4741 tgggaagaag ctgatcctgc aacaagagag tctgaggtta gaccaggagt  
ggaacttct  
4801 tagcagtggg cctgggggtg tgctgggcag ggtgaggtat gttgggtgga  
gggccgggga  
4861 gggctctgga acctgccctc ctgcctctcc cattcctgca tgtaccctt  
ctttctata  
4921 tgacatctgc cactcaccac agccattctt tgaccagtc tgggcccggg  
gcccaggctt  
4981 caccgaagct ctttttctt tttttttttt ttttttttg agacagggtc  
tcgtctgtc  
5041 gccaggctg ctgtgcaatg gcgtgatcac agctcactgc tgtctctgcc  
tcccaggctc  
5101 aagtgattct cctgccccag cctcctgagt agctgggatt acaggcaccc  
gccaccatgc  
5161 ccagctaatt tttgtatttt ttgtagagac agggttttgc catgttgccc  
aggtgggtct  
5221 cgaactcctg gectcaaag acctgccctt cttggcctcc caaagtgtctg  
ggattacagg  
5281 tgtgagccac tgcaccggc caacatgacc caaactctt gtgcaacttc  
agaatctatg  
5341 cctggcacct ctctgggct cagtagactg atgttctgga attttttct  
tttttttct

5401 tttttttttt ttttggagac agagtcttgc tctttctgtc atccaagctg  
gagtgcagtg  
5461 atgctatctt ggctcactac agcctcaacc acctgggctc aagtgatcct  
cacacctcag  
5521 cctcccaagg agctaagact acaggcctgc gccaccacac ctggctaatt  
tttaaatttt  
5581 ttttgtagag acagggtttt gctatgttac ccaggctggt ctcaaactcc  
tcagctcaag  
5641 caatcttcct gccttgacct cccaaagtgc tgggattaca ggcatgagcc  
actgtgcctg  
5701 gcctggaact ttttttgtga aaggggagat cagatgcaa gaaacagaga  
ctcagggaga  
5761 gagagggcca gcagcaggat gcagagaggc cattcatcaa cccactcggt  
caatcatgaa  
5821 cccactcgtc cacgcatgag catggagggc acatgctccg tgccaggcgg  
tgggaataag  
5881 gcagtgaaca aggtccactg atgtccctgc cttcatgggc ttcaccagcc  
gagagaatca  
5941 gaaagagagg cctggcgagg tggctcacac ctgtaatccc agcacttttg  
gaggccgagg  
6001 cgggaggatc acttgaggtc aggagtttga gaccagcctg acacacatgg  
tgaaacctta  
6061 tctctactaa aaatacaaaa attagctggg catggtggca tgcttctgta  
atcccagcta  
6121 cttgggaggc tgaggcagg gaattgcttg aacctgggag gtggagggtg  
tagtgagcca  
6181 agatggtgcc actgcactcc agcctgggag acagagcgag actcgggtctt  
gaaaaaaaaa  
6241 aaaaaaaaaa aaaggagaga gagagacaca gatgcaggga catggtagga  
gaaacaggga  
6301 acaccaaga tggaaagggt gtgatggagg ttgggaataa gagcctgtaa  
gagagactcg  
6361 gagaatgaga gttgcgggtg agaggacaga cagtggggg cagaacagtg  
gggagcggca  
6421 ggagcgctg agtgtccgtg gaggggtgca aggtggggga ctgcgtgcct  
gccaccgct  
6481 cagccgtcgc caccggcagc aggtactggg tgcgcctggg ggaacacagc  
ctcagccagc  
6541 tcgactggac cgagcagatc cggcacagcg gcttctctgt gacctatccc  
ggctacctgg  
6601 gagcctcgac gagccacgag cacgacctcc ggctgctgag gctgcgcctg  
ccggtccgag  
6661 taaccagcag cgttcaacct ctgcccctgc ccaatgactg tgcaaccgct  
ggcaccgagt  
6721 gccacgtctc aggtctgggg atcaccaacc acccagggag taaggggccc  
agggccaggg  
6781 gtcaggggtc aggatgggta caagtctggg atgcagggcg agaggctgaa  
tcatgacacc  
6841 tcagaggaag gatgggtaaa gggtcagggg gtgggatggg acatcaggat  
catgggtttg  
6901 ggtcagagat tatggtggat tggggtcttg ggagccaaag ggggttaaagg  
actgggtatg  
6961 aagtcaggga tcagaggtca gaggtcagag tgtgtcagag gtcatacac  
tgagcaaaa  
7021 ggcataatata tatatatatg tatgtatagg atatgggcat tgtgggtcat  
gggtctgggg  
7081 ttagaggtca ccgtagaatt aaggtcatgg gatccagagg ttgtacaatc  
tgggtcaaat  
7141 ctgaggatgg aaattgggat tctatccaaa atcacatatc tgagattgga  
ggcatagcg

7201 tttggggtgt ggggcccga gtttggggtc atggaggctg gggcccaata  
aactaggatc  
7261 aggggacact ggcgttgga gcaagtgggt ttggaagatg cagagctgag  
gttggagggt  
7321 aaggtaaaga cagggacatg gggtcaggag acagaagata tgagatcaag  
ctgggatcat  
7381 aaggtaataa gacagaaggt caaagatcac agtagctggc attgaagagg  
gtcaggctctg  
7441 gattcgttgt ctctgacgct ggagagacaa gaaagttctt gagttatgcc  
actcaaagtc  
7501 aaatgtcaaa gatcaaagag accgtcaatc atctggggtc atgattcata  
tgaaattaag  
7561 tcataaatat gtaacttgga ggtttcggga ttgtagtaca ggtcggtgag  
gggcaggggt  
7621 attgacatgg atgggccaca tccagggag agggacgtgg cctcaaagtg  
gggagattta  
7681 ggggaccctg cagcacgcat gttctctctc cagaccatt cccggatctg  
ctccagtgcc  
7741 tcaacctctc catcgctctc catgccacct gccatggtgt gtatccccgg  
agaatcacga  
7801 gcaacatggt gtgtgcaggc ggcgtcccg ggccaggatgc ctgccagggtg  
agccagtga  
7861 ggcagcgtgc gtggtcacca ggacaggaag tgaaggggag gggctggaag  
caggagggga  
7921 actgatggag gatgaatcag ggaaagggga tgctgcagag agacggggtc  
aaaaaggaag  
7981 ggagaggctg gttacggagg ctcacacctg taatcccagc actttgggag  
gccgaggcgg  
8041 gcggatcact tgaggtcagg agttcaagac aagcctggcc aacacgggtga  
gactctgaat  
8101 ctactaaaaa taccagaatt agccgggggt ggtggtgcaa gcctgtggcc  
ccagctactt  
8161 ggaaggctga ggcaggagaa tcgcttgatc ccgggaggcg gaggttgag  
tgagctgaga  
8221 tcacgccact gcaactccagc ctgggcgaca gagccagact ctgtctcaaa  
acaaaataat  
8281 taataataat aataataata ataataataa taatggagga gaggcccagg  
ataagggagg  
8341 gagagagaca gggagtaaaa gggaggaccg gggaatggag gagggggagg  
ggcagggaga  
8401 gagaggagg aagggaaacag agaaggaaag atggggcagg ggttacagag  
agagacagca  
8461 aaacagacgg agaggactgg gagccagac agggaaccag ctgtttctgg  
ggctctaagt  
8521 ctttccata ccactctcca gttggtgctg tcccagactg agagagattt  
gaggatggcg  
8581 gtctctcccc tcattggtca gggccccagc cattgtcctt gagagaactc  
tgtgcttttg  
8641 atggagtcct gccaccttc cctgggattg gtcatttttg atggcactct  
ctccctcat  
8701 tggtcagaac ccaggcatt gtccttgaga gaacctctat cctttatgga  
gtcccacct  
8761 cctcccctgg gattggctcat tgataatagt gttctctctc ctcatgggtc  
agggccccag  
8821 ccattgtcct tgagagaatg ctgactctt tatgttgtct tgacagcctc  
ccctgagatt  
8881 ggtcattaat gactgtgctc tctctctca ttggtcaggg cccagccat  
tgtccttgag  
8941 agaacctctg tcctttatgg agttccacce ttcttccctg ggattggccc  
ctagagacag

9001 tggttcttct ctttttggtta gccattgcc a ttgtcctccg ggaaagtgat  
tatactcttt  
9061 tgtctaata ga ccagacttgg agccctcccc aaggcccagg actgggttga  
aggggttgggg  
9121 aggaaaacag aaataagatg tctcccttgt tcagacagta cttctcttcc  
cttccagggt  
9181 gattctgggg gccccctggt gtgtggggga gtccttcaag gtctgtgtgc  
ctgggggtct  
9241 gtggggccct gtggacaaga tggcatccct ggagtctaca cctatatattg  
caagtatgtg  
9301 gactggatcc ggatgatcat gaggaacaac tgacctgttt cctccacctc  
cacccccacc  
9361 ccttaacttg ggtaccctc tggccctcag agcaccaata tctcctccat  
cacttcccct  
9421 agctccactc ttgttgacct gggaacttct tgggaacttta actcctgcc a  
gcccttctaa  
9481 gaccacagag cggggtgaga gaagtgtgca atagtctgga ataaatataa  
atgaaggagg  
9541 ggccatgtct gtccatttga agtccctcatg ctgggtgaga ctggaagaag  
gactcagcag  
9601 ttccctatc tcataggagt agaaacagag ctcaaataag gccaggcaca  
gtggctcaca  
9661 cctgtaatcc catcactttg ggaagctgag gcagggtgat cacctgaggt  
caggaactcg  
9721 ggaccagcct ggtcaacata gtgaaacccc aactctacta aaaatgcaaa  
aattagccag  
9781 gcatgggtggc gcatgcctgt aatcccagct actcaggagg ctgagacagg  
agaatagcat  
9841 gaaccctgta ggcagaggct gcagcgagcc gagattgaac cattacactc  
cagcctgggc  
9901 gacagagcga gactccatct caaaaacaaa caaacaaaaa acccagtgtc  
caaataggat  
9961 gaggggtcttc cctgagtagt tactcagaaa tggagtagaa aaagttactt  
ttaataatat  
10021 aggccgggtg cagtggccca cgcctgtaat cccagcactt tgggaggccg  
aggtgggagg  
10081 atggcttgag ctcagatttc gagatcagcc tggcaacaca gtgaaatctt  
gtcactacaa  
10141 aaacacaaaa aattagctgg gtgtggtggt gcgtgcctgt agtcccagct  
acttgggaag  
10201 ctgagggtggg aggatcaccc gagccgggga ggtggaggct gcaaagagcc  
gagatcatgc  
10261 cactgcactc cagcctgggc aataaagtga gaccttgtct caaaaacaaa  
aaccagcaa  
10321 tataaataag acacatgttt cttcatctgg cataatagaa atagtgccca  
gagcttataa  
10381 gcttttcaag agtccacaaa agaccgaaa aagaaaaaga aaattgttag  
ctccaaaata  
10441 ccagatgaaa gctgcaaagt caacatttat gaccatttaa tccaatgtcc  
ataaaacgta  
10501 gcattctttc cactagccaa ctgcagttta ctttcttgta atgaagcata  
cattgtatct  
10561 ttaatgtggg acgtggcttt gttctaataa gacgaagggt ggagtgcagg  
cttggaaagg  
10621 aggagagctc agcctacgtc tttaatcctc ctgcccaccc cttggattct  
gtctccactg  
10681 ggactcaaga ggtgaggaga gaccatctcc ccaaagcac tgaagggaaa  
ctggaggagg  
10741 gagggagtga ggggtgatca taccagcgga ggcacatttg ctgagcccc  
ccgcagtctg

10801 ctcttttccaa gtggaccctc ctggaagcct gatcccaacc tcccctgcaa  
 gcaggtctgt  
 10861 cacccccata tctcagatga agaaactgag ccttgaggg gtggagtccc  
 ttgtccccac  
 10921 gtcataaggg tagtcatagt agtaggaaga ggaagcacct aggtttgagg  
 ccagggtcgg  
 10981 ctgctgtcag aacctaggcc ctccctgcc ttgctccaca cctggtcagg  
 ggagagaggg  
 11041 gaggaagcc aagggaaggg acctaactga aaacaaaca gctgggagaa  
 gcaggaatct  
 11101 gcgctcgggt tccgcagatg cagaggttga ggtggctgcg ggactggaag  
 tcacgaggca  
 11161 gaggtctcac agcagccagt aagtgaacag ctggactcgg gctgcctggg  
 cggcaggagg  
 11221 aagcgggagc ggggaagggc agcagaggag cgaggccca gaggagccct  
 ggggtggagc  
 11281 acagccaagg gctctgttcc ctttcctgga ctgggttcc acaggccctg  
 acctgcctcc  
 11341 cccacctcc ggtcctgcc ctgtgcctgg cagcagcccc acctgtgtga  
 catcccagca  
 11401 cccccccct ctccttgcaa aggagaaggg agcggcctag gggaggccag  
 gggcccacct  
 11461 gggctggggc tgtggagagg gagggtcgg gacgggagga aaaagagaga  
 cggagattag  
 11521 atggaagaag agggatttca agacaaattg ccagagatgc agtcagagag  
 actgactgag  
 11581 agacacaaag atagaaggaa ttagagaaag ggccacacag agccagacag  
 agagagaaga  
 11641 gtggagatgg agacagggac gaggacagag aaaggcagac agacacatag  
 ggacagaaag  
 11701 agaaaaatca cacaaagtca gaattactga atgacaggga atgacacata  
 gaacgagaca  
 11761 cagattcaga gactcagggc agggaaagga aggctgcaga cagacagaca  
 gacagaggga

SEQ.ID.NO. 57

KLK-L5 AA

LSQAATPKIFNGTECGRNSQPWQVGLFEGTSLRCGGVLIDHRWVLTAHCSG  
 SRYWVRLGEHSLSQLDWTEQIRHSGFSVTHPGYLGASTSHEHDLRLRLRLP  
 VRVTSSVQPLPLPNDCATAGTECHVSGWGITNHPNPFDDLQCLNLSIVSHA  
 TCHGVYPGRITSNMVCAGGVPGQDACQ

SEQ.ID.NO. 58

KLK-L5 AA – alternatively spliced

MGLSIFLLLCVLGLSQAATPKIFNGTECGRNSQPWQVGLFEGTSLRCGGVLID  
 HRWVLTAHCSGRPIPGSAPVPQPLHRLPCHLPWCVSRENHEQHGVCRRRPG  
 AGCLPG



SEQ.ID.NO. 59

KLK-L5 AA – alternatively spliced

MGLSIFLLLCVLGLSQAATPKIFNGTECGRNSQPWQVGLFEGTSLRCGGVLID  
HRWVLTAAHCSGSRYWVRLGEHSLSQLDWTEQIRHSGFSVTHPGYLGASTS  
HEHDLRLLRLRLPVRVTSSVQPLPLPNDCATAGTECHVSGWGITNHPNPPFD  
LLQCLNLSIVSHATCHGVYPGRITSNMVCAGGVPQDACQGDSGGPLVCGG  
VLQGLVSWGSVGPCGQDGIPGVYTYICNSTLVGLGTSWNFNSCQPF

SEQ.ID.NO. 60

KLK-L5-AA

MGLSIFLLLCVLGLSQAATPKIFNGTECGRNSQPWQVGLFEGTSLRCGGVLID  
HRWVLTAAHCSGSRYWVRLGEHSLSQLDWTEQIRHSGFSVTHPGYLGASTS  
HEHDLRLLRLRLPVRVTSSVQPLPLPNDCATAGTECHVSGWGITNHPNPPFD  
LLQCLNLSIVSHATCHGVYPGRITSNMVCAGGVPQDACQGDSGGPLVCGG  
VLQGLVSWGSVGPCGQDGIPGVYTYICKYVDWIRMIMRNN

SEQ.ID.NO. 61

Table 17

TCAGCCAGGCAGCCACACCG

SEQ.ID.NO. 62

Table 17

TTGGTGATGCCCCAGCCTGA

SEQ.ID.NO. 63

Table 17

CCACACCGAAGATTTTCAAT

SEQ.ID.NO. 64

Table 17

GCCCTCCTTCATTTATA

SEQ.ID.NO. 65

## KLK-L6 NA

1 atcgtgtaat caccgccaca tccagtgcaa agctgattcg tcaccacaga  
gcagctccct  
61 cctgccaccc catccctggg tcccaagaga accctttctt aaaagaggga  
gttcttgacg  
121 ggtgtggtgg ctcatgcctg taatccttgc actttgggag gccaaggagg  
gtggatcatt  
181 tgaggtcagg agtttgagac cagactggcc aacatggtga aaccctgtct  
ttactaaaaa  
241 tacaaaaaaa tgagcggggc atggtggtgg gtgcctatag cccagctac  
tcaggaggct  
301 gaggcaggag aatcgcttga acccaggagg cagaggttgc agtgagccga  
gattgagcca  
361 ctgcactcca gccggggcta aagagtgaga ctctgtctca aaaaaaaaaa  
aaagaaaaag  
421 aaaaaaagaa aaaaaataa aataaataa taaataaat aaatttaaaa  
atttaaaaat  
481 aaagaggggg ttcttgtgtt gatgccgagc ctgaaccaag gcagaggagg  
ccgggaaggc  
541 ttccaaggc cttcagctca aagcaggagg gcccatagtt aaacagaaac  
agttcaggaa  
601 tcacagaaag gcacctggg agagatgggt gtgtggctcc agatgcagg  
gccagacag  
661 tgcgtcccca ggtgtacaga cagaccagg ccaagctcca gctcaaagag  
ccagcctagg  
721 ggggtgccga ggtggaggga ggctgagtca ggctgaggcc ggggaacagt  
tggggtagcc  
781 aaggagggca agcagcctcc tgagtcacca cgtgggtccag gtacggggct  
gccaggccc  
841 agagacggac acaagcactg gggaatttaa ggggctaggg gaggggctga  
ggagggtagg  
901 cctccccca aatgaggatg gaaccccc aactccagaa cccccctgca  
ggctggccag  
961 aatccttccc catctcatc actctgtctc tctgtctctc tgccgtctcc  
tattttgaat  
1021 ttccaacccc gtctgttaag actgtcctc tgtctctgaa tctctgtccc  
cttctcttcc  
1081 tgggtctctc tccctctccc tctgggtctc tgctccctc tctgggtctc  
tgtcactctc  
1141 tctttgcac tccagctctc actttgtctc tgcacctagc agatcccaag  
ctggggaatg  
1201 ccagttctgg caccaacctt cctgtctcct gctggggcct ctgctcccc  
atctctcagg  
1261 agtcgaaagt gaaaaagcaa ggtgggcagc tctgtctcag gtccaggat  
ctcccgccca  
1321 cctcctgccc gtcctctatc ccacctctc tctccatctc tccctggcgc  
tgccatctct  
1381 catctaggcc tccgtctcct ctgtcattgt ccccatcccc tgtagggtgc  
catccttccc  
1441 gtctccctc tgccatcggc ctgcctgtcc catcctcttt ctcccacat  
gtcccgttct  
1501 cttccacgtc tcatgcccgc actgccttca tcatcatcgc tgttgttctg  
tgtgtgtttg  
1561 tgggtgagtgc cgcattggtg gggcgtctcg gcctctctcc tctctctcca  
ctgttttctc  
1621 tttctgtgtg tctgtttcca ttctatctcc acctctctcc ctccgtcttt  
tgcttttcta  
1681 tctccacttc tccacacccc tctctccctg cgtctctgtg tctccctctt  
cctctgtctt

1741 gtttttttcc caccgtctgc ctcttctgtt ccctgtcaca tccaacttcc  
accggtttct  
1801 ccagctctct cctcagttcc ttctctcatg agcacacctg cctctgtgct  
cgtattcctg  
1861 gactcctctc tctccactgt catatcttct cattcatttt cccagtctct  
ctctgtctct  
1921 tgctctcccc ctctctgtca ctctgtctct gtctctctct ttctctctct  
ctctctgtgt  
1981 ctctctgtct ggctctctct ctgtctctct ctccatctct ctctctctct  
ccccccgtc  
2041 accctgtctc tgtctctctc tgtctgtgtg tctctctgtc ttctctctct  
tccatctctc  
2101 tctgtctctc ttctctctct tctctctctc cctctctccc tccctccgtg  
actcctctc  
2161 tcagtccatc tcttctctcc tctctcagcc ccttcgtgcc ctttctctg  
acactcccca  
2221 ccctggtttc ctgactccac cactagatcc accacctcca gcaactggga  
accctccct  
2281 gccaccctg ccctgggggc cctcccagg attccttcta gattatagca  
tcttccctgg  
2341 gcgggttctc atgaacaatt gtggctgctt ttttggccag acaggggagg  
gaggggatgg  
2401 gatcagggag tcctggaatg ggaactaggc aataaaaaaa aaaaaatgtc  
agaagcaggg  
2461 cggcgggagg tgggggcagg gccagctgtc cttaccaggg ataaaaggct  
ttgccagtgt  
2521 gactaggaag agagacacct cccctcttc cttcatcaag acatcaaggga  
gggacctgtg  
2581 ccctgtctca catcctccca cctgccgcc gcagagcctg caggccccgc  
ccccctctc  
2641 tctgggtccct acctctctgc tgtgtcttca tgtccctgag ggtcttgggc  
tctgggtaag  
2701 tgccccttgc tgtctctgcc tctcagcccc cggttctgtt gaaggttcct  
tctctctcac  
2761 tttttctctg catttgacag gacctggccc tcagccccca aaatgttctc  
cctgtgaca  
2821 gcacttcaag tcctggctat aggttaagaga acggttgggt atgacacaag  
ggggtccct  
2881 ggagactctg agaagagatg gggatgggtc cttggggccc ctggatgtc  
atggtgacct  
2941 cataagaaag agcagggagt ggtttggggg tcatggtggg ggaacgtgct  
ggaggcctaa  
3001 attcctagtt gtggaggtgc tagggaattg tggggccggg gagagaggtg  
tttataaggt  
3061 ctggtgcaaa atacataagg aatcttaggg aactattagg tcctgagtgg  
gtcatagcag  
3121 aaagatcacg gggctctacc tgactgtgtt aggaaagaaa caatgtcaga  
aagatgtttt  
3181 gttgtcagag ggaaggtgga gaaggatgat gggatggcgg gatcgtggca  
tggggtggcg  
3241 ggatcgtggc atgggtgtgt gaggtggatg ggggcaagtg tggggcaaga  
gatggcggat  
3301 ccttgggggc cactgagtg ggaacgttgg ggaggagaca gggaggtcct  
tgaatgtgtt  
3361 ggggaaggac tcattggggg gaaatgtggc atatttcgag aagtgatcac  
agaaattatg  
3421 ggagcataga gctaagggtc gtagatgtag caaggccctg gataaggtgg  
ccacgcaca  
3481 aaataagaga tgctacggag gtgacttggg aggtgagtca gaaagctctc  
cgtgctgggg

3541 caataacggg gtcaatattg ggcattgtct accctgggtg ggacagatag  
aggcgggcag  
3601 ttttaggggtt agacccaaaag gaaggggatt tgtcagtttt ggaatcctac  
aaacttgtgg  
3661 agtggagagt gtttgctcat ctactttccc caccctaatcc tgtccactcc  
tagccatgac  
3721 acagagccaa gaggatgaga acaagataat tggtaggcat acgtgcaccc  
ggagctccca  
3781 gccgtggcag gcggccctgc tggcgggtcc caggcgccgc ttcctctgcg  
gaggcgccct  
3841 gctttcaggc cagtgggtca tcaactgtgc tcaactgggc cgcccgtaag  
tgacccctc  
3901 ccctgtccct gtacctagtg aattccagag tctaaagccc tagagctgag  
ctgagaacct  
3961 ggatctctgt atagaaccca atgtagtggc tggctcctgg tttgaggtct  
agagaagagc  
4021 ctggaacaaa aacacagctc gggatgtggg ctccctccata aatctcgaac  
tcagcatagg  
4081 ttctgaaagc agatgggcag cttggaaccc atggacctgc tgagaaccga  
acatctgatc  
4141 cagtgattct tccagaggcc acacattaca tcgagaccaa gcttagccca  
ttccagattg  
4201 gtggctgaat tcaggacccc gtctacattc agaaactcag gacactacgt  
agaactcaga  
4261 gccagttca ggacctgcag tctagccata aatccagaac tagaacgctg  
ctcacagctg  
4321 gaacatacaa ctctaagaat agaggcaaaa cctggagggt gtttcacacc  
caaggtttag  
4381 ttcagagtct agtctatagc tccgctatga gcagacttca acccagtgtt  
tgaatcccag  
4441 aatgtggcgg gtgcggtggc tcatgcctat aatccctagca ctttgggatg  
ctgaggcagg  
4501 cagatcacct gaggtcagga gtctgagacc agcctgagca acatagagaa  
accctgtctc  
4561 tactaaaaat gcaaaattag ccaggcatgg tggcacatgc ctgtaatccc  
agccactcgg  
4621 gaggctgagg caggagaatc acttgaacct gggaggcgga ggttgacgtg  
agtcaagatc  
4681 gcaccattgc actccaggct aggcaacaag agcgaaactc catatcaatc  
aatcaatcaa  
4741 taaatcccag aatgcagatc ctaatcagaa gcccataata aaacctagac  
ccctcctaaa  
4801 ttctagatct gaacttaciaa ccagacccc agccaagagg tcaaatgcc  
tataagccat  
4861 atctatgcca taaacaggtc agtctagaac ctagagatca aagctcaggc  
cagagtctag  
4921 aatataaagg ccagaatgca aaccagactc tagaatcttg gatccgggcc  
ataacctaga  
4981 gctccaacta gaaccagag cccaacctga ggtcaagggc tagggccaga  
gtccagaacc  
5041 aagagcccta taatccaata tgaaacagac ctgtagaggc tgggtgcggt  
ggctcacgcc  
5101 tgtaatccca gcactttggg aggctgaggc gggagaatca cttgaactgg  
gagttggagg  
5161 tcgagagtga gctgagatcg tgccactgca ctccagccta ggtgacagag  
cgagactcca  
5221 tcacaaaaaa aaaataaata aataaatcaa gtcataatcc aggttcgatc  
tagaatcctg  
5281 atcttagcat agagtcaaaa gtttaagatg tctagaactc agaaccagg  
ctagaacag

5341 aatggtgcct actccggaat atcagttccg atttagagcc tagactcata  
acgcagtttc  
5401 gcttaggact caatgcaccg agcccagcac agaccctggc acggagccaa  
gctctcccaa  
5461 tcatcacctt ctcccaagc caggagctgg agcccagccc aagagcggaa  
ggagaggcag  
5521 ctggggctgg gccgagagaa tgccctggcc atggggaagg gcacaggagg  
ccaagaatgc  
5581 tgggcctgca gttagtgaga agcaggctag acctcgggga agactcgtca  
cccggccagg  
5641 gaaccgggct ggagggtggg gaggagtctc tggctcagac cctgagcagc  
gcttctcttg  
5701 ggggtcgtgg ccaggatcct tcaggttgcc ctgggcaagc acaacctgag  
gaggtgggag  
5761 gccaccagc aggtgctgcg cgtggttcgt cagggtgacgc accccaacta  
caactcccgg  
5821 acccacgaca acgacctcat gctgctgcag ctacagcagc ccgcacggat  
cgggagggca  
5881 gtcaggccca ttgaggtcac ccaggcctgt gccagccccg ggacctcctg  
ccgagtgtca  
5941 ggctggggaa ctatatccag ccccatcggg gaggactcct gcgtcttggg  
aagcagggga  
6001 ctgggcctgg gtcctgggt ctccaggagg tggagctggg gggactgggg  
ctcctgggtc  
6061 tgaggagga ggggctgggc ctggactcct gggctgagg gaggaggggg  
ctgaggcctg  
6121 gactcctggg tctcaaggag gaggagctgg gcctggactc atacgtctga  
gggaggaggg  
6181 gctggagcct ggactcctgg gtctcaagga ggaggggctg ggctggact  
tctgggtctg  
6241 agggaggagg ggctggggac ctggactccc gggctgagg gaggagggac  
tgggggtctg  
6301 gactcctggg tctgaggag gaggggctgg gggcctggac tctgggtct  
gagggaggag  
6361 gtgctggggc tggactcctg ggtcgggaagg aggaggggct gggggcctgg  
acccttgggt  
6421 cttatgggag ggtagacca gttataacct tgcagtgtcc ccagccagg  
taccgcct  
6481 ctctgcaatg cgtgaacatc aacatctccc cggatgaggt gtgccagaag  
gcctatccta  
6541 gaaccatcac gcctggcatg gtctgtgcag gagttcccca gggcgggaag  
gactcttgtc  
6601 aggtaaggcc caggatggga gctgtggtag ggattatttg ggactgggat  
ttaagcaaat  
6661 gatgtcagga gcatggaagt ctgcagaggt cttcagaaga gagtgaaccg  
caggcacaga  
6721 gagattccga tagccaggcc accctgcttc ctagccctgt gcccctggg  
taatggactc  
6781 agagcattca tgcctcagtt tccatctctg tcagggtggg gtaaccctct  
tagggtagtt  
6841 ggtggaatgg gatgaggcag gttggggaaa gatcgagag tggcctctgc  
tcatatgggt  
6901 ctgggaaagg ctgtgctgag gcttctagaa atcttaatgc atccttgagg  
gaggcagaga  
6961 tggggaaata gaaaaagaga gacacacaaa tgttctacag ttggagcgaa  
cagagagggg  
7021 cctggtgaga ttcaagggac aggcaggtgc acacagagac agagccagac  
ccagcggaga  
7081 gggaaggaag tgccccgacc tccggggctg agacctcaga gctggggcag  
gactgtgtcc

7141 ctaactgtcc accagtgtct ctgcctgtct ccctgtgtct gcttctcggg  
ttctctgtgc  
7201 catggtggct ctggctacct gtccatcagt gtctccattt ctgttcctcc  
ccctcagggt  
7261 gactctgggg gacccctggg gtgcagagga cagctccagg gcctcgtgtc  
ttgggggaatg  
7321 gagcgtgcg ccctgcctgg ctaccccggt gtctacacca acctgtgcaa  
gtacagaagc  
7381 tggattgagg aaacgatgcg ggacaaatga tggctttcac ggtgggatgg  
acctcgtcag  
7441 ctgcccaggc cctcctctct ctactcagga cccaggagtc caggccccag  
ccctcctcc  
7501 ctcagacca ggagtccagg ccccagccc ctctccctc agaccggga  
gtccaggccc  
7561 ccagcccctc ctccctcaga cccaggagtc caggccccag ccctcctcc  
ctcagaccg  
7621 ggagtccagg ccccagccc ctctccctc agaccagga gtccaggccc  
cagtcctcc  
7681 tccctcagac ccaggagtcc aggccccag ccctcctcc ctcagacca  
ggaatccagg  
7741 cccagcccct cctccctcag acccaggagc cccagtcccc cagccccctc  
tccttgagac  
7801 ccaggagtcc aggcccagc cctcctccct cagaccagga agccccagtc  
cccagcatcc  
7861 tgatctttac tccggtctg atctctcct tcccagagca gttgcttcag  
gcgttttctc  
7921 cccaccaagc cccaccctt gctgtgtcac catcactact caagaccgga  
ggcacagagg  
7981 gcaggagcac agaccctta aaccggcatt gtattccaaa gacgacaatt  
ttaaacacgc  
8041 ttagtgtctc taaaaaccga ataaataatg acaataaaaa tggaatcatc  
ctaaattgta  
8101 ttcattcatc catgtgttta ctttttattt tttgagacaa ggtcttgctc  
agtctcctgg  
8161 tgaaatgctg taacgcaatc atagctcact gcaaccgtga cctcctgggc  
tccagtgatc  
8221 ctctlacctc agcctcccga gtagctggga ccacaggtgc ccgtaccat gccccgtac

SEQ.ID.NO. 66

KLK-L6 AA

MTQSQEDENKIIGGHTCTRSSQPWQAALLAGPRRRFLCGGALLSGQWVITAA  
HCGRPILQVALGKHNLRWEATQQVLRVVRQVTHPNYNSRTHDNDLMLLQL  
QQPARIGRAVRPIEVTQACASPGTSCRVS GWTISSPIARYPASLQCVNINISPD  
EVCQKAYPRTITPGMVCAGVPQGGKDS CQGDSSGGLVCRGQLQGLVSWGM  
ERCALPGYPGVYTNLCKYRSWIEETMRDK

SEQ.ID.NO. 67

KLK-L6 AA

MFLLLTALQVLAIAMTQSQEDENKIIGGHTCTRSSQPWQAALLA  
GPRRRFLCGGALLSGQWVITAAHCGRPILQVALGKHNLRWEATQQVLRVV  
RQVTHPNYNSRTHDNDLMLLQLQQPARIGRAVRPIEVTQACASPGTSCRVS  
GWTISSPIARYPASLQCVNINISPD EVCQKAYPRTITPGMVCAGVPQGGKDS

QGDSSGGLVCRGQLQGLVSWGMECALPGYPGVYTNLCKYRSWIEETMRD  
K

SEQ.ID.NO. 68

Figure 9

protease

MATAGNPWGWFGLGYLILGVAGSLVSGSCSQIINGEDCSPHSQPWQAALVME  
NELFCSGVLVHPQWVLSAAHCFQNSYTIGLGLHSLEADQEPGSQMVEASLSV  
RHPEYNRPLLANDLMLIKLDES VSESDTIRSISIASQCPTAGNSCLVSGWGLLA  
NGRMPTVLQCVNVS VVSEEVCSKLYDPLYHPSMFCAGGGHDQKDSCNGDSG  
GPLICNGYLQGLVSFGKAPCGQVGVPGVYTNLCKFTEWIEK

SEQ.ID.NO. 69

Figure 9

EMSP

MATAGNPWGWFGLGYLILGVAGSLVSGEMSPSCSQIINGEDCSPHSQPWQAAL  
VMENELFCSGVLVHPQWVLSAAHCFQNSYTIGLGLHSLEADQEPGSQMVEAS  
LSVRHPEYNRPLLANDLMLIKLDES VSESDTIRSISIASQCPTAGNSCLVSGWG  
LLANGRMPTVLQCVNVS VVSEEVCSKLYDPLYHPSMFCAGGGHDQKDSCNG  
DSGGPLICNGYLQGLVSFGKAPCGQVGVPGVYTNLCKFTEWIEK 249

SEQ.ID.NO. 70

Figure 9

KLK-L2

MATARPPWMWVLCALITALLGVTEHVLANNDVSCDHPSNTVPSGSNQDLG  
AGAGEDARSDDSSSRIINGSDCDMHTQPWQAALLLRPNQLYCGAVLVHPQW  
LLTAAHCRKKVFRVRLGHYSLSPVYESGQMFQGVKSIPHPGYSHPGHSNDL  
MLIKLNRIRPTKDV RPINVS SHCPSAGTKCLVSGWGTTKSPQVHFPKVLQCL  
NISVLSQKRCEDAYPRQIDDTMFCAGDKAGRDSCQGDSSGGPVVCNGSLQGL  
VSWG DYPCARPNRPGVYTNLCKFTKWIQE

SEQ.ID.NO. 71

Figure 9

zyme

MKKLMVVLSLIAAAWAEEQNKLVHGGPCDKTSHPYQAALYTSGHLLCGGV

LIHPLWVLTA AHCKKPNLQVFLGKHNL RQRESSQE QSSVVRAVIHPDYDAAS  
HDQDIMLLRLARPAKLSELIQPLPLERDCSANTTSCHILGWGKTADGDFPDTI  
QCA YIHLVSREECEHAYPGQITQNMLCAGDEK YGKDSCQGDSGGPLVCGDH  
LRGLVSWGNIPCGSKEKPGVYTNVCRYTNWIQK

SEQ.ID.NO. 72

Figure 9

neuropsin

MGRPRPRAAKTWMFLLLGGAWAGHSRAQEDKVLGGHECQPHSQPWQAA  
LFQGGQQLLCGGVLVGGNWWVLTA AHCKKPKYTVRLGDHSLQNKDGPEQEIPV  
VQSIPHPCYNSSDVEDHNHDLMLLQLRDQASLGSKVKPISLADHCTQPGQKC  
TVSGWGTVTSPRENFPTLNCAEVKIFPQKKCEDA YPGQITDGMVCAGSSKG  
ADTCQGDSGGPLVCDGALQGITSWGSDPCGRSDKPGVYTNICRYLDWIKKTL  
SPMRILQLILLALATGLVG

SEQ.ID.NO. 73

Figure 9

TLSP

GETRIIKGFECKPHSQPWQAALFEKTRLLCGATLIAPRWLLTA AHCLKPRYIV  
HLGQHNLQKEEGCEQTRTATESFPHPGFNNSLPNKDHRNDIMLVKMASPVSI  
TWA VRPLTLSSRCVTAGTSC LISGWGSTSSPQLRLPHTLR CANITHIEHQKCN  
AYPGNITDTMVCASVQEGGKDSCQGDSGGPLVCNQSLQGIISWGQDPCAIR  
KPGVYTKVCKYVDWIQE

SEQ.ID.NO. 74

Figure 9

PSA

MWVPVVFLTLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVASRGRAVCG  
GVLVHPQWVLTA AHCIRNKS VILLGRHSLFHPEDTGQVFQVSHSFPHPLYDM  
SLLKNRFLRPGDDSSHDLM LRLSEPAELTDA VKVMDLPTQEPALGTTCYAS  
GWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQKVTKFMLCAGRWTGGK  
STCSGDSGGPLVCNGVLQGITSWGSEPCALPERPSLYTKVVHYRKWIKD

SEQ.ID.NO. 75

Figure 9



KLK2

MWDLVLSIALSVGCTGAVPLIQSRIVGGWECEKHSQPWQVAVYSHGWAHCG  
GVLVHPQWVLTAAHCLKKNSQVWLGRHNLFEPEDTGQRVPVSHSFPHPLYN  
MSLLKHQSLRPDEDSSHDLMLLRLSEPAKITDVVKVLGLPTQEPALGTTTCYAS  
GWGSIEPEEFLRPRSLQCVSLHLLSNDMCARAYSEKVTEFMLCAGLWTGGKD  
TCGGDSGGPLVCNGVLQGITSWGPEPCALPEKPAVYTKVVHYRKWIKD

SEQ.ID.NO. 76

Figure 9

KLK1

MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGG  
ILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMS  
LLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASG  
WGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDT  
CVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSSAVRVLSSYVKWIED

SEQ.ID.NO. 77

Figure 9

trypsinogen

MNPLLILTFVAAALAAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSLI  
NEQWVVSAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNN  
DIMLIKLSRAVINARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQC  
LDAPVLSQAKCEASYPGKITSNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQ  
GVVSWG-DGCAQKNKPGVYTKVYNYVKWIKN

SEQ.ID.NO. 78

Figure 17, 27, 36, 43

PSA

MWVPVVFLLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVASRGRAVCG  
GVLVHPQWVLTAAHCIRNKSIVLLGRHSLFHPEDTGQVFQVSHSFPHPLYDM  
SLLKNRFLRPGDDSSHDLMLLRLSEPAELTDAVKVMDLPTQEPALGTTTCYAS  
GWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQKVTKFMLCAGRWTGGK  
STCSGDSGGPLVCNGVLQGITSWGSEPCALPERPSLYTKVVHYRKWIKDTIVA  
NP

SEQ.ID.NO. 79

Figure 17, 27, 36, 43

KLK2

MWDLVLSIALSVGCTGAVPLIQSRIVGGWECEKHSQPWQVAVYSHGWAHCG  
GVLVHPQWVLTAAHCLKKNSQVWLGRHNLFEPEDTGQRPVSHSFPHPLYN  
MSLLKHQSLRPDEDSSHDLMLLRLSEPAKITDVVKVLGLPTQEPALGTTTCYAS  
GWGSIEPEEFLRPRSLQCVSLHLLSNDMCARAYSEKVTEFMLCAGLWTGGKD  
TCGGDSGGPLVCNGVLQGITSWGPEPCALPEKPAVYTKVVHYRKWIKDTIAA  
NP

SEQ.ID.NO. 80

Figure 17, 27, 36, 43

KLK1

MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGG  
ILVHRQWVLTAAHCISDNYQLWLGRHNLFDDETAQFVHVSESFPHPGFNMS  
LLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASG  
WGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDT  
CVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPVSVAVRVLSYVKWIEDTIAE  
NS

SEQ.ID.NO. 81

Figure 17, 27, 36, 43

prostase

MATAGNPWGWFGLGYLILGVAGSLVSGSCSQIINGEDCSPHSQPWQAALVME  
NELFCSGVLVHPQWVLSAAHCFQNSYTIGLGLHSLEADQEPGSQMVEASLSV  
RHPEYNRPLLANDLMLIKLDESVS-  
ESDTIRSISIASQCPTAGNSCLVSGWGLLANG—  
RMPTVLQCVNVSVVSEEVCSKLYDPLYHPSMFCAGGGHDQKDSCNGDSGGP  
LICNGYLQGLVSFGKAPCGQVGVPGVYTNLCKFTEWIEKTVQAS

SEQ.ID.NO. 82

Figure 17, 27

trypsinogen

MNPLLILTFVAAALAAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSLI  
NEQWVVSAGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNN  
DIMLIKLSRAVINARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQC  
LDAPVLSQAKCEASYPGKITSNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQ  
GVVSWG-DGCAQKNKPGVYTKVYNYVKWIKNTIAANS

SEQ.ID.NO. 83

Figure 17, 27, 36, 43

neuropsin

MGRPRPRAAKTWMFLLLLGGAWAGHSRAQEDKVLGGHECQPHSQPWQAA  
LFQGGQQLLCGGVLVGGNWVLTA AHCKKPKYTVRLGDHSLQNKDGP EQEIPV  
VQSIPHPCYNSSDVEDHNHDLMLLQLRDQASLGSKVKPISLADHCTQPGQKC  
TVSGWGTVTSPRENFPTLNC AEVKIFPQKKCEDA YPGQITDGMVCAGSSKG  
ADTCQGDSGGPLVCDGALQGITSWGS DPCGRSDKPGVYTNICRYLDWIKKIIG  
SKG

SEQ.ID.NO. 84

Figure 17, 27, 36, 43

zyme

MKKLMVVLSLIAAAWAE EQNKL VHGGPCDKTSHPYQAALYTS GHLLCGGV  
LIHPLWVLTA AHCKKPNLQVFLGKHNL RQRESSQE QSSVVRAVIHPDYDAAS  
HDQDIMLLRLARPAKLSELIQPLPLERDCSANTTSCHILGWGKTADGDFPTI  
QCA YIHLVSREECEHA YPGQITQNM L CAGDEKYGKDSCQGDSGGPLVCGDH  
LRGLVSWGNI PCGSKEKPGVYTNVCRYTNWIQKTIQAK

SEQ.ID.NO. 85

Figure 27

EMSP

MATAGNPWGWF LGYLILGVAGSLVSGEMSPSCSQIINGEDCSPHSQPWQAAL  
VMENELFCSGVLVHPQWVLSAAHCFQNSYTIGLGLHSLEADQEPGSQMVEAS  
LSVRHPEYNRPLL ANDLMLIKLDES VSESDTIR SISI ASQCPTAGNSCLVSGWG  
LLANGRMPTVLQCVNVSVVSEEVCSKLYDPLYHPSMFCAGGGHDQKDSCNG  
DSGGPLICNGYLQGLVSFGKAPCGQVGVPGVYTNLCKFTEWIEKTVQAS

SEQ.ID.NO. 86

Figure 27

TLSP

MRI-LQLILLALATGLVGGETRIIKGF ECKPHSQPWQAALFEKTRLLC  
GATLIAPRWLLTA AHCLKPRYIVHLGQHNLQKEEGCEQTRTATESFPHPGFNN  
SLPNKDHNRNDIMLVKMASPV SITWAVRPLTLSSRCV TACTSCLISGWGSTSSP  
QLRLPHTLR CANITIEHQKCENAYPGNITDTMVCASVQEGGKDSCQGDSGGP  
LVCNQSLQGIISWGQDPCAITRKPGVYTKVCKYVDWIQETMKNN

SEQ.ID.NO. 87

Figure 27

HSCEE

MARSLLLPLQILLLSLALETAGEEAQGDKIIDGAPCARGSHPWQVALLSGNQL  
HCHSCCEGGVLVNERWVLTAAHCKMNEYTVHLGSDTLGDRRAQRIKASKSF  
RHPGYSTQTHVNDLMLVKLNSQARLSSMVKKVRLPSRCEPPGTTCTVSGWG  
TTTSPDVTFPDLMCVDVKLISPQDCTKVYKDLENSMLCAGIPDSKKNACNG  
DSGGPLVCRGTLQGLVS WGTFFCGQPNDPGVYTQVCKFTKWINDTMKKHR

SEQ.ID.NO. 88

Figure 27

NES1

MRAPHLHLSAASGARALAKLLPLLMAQLWAAEAALLPQNDTRLDPEAYGAP  
CARG SQPWQVSLFNGLSFH CAGVLVDQSWVLTAAHCGNKPLWARVGDDH  
LL-LLQG-EQLRRTT RSVVHPKYHQSGPI LPRRTDEHDLML LKLARPVV-  
PGPRVR ALQLPYR-CAQPGDQ CQVAGWGTTAARRVK YNKGLTCSSITLSP  
KECEVFYPGVVTNNM ICAGLDR-GQDPCQS DSGGPLVCDETLQGI LSWG-  
VYPCGSAQHPAVYTQICKYMSWINK VIRSN

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/00258

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/57 C12N9/64 C12N15/63 C07K16/40 C12Q1/68  
G01N33/53 A61K39/395 A61K48/00 A61K38/48 A01K67/027

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K C12Q G01N A61K A01K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J.P. SIMMER ET AL.: "Purification, characterization, and cloning of Enamel Matrix Serine Proteinase 1" JOURNAL OF DENTAL RESEARCH, vol. 77, no. 2, February 1998 (1998-02), pages 377-386, XP000910876 page 380, right-hand column, paragraph 2 -page 384, right-hand column, paragraph 1; figure 6	1-8, 14-31
A	--- P.H.J. RIEGMAN ET AL.: "Characterization of the human Kallikrein locus" GENOMICS, vol. 14, 1992, pages 6-11, XP002058183 cited in the application the whole document --- -/--	1-8, 14-31



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

6 July 2000

Date of mailing of the international search report

18. 10. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

MONTERO LOPEZ B.

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LYNETTE J. SCHEDLICH ET AL.: "Primary structure of a human glandular Kallikrein gene" DNA, vol. 6, no. 5, 1987, pages 429-437, XP002044466 cited in the application the whole document	1-8, 14-31
A	--- P.H.J. RIEGMAN ET AL.: "Characterization of the prostate-specific gene: A novel human Kallikrein-like gene" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 159, no. 1, 28 February 1989 (1989-02-28), pages 95-102, XP002141957 ORLANDO, FL US cited in the application the whole document	1-8, 14-31
A	--- WO 98 20117 A (INCYTE PHARMACEUTICALS, INC.) 14 May 1998 (1998-05-14) page 10, line 25 -page 36, line 18	1-8, 14-31
P,X	--- GEORGE M. YOUSEF ET AL.: "Prostase/KLK-L1 is a new member of the human Kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated" CANCER RESEARCH, vol. 59, no. 17, 1 September 1999 (1999-09-01), pages 4252-4256, XP002141958 MD US the whole document	1-8, 14-31
P,X	--- PETER S. NELSON ET AL.: "Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 96, no. 6, 16 March 1999 (1999-03-16), pages 3114-3119, XP002141959 WASHINGTON US abstract page 3115, right-hand column, paragraph 3 -page 3116, right-hand column, paragraph 3 page 3117, right-hand column, paragraph 2 -page 3119, left-hand column, paragraph 2 --- -/--	1-8, 14-31

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/00258

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>STEPHENSON S A ET AL.: "Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4" JOURNAL OF BIOLOGICAL CHEMISTRY, [Online] vol. 274, no. 33, 13 August 1999 (1999-08-13), pages 23210-23214, XP002141960 MD US</p> <p>Retrieved from the Internet:            &lt;URL:http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query_old?uid=10438493&amp;form=6&amp;db=m&amp;Dopt=b&gt; [retrieved on 2000-05-17]            page 23211, left-hand column, paragraph 1            page 23211, right-hand column, paragraph 2 - paragraph 3; figure 1            page 23212, right-hand column, paragraph 2            -page 23214, left-hand column, last paragraph</p> <p>---</p>	1-8, 14-31
P,X	<p>DIAMANDIS E.P. ET AL: "The new human kallikrein gene family: Implications in carcinogenesis." TRENDS IN ENDOCRINOLOGY AND METABOLISM, (2000) 11/2 (54-60)., XP000910866            page 54, middle column, paragraph 2            -right-hand column, paragraph 2            page 56, right-hand column, paragraph 2            page 59, left-hand column, paragraph 2            -middle column, paragraph 2; figure 1; tables 1-3</p> <p>---</p>	1-8, 14-31
P,X	<p>GEORGE M. YOUSEF ET AL.: "Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4" ANTICANCER RESEARCH, vol. 19, July 1999 (1999-07), pages 2343-2352, XP000911217            page 2845, right-hand column, paragraph 2            -page 2851, left-hand column, last paragraph; figure 1; table II</p> <p>---</p> <p>-/--</p>	1-8, 14-31

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/00258

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>B.R. DUPONT ET AL.: "Assignment of serine protease 17 (PRSS17) to human chromosome bands 19q13.3-q13.4 by in situ hybridization" CYTOGENETICS AND CELL GENETICS, [Online] vol. 86, no. 3-4, 22 April 1999 (1999-04-22), pages 212-213, XP000911088 Retrieved from the Internet: &lt;URL:http://www3.ncbi.nlm.nih.gov/htbin-post/Omim/dispim?603767#Referencel&gt; [retrieved on 2000-05-17] the whole document -----</p>	



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 00/00258**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 26 and 27 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.
2. ☒ Claims Nos.: 26-29 partially  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
8 and partially claims 1-7 and 14-31

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 206

Continuation of Box 3.

Although claims 26 and 27 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.

-----

Further defect(s) under Article 17(2)(a):

Continuation of Box 3.

Claims Nos.: 26-29 partially

Present claims 26-29 relate, partially, to a substance or compound identified according to the method of claim 22 or 23, defined by reference to a desirable characteristic or property, namely associating with, or modulating the biological activity of a protein of claims 8-13. The claims cover all substances or compounds having this characteristic or property, whereas the application does not provide support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for any specific example of such substances or compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved or a process for their preparation. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds other than identified according to the methods of claim 22 or 23.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 1. Claims: Claim 8 and partially claims 1-7 and 14-31

Kallikrein-like nucleic acid KLK-L1 and variants thereof; its regulatory sequence, vector and host cell comprising it and use thereof for preparing a protein; KLK-L1 protein and antibody against it; KLK-L1 probe; diagnostic and screening tests using KLK-L1 protein and nucleic acids; therapeutic uses thereof and their application in transgenic animals.

## 2. Claims: Claim 9 and partially claims 1-7 and 14-31

Kallikrein-like nucleic acid KLK-L2 and variants thereof; its regulatory sequence, vector and host cell comprising it and use thereof for preparing a protein; KLK-L2 protein and antibody against it; KLK-L2 probe; diagnostic and screening tests using KLK-L2 protein and nucleic acids; therapeutic uses thereof and their application in transgenic animals.

## 3. Claims: Claim 10 and partially claims 1-7 and 14-31

Kallikrein-like nucleic acid KLK-L3 and variants thereof; its regulatory sequence, vector and host cell comprising it and use thereof for preparing a protein; KLK-L3 protein and antibody against it; KLK-L3 probe; diagnostic and screening tests using KLK-L3 protein and nucleic acids; therapeutic uses thereof and their application in transgenic animals.

## 4. Claims: Claim 11 and partially claims 1-7 and 14-31

Kallikrein-like nucleic acid KLK-L4 and variants thereof; its regulatory sequence, vector and host cell comprising it and use thereof for preparing a protein; KLK-L4 protein and antibody against it; KLK-L4 probe; diagnostic and screening tests using KLK-L4 protein and nucleic acids; therapeutic uses thereof and their application in transgenic animals.

## 5. Claims: Claim 12 and partially claims 1-7 and 14-31

Kallikrein-like nucleic acid KLK-L5 and variants thereof; its regulatory sequence, vector and host cell comprising it and use thereof for preparing a protein; KLK-L5 protein and antibody against it; KLK-L5 probe; diagnostic and screening tests using KLK-L5 protein and nucleic acids; therapeutic uses thereof and their application in transgenic animals.

## 6. Claims: Claim 13 and partially claims 1-7 and 14-31

Kallikrein-like nucleic acid KLK-L6 and variants thereof; its regulatory sequence, vector and host cell comprising it and use thereof for preparing a protein; KLK-L6 protein and

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

antibody against it; KLK-L6 probe; diagnostic and screening tests using KLK-L6 protein and nucleic acids; therapeutic uses thereof and their application in transgenic animals.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9820117 A	14-05-1998	US 5786148 A	28-07-1998
		AU 5165998 A	29-05-1998
		EP 0941313 A	15-09-1999
		US 5922321 A	13-07-1999
-----			

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**